
<html lang="en"     class="pb-page"  data-request-id="f4c38694-0d63-46d5-b784-4b95f989efa5"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:10.1021/jmcmar.2013.56.issue-17;article:article:10.1021/jm400822z;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)" /></meta><meta name="dc.Creator" content="Richard A.  Ward" /></meta><meta name="dc.Creator" content="Mark J.  Anderton" /></meta><meta name="dc.Creator" content="Susan  Ashton" /></meta><meta name="dc.Creator" content="Paul A.  Bethel" /></meta><meta name="dc.Creator" content="Matthew  Box" /></meta><meta name="dc.Creator" content="Sam  Butterworth" /></meta><meta name="dc.Creator" content="Nicola  Colclough" /></meta><meta name="dc.Creator" content="Christopher G.  Chorley" /></meta><meta name="dc.Creator" content="Claudio  Chuaqui" /></meta><meta name="dc.Creator" content="Darren A. E.  Cross" /></meta><meta name="dc.Creator" content="Les A.  Dakin" /></meta><meta name="dc.Creator" content="Judit É.  Debreczeni" /></meta><meta name="dc.Creator" content="Cath  Eberlein" /></meta><meta name="dc.Creator" content="M. Raymond V.  Finlay" /></meta><meta name="dc.Creator" content="George B.  Hill" /></meta><meta name="dc.Creator" content="Matthew  Grist" /></meta><meta name="dc.Creator" content="Teresa C. M.  Klinowska" /></meta><meta name="dc.Creator" content="Clare  Lane" /></meta><meta name="dc.Creator" content="Scott  Martin" /></meta><meta name="dc.Creator" content="Jonathon P.  Orme" /></meta><meta name="dc.Creator" content="Peter  Smith" /></meta><meta name="dc.Creator" content="Fengjiang  Wang" /></meta><meta name="dc.Creator" content="Michael J.  Waring" /></meta><meta name="dc.Description" content="A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with ..." /></meta><meta name="Description" content="A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="August 30, 2013" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/jm400822z" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2013 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Fjm400822z" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Fjm400822z" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Fjm400822z" /></link>
        
    
    

<title>Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR) | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/jm400822z" /></meta><meta property="og:title" content="Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0052.jpeg" /></meta><meta property="og:description" content="A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to support design." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/jm400822z"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/jm400822z">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Fjm400822z&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Fjm400822z&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/jm400822z&amp;href=/doi/10.1021/jm400822z" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2013</span><span class="cit-fg-volume">, 56</span><span class="cit-fg-issue">, 17</span><span class="cit-fg-pageRange">, 7025-7048</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/56/17" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/jm400820m" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/jm400826j" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Richard+A.++Ward">Richard A. Ward</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+J.++Anderton">Mark J. Anderton</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Susan++Ashton">Susan Ashton</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Paul+A.++Bethel">Paul A. Bethel</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Box">Matthew Box</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Sam++Butterworth">Sam Butterworth</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicola++Colclough">Nicola Colclough</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Christopher+G.++Chorley">Christopher G. Chorley</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Claudio++Chuaqui">Claudio Chuaqui</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Darren+A.+E.++Cross">Darren A. E. Cross</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Les+A.++Dakin">Les A. Dakin</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Judit+%C3%89.++Debreczeni">Judit É. Debreczeni</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cath++Eberlein">Cath Eberlein</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=M.+Raymond+V.++Finlay">M. Raymond V. Finlay</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=George+B.++Hill">George B. Hill</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Matthew++Grist">Matthew Grist</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Teresa+C.+M.++Klinowska">Teresa C. M. Klinowska</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Clare++Lane">Clare Lane</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Scott++Martin">Scott Martin</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jonathon+P.++Orme">Jonathon P. Orme</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Smith">Peter Smith</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Fengjiang++Wang">Fengjiang Wang</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+J.++Waring">Michael J. Waring</a></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">AstraZeneca, Oncology & Discovery Sciences Innovative Medicines, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">†</span> <span class="aff-text">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: +44 (0)1625 519045. E-mail: <a href="/cdn-cgi/l/email-protection#11637872797063753f703f667063755170626563706b747f7472703f727e7c"><span class="__cf_email__" data-cfemail="cfbda6aca7aebdabe1aee1b8aebdab8faebcbbbdaeb5aaa1aaacaee1aca0a2">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Fjm400822z&amp;href=/doi/10.1021%2Fjm400822z" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2013</span></span><span class="cit-volume">, 56</span><span class="cit-issue">, 17</span><span class="cit-pageRange">, 7025–7048</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">August 9, 2013</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>3 June 2013</li><li><span class="item_label"><b>Published</b> online</span>30 August 2013</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 12 September 2013</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/jm400822z" title="DOI URL">https://doi.org/10.1021/jm400822z</a></div><div class="article_header-article-copyright"><strong>Copyright © 2013 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D7025%26pageCount%3D24%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DRichard%2BA.%2BWard%252C%2BMark%2BJ.%2BAnderton%252C%2BSusan%2BAshton%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D56%26issueNum%3D17%26contentID%3Djm400822z%26title%3DStructure-%2Band%2BReactivity-Based%2BDevelopment%2Bof%2BCovalent%2BInhibitors%2Bof%2Bthe%2BActivating%2Band%2BGatekeeper%2BMutant%2BForms%2Bof%2Bthe%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%26numPages%3D24%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D7048%26publicationDate%3DSeptember%2B2013">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/jm400822z"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">10245</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">131</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/jm400822z" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Richard&quot;,&quot;last_name&quot;:&quot;A. Ward&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;J. Anderton&quot;},{&quot;first_name&quot;:&quot;Susan&quot;,&quot;last_name&quot;:&quot;Ashton&quot;},{&quot;first_name&quot;:&quot;Paul&quot;,&quot;last_name&quot;:&quot;A. Bethel&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Box&quot;},{&quot;first_name&quot;:&quot;Sam&quot;,&quot;last_name&quot;:&quot;Butterworth&quot;},{&quot;first_name&quot;:&quot;Nicola&quot;,&quot;last_name&quot;:&quot;Colclough&quot;},{&quot;first_name&quot;:&quot;Christopher&quot;,&quot;last_name&quot;:&quot;G. Chorley&quot;},{&quot;first_name&quot;:&quot;Claudio&quot;,&quot;last_name&quot;:&quot;Chuaqui&quot;},{&quot;first_name&quot;:&quot;Darren&quot;,&quot;last_name&quot;:&quot;A. E. Cross&quot;},{&quot;first_name&quot;:&quot;Les&quot;,&quot;last_name&quot;:&quot;A. Dakin&quot;},{&quot;first_name&quot;:&quot;Judit&quot;,&quot;last_name&quot;:&quot;É. Debreczeni&quot;},{&quot;first_name&quot;:&quot;Cath&quot;,&quot;last_name&quot;:&quot;Eberlein&quot;},{&quot;first_name&quot;:&quot;M.&quot;,&quot;last_name&quot;:&quot;Raymond V. Finlay&quot;},{&quot;first_name&quot;:&quot;George&quot;,&quot;last_name&quot;:&quot;B. Hill&quot;},{&quot;first_name&quot;:&quot;Matthew&quot;,&quot;last_name&quot;:&quot;Grist&quot;},{&quot;first_name&quot;:&quot;Teresa&quot;,&quot;last_name&quot;:&quot;C. M. Klinowska&quot;},{&quot;first_name&quot;:&quot;Clare&quot;,&quot;last_name&quot;:&quot;Lane&quot;},{&quot;first_name&quot;:&quot;Scott&quot;,&quot;last_name&quot;:&quot;Martin&quot;},{&quot;first_name&quot;:&quot;Jonathon&quot;,&quot;last_name&quot;:&quot;P. Orme&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Smith&quot;},{&quot;first_name&quot;:&quot;Fengjiang&quot;,&quot;last_name&quot;:&quot;Wang&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;J. Waring&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2013&quot;,&quot;month&quot;:&quot;08&quot;,&quot;day&quot;:&quot;30&quot;,&quot;issue&quot;:&quot;17&quot;,&quot;volume&quot;:&quot;56&quot;,&quot;pages&quot;:&quot;7025-7048&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/jm400822z&quot;},&quot;abstract&quot;:&quot;A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to s&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400822z&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400822z" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400822z&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400822z" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Fjm400822z&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400822z" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Fjm400822z&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=jm400822z&amp;href=/doi/10.1021/jm400822z" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/jm400822z" /></input><a href="/doi/pdf/10.1021/jm400822z" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/jm400822z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Fjm400822z%26sid%3Dliteratum%253Aachs%26pmid%3D23930994%26genre%3Darticle%26aulast%3DWard%26date%3D2013%26atitle%3DStructure-%2Band%2BReactivity-Based%2BDevelopment%2Bof%2BCovalent%2BInhibitors%2Bof%2Bthe%2BActivating%2Band%2BGatekeeper%2BMutant%2BForms%2Bof%2Bthe%2BEpidermal%2BGrowth%2BFactor%2BReceptor%2B%2528EGFR%2529%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D56%26issue%3D17%26spage%3D7025%26epage%3D7048%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (1)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=291439" title="Genetics">Genetics</a>,</li><li><a href="/action/doSearch?ConceptID=292169" title="Antioxidants">Antioxidants</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291452" title="Reactivity">Reactivity</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/56/17" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jmcmar.2013.56.issue-17/production/jmcmar.2013.56.issue-17.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0052.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">A novel series of small-molecule inhibitors has been developed to target the double mutant form of the epidermal growth factor receptor (EGFR) tyrosine kinase, which is resistant to treatment with gefitinib and erlotinib. Our reported compounds also show selectivity over wild-type EGFR. Guided by molecular modeling, this series was evolved to target a cysteine residue in the ATP binding site via covalent bond formation and demonstrates high levels of activity in cellular models of the double mutant form of EGFR. In addition, these compounds show significant activity against the activating mutations, which gefitinib and erlotinib target and inhibition of which gives rise to their observed clinical efficacy. A glutathione (GSH)-based assay was used to measure thiol reactivity toward the electrophilic functionality of the inhibitor series, enabling both the identification of a suitable reactivity window for their potency and the development of a reactivity quantitative structure-property relationship (QSPR) to support design.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_16564" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_16564" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Ligand-induced activation of receptor tyrosine kinases such as the epidermal growth factor receptor (EGFR) promote the subsequent activation of downstream signaling pathways, which in turn drive pro-proliferative and survival cellular signals.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In a subset of non-small cell lung cancer (NSCLC) patients, EGFR has gained activating mutations such as L858R and exon 19 deletion, which largely renders the receptor constitutively activated, independent of ligand stimulation.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> This results in sustained hyper-activation of signaling pathways downstream of EGFR, such as AKT (protein kinase B) and ERK (extracellular signal-regulated kinase), and promotes the oncogenic dependency of the cell on these pro-proliferative and survival drives resulting from the mutated EGFR. Therefore, inhibition of activated EGFR using small-molecule kinase inhibitors prevents its signaling and reduces the oncogenic drive, ultimately resulting in the inhibition of tumor growth.</div><div class="NLM_p">First generation EGFR tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib are now established therapies in NSCLC patients having activating mutations in EGFR.<a onclick="showRef(event, 'ref3 ref4'); return false;" href="javascript:void(0);" class="ref ref3 ref4">(3, 4)</a> Around 70% of patients respond initially but develop resistance with a median time to progression of 10–16 months. In at least 50% of these initially responsive patients, disease progression is associated with the gain of a secondary mutation, T790M in exon 20 of EGFR (typically referred to as the gatekeeper mutation), in combination with an activating mutation.<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a></div><div class="NLM_p">The specific mechanism by which the activating mutants exert their effect is not entirely clear, but studies on the L858R mutation have shown there to be a decreased affinity for ATP (Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a>).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> It has been proposed that the activating mutations may favor the active conformation of the kinase to which compounds such as gefitinib (<b>1</b>)<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> and erlotinib (<b>2</b>)<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(7)</a> may bind (Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>).<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(8)</a> Further reports have suggested additional and alternative mechanisms of activation, including the differential ability of the mutants to sample the active and inactive conformations.<a onclick="showRef(event, 'ref10 ref11'); return false;" href="javascript:void(0);" class="ref ref10 ref11">(9, 10)</a> However, the secondary mutation, T790M, increases the affinity of the kinase for ATP.<a onclick="showRef(event, 'ref6 ref12'); return false;" href="javascript:void(0);" class="ref ref6 ref12">(6, 11)</a> An increase in the kinase domain’s ATP affinity reduces the inhibitory activity of ATP-competitive inhibitors such as gefitinib and erlotinib against EGFR. This amino acid is known as the gatekeeper residue, and it is positioned at the entrance of what is typically referred to as the back pocket.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(12)</a> The size and nature of this residue has a significant effect on determining which compounds are tolerated in this region of the binding site. It is therefore also possible that there is a steric component to the resistance mechanism against early EGFR inhibitors, which specifically affects compounds such as gefitinib and erlotinib that were identified by targeting the wild-type threonine gatekeeper. In addition, it has been proposed that the T790M mutation can lead to differential structural rearrangements of the protein across inhibitor classes,<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(9)</a> impacting the potency and selectivity of compounds against the mutations.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Location of activating (L858R and exon 19 deletion) and resistant secondary mutations (T790M) in the kinase domain of EGFR (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(13)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Selection of published EGFR inhibitors disclosed in the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">A number of second-generation irreversible inhibitors were subsequently developed on the basis of the anilinoquinazoline template of gefitinib. These inhibitors contained an acrylamide functionality that covalently targets Cys-797, which is positioned in the solvent channel of the kinase.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(14, 15)</a> Such reported compounds include afatinib, <b>3</b>,<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(16)</a> canertinib, <b>4</b>,<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(17)</a> and dacomitinib, <b>5</b>,<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(18)</a> shown in Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a>. The covalent mechanism is thought to overcome the increase in ATP affinity of the double mutant, resulting in the potent activity of these compounds in cellular models. However, Cys-797 is present in all relevant forms of EGFR; these second-generation compounds, therefore, not only have increased activity against the activating and resistant mutations but also against wild-type EGFR. The inhibition of wild-type EGFR is not thought to contribute to their clinical efficacy but is thought to be responsible for the side-effects of skin rash and diarrhea.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(19)</a> As these side effects are typically dose limiting in patients, it is possible that the activity of these inhibitors against wild-type EGFR will limit their achievable activity against the T790M mutation in patients.</div><div class="NLM_p">Our initial aim was to identify a double-mutant-selective template by exploiting the differences in the properties of the respective threonine and methionine gatekeeper residues. We hypothesized that exploiting the methionine gatekeeper residue to leverage the increased potency might lead to a selectivity profile in which the compounds are active against the double mutant enzyme but with reduced activity against wild-type EGFR. Ideally, compounds would also show greater activity against the activating EGFR mutations than against wild-type EGFR.</div><div class="NLM_p last">From the time that we initiated our efforts to identify compounds with this preferred selectivity profile, other compounds have been reported that exploit similar principles. An early published example was from the Dana-Farber Cancer Institute (WZ-4002, <b>6</b>)<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(20)</a> and was based on a pyrimidine template. More recently, additional covalent inhibitors from Clovis Oncology (CO-1686) and Hanmi Pharmaceuticals (HM61713) are reported to be in clinical studies, although their chemical structures are yet to be disclosed. Also reported is the reversible anaplastic lymphoma kinase (ALK) inhibitor (AP26113) from ARIAD, with reported activity against the double mutant form of EGFR. Further publications have also been disclosed, from the time that we initiated this work, reporting on other potential compound series active against the EGFR double mutation.<a onclick="showRef(event, 'ref22 ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref22 ref23 ref24">(21-23)</a></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83557" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83557" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Chemistry</h3><div class="NLM_p">Where possible, compounds were prepared according to the general strategy outlined in Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> from commercially available pyrimidines (<b>A</b>). Installation of the reactive warhead, where present, at the last or penultimate step was desirable because it was not expected to be robust enough during further chemical manipulation. Although Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a> captures the synthesis approach to the majority of the key examples from this manuscript (shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>), because of the structural diversity of the compounds reported, some examples were not synthesized using this approach. However, the full synthesis of all compounds can be found in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> or in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis Approach to the Key Novel Compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) Reported in This Manuscript<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Aniline displacement: excess NaHCO<sub>3</sub>, 2-pentanol or EtOH, 85 °C; suzuki coupling: Na<sub>2</sub>CO<sub>3</sub>, ArB(OR)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, MeCN, water, 100 °C; indole displacement: MeMgBr (1 equiv, 3.2 M in 2-methyl THF), indole (1 equiv), THF, 0–60 °C. (ii) Et<sub>3</sub>N (1.1 equiv), butyl-vinyl-ether (1.1 equiv), Pd(OAc)<sub>2</sub> (0.03 equiv), PEG 200, 80 °C. (iii) Either 1-aminopyridinium iodide (1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.5 equiv), DMA, 110 °C or 2-amino-pyridine (1 equiv), NBS (1.2 equiv), 1,4-dioxane, water, 85 °C. (iv) Either aniline (1.1 equiv), <i>p</i>-TSA (1.1 equiv), 2-pentanol, 80–120 °C, or aniline (1.1 equiv), 4 M HCl in 1,4-dioxane, TFE, 150 °C (μW), or aniline (1.1 equiv), Pd(OAc)<sub>2</sub> (0.08 equiv), Xantphos (0.1 equiv), Cs<sub>2</sub>CO<sub>3</sub> (2 equiv), 1,4-dioxane, 80 °C. (v) Acetyl aniline (1 equiv), <i>p</i>-TSA (3 equiv), <i>n</i>-pentanol/NMP, 150 °C. (vi) 1-Methylpiperazine (2.5 equiv), TFE, 120 °C. (vii) Either iron (3 equiv), NH<sub>4</sub>Cl (0.7 equiv), EtOH, water, 100 °C or Pt/C (1 equiv), ZnI<sub>2</sub> (0.1 equiv), H<sub>2</sub>, MeOH, EtOAc. (viii) Either acryloyl chloride (1M, THF, 1 equiv), DIPEA (1.1 equiv), THF, 0 °C, or (<i>E</i>)-4-(dimethylamino)but-2-enoic acid (1 equiv), HATU (1.1 equiv), DIPEA (2.5 equiv), DCM, or (<i>E</i>)-4-bromobut-2-enoic acid (1.1 equiv), HATU (1.1 equiv), DIPEA (2.5 equiv), 0 °C then Me<sub>2</sub>NH (20 equiv). (ix) Deprotection (where required): Either K<sub>2</sub>CO<sub>3</sub> (3 equiv), THF, MeOH or Cs<sub>2</sub>CO<sub>3</sub> (3 equiv), THF, MeOH, 0 °C. (x) Zn(CN)<sub>2</sub> (0.6 equiv), Zn (0.1 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.1 equiv), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine (0.2 equiv), DMA, 90 °C.</p></p></figure><div class="NLM_p">Installation of the 4-substituent of the pyrimidine was achieved by direct regioselective displacement of 4-chloro under basic conditions or by Suzuki coupling. Where necessary, the aryl group was constructed from vinyl butyl ether intermediate <b>B</b>, which in turn was synthesized from the 4-chloro-pyrimidine via Heck coupling. Subsequent cyclization reactions afforded aryl pyrimidines <b>C</b>.</div><div class="NLM_p">The aniline addition to 2-chloropyrimidines <b>C</b> was achieved via Buchwald–Hartwig coupling with substituted anilines or by acid-catalyzed S<sub>N</sub>Ar reaction, typically by heating with <i>p</i>-TSA in 2-pentanol. For compounds where R<sub>3</sub> = H, commercial 5-nitro-2-methoxy-aniline was used. Where R<sub>3</sub> = F, the aniline was not commercially available and was synthesized by nitration of 2-methoxy-4-fluoro-aniline prior to use. Amine substitution of the fluorine by S<sub>N</sub>Ar proceeded in fair to good yield by heating with either an excess of the amine or using DIPEA as base. Subsequent reduction of the nitro group and reaction with acryloyl chloride (R<sub>4</sub> = H) or HATU coupling with commercial (<i>E</i>)-4-(dimethylamino)but-2-enoic acid yielded test compounds <b>F</b> in moderate yield.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Novel Compounds from This Manuscript Synthesized Using Scheme <a class="ref internalNav" href="#sch1" aria-label="1">1</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0016.gif" alt="" id="fx20" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0017.gif" alt="" id="fx21" /></img><div></div></div><div class="NLM_p">For compound 7, which does not contain an acrylamide, the anilino substituent could be installed fully elaborated. This portion was constructed from commercial starting materials, as detailed in Scheme <a class="ref internalNav" href="#sch2" aria-label="2">2</a>.</div><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Intermediate for Compound <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 1-Acetyl piperazine (1.2 equiv), DIPEA (1 equiv), DMA, 90 °C, 18 h, 90%. (ii) Platinum oxide (5 mol %), EtOH, hydrogen (1.3 bar), 3 h, 99%. (iii) Acetic anhydride (6.6 equiv), acetic acid (4.5 equiv), 1 h, 73%.</p></p></figure><div class="NLM_p last">The full synthesis and characterization of the novel compounds within this manuscript is detailed in the <a class="ref internalNav" href="#sec4" aria-label="Experimental Section">Experimental Section</a> (key compounds <b>7</b>, <b>9</b>, <b>15</b>, and <b>58</b>) and in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a> for the remaining examples.</div></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i7" class="anchor-spacer"></div><h3 class="article-section__title" id="_i7"> Activity Profile of Published EGFR Inhibitors</h3><div class="NLM_p">We measured the cellular activity of a number of known inhibitors against the different forms of EGFR (Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a>) using phosphorylation end points. These included the wild-type enzyme (WT) with a human LoVo cell line and the exon 19 deletion activating mutation (AM) using a PC9 cell line. Activity against the L858R/T790M double-mutant enzyme (DM) was measured using a NCI-H1975 cell line. Although much of this data set was already in the public domain from a number of different groups, it was useful to measure their activities in consistent assays to allow an accurate comparison of their profile across the mutants.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Cellular Activity Profile of Published EGFR Inhibitors against the Double Mutant (DM), Activating Mutant (AM), and Wild-Type (WT) Enzymes<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">DM cell (μM)</th><th class="colsep0 rowsep0" align="center">AM cell (μM)</th><th class="colsep0 rowsep0" align="center">WT cell (μM)</th><th class="colsep0 rowsep0" align="center">DM/WT margin</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gefitinib (<b>1</b>)</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">0.0087</td><td class="colsep0 rowsep0" align="left">0.062</td><td class="colsep0 rowsep0" align="left">0.02</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Erlotinib (<b>2</b>)</td><td class="colsep0 rowsep0" align="left">7.6</td><td class="colsep0 rowsep0" align="left">0.0059</td><td class="colsep0 rowsep0" align="left">0.077</td><td class="colsep0 rowsep0" align="left">0.01</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Afatinib (<b>3</b>)</td><td class="colsep0 rowsep0" align="left">0.023</td><td class="colsep0 rowsep0" align="left">0.00057</td><td class="colsep0 rowsep0" align="left">0.012</td><td class="colsep0 rowsep0" align="left">0.53</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Dacomitinib (<b>5</b>)</td><td class="colsep0 rowsep0" align="left">0.042</td><td class="colsep0 rowsep0" align="left">0.00063</td><td class="colsep0 rowsep0" align="left">0.011</td><td class="colsep0 rowsep0" align="left">0.27</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">WZ-4002 (<b>6</b>)</td><td class="colsep0 rowsep0" align="left">0.023</td><td class="colsep0 rowsep0" align="left">0.044</td><td class="colsep0 rowsep0" align="left">1.18</td><td class="colsep0 rowsep0" align="left">51</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">Activity data in this manuscript are quoted as the geometric mean IC<sub>50</sub> of at least three independent measurements. The DM/WT margin is calculated by dividing the mean wild-type IC<sub>50</sub> by the mean double-mutant IC<sub>50</sub>.</p></div></div></div><div class="NLM_p last">As expected, gefitinib and erlotinib were shown to be active against wild-type EGFR and to have a greater activity against the activating mutant but significantly reduced cellular activity against double-mutant EGFR (3.3 and 7.6 μM, respectively). Afatinib (<b>3</b>) and dacomitinib (<b>5</b>) have increased activity against wild-type and activating-mutant EGFR along with increased activity against the double mutant compared to gefitinib and erlotinib. However, the potency of these compounds against the double mutant is lower than the potency against wild-type EGFR (i.e., double mutant to wild-type margin of <1). WZ-4002 (<b>6</b>) is more active against the double-mutant enzyme and maintains activity against the activating mutant but with a margin over the wild-type enzyme broadly consistent with the published data.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(24)</a></div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9"> Identification of Double-Mutant-Selective Templates</h3><div class="NLM_p">To identify mutant-selective templates, a set of compounds was selected and tested against the EGFR wild-type and double-mutant enzymes using biochemical assays at an external CRO<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(25)</a> (Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a>). This compound set included some reversible EGFR inhibitors from our compound collection (red) along with a selection of published irreversible EGFR inhibitors (yellow) for reference. Additional examples of compounds from our collection were added that have shown activity against kinases with methionine gatekeepers during previous AstraZeneca drug-discovery projects (blue). The reversible EGFR inhibitors showed increased activity against the wild-type enzyme when compared to the double mutant, consistent with the described activity profiles of gefitinib and erlotinib. The irreversible anilinoquinazoline-based EGFR inhibitors (including <b>3</b>, <b>4</b>, and <b>5</b>) showed significant activity in both assays, consistent with an increase in activity from the formation of the covalent bond. Note that it is difficult to accurately compare the relative potencies of the reversible versus irreversible compounds in these assays because of their different mechanism of action, with irreversible inhibitors often demonstrating time-dependent inhibition.<a onclick="showRef(event, 'ref27 ref28'); return false;" href="javascript:void(0);" class="ref ref27 ref28">(26, 27)</a> However, the set of compounds that was of particular interest were the examples from internal AstraZeneca projects that had shown activity against kinases with a methionine gatekeeper.</div><figure id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EGFR wild-type (WT) and T790M/L858R (DM) biochemical inhibition data on a probe set of compounds. Red points show reversible EGFR inhibitors, yellow points show covalent EGFR inhibitors, and blue points show selected compounds from internal AstraZeneca projects. Compound activity is expressed as a pIC<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, these compounds were active against double-mutant EGFR with selectivity over wild-type, a common feature of which was a pyrimidine core. A representative example, <b>7</b> (Table <a class="ref showTableEvent internalNav" data-ID="tbl3" href="#tbl3">3</a>), contains an indole headgroup with an IC<sub>50</sub> of 0.009 μM against the double mutant and with an 88-fold selectivity over wild-type EGFR. Although this reversible inhibitor was active in this biochemical double-mutant assay, we observed a large enzyme-to-cell drop-off of around 90-fold when it was tested in our double-mutant cellular assay (IC<sub>50</sub> 0.77 μM), which is likely driven by the high ATP affinity of this enzyme and the high ATP concentration present in the cellular environment.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(28)</a> Therefore, we aimed to convert compound <b>7</b> into a covalent inhibitor to partially overcome the effect of the increased affinity of ATP for the mutant kinase while hoping to maintain the intrinsic selectivity over the wild-type enzyme.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. Identified Double-Mutant (DM)-Selective Reversible EGFR Enhibitor</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0018.gif" alt="" id="fx22" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">DM enzyme (μM)</th><th class="colsep0 rowsep0" align="center">WT enzyme (μM)</th><th class="colsep0 rowsep0" align="center">DM/WT selectivity</th><th class="colsep0 rowsep0" align="center">DM cell (μM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>7</b></td><td class="colsep0 rowsep0" align="center">0.009</td><td class="colsep0 rowsep0" align="center">0.79</td><td class="colsep0 rowsep0" align="center">88</td><td class="colsep0 rowsep0" align="center">0.77</td></tr></tbody></table></div></div></div><div id="sec2_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11"> Structure-Based Design Targeting Cys-797</h3><div class="NLM_p">A predicted binding mode of compound <b>7</b> was modeled using GLIDE,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(29)</a> utilizing a public domain crystal structure of the EGFR-T790M mutation (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT">2JIT</a><a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a>) following protocols detailed in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>. Although this structure does not contain an activating mutation, we hoped that it would be adequate for the modeling of potential binding modes that we could exploit by structure-based design.</div><div class="NLM_p">Of the various potential binding modes suggested by the modeling, we decided to progress with the hypothesis that the pyrimidine core of the molecule formed a hydrogen bond to the kinase hinge, specifically to the backbone of Met-793 (Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>). In this binding mode, the chlorine substituent is directed toward the methionine gatekeeper. The indole group is positioned adjacent to the region of the kinase referred to as the back pocket. The anilino group of the inhibitor is oriented toward the solvent channel of the ATP pocket and was predicted to form an additional hydrogen bond to the hinge. Assuming this modeled binding mode, we attempted to design compounds with a reactive substituent positioned in a manner that would enable targeting Cys-797 via the formation of a covalent bond. The meta position of the aniline appeared to be the most suitable location, and such examples were prioritized. A range of different substituents were modeled to estimate their potential to target Cys-797, and from this work we decided to incorporate an acrylamide-based side chain. A particular example of interest was compound <b>8</b>, which showed improved cellular activity in the activating- and double-mutant cell assays with selectivity over wild-type (Table <a class="ref showTableEvent internalNav" data-ID="tbl4" href="#tbl4">4</a>).</div><figure id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modeled binding mode of compound <b>7</b> in a published EGFR crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT">2JIT</a>) that contains a T790M mutation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. Activity Data for Synthesized Inhibitors Targeting Cys-797 Using the Acrylamide Functionality</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0019.gif" alt="" id="fx23" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">DM enzyme (μM)</th><th class="colsep0 rowsep0" align="center">AM cell (μM)</th><th class="colsep0 rowsep0" align="center">DM cell (μM)</th><th class="colsep0 rowsep0" align="center">WT cell (μM)</th><th class="colsep0 rowsep0" align="center">DM/WT selectivity</th><th class="colsep0 rowsep0" align="center">LogD<sub>7.4</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.053</td><td class="colsep0 rowsep0" align="left">0.27</td><td class="colsep0 rowsep0" align="left">0.081</td><td class="colsep0 rowsep0" align="left">3.5</td><td class="colsep0 rowsep0" align="left">43</td><td class="colsep0 rowsep0" align="left">>4.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">OMe</td><td class="colsep0 rowsep0" align="left">0.0063</td><td class="colsep0 rowsep0" align="left">0.029</td><td class="colsep0 rowsep0" align="left">0.022</td><td class="colsep0 rowsep0" align="left">0.55</td><td class="colsep0 rowsep0" align="left">25</td><td class="colsep0 rowsep0" align="left">>4.3</td></tr></tbody></table></div></div><div class="NLM_p">From a set of further analogues synthesized, an example with an ortho-methoxy group at R<sub>1</sub> (compound <b>9</b>) showed increased biochemical and cellular activity. Further examples were synthesized with the acrylamide attached to different regions of the molecule. Interestingly, moving the acrylamide to the para position (compound <b>10</b>), which is also likely to be positioned near Cys-797, appears not to result in covalent inhibition (Table <a class="ref showTableEvent internalNav" data-ID="tbl5" href="#tbl5">5</a>). Compound <b>10</b> showed only moderate activity in the double-mutant biochemical assay (0.3 μM) and minimal activity in cellular assays. The acrylamide was also appended to a dihydroindole ring; however, this compound (<b>11</b>) was less potent in the double-mutant assays (0.052 and 2.1 μM vs enzyme and cell, respectively). Furthermore, nitrile-based compound <b>12</b> was synthesized in an attempt to form a reversible covalent interaction resulting in a thioimidate adduct, as precedented in cysteine and serine protease inhibitors.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(30)</a> Although this compound was active in the double-mutant biochemical assay (IC<sub>50</sub> 0.065 μM), <b>12</b> showed minimal cellular activity (IC<sub>50</sub> 2.8 μM), suggesting that this functional group was perhaps not suitable for the cysteine in EGFR or that a suitable geometry had not been achieved for the covalent bond to form.</div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Activity Data for Synthesized Compounds Exploring SAR around the Covalent Bond Interaction</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0020.gif" alt="" id="fx24" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0021.gif" alt="" id="fx25" /></img><div></div></div><div class="NLM_p">To gain further confidence that our early compounds would be able to form the desired covalent bond, <b>9</b> was prioritized for crystallization in an EGFR wild-type structural system, which was available via an external CRO.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(31)</a> The binding mode of compound <b>9</b> was subsequently solved (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LI5">4LI5</a>), as shown in Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a>, demonstrating that a covalent bond was formed to Cys-797. In this case, the binding mode of this template in the EGFR receptor was consistent with the binding mode found in our earlier modeling work.</div><figure id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Protein crystal structure of compound <b>9</b> bound in wild-type EGFR. The described covalent bond to Cys-797 is shown (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LI5">4LI5</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Focus on Reducing Lipophilicity</h3><div class="NLM_p">One of the key issues with our initial compounds described above was their high lipophilicity (LogD<sub>7.4</sub> >4.3). This level of lipophilicity can often translate into poor physicochemical properties and pharmacokinetics (PK), hindering later development.<a onclick="showRef(event, 'ref33 ref34'); return false;" href="javascript:void(0);" class="ref ref33 ref34">(32, 33)</a> We were also keen to ensure low activity against the hERG potassium ion channel. A key aim of the evolution of this series was therefore to reduce the overall lipophilicity, indicated in subsequent tables by the experimental LogD<sub>7.4</sub> measurements, while retaining the existing levels of EGFR potency and the favorable selectivity profile. The activity and wild-type selectivity of subsequent compounds was monitored using in-house cellular assays. We no longer routinely measured the biochemical activity of our compounds.</div><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Activity and Lipophilicity Data for Compounds Targeting an Improved Physicochemical Property Space</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0022.gif" alt="" id="fx26" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0023.gif" alt="" id="fx27" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>Table a</sup><p class="last">LLE (DM) = pIC<sub>50</sub> DM (cell) − LogD<sub>7.4</sub>.</p></div></div><div></div></div><div class="NLM_p last">To improve the physical properties of compounds within this series, we decided to modify what we referred to as the head group. In addition, we decided to assess the effect of the addition of a basic group to the acrylamide (Table <a class="ref showTableEvent internalNav" data-ID="tbl6" href="#tbl6">6</a>). Out of these head groups, the pyrollopyridine system (compound <b>13</b>) was especially interesting, maintaining reasonable potency in our double- and activating-mutant cell assays (IC<sub>50</sub> 0.033 and 0.15 μM) but with an improved margin to wild-type EGFR (390-fold). Furthermore, the basic acrylamide-based side chains of template B (examples <b>14</b> and <b>15</b>), although showing a small decrease in activity of 2 to 3 fold compared to the neutral equivalents, did show a marked reduction in LogD<sub>7.4</sub> to a level at which meaningful experimental values could be measured. On the basis of the overall potency, selectivity, and physical property profile of <b>15</b>, this compound was selected as a key in vivo probe compound for this template. These compounds also began to populate a more favorable area of physicochemical property space, with a LLE (ligand lipophilicity efficiency) of 3.4 for example <b>15</b> using the double-mutant cell assay and experimental LogD<sub>7.4</sub>.</div></div><div id="sec2_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Investigating the Effect on 5-Position Substituents on the Pyrimidine</h3><div class="NLM_p">The 5-position of our template was predicted by our modeling to be positioned adjacent to the gatekeeper residue, so we thought that varying this position may have some interesting effects on the potency and selectivity of compounds within our series. Our initial hit contained chlorine in this position, which is relatively lipophilic; therefore, varying this group offered the potential for compound lipophilicity to be reduced.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(34)</a> A range of 5-substituted compounds was subsequently prepared and assessed across our in-house cellular assays (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>).</div><div class="NLM_table-wrap" id="tbl7"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 7. Activity and Lipophilicity Data of Compounds Exploring the Effect of the 5-Substituent Position (R<sub>1</sub>) on the Pyrimidine</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0024.gif" alt="" id="fx28" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">AM cell (μM)</th><th class="colsep0 rowsep0" align="center">DM cell (μM)</th><th class="colsep0 rowsep0" align="center">WT cell (μM)</th><th class="colsep0 rowsep0" align="center">DM/WT selectivity</th><th class="colsep0 rowsep0" align="center">LogD<sub>7.4</sub></th><th class="colsep0 rowsep0" align="center">LLE (DM)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">0.40</td><td class="colsep0 rowsep0" align="left">0.096</td><td class="colsep0 rowsep0" align="left">23</td><td class="colsep0 rowsep0" align="left">237</td><td class="colsep0 rowsep0" align="left">3.6</td><td class="colsep0 rowsep0" align="left">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.39</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">20</td><td class="colsep0 rowsep0" align="left">80</td><td class="colsep0 rowsep0" align="left">2.6</td><td class="colsep0 rowsep0" align="left">4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">0.38</td><td class="colsep0 rowsep0" align="left">0.22</td><td class="colsep0 rowsep0" align="left">19</td><td class="colsep0 rowsep0" align="left">85</td><td class="colsep0 rowsep0" align="left">3.3</td><td class="colsep0 rowsep0" align="left">3.4</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>18</b></td><td class="colsep0 rowsep0" align="left">Me</td><td class="colsep0 rowsep0" align="left">0.25</td><td class="colsep0 rowsep0" align="left">0.29</td><td class="colsep0 rowsep0" align="left">24</td><td class="colsep0 rowsep0" align="left">82</td><td class="colsep0 rowsep0" align="left">3</td><td class="colsep0 rowsep0" align="left">3.5</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>19</b></td><td class="colsep0 rowsep0" align="left">S(=O)Me</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">15.2</td><td class="colsep0 rowsep0" align="left">>30</td><td class="colsep0 rowsep0" align="left">>2</td><td class="colsep0 rowsep0" align="left">1.3</td><td class="colsep0 rowsep0" align="left">3.5</td></tr></tbody></table></div></div><div class="NLM_p last">The range of R<sub>1</sub> substituents that we investigated varied in both size and lipophilicity. Although potency varied across the double-mutant cell assay, the LLE (using the double-mutant cell data) remained constant at around 3.4 to 3.5 except for R<sub>1</sub>═H where it was increased to 4. This was an interesting result because removing the chlorine of compound <b>15</b> (giving compound <b>16</b>) reduced LogD<sub>7.4</sub> by an order of magnitude (3.6 compared to 2.6) and might allow the physicochemical properties of this series to be improved further. Although the double-mutant activity was reduced for compound <b>16</b>, compared to <b>15</b> (0.25 vs 0.096 μM) the activity against the activating-mutant form was unchanged (0.39 vs 0.40 μM). The double-mutant selectivity of <b>16</b> was reduced to 80-fold, from 237-fold, for compound <b>15</b>, potentially resulting from chlorine interacting more effectively with the methionine gatekeeper residue. However, our collective data on these compounds suggested that it might be possible to achieve reasonable potency in the EGFR double and activating mutants while leveraging the selectivity over wild-type without a chlorine in the 5-position. We postulated that removing the chlorine might improve the physicochemical properties via the reduction in overall lipophilicity of these molecules.</div></div><div id="sec2_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> Modulating Compound Reactivity</h3><div class="NLM_p">The potency of covalent inhibitors is influenced by both the reversible binding properties of the compound to the protein (<i>K</i><sub>i</sub>) and the ability of the compounds to covalently bind to a suitable residue in the active site (<i>k</i><sub>inact</sub>). As such, it is important to aim for compounds of sufficient chemical reactivity toward an active-site residue (in this example cysteine) while balancing against unwanted off-target binding that could lead to high compound clearance and or idiosyncratic toxicity.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(35)</a> One method of optimizing covalent compounds in this way is through the measurement of the <i>k</i><sub>inact</sub>/<i>K</i><sub>i</sub> values for compounds within a series. This approach, however, proved technically challenging using our assays, so we were unable to exploit it for driving SAR routinely.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(26)</a> Our alternative approach was to establish a suitable ‘reactivity window’ for our compounds and to develop an understanding of how to synthesize compounds that were more likely to fall within the intended range. As a measure of thiol reactivity, we have used an assay based on determining the second-order rate constant (<i>k</i><sub>GSH</sub>) for the reaction of our compounds with glutathione (GSH).<a onclick="showRef(event, 'ref37 ref38 ref39'); return false;" href="javascript:void(0);" class="ref ref37 ref38 ref39">(36-38)</a></div><div class="NLM_table-wrap" id="tbl8"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 8. Glutathione (GSH) Reactivity of 6-Membered Ring Aromatic Model Compounds<a class="ref internalNav" href="#tbl8-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0025.gif" alt="" id="fx29" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">GSH <i>t</i><sub>1/2</sub> (min)</th><th class="colsep0 rowsep0" align="center">Log <i>k</i><sub>GSH</sub>* (M<sup>-1</sup> s<sup>-1</sup>)</th><th class="colsep0 rowsep0" align="center">R<sub>1</sub></th><th class="colsep0 rowsep0" align="center">R<sub>2</sub></th><th class="colsep0 rowsep0" align="center">R<sub>3</sub></th><th class="colsep0 rowsep0" align="center">R<sub>4</sub></th><th class="colsep0 rowsep0" align="center">R<sub>5</sub></th><th class="colsep0 rowsep0" align="center">R<sub>1</sub> σ<sub>meta</sub></th><th class="colsep0 rowsep0" align="center">R<sub>1</sub> σ<sub>I</sub></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>20</b></td><td class="colsep0 rowsep0" align="left">816</td><td class="colsep0 rowsep0" align="left">–2.51</td><td class="colsep0 rowsep0" align="left">4-aminophenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">–0.006</td><td class="colsep0 rowsep0" align="left">0.052</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>21</b></td><td class="colsep0 rowsep0" align="left">323</td><td class="colsep0 rowsep0" align="left">–2.11</td><td class="colsep0 rowsep0" align="left">4-fluorophenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.12</td><td class="colsep0 rowsep0" align="left">0.13</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>22</b></td><td class="colsep0 rowsep0" align="left">2940</td><td class="colsep0 rowsep0" align="left">–3.07</td><td class="colsep0 rowsep0" align="left">benzyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">–0.08</td><td class="colsep0 rowsep0" align="left">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23</b></td><td class="colsep0 rowsep0" align="left">436</td><td class="colsep0 rowsep0" align="left">–2.24</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>24</b></td><td class="colsep0 rowsep0" align="left">299</td><td class="colsep0 rowsep0" align="left">–2.08</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>25</b></td><td class="colsep0 rowsep0" align="left">428</td><td class="colsep0 rowsep0" align="left">–2.23</td><td class="colsep0 rowsep0" align="left">2-methylphenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.07</td><td class="colsep0 rowsep0" align="left">0.119</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>26</b></td><td class="colsep0 rowsep0" align="left">524</td><td class="colsep0 rowsep0" align="left">–2.32</td><td class="colsep0 rowsep0" align="left">4-methoxyphenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.05</td><td class="colsep0 rowsep0" align="left">0.11</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>27</b></td><td class="colsep0 rowsep0" align="left">37.2</td><td class="colsep0 rowsep0" align="left">–1.17</td><td class="colsep0 rowsep0" align="left">2-cyanophenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.18</td><td class="colsep0 rowsep0" align="left">0.194</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>28</b></td><td class="colsep0 rowsep0" align="left">145</td><td class="colsep0 rowsep0" align="left">–1.76</td><td class="colsep0 rowsep0" align="left">3-fluorophenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.15</td><td class="colsep0 rowsep0" align="left">0.16</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>29</b></td><td class="colsep0 rowsep0" align="left">361</td><td class="colsep0 rowsep0" align="left">–2.16</td><td class="colsep0 rowsep0" align="left">4-methylphenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>30</b></td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="left">–0.94</td><td class="colsep0 rowsep0" align="left">2-pyridyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.33</td><td class="colsep0 rowsep0" align="left">0.25</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>31</b></td><td class="colsep0 rowsep0" align="left">32.9</td><td class="colsep0 rowsep0" align="left">–1.12</td><td class="colsep0 rowsep0" align="left">4-cyanophenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.221</td><td class="colsep0 rowsep0" align="left">0.175</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>32</b></td><td class="colsep0 rowsep0" align="left">>8640</td><td class="colsep0 rowsep0" align="left">< −3.54</td><td class="colsep0 rowsep0" align="left">tert-butyl-phenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">–0.043</td><td class="colsep0 rowsep0" align="left">0.05</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>33</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">< −3.60</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">< −3.60</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>35</b></td><td class="colsep0 rowsep0" align="left">>10 000</td><td class="colsep0 rowsep0" align="left">< −3.60</td><td class="colsep0 rowsep0" align="left">phenyl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">C</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">0.06</td><td class="colsep0 rowsep0" align="left">0.12</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl8-fn1"><div class="footnote" id="tbl8-fn1"><sup>a</sup><p class="last">The full list of the explicit structures for compounds in this table can be found in <a class="ref internalNav" href="#notes-2" aria-label="Table S1">Table S1</a> of the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>. Note that the rate constant, <i>k</i>, was derived using [GSH] 4.61 mM. σ values were determined using ACD/Laboratories software (version 12.01). All compounds with an absolute rate constant showed a more polar product peak of mass parent +307 except for example <b>22</b> where no products were observed (reflecting a much slower reaction compared to other compounds coupled to the detection limits of LC–MS).</p></div></div></div><div class="NLM_p">To determine the structural and electronic features that influenced the chemical reactivity of our compounds, a set of six-membered aromatic ring acrylamide-containing models were initially investigated in the glutathione assay (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). These model acrylamides have relatively good aqueous solubility and thus we avoid any complication of reaction kinetics that might have arisen because of precipitation issues. All compounds investigated were stable in phosphate buffer alone at pH 7.4. In the presence of glutathione, a simple addition reaction (Scheme <a class="ref internalNav" href="#sch3" aria-label="3">3</a>) was observed, generating the more polar glutathione adduct, which is seen by liquid chromatography–mass spectrometry (LC–MS) as a mass increase of 307 units.</div><figure id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Addition Reaction of Model Compounds with Glutathione</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">The Hammett plots in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> enable a quantitative understanding of the relationship between the electronic effects exerted through the R<sub>1</sub> position of the acrylamide, expressed as σ values, and glutathione reactivity. Consequently, this knowledge can be applied to design elaborated compounds that sit in the desired reactivity window using appropriate R<sub>1</sub> σ values. From our results set, the rate of the reaction appeared to be dependent on the electron-withdrawing ability of groups in the R<sub>1</sub> position (Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a>) of the acrylamide. In particular, the inductive effect of the R<sub>1</sub> group (represented either as σ<sub>meta</sub> or σ<sub>ind</sub>) was seen to determine thiol reactivity with ρ values of 5.56 and 9.23, respectively. The addition of further electronic descriptors such as σ<sub>para</sub> or σ<sub>meso</sub> to the Hammett equations (<b>1</b>) and (<b>2</b>) in Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a> did not appear to be significant. Such inductive electron withdrawal at the R<sub>1</sub> position would be consistent with enhanced polarization of the alkene bond via carbonyl conjugation and also serves to stabilize the enolic transition state. The introduction of methyl groups onto either the α or β carbon of the model acrylamides (R<sub>3</sub> and R<sub>4</sub>) resulted in no reaction being observed with glutathione, ruling out these substituents as options on elaborated compounds. A similar decrease in thiol reactivity following methylation at the α and β carbon has been observed by other workers in their investigations with α,β-unsaturated aldehydes, ketones, esters, acids, and amides.<a onclick="showRef(event, 'ref40 ref41 ref42 ref43'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42 ref43">(39-42)</a> Engels et al. calculated via quantum mechanical/molecular modeling (QM/MM) an increased energy barrier to methyl thiolate attack on α,β-unsaturated phenyl ketones with an elevated energy of the enolate intermediate upon methylation at the α and β positions, suggesting steric effects as a possible reason for such a reactivity change.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(41)</a> Although other workers have similarly suggested steric effects as an explanation for decreased reactivity for α and β methylation,<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(39)</a> Kerske et al. argue that reactant stabilization by hyperconjugation of α and β methyls and not steric hindrance is the reason for the lowered reactivity.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(42)</a></div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Hammett plot of σ<sub>meta</sub> and σ<sub>ind</sub> properties versus compound reactivity (Log <i>k</i><sub>GSH</sub>) across the model compound set.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a> captures the glutathione reactivity constant data of more elaborated compounds. This compound set consists of examples containing pyrimidine, anilinoquinazoline, and anilinoquinoline scaffolds. To increase the diversity of the structures within this data set, we have also included examples from an additional template we identified on the basis of a <i>bis-</i>anilino-pyrimidine scaffold, some examples from which have since been disclosed in the literature.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(43)</a></div><div class="NLM_table-wrap" id="tbl9"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 9. Glutathione (GSH) Reactivity Data of Elaborated Acrylamide-Containing Compounds<a class="ref internalNav" href="#tbl9-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0026.gif" alt="" id="fx30" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0027.gif" alt="" id="fx31" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl9-fn1"><div class="footnote" id="tbl9-fn1"><sup>Table a</sup><p class="last">The full list of the explicit structures for compounds in this table can be found in <a class="ref internalNav" href="#notes-2" aria-label="Table S2">Table S2</a> of the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>. *R<sub>1</sub> σ<sub>meta</sub> is defined in the scheme in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a> and all other substituents are defined in the figure above.</p></div></div><div></div></div><div class="NLM_p">With the more diverse elaborated compounds (Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>), the dependence of reactivity on the inductive effect at R<sub>1</sub> as expressed by R<sub>1</sub> σ<sub>meta</sub> is observed across a variety of R<sub>1</sub> templates and fits the same Hammett line as seen with the model systems. This suggests that the learning from our model systems can be applied to more leadlike molecules.</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Reactivity data for elaborated acrylamide compounds overlaid onto Log <i>k</i><sub>GSH</sub> versus σ<sub>meta</sub> Hammett plot for model systems. Data on the model-system compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>) are shown in red and elaborated compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>) are shown in green. The data is further classified by a selection of the β substituents (R<sub>1</sub>′) defined in Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a> (not defined for compounds <b>47</b> and <b>48</b> because of a lack of observed reactivity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Looking across the anilinopyrimidine-containing compounds (core i, Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>), there is a consistent drop in reactivity of 0.43 in Log <i>k</i><sub>GSH</sub> (factor 2.7) on substituting hydrogen for methoxy in the R<sub>4</sub>′ position of the aniline (matched pairs <b>36</b>/<b>14</b> and <b>43</b>/<b>44</b>). In contrast, varying the substituent at R<sub>5</sub>′ (cyano, methyl, hydrogen, and chlorine) on the pyrimidine had no significant effect on reaction rate, with the largest difference in Log <i>k</i><sub>GSH</sub> being 0.13 (factor 1.3). This is consistent with the increased distance of R<sub>5</sub>′ from the acrylamide group, thereby exerting minimal electronic effect. Similarly, varying the R<sub>4</sub>′ position in the quinoline series (core iv, examples <b>53</b> and <b>54</b>) produced no significant effect on the reaction rate. There are, however, clear outliers on the Hammett plot in Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>. Compound <b>46</b> shows a significantly faster reaction than was expected from an R<sub>1</sub> inductive effect alone. Analysis of the reaction products of <b>46</b> using LC–MS indicates the substitution of the morpholine group for glutathione (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>). The increased reaction rate is believed to be due to intramolecular base catalysis by the α-morpholine group, which is able to form a six-membered hydrogen-bond ring in the transition state, facilitating nucleophilic attack. Two mechanisms can be postulated to occur, namely, a two step addition/elimination with the morpholine stabilizing the enolate transition state (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>a) or a concerted reaction where the morpholine base activates the glutathione by removal of a proton (Scheme <a class="ref internalNav" href="#sch4" aria-label="4">4</a>b). Identifying which of these mechanisms is dominant is not clear on the basis of the present data. In work by Tsou et al. that looked at quinazoline acrylamides, the activation of glutathione by α-morpholine has been proposed as a mechanism to explain the observed reactivity in a competition assay in THF/H<sub>2</sub>O/Methanol.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(44)</a></div><figure id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Postulated Mechanisms for the Nucleophilic Substitution Reaction Observed for Compound <b>46</b> with Glutathione</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>41</b> (core ii) also appeared to react more quickly than expected from the σ<sub>meta</sub> value. The reason for this is unclear, but the reaction represents the only example in this data set involving a five-membered heterocyclic substituent attached to the acrylamide. Also of interest was <b>38</b>, which proved to be highly unstable in pH 7.4 buffer alone. The introduction of the dimethylaminobenzyl group into the acrylamide phenyl ring facilitated rapid intramolecular attack by the amine to form a stable cyclic quaternary ion (Scheme <a class="ref internalNav" href="#sch5" aria-label="5">5</a> and <a class="ref internalNav" href="#notes-2" aria-label="Figure S1">Figure S1</a>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>).</div><figure id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0015.jpeg" id="gr15" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Proposed Intramolecular Reaction of Compound <b>38</b> in Buffer at pH 7.4<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Formation of cyclic quaternary confirmed by MSMS <i>m</i>/<i>z</i> = 478.18.</p></p></figure><div class="NLM_p">Substitution at the acrylamide α and β positions, R<sub>1</sub>′ and R<sub>2</sub>′, with a cyclic piperidine (<b>47</b> and <b>48</b>, Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a>) resulted in no measurable reaction with glutathione. This indicates that the electronic activation afforded by the electron-withdrawing partially protonated amine groups (<i>p</i>K<sub>a</sub> of 7.9 and 7.4, respectively) toward the α and β carbons is insufficient to overcome the steric barrier from the ring.</div><figure id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Novel compounds reported in this manuscript containing alpha substitutions (R<sub>2</sub>′).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Interestingly, other workers have shown that the introduction of electron-withdrawing groups cyano and hydroxyl at the α and β positions of alkenals and acrylates affords an enhanced reaction rate with thiols.<a onclick="showRef(event, 'ref40 ref46'); return false;" href="javascript:void(0);" class="ref ref40 ref46">(39, 45)</a> When the dimethyl amine group is introduced as a pendant substituent at the β-carbon in <b>15</b> (p<i>K</i><sub>a</sub> 7.8), a measurable reaction with glutathione is observed (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>). Unfortunately, the matched pair compound of <b>15</b> without the pendant amine group was too insoluble to measure a glutathione reaction constant, but the matched pair of <b>44</b> and <b>45</b> reveals that the pendant amine group does not offer a significant enhancement of the reaction rate over the unsubstituted compound (factor of 2). This is borne out by Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a>, where compounds with (+) and without (open squares) a pendant base (β substituent R<sub>1</sub>′) both sit on the same Hammett equation line. Significantly enhanced reactivity resulting from the pendant base (+) would have been seen as points sitting above the line. Because an electronically significant difference would not be expected in terms of the amine-group activation of the β carbon between <b>15</b> and <b>48</b>, this suggests that the unconstrained pendant base in <b>15</b> offers less steric resistance to glutathione attack than <b>48</b>. The unconstrained β-pendant base in <b>15</b> would also be expected to more readily able to undertake intramolecular base catalysis than <b>48</b>, but no significantly enhanced reaction rate is observed. This contrasts with earlier studies by Tsou et al. who showed a significant enhancement when a β-pendant base was added to quinazoline acrylamides in a competition assay.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(44)</a> It is suggested that this difference may be due to solvent effects.</div><div class="NLM_p">Alternative thiol reactive groups to acrylamides, namely, acetylenes and ethene sulphonamides have also been investigated in the glutathione assay (<b>49</b>, <b>50</b>, <b>51</b>, and <b>52</b>, shown in Table <a class="ref showTableEvent internalNav" data-ID="tbl10" href="#tbl10">10</a>).</div><div class="NLM_table-wrap" id="tbl10"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 10. Selection of Alternative Covalent Modifying Groups to Acrylamide Synthesized as Part of This Work<a class="ref internalNav" href="#tbl10-fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0028.gif" alt="" id="fx32" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-tbl10-fn1"><div class="footnote" id="tbl10-fn1"><sup>Table a</sup><p class="last">The R<sub>1</sub> substituent is defined in Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>.</p></div></div><div></div></div><div class="NLM_p">Comparing the matched pairs <b>44</b>/<b>51</b> and <b>42</b>/<b>52</b> indicates that both acetylenes and ethene sulphonamide groups are significantly more reactive to glutathione than acrylamides (26.4 and 26.9 times more reactive, respectively). Interestingly, when a pendant dimethyl amine base is added to the acetylene group in <b>49</b>, the compound is >58.7 times more reactive than the acrylamide matched pair <b>15</b>, suggesting that the basic group has a significant activating effect not observed with acrylamides. This is also supported by a comparison of <b>49</b> with <b>51</b>, which both share the same R<sub>1</sub> σ<sub>meta</sub>/σ<sub>I</sub> values but show >5.8 fold difference in glutathione reactivity when the pendant base is added to the acetylene. <b>52</b> also shares the same σ<sub>meta</sub>/σ<sub>I</sub> values as <b>49</b> and <b>51</b>, indicating that the ethene sulphonamide group has comparable glutathione reactivity to the acetylene group (cf. <b>51</b>). As with the acrylamides, the substitution of a methyl group at the β position of the acetylene (<b>50</b>) deactivates the acetylene to thiol reaction. Comparing compound <b>50</b> to acrylamide <b>55</b>, which share the same R<sub>1</sub> σ<sub>meta</sub>/σ<sub>I</sub> values (differing in their R<sub>1</sub> structure by a distal Br for Me change on aniline R<sub>3</sub> substituent), shows that the methyl acetylene is 2.6 times less reactive to glutathione than the acrylamide.</div><div class="NLM_p">A selection of compounds from both the model and elaborated series covering a range of reactivities with glutathione were also studied in the presence of the human glutathione-S-transferase enzyme (<a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>, <a class="ref internalNav" href="#notes-2" aria-label="Table S3">Table S3</a>). This revealed that the glutathione reaction was not catalyzed by the glutathione-S-transferase enzyme.</div><div class="NLM_p">In seeking to define a suitable ‘reactivity window’, the elaborated compounds studied for glutathione reactivity were simultaneously analyzed in the double-mutant cell assay. Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a> reveals the relationship between the target potency and glutathione reactivity for the data set discussed in this section. As we hoped, there is not a strong correlation because the initial target noncovalent binding (<i>K</i><sub>i</sub>) will play a key part in defining potency (<i>R</i><sup>2</sup> 0.52 and RMS 0.53). The noncovalent contribution to the binding is essential for driving the selectivity of these compounds over other proteins with accessible cysteine residues. However, there is a general trend toward more reactive compounds showing increased activity, and compounds with pIC<sub>50</sub> values >7 for the most part tend to have glutathione half-lives <400 min. As such, we took a glutathione half-life of 400 min as a guide for a suitable lower limit of reactivity. Afatinib (<b>3</b>) is currently in phase III clinical studies, and the reported clinical side effects of the compound appear to be linked to the inhibition of wild-type EGFR rather than off-target effects resulting from covalent binding. As such, this seemed to be a good compound to benchmark in our glutathione assay, generating a half-life of 25 min. Therefore, we used a half-life of 25 min as the higher limit to the window of reactivity that we aimed to work within.</div><figure id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound reactivity measured by Log <i>k</i><sub>GSH</sub> (M<sup>–1</sup> s<sup>–1</sup>) plotted against EGFR double-mutant (DM) cellular pIC<sub>50</sub> for the elaborated compounds reported in this manuscript. Dashed lines indicate the ‘reactivity window’ in which the design of novel compounds was subsequently focused.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Further Optimizing of the Lead Series</h3><div class="NLM_p">Our aim was to increase further the potency of our series by exploiting additional interactions with the protein along with the learning from our exploration of compound reactivity. As part of this, we synthesized a set of compounds with a piperazine substituent on the para position of the aniline (Table <a class="ref showTableEvent internalNav" data-ID="tbl11" href="#tbl11">11</a>). We expected that the addition of the piperazine adjacent to the acrylamide would effect the conformation and geometry of both substituents, so we were keen to assess whether this combination was compatible with good potency on our template. We combined this change with the 5-position SAR described in the previous section using both our indole and pyrollopyridine head groups.</div><div class="NLM_table-wrap" id="tbl11"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 11. Activity and Lipophilicity Data on Compounds with the Addition of a Piperazine Group</div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0029.gif" alt="" id="fx33" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0030.gif" alt="" id="fx34" /></img><div></div></div><div class="NLM_p last">The data on this compound set suggests a general improvement in potency with the addition of the piperazine substituent. Compound <b>56</b> is more potent than <b>15</b> in both primary cell assays (0.14 vs 0.4 μM in the activating-mutant and 0.019 vs 0.096 μM in the double-mutant assays), maintaining a good selectivity for the double mutant over wild-type of 620-fold. There is also a small increase in reactivity with glutathione for compound <b>56</b> (<i>t</i><sub>1/2</sub> 188 min) compared to 352 min for compound <b>15</b>, which is consistent with the small increase in electron-withdrawing ability of the group attached to the acrylamide nitrogen (σ<sub>meta</sub> 0.09 compared to σ<sub>meta</sub> 0.07). A number of factors could influence this increase in activity, including the preference for a basic group in this region of the protein, the increased compound reactivity, and the effect on acrylamide geometry. The LLE of these compounds is generally improved, with <b>56</b> showing an increased LLE of 4.1 compared to 3.4 for <b>15</b>. Removal of the chlorine (compound <b>57</b>) showed a reduction in double-mutant cellular activity, 0.071 μM compared to 0.019 μM, but no effect on activating-mutant activity, as observed previously. The transferring of this learning back to the indole head group identified compounds that were significantly more potent against the activating and double mutant. Example <b>58</b> is a particularly potent compound, with an LLE of 4.6. The data on these compounds is also consistent with the early data on this head group, with the indole-containing compounds showing a reduced margin with wild-type EGFR (140-fold and 19-fold for <b>58</b> and <b>59</b>, respectively), albeit with greater absolute double-mutant activity. Whether a more potent EGFR double- and activating-mutant inhibitor with a smaller margin to wild-type is preferable over a less potent inhibitor with a greater margin to wild-type will require further assessment.</div></div><div id="sec2_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> In Vivo Efficacy of Compound <b>15</b></h3><div class="NLM_p">Compound <b>15</b> was identified as a suitable in vivo proof-of-concept compound from our scoping work. To build further confidence in the covalent mechanism of action, the equivalent nonreactive propionamide was synthesized (compound <b>60</b>, <a class="ref internalNav" href="#notes-2" aria-label="Figure S2">Figure S2</a>, <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>), showing a lower double-mutant biochemical activity (0.018 μM) and significantly reduced cellular activity (2.3 μM). Although not the most potent (or wild-type selective) example synthesized, the overall balance of properties identified <b>15</b> as having an acceptable combination of activity and pharmacokinetic (PK) properties to validate our approach (Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a>). In addition, <b>15</b> demonstrated encouraging antiproliferative activity when tested in our H1975 (double mutant), PC9 (activating mutant), and Calu3 (wild-type) cell lines with an EC<sub>50</sub> of 0.099, 0.14, and 1.78 μM respectively. This profile is consistent with our described cellular data showing significant activity in the double and activating mutants with selectivity over the wild-type enzyme. Subsequently, <b>15</b> was orally dosed in an in vivo efficacy study using an H1975 double-mutant xenograft model in immune-compromised mice (Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a>). Briefly, tumor cells were inoculated subcutaneously, and the mice were randomized into groups of 4–10 mice prior to compound dosing when tumors reached approximately 0.2–0.4 cm<sup>3</sup>. Tumor growth was measured from the start of treatment, assessed by comparison of the mean change in the tumor volume for the control and treated groups, and represented as tumor growth inhibition (where >100% TGI is a regression from the starting size). Statistical significance was evaluated using a one-tailed <i>t</i> test. Compound <b>15</b> showed significant efficacy of 105% total growth inhibition (TGI) after 7 days at an oral dose of 60 mg/kg/day (formulated as the mesylate salt). This dose and formulation was chosen because we had observed good exposure in the nude (<i>C</i><sub>max</sub> of 7.1 μM and AUC<sub>0–t</sub> 48.2 μM h) and severe-combined immunodeficiency (SCID) (<i>C</i><sub>max</sub> 8.1 μM and AUC<sub>0–t</sub> 119.3 μM h) mice  that are used in these models, which also compared well with the rat PK reported in Table <a class="ref showTableEvent internalNav" data-ID="tbl12" href="#tbl12">12</a> (<i>C</i><sub>max</sub> of 5.32 μM and AUC<sub>0–t</sub> 92.7 μM h).</div><div class="NLM_table-wrap" id="tbl12"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 12. Overview of Activity, Physicochemical, and PK Data of Compound <b>15</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col><col align="center" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">AM cell (μM)</th><th class="colsep0 rowsep0" align="center">DM cell (μM)</th><th class="colsep0 rowsep0" align="center">WT cell (μM)</th><th class="colsep0 rowsep0" align="center">solubility (μM)<a class="ref internalNav" href="#t12fn1" aria-label="a">a</a></th><th class="colsep0 rowsep0" align="center">PPB (% free) (M/R/H)<a class="ref internalNav" href="#t12fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center">Human Heps Clint (μL min<sup>–1</sup> × 10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">Rat Heps Clint (μL min<sup>–1</sup> × 10<sup>6</sup> cells)</th><th class="colsep0 rowsep0" align="center">hERG (μM)</th><th class="colsep0 rowsep0" align="center">Rat PK CL/F<a class="ref internalNav" href="#t12fn3" aria-label="c">c</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="center"><b>15</b></td><td class="colsep0 rowsep0" align="center">0.40</td><td class="colsep0 rowsep0" align="center">0.096</td><td class="colsep0 rowsep0" align="center">23</td><td class="colsep0 rowsep0" align="center">1.6</td><td class="colsep0 rowsep0" align="center">1.2/1.2/0.8</td><td class="colsep0 rowsep0" align="center"><3</td><td class="colsep0 rowsep0" align="center">18</td><td class="colsep0 rowsep0" align="center">4.2</td><td class="colsep0 rowsep0" align="center">8.1/45%</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t12fn1"><div class="footnote" id="t12fn1"><sup>a</sup><p class="last">Solubility was evaluated under thermodynamic conditions using crystalline solid.</p></div><div class="footnote" id="t12fn2"><sup>b</sup><p class="last">Plasma protein binding (PPB) was assessed by equilibrium dialysis in the appropriate species (mouse/rat/human) at 37 °C. Free and bound concentrations were quantified by LC–MS.</p></div><div class="footnote" id="t12fn3"><sup>c</sup><p class="last">Intravenous clearance (mL min<sup>–1</sup> kg<sup>–1</sup>) was assessed in male Han Wistar rats when dosed with a 3 μmol kg<sup>–1</sup> solution. Oral bioavailability was observed with a 6 μmol kg<sup>–1</sup> solution dosed in male Han Wistar Rats.</p></div></div></div><figure id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Antitumor efficacy study data on compound <b>15</b> across the double (H1975), activating (PC9), and wild-type (A431) EGFR xenograft models. Tumor growth inhibition (% TGI) was calculated between the compound treated and vehicle groups, with a % TGI > 100 indicating tumor regression from the initial tumor size.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>15</b> was subsequently taken into an efficacy study in a PC9 activating-mutant cell line and a wild-type A431 cell line in immunocompromised mice. The activity against the PC9 xenograft model at the same dose (134% TGI, resulting in tumor regression) was also encouraging, and the compound showed reduced activity against the A431 xenograft model (46% TGI), as was hoped from the wild-type margin demonstrated from the in vitro cellular profile.</div><div class="NLM_table-wrap" id="tbl13"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 13. Summary of the Efficacy Data from Xenograft Studies on Compound <b>15</b> Compared to Gefitinib (<b>1</b>)<a class="ref internalNav" href="#tbl13-fn1" aria-label="b">b</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">oral dose (mg/kg/day)</th><th class="colsep0 rowsep0" align="center">H1975 (% TGI)</th><th class="colsep0 rowsep0" align="center">PC9 (% TGI)</th><th class="colsep0 rowsep0" align="center">A431 (% TGI)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="left">105 (<i>p </i>< 0.001)</td><td class="colsep0 rowsep0" align="left">134 (<i>p </i>< 0.01)</td><td class="colsep0 rowsep0" align="left">46 (<i>p </i>< 0.05)</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Gefitinib (<b>1</b>)</td><td class="colsep0 rowsep0" align="left">6.25</td><td class="colsep0 rowsep0" align="left">8 (<i>p</i> NS)<a class="ref internalNav" href="#t13fn1" aria-label="a">a</a></td><td class="colsep0 rowsep0" align="left">142 (<i>p </i>< 0.001)</td><td class="colsep0 rowsep0" align="left">79 (<i>p</i> < 0.001)</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t13fn1"><div class="footnote" id="t13fn1"><sup>a</sup><p class="last">Data from a 100 mg/kg/day oral dose of gefitinib.</p></div><div class="footnote" id="tbl13-fn1"><sup>b</sup><p class="last">Statistical significance (<i>p</i> values in brackets) was calculated from compound-treated and vehicle groups using a one-tailed <i>t</i>-test. NS indicates that the % TGI was not significant compared to the vehicle-treated group.</p></div></div></div><div class="NLM_p last">As a comparison, an oral dose of gefitinib of 6.25 mg/kg/day (representative of the clinically relevant human dose), showed 142% TGI in the PC9 xenograft model and 79% TGI in the A431 xenograft model after 7 days (Table <a class="ref showTableEvent internalNav" data-ID="tbl13" href="#tbl13">13</a>). Gefitinib showed little activity in the H1975 xenograft model, even at the higher oral dose of 100 mg/kg/day, which resulted in an 8% TGI (not significant) after 7 days.</div></div><div id="sec2_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> Kinase Selectivity of Compound <b>15</b></h3><div class="NLM_p last">Compound <b>15</b> was submitted to a broad panel of >70 diverse kinases at The University of Dundee,<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(46)</a> where it was tested at a concentration of 1 μM in biochemical assays to assess wider kinase selectivity. The compound showed >75% inhibition for 10 kinases, which were IGF1R, insulin receptor (IR), CAMKKbeta, CHK2, PBK, FLT1, MAP3K11, smMLCK, BTK, and MELK. However, out of these kinases, only BTK has a cysteine in the same position as EGFR, so the mode of inhibition is likely to be via a reversible mechanism toward the majority of these targets. The full selectivity profile of compound <b>15</b> can be viewed in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a> (<a class="ref internalNav" href="#notes-2" aria-label="Table S4">Table S4</a>). We do not believe these off-target activities contributed to the efficacy in the reported xenograft models; however, information on the optimization of the selectivity profile of this series will be reported in future disclosures.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i31">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40631" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40631" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have reported the development of a series of potent inhibitors of the activating and resistant mutants of EGFR with varying degrees of selectivity over the wild-type enzyme. This activity profile across the mutants would appear to be suitable to demonstrate activity against the activating and resistant mutants of EGFR but with an improved margin to toxicity associated with wild-type activity. As part of this approach, we simultaneously optimized the covalent and noncovalent elements of binding into a suitable range to identify compounds with satisfactory potency and intrinsic reactivity. This approach may be exploited more generally to optimize covalent inhibitors across a broader range of targets. Also reported is encouraging antitumor efficacy in H1975 double-mutant and PC9 activating-mutant models with compound <b>15</b>. This compound was also observed to have significantly lower activity in the A431 model used here as a measure of EGFR wild-type activity. However, the relatively poor solubility (1.6 μM) and the hERG IC<sub>50</sub> of 4.2 μM demonstrated the need for further development efforts for this compound and across the scaffold more generally. Further evolution of this series will be reported at a later date; in particular, this will focus on improving the potency, kinase selectivity, and properties of the series toward a clinical candidate.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i32">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_83826" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_83826" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec4_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> Biochemical and Cellular Activity Assays</h3><div class="NLM_p last">Compounds were tested at a range of concentrations. The mean data values for each concentration along with untreated control wells and 100% inhibition/competition control wells were used to derive a plot of inhibition/competition against concentration. Origin software was used to interpolate the IC<sub>50</sub> values by nonlinear regression.</div></div><div id="sec4_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> Kinase Inhibition Assay Using HTRF (Homogenous Time-Resolved Fluorescence)</h3><div class="NLM_p last">The inhibitory activity of compound against the kinases EGFR (T790M/L858R) was determined with CisBio HTRF (homogenous time-resolved fluorescence) KinEASE TK (#62TKOPEC). The enzyme reaction contains recombinant N-terminal GST-tagged human EGFR (T790M/L858R), which phosphorylates the HTRF tyrosine kinase biotinylated substrate. The sequence of the substrate is proprietary to CisBio. Compounds were serially diluted in 100% (v/v) DMSO before being acoustically dispensed from an Echo 555 (Labcyte) into black Corning 1536-well assay plates. Kinase activity assays were performed in a total reaction volume of 3 μL per well. A 1.5 μL enzyme reaction consisted of 1.6 nM EGFR (T970M, L858R), 1 mM DTT, and 10 mM MgCl<sub>2</sub>. A 1.5 μL substrate mix consisted of 1 μM TK substrate, 30 μM ATP, 1 mM DTT, and 10 mM MgCl<sub>2</sub>. Following a 50 min incubation, 3 μL of stop mix was added, which consisted of 250 nM Strep-XL665 and TK Ab-Cryptate diluted in kit detection buffer. The plates were incubated for 1 h before being read on Pherastar using standard HTRF settings. N-terminal GST-tagged recombinant human EGF receptor, with amino acids 696-end containing the T790M and L858R mutations, was obtained from Millipore.</div></div><div id="sec4_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> Measurement of Cellular Phosphorylation Assay</h3><div class="NLM_p last">For EGFR (T790M/L858R), the human lung cell line NCI-H1975 was obtained from the American Type Culture Collection. For EGFR (Exon 19 deletion), the human lung cell line PC9 was obtained from the Akiko Hiraide from Preclinical Sciences R&D AZ Japan. The growth media was RPMI 1640 containing 10% fetal calf serum and 2 mM glutamine. For EGFR (wild type), the human colon adenocarcinoma cell line LoVo was obtained from the European Collection of Cell Cultures. LoVo growth media was RPMI 1640 containing 3% charcoal-stripped fetal calf serum and 2 mM glutamine. All cells were used from assay-ready frozen cryo banks. Assays to measure cellular phosphorylation of endogenous p-EGFR in cell lysates were carried out according to the protocol described in the R&D Systems DuoSet IC Human Phospho-EGFR ELISA (R&D Systems, no. DYC1095). Following thawing and resuspension, 40 μL of cells were seeded (10 000 cells/well for NCI-H1975 and PC9 or 15 000 cells/well for LoVo) in growth medium in Corning black, clear-bottomed 384-well plates and incubated at 37 °C with 5% CO<sub>2</sub> overnight. The cells were acoustically dosed using an Echo 555 with compounds serially diluted in 100% DMSO (v/v). The cells were incubated for a further 2 h and following aspiration of medium, 40 μL of 1× lysis buffer was added to each well. LoVo were stimulated with EGF (25 ng/mL) for 10 min before lysis. Greiner black high-bind 384-well plates were coated with capture antibody and then blocked with 3% BSA. Following the removal of the blocking solution, 15 μL of lysate was transferred to the Greiner black high-bind 384-well plates and incubated for 2 h. Following aspiration and washing of the plates with PBS/A, 20 μL of detection antibody was added and incubated for 2 h. Following aspiration and washing of the plates with PBS/T, 20 μL of QuantaBlu fluorogenic peroxidase substrate (ThermoFisher Scientific, no. 15169) was added and incubated for 1 h. Twenty microliters of QuantaBlu stop solution was added to the plates, and fluorescence was read on an Envision plate reader using an excitation wavelength of 352 nm and an emission wavelength of 460 nm.</div></div><div id="sec4_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> Experimental Procedure for Cellular Proliferation Experiments</h3><div class="NLM_p last">Cell lines were plated in 384–well plates at between 500 and 1000 cells per well, depending on the cell line, in 70 μL per well of RPMI media containing 10% fetal calf serum, 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, and 1% penicillin/streptomycin. The cells were allowed to attach overnight at 37 °C under 5% CO<sub>2</sub>. The following day, titrations of test compound were added to the assay plates using an Echo Liquid Handler Labcyte, and the treated cells were incubated for a further 72 h at 37 °C under 5% CO<sub>2.</sub> Each compound was tested as an 11-point dose response, with a top concentration of 10 μM using 1:3 dilutions. Following a 72 h incubation of the compound-treated plates, 5 μL of 2 μM SYTOX Green Nucleic Acid Stain, Life Technologies was added per well, and the plates were incubated at room temperature for 1 h. The number of fluorescent cells per well was measured with an Acumen TTP LabTech Ltd., with this number representing the dead cell count. Ten microliters of 0.25% saponin was added per well, and the plates were incubated overnight at room temperature. The total number of fluorescent cells per well was acquired with the Acumen. The number of dead cells was subtracted from the total number of cells, and the live cell number was plotted to determine EC<sub>50</sub> values.</div></div><div id="sec4_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> X-ray Crystallography</h3><div class="NLM_p">The kinase domain of the wild-type EGFR protein was expressed in Sf9 insect cells as a GST-fusion protein with a thrombin cleavage site.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(47)</a> After affinity purification and cleavage of the GST tag, a gel-filtration step was performed, and the resulting protein was concentrated to 6 mg/mL. Apo crystals were prepared using the vapor-diffusion technique by drops equilibrated against 0.2 M NH<sub>4</sub>Cl and 1.2 M Na–K-tartrate buffered with 10 mM acetate at pH 4.6 and 0.15 M hepes, pH 7.0. Protein–ligand complex crystals were generated by soaking apo-crystlas with 2 mM of the compound (dissolved in DMSO at 100 mM). The Free Mounting System (Proteros biostructures<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(31)</a>) was used for cryo cooling. Diffraction data were collected at the Swiss Light Source at 100 K on a Pilatus6M detector, and the data was processed using XDS and XSCALE.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(48)</a> The crystallographic model was completed in Coot<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(49)</a> and refined with Refmac5.<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(50)</a> Crystallographic data and refinement parameters are summarized in Table <a class="ref showTableEvent internalNav" data-ID="tbl14" href="#tbl14">14</a>.</div><div class="NLM_table-wrap" id="tbl14"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 14. Crystallographic Data Collection and Refinement Summary</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col></colgroup><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">data collection statistics</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Cell: a = b = c, α = β = γ (Å, deg)</td><td class="colsep0 rowsep0" align="left">144.89, 90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">resolution (Å)</td><td class="colsep0 rowsep0" align="left">2.64 (2.96–2.78)<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">unique reflections</td><td class="colsep0 rowsep0" align="left">15 026 (2185)<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">multiplicity</td><td class="colsep0 rowsep0" align="left">24.4 (25.5)<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">completeness (%)</td><td class="colsep0 rowsep0" align="left">99.9 (100.0)<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i><sub>sym</sub> (%)</td><td class="colsep0 rowsep0" align="left">9.2 (44.5)<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">mean (<i>I</i>)/sd</td><td class="colsep0 rowsep0" align="left">32.02 (9.75)<a class="ref internalNav" href="#t14fn1" aria-label="a">a</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">refinement statistics</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">number of reflections (working/test)</td><td class="colsep0 rowsep0" align="left">14 487/539</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><i>R</i>/<i>R</i><sub>free</sub> (%)</td><td class="colsep0 rowsep0" align="left">16.5/20.3</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">number of atoms</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">protein</td><td class="colsep0 rowsep0" align="left">2245</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">water</td><td class="colsep0 rowsep0" align="left">69</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ligand</td><td class="colsep0 rowsep0" align="left">30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">ions</td><td class="colsep0 rowsep0" align="left">1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">deviation from ideal geometry</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond lengths (Å)</td><td class="colsep0 rowsep0" align="left">0.007</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bond angles (deg)</td><td class="colsep0 rowsep0" align="left">1.04</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">bonded B’s (Å<sup>2</sup>)</td><td class="colsep0 rowsep0" align="left">2.10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Ramachandran plot</td><td class="colsep0 rowsep0" align="center"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">most favored region</td><td class="colsep0 rowsep0" align="left">92.1</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">additional allowed region</td><td class="colsep0 rowsep0" align="left">7.9</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">generously allowed region</td><td class="colsep0 rowsep0" align="left">0</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">disallowed region</td><td class="colsep0 rowsep0" align="left">0</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t14fn1"><div class="footnote" id="t14fn1"><sup>a</sup><p class="last">Data in parentheses refer to the highest resolution shell.</p></div></div></div></div><div id="sec4_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Synthesis and Characterization of Key Compounds <b>7</b>, <b>9</b>, <b>15</b>, and <b>58</b></h3><div id="sec4_6_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i40" class="anchor-spacer"></div><h4 class="article-section__title" id="_i40"> General Chemistry Statement</h4><div class="NLM_p last">Microwave reactions were performed using one of the following reactors: Biotage Initiator, Personal Chemistry Emrys Optimizer, Personal Chemistry Smithcreator, or CEM Explorer. Work-up procedures were carried out using traditional phase-separating techniques or by using strong cation-exchange (SCX) chromatography using an Isolute SPE flash SCX-2 column (International Sorbent Technology Limited); when necessary, organic solutions were dried over anhydrous MgSO<sub>4</sub> or Na<sub>2</sub>SO<sub>4</sub>. Flash column chromatography (FCC) was performed on Merck Kieselgel silica (Art. 9385), on Silicycle cartridges (40–63 μm silica, 4–330 g weight), or on Grace resolv cartridges (4–120 g) either manually or automated using an Isco Combi Flash Companion system. Preparative reverse-phase HPLC (RP HPLC) was performed with C18 reversed-phase silica, for example, with a Waters Xterra or XBridge preparative reversed-phase column (5 μm silica, 19 mm diameter, 100 mm length) or with a Phenomenex Gemini axia preparative reversed-phase column (5 μm silica, 110A, 21.1 mm diameter, 100 mm length) using decreasingly polar mixtures as eluent (e.g., 1–5% formic acid or 1–5% aqueous ammonium hydroxide (d = 0.88)) as solvent A and acetonitrile as solvent B or MeOH/MeCN 3:1. The intermediates were not necessarily fully purified, but their structures and purity were assessed by TLC, NMR, HPLC, and mass spectral techniques, and they are consistent with the proposed structures. The purities of compounds used for biological testing were assessed by NMR, HPLC, and mass spectral techniques, and they are consistent with the proposed structures; the purity was ≥95%. FT <sup>1</sup>H and <sup>13</sup>C NMR spectra were obtained either with a 400 MHz (<sup>1</sup>H, 400 MHz; <sup>13</sup>C, 101 MHz), 500 MHz (<sup>1</sup>H, 500 MHz; <sup>13</sup>C, 126 MHz), or 700 MHz (<sup>1</sup>H, 700 MHz; <sup>13</sup>C, 176 MHz) Bruker spectrometer. <sup>1</sup>H and <sup>13</sup>C shifts are given in ppm and are measured relative to the internal residual solvent peak (CDCl<sub>3</sub> 7.25 ppm/77 ppm). Peak multiplicities are expressed as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; br s, broad singlet; and m, multiplet. Analytical HPLC was performed on C18 reverse-phase silica with a Phenomenex Gemini reversed-phase column (5 μm silica, 110 A, 2 mm diameter, 50 mm length) using decreasingly polar mixtures as eluent (e.g., decreasingly polar mixtures of water containing 0.1% formic acid or 0.1% ammonia as solvent A and acetonitrile as solvent B or MeOH/MeCN 3:1), with a flow rate of about 1 mL/min. Detection was by electrospray mass spectrometry and by UV absorbance at a wavelength of 254 nm. Electrospray mass spectral data were obtained using a Waters ZMD or Waters ZQ LC/mass spectrometer acquiring both positive and negative ion data, and generally, only ions relating to the parent structure are reported. Accurate mass and MSMS fragmentation data were obtained using a ThermoScientific hybrid LTQ–FT mass spectrometer with an Agilent 1100 quaternary pump with PDA and Autosampler. FIve microliters of sample dissolved in 50:50 acetonitrile/water in 0.1% formic acid was injected onto a Thermo Scientific Hypersil Gold 50 × 2.1 mm, 5 μm particle LC column. The gradient was 5–100% B over 17 min, with a 3 min re-equilibration time at 5% B. The flow rate was 0.5 mL/min, with A being 0.1% formic acid in water and B being 0.1% formic acid in acetonitrile. The MS and MSMS spectra were obtained in ESI +ve mode in both the ion trap and ion cyclotron resonance (ICR) cell using helium as the collision gas at a normalized collision energy of 35 eV. The ICR cell was run at resolution settings of 25 000 in MS mode and 12 500 in MSMS mode.</div></div></div><div id="sec4_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> Synthesis of Compound <b>7</b></h3><div id="sec4_7_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i42" class="anchor-spacer"></div><h4 class="article-section__title" id="_i42"> 3-(2,5-Dichloropyrimidin-4-yl)-1<i>H</i>-indole (<b>61</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0031.gif" alt="" id="fx1" /></img><div class="NLM_p last">Methylmagnesium bromide (3.2 M in 2-methyltetrahydrofuran, 3.37 mL, 10.79 mmol) was added dropwise over 10 min to a solution of indole (1.28 g, 10.79 mmol) in THF (6 mL) at 0 °C. The solution was stirred at 0–2 °C for 30 min. 2,4,5-Trichloropyrimidine (1 g, 5.40 mmol) was added dropwise, resulting in a yellow solution. The ice bath was removed, and the solution was stirrred at ambient temperature for 1 h, resulting in a red solution. The temperature was elevated to 60 °C, and the mixture was stirred at 60 °C for 1.5 h. The mixture was cooled to 25 °C, and acetic acid (634 μL, 11.06 mmol) was added dropwise. Water (9.90 mL) and THF (2 mL) were added, and the mixture was stirred for 20 min at 60 °C, resulting in a biphasic solution. The layers were partitioned, and heptane (11 mL) was added to the organic solution, resulting in the crystallization of a solid. The solid was collected by filtration, washed with heptane (2 mL), and dried in a vacuum oven to yield 3-(2,5-dichloropyrimidin-4-yl)-1<i>H</i>-indole (1.015 g, 66%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.24–7.32 (2H, m), 7.55–7.58 (1H, m), 8.52–8.55 (1H, m), 8.71–8.73 (2H, m), 12.24 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 264/266.</div></div><div id="sec4_7_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i43" class="anchor-spacer"></div><h4 class="article-section__title" id="_i43"> 4-Fluoro-2-methoxy-1-nitrobenzene (<b>62</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0032.gif" alt="" id="fx2" /></img><div class="NLM_p last">Potassium carbonate (44 g, 318.27 mmol) and 5-fluoro-2-nitrophenol (50 g, 318.27 mmol) dissolved in acetone (750 mL) were stirred under argon for 30 min, and methyl iodide (19.81 mL, 318.27 mmol) was added dropwise. The resulting solution was stirred at 60 °C overnight, allowed to cool to room temperature, and concentrated to dryness. Water (500 mL) was added, and the resulting mixture was extracted with EtOAc (3 × 200 mL). The organic layers were combined, washed with a 1 M aqueous solution of NaOH (2 × 200 mL) and brine (200 mL), dried (MgSO<sub>4</sub>), and concentrated to afford the crude product as an oil, which was crystallized to give 4-fluoro-2-methoxy-1-nitrobenzene (53.8 g, 99%) as a clear beige solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.93 (3H, s), 6.93–6.98 (1H, m), 7.28–7.31 (1H, m), 7.99–8.02 (1H, m). No ionization in LC–MS.</div></div><div id="sec4_7_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i44" class="anchor-spacer"></div><h4 class="article-section__title" id="_i44"> 1-[4-(3-Methoxy-4-nitrophenyl)piperazin-1-yl]ethanone (<b>63</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0033.gif" alt="" id="fx3" /></img><div class="NLM_p last">1-Acetylpiperazine (12.36 g, 96.42 mmol) and DIPEA (18.32 mL, 105.19 mmol) were added to a stirred solution of 4-fluoro-2-methoxy-1-nitrobenzene (<b>62</b>) (15 g, 87.65 mmol) dissolved in DMA (45 mL) under argon. The resulting solution was stirred at 90 °C overnight. The reaction mixture was allowed to cool to room temperature and quenched with water (500 mL). The aqueous layer was extracted with EtOAc (×3). The combined organic layers were washed with water (×2) and brine, dried (MgSO<sub>4</sub>), and concentrated to afford 1-(4-(3-methoxy-4-nitrophenyl)piperazin-1-yl)ethanone (22.0 g, 90%) as a yellow solid. <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ 2.15 (3H, s), 3.43 (4H, dt), 3.67 (2H, t), 3.80 (2H, t), 6.33 (1H, d), 6.42 (1H, dd), 8.00 (1H, d); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 280.35.</div></div><div id="sec4_7_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i45" class="anchor-spacer"></div><h4 class="article-section__title" id="_i45"> 1-[4-(4-Amino-3-methoxyphenyl)piperazin-1-yl]ethanone (<b>64</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0034.gif" alt="" id="fx4" /></img><div class="NLM_p last">A suspension of 1-(4-(3-methoxy-4-nitrophenyl)piperazin-1-yl)ethanone (7 g, 25.06 mmol) and platinum oxide (0.398 g, 1.75 mmol) in EtOH (200 mL) at 25 °C was stirred under 1.3 bar hydrogen at 25 °C for 3 h. The resulting suspension was filtered through Dicalite Speed Plus, and the filtrate was concentrated to dryness to afford 1-(4-(4-amino-3-methoxyphenyl)piperazin-1-yl)ethanone (6.19 g, 99%) as a purple solid. <sup>1</sup>H NMR (400 MHz, DMSO-d<sub>6</sub>) δ 2.03 (3H, s), 2.87 (2H t, <i>J</i> = 5.2 Hz), 2.94 (2H t, <i>J</i> = 5.2 Hz), 3.53–3.57 (4H, m), 3.75 (3H, s), 4.28 (2H, s), 6.30–6.33 (1H, m), 6.52–6.54 (2H, m); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 250.27.</div></div><div id="sec4_7_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i46" class="anchor-spacer"></div><h4 class="article-section__title" id="_i46"> <i>N</i>-[4-(4-Acetylpiperazin-1-yl)-2-methoxyphenyl]acetamide (<b>65</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0035.gif" alt="" id="fx5" /></img><div class="NLM_p last">1-(4-(4-Amino-3-methoxyphenyl)piperazin-1-yl)ethanone (<b>64</b>) (3 g, 12.03 mmol) was added to a stirred mixture of acetic anhydride (7.49 mL, 79.42 mmol) and acetic acid (3.10 mL, 54.15 mmol). The resulting deep-blue solution was stirred at 25 °C for 1 h. The reaction mixture was then diluted in Et<sub>2</sub>O (500 mL) under stirring. The precipitate was collected by filtration and washed with Et<sub>2</sub>O to give <i>N</i>-(4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)acetamide (2.55 g, 73%) as a clear purple solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.02 (3H, s), 2.06 (3H, s), 3.09 (4H, ddd), 3.58 (4H, m), 3.81 (3H, s), 6.45 (1H, d), 6.63 (1H, s), 7.61 (1H, d), 8.92 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 292.36.</div></div><div id="sec4_7_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i47" class="anchor-spacer"></div><h4 class="article-section__title" id="_i47"> 1-[4-[4-[[5-Chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazin-1-yl]ethanone (<b>7</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0036.gif" alt="" id="fx6" /></img><div class="NLM_p last">3-(2,5-Dichloropyrimidin-4-yl)-1<i>H</i>-indole (<b>61</b>) (0.25 g, 0.95 mmol), 1-(4-(4-amino-3-methoxyphenyl)piperazin-1-yl)ethanone (0.271 g, 0.95 mmol), and <i>p</i>-toluene sulfonic acid monohydrate (0.552 mL, 2.84 mmol) in <i>n</i>-pentanol (4 mL)/NMP (1 mL) were stirred at 150 °C for 1 h. The reaction mixture was filtered and concentrated in vacuo, and the residue was purified by reverse-phase HPLC (acetonitrile/water/0.1% TFA) using an Atlantis Prep T3 OBD column to afford 1-[4-[4-[[5-chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]amino]-3-methoxyphenyl]piperazin-1-yl]ethanone (138 mg, 31%) as a white solid and the deacetylated product as a white solid (42 mg, 10%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.07 (3H, s), 3.13–3.39 (4H, m), 3.65 (4H, d), 3.73–3.88 (3H, m), 6.63 (1H, dd), 6.82 (1H, d), 7.01 (1H, t), 7.14–7.23 (1H, m), 7.47 (1H, d), 7.54 (1H, d), 8.28 (1H, d), 8.34 (1H, s), 8.54 (1H, d), 11.94 (1H, br s); <sup>13</sup>C NMR (DMSO-d<sub>6</sub>) δ 21.10, 40.70, 45.49, 49.02, 49.35, 55.46, 100.86, 107.30, 110.88, 111.55, 114.07, 120.36, 120.70, 122.24, 123.17, 125.71, 126.12, 130.71, 135.87, 149.04, 153.11, 157.11, 157.75, 159.39, 168.17; HRMS–ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>25</sub>H<sub>25</sub>O<sub>2</sub>N<sub>6</sub>Cl, 477.17969; found, 477.18003.</div></div></div><div id="sec4_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> Synthesis of Compound <b>9</b></h3></div><div id="sec4_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> 5-Chloro-4-(1<i>H</i>-indol-3-yl)-<i>N</i>-(2-methoxy-5-nitrophenyl)pyrimidin-2-amine (<b>66</b>)</h3><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0037.gif" alt="" id="fx7" /></img><div class="NLM_p">2-Methoxy-5-nitroaniline (0.971 g, 5.77 mmol), <i>p</i>-toluene sulfonic acid monohydrate (2.197 g, 11.55 mmol), and 3-(2,5-dichloropyrimidin-4-yl)-1<i>H</i>-indole (<b>61</b>) (1.525 g, 5.77 mmol) were heated at 120 °C in 2-pentanol (20 mL) for 24 h. The reaction mixture was evaporated to dryness, redissolved in DCM (50 mL) and MeOH (5 mL), and washed sequentially with saturated NaHCO<sub>3</sub> (25 mL), water (25 mL), and saturated brine (25 mL). The organic layer was dried (MgSO<sub>4</sub>) and evaporated to afford the crude product. The resultant solid was triturated with DCM/MeOH (9:1), filtered, and washed with DCM to give 5-chloro-4-(1<i>H</i>-indol-3-yl)-<i>N</i>-(2-methoxy-5-nitrophenyl)pyrimidin-2-amine (1.20 g, 53%) as a yellow solid (1.2 g, 53%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 4.01 (3H, s), 6.95–7.10 (1H, m), 7.21 (1H, t), 7.32 (1H, d), 7.50 (1H, d), 8.03–8.12 (1H, m), 8.32–8.42 (1H, m), 8.49–8.58 (2H, m), 8.62 (1H, s), 8.93 (1H, d), 11.93 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 396.13.</div><div id="sec4_9_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i50" class="anchor-spacer"></div><h4 class="article-section__title" id="_i50"> <i>N</i>′-[5-Chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]-4-methoxybenzene-1,3-diamine (<b>67</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0038.gif" alt="" id="fx8" /></img><div class="NLM_p last">5-Chloro-4-(1<i>H</i>-indol-3-yl)-<i>N</i>-(2-methoxy-5-nitrophenyl)pyrimidin-2-amine (<b>66</b>) (1.2 g, 3.03 mmol), iron (1.016 g, 18.19 mmol), and ammonium chloride (0.114 g, 2.12 mmol) were heated in ethanol (15 mL) and water (5 mL) at reflux for 3 h. The mixture was cooled and concentrated to a thick slurry. DCM (100 mL), MeOH (5 mL), and water were added, and the mixture stirred for 15 min and filtered. The filtrate layers were separated, and the aqueous layer was re-extracted with DCM. The combined organics were dried (MgSO<sub>4</sub>) and concentrated. The crude product was purified by flash silica chromatography, eluting with 1–5% MeOH in DCM. Pure fractions were evaporated to dryness to afford <i>N</i>1-(5-chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl)-6-methoxybenzene-1,3-diamine (0.825 g, 74%) as a white/pale-yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.71 (3H, s), 4.55 (2H, s), 6.36 (1H, dd), 6.80 (1H, d), 7.08–7.13 (1H, m), 7.17–7.23 (1H, m), 7.26 (1H, d), 7.49 (1H, d), 8.13 (1H, s), 8.39 (1H, s), 8.42 (1H, d), 8.49 (1H, d), 11.85 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 366.17</div></div><div id="sec4_9_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i51" class="anchor-spacer"></div><h4 class="article-section__title" id="_i51"> <i>N</i>-[3-[[5-Chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl]prop-2-enamide (<b>9</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0039.gif" alt="" id="fx9" /></img><div class="NLM_p last">Acryloyl chloride (0.040 mL, 0.49 mmol) was added dropwise to <i>N</i>′-[5-chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]-4-methoxybenzene-1,3-diamine (<b>67</b>) (180.2 mg, 0.49 mmol) and DIPEA (0.146 mL, 0.54 mmol) in THF (5 mL) at 0 °C under nitrogen. The resulting suspension was stirred at 0 °C for 2 h and then allowed to warm to room temperature. The reaction mixture was diluted with water (15 mL) and extracted with DCM (40 mL). The organics were washed sequentially with saturated Na<sub>2</sub>CO<sub>3</sub> (20 mL) and saturated brine (20 mL). The organic layer was dried (MgSO<sub>4</sub>) and evaporated to afford the crude product. The crude product was purified by flash silica chromatography, eluting with 1–8% MeOH in DCM. Pure fractions were evaporated to dryness to afford <i>N</i>-[3-[[5-chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxyphenyl]prop-2-enamide (125 mg, 60%) as a pale-brown solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.80 (3H, s), 5.70 (1H, dd), 6.22 (1H, dd), 6.40 (1H, dd), 6.99 (1H, t), 7.06 (1H, d), 7.16 (1H, t), 7.46 (1H, d), 7.55 (1H, dd), 8.05 (1H, d), 8.33 (1H, d), 8.40 (2H, s), 8.51 (1H, d), 9.97 (1H, s), 11.85 (1H, s); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 55.77, 110.74, 111.27, 111.61, 114.97, 115.71, 116.06, 120.53, 122.28, 123.00, 126.04, 128.16, 131.02, 131.90, 131.99, 135.93, 147.87, 157.14, 158.02, 158.70, 162.67; HRMS–ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>22</sub>H<sub>19</sub>O<sub>2</sub>N<sub>5</sub>Cl, 420.12198; found, 420.12218.</div></div></div><div id="sec4_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> Synthesis of Compound <b>15</b></h3><div id="sec4_10_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i53" class="anchor-spacer"></div><h4 class="article-section__title" id="_i53"> (<i>E</i>)-4-(2-Butoxyvinyl)-2,5-dichloropyrimidine (<b>68</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0040.gif" alt="" id="fx10" /></img><div class="NLM_p last">Triethylamine (80 mL, 572.45 mmol), butyl vinyl ether (74.1 mL, 572.45 mmol), and palladium(II) acetate (4.28 g, 19.08 mmol) were added to a stirred solution of 2,4,5-trichloropyrimidine (100 g, 545.2 mmol) in poly(ethylene glycol) 200 (600 mL, 545.2 mmol) under nitrogen. The mixture was stirred at 80 °C for 70 min and then cooled to room temperature. The mixture was extracted with Et<sub>2</sub>O (4 × 1 L). The combined organics were washed with water (2 × 1 L) and brine (1 L). The solution was then dried (MgSO<sub>4</sub>) and concentrated in vacuo. Purification by flash silica chromatography and elution with 0–40% DCM in isohexane afforded (<i>E</i>)-4-(2-butoxyvinyl)-2,5-dichloropyrimidine (68.2 g, 51%) as a light-yellow oil. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 0.91 (3H, t), 1.33–1.42 (2H, m), 1.62–1.69 (2H, m), 4.11 (2H, t), 6.05 (1H, d), 8.04 (1H, d), 8.62 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 247.30</div></div><div id="sec4_10_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i54" class="anchor-spacer"></div><h4 class="article-section__title" id="_i54"> 3-(2,5-Dichloropyrimidin-4-yl)pyrazolo[1,5-<i>a</i>]pyridine (<b>69</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0041.gif" alt="" id="fx11" /></img><div class="NLM_p last">To a stirred solution of (<i>E</i>)-4-(2-butoxyvinyl)-2,5-dichloropyrimidine (<b>68</b>) (8 g, 32.37 mmol) in DMA (100 mL) was added 1-aminopyridinium iodide (7.19 g, 32.37 mmol) followed by K<sub>2</sub>CO<sub>3</sub> (11.19 g, 80.93 mmol). The mixture was stirred at 110 °C for 5 h. After cooling to room temperature, the mixture became solid. The mixture was diluted with EtOAc and a small amount of MeOH and was then washed with water followed by saturated brine. The mixture was filtered to remove the solid from the phase interface. This solid contained some desired product. The solid was dissolved in EtOAc/MeOH and was combined with the organic extract. Purification by flash silica chromatography and elution with 20–70% EtOAc in heptane provided 3-(2,5-dichloropyrimidin-4-yl)pyrazolo[1,5-<i>a</i>]pyridine (2.86 g, 33%) as an orange solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 7.28 (1H, td), 7.73 (1H, ddd), 8.57 (1H, dt), 8.81 (1H, s), 8.97 (1H, dt), 9.09 (1H, s); (1H, d), 9.54 (1H, t); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 265.</div></div><div id="sec4_10_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i55" class="anchor-spacer"></div><h4 class="article-section__title" id="_i55"> 5-Chloro-<i>N</i>-(2-methoxy-5-nitrophenyl)-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-amine (<b>70</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0042.gif" alt="" id="fx12" /></img><div class="NLM_p last">4-Methylbenzenesulfonic acid hydrate (15.79 g, 82.99 mmol) was added in one portion to 2-methoxy-5-nitroaniline (12.69 g, 75.44 mmol) and 3-(2,5-dichloropyrimidin-4-yl)pyrazolo[1,5-<i>a</i>]pyridine (20 g, 75.44 mmol) in 2-pentanol (300 mL). The resulting mixture was stirred at 100 °C for 2 days. The resulting precipitate was collected by filtration, washed with 2-pentanol (5 mL), and dried in vacuo to give a yellow solid. The solid was slurried in acetonitrile, filtered, and dried in vacuo to give 5-chloro-<i>N</i>-(2-methoxy-5-nitrophenyl)-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-amine (22.97 g, 77%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>, 100 °C) δ 4.05 (3H, s), 7.15 (1H, t), 7.33 (1H, d), 7.43 (1H, t), 8.04 (1H, dd), 8.45–8.51 (2H, m), 8.57 (1H, s), 8.81 (1H, d), 8.93–8.95 (2H, m); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 397.</div></div><div id="sec4_10_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i56" class="anchor-spacer"></div><h4 class="article-section__title" id="_i56"> <i>N</i>1-[5-Chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-yl]-6-methoxybenzene-1,3-diamine (<b>71</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0043.gif" alt="" id="fx13" /></img><div class="NLM_p last">5-Chloro-<i>N</i>-(2-methoxy-5-nitrophenyl)-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-amine (22.9 g, 57.71 mmol), iron (powder, 325 mesh, 19.34 g, 346.28 mmol), and an NH<sub>4</sub>Cl solution (1.412 mL, 40.40 mmol) were added to a mixture of EtOH (1145 mL) and water (382 mL). The mixture was then heated at reflux for 1 h and then cooled and concentrated to a thick slurry. This residue was triturated with EtOAc (450 mL) and a small amount of saturated NaHCO<sub>3</sub> and then filtered. The isolated solid was washed with water (250 mL) and then slurried with 10% MeOH/DCM (1 L) for 15 min. The mixture was filtered, and the isolated solid was reslurried with 10% MeOH/DCM (250 mL) and filtered. The combined filtrates were separated from the residual water, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated in vacuo. The resulting solid was suspended in MeOH (150 mL), filtered, washed with MeOH and Et<sub>2</sub>O, and dried on the filter to provide <i>N</i>1-[5-chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-yl]-6-methoxybenzene-1,3-diamine (17.1 g, 81%) as a yellow powder. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.68 (3H, s), 4.63 (2H, s), 6.41 (1H, dd), 6.82 (1H, d), 7.06 (1H, d), 7.13 (1H, td), 7.38–7.45 (1H, m), 8.39 (1H, s), 8.42 (1H, s), 8.48 (1H, d), 8.84 (1H, d), 8.95 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 367.</div></div><div id="sec4_10_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i57" class="anchor-spacer"></div><h4 class="article-section__title" id="_i57"> (<i>E</i>)-<i>N</i>-{3-[5-Chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}-4-(dimethylamino)but-2-enamide (<b>15</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0044.gif" alt="" id="fx14" /></img><div class="NLM_p last">DIPEA (0.119 mL, 0.68 mmol), (<i>E</i>)-4-bromobut-2-enoic acid (49.5 mg, 0.30 mmol), and HATU (114 mg, 0.30 mmol) were added to a stirred solution of <i>N</i>1-[5-chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-yl]-6-methoxybenzene-1,3-diamine (<b>71</b>) (100 mg, 0.27 mmol) in DMF (10 mL) at 0 °C. The mixture was stirred at 1 °C under nitrogen for 2 h, allowed to warm to room temperature, and stirred for a further 2 h. The mixture was then recooled to 0 °C, and dimethylamine (2 M in THF, 2.73 mL, 5.45 mmol) was added. The mixture was stirred at 1 °C for 5 min, allowed to warm to room temperature, and stirred for a further 3 h. The mixture was then diluted with EtOAc (50 mL) and was washed with water (2 × 50 mL) and saturated brine (50 mL). The solution was dried (MgSO<sub>4</sub>) and concentrated in vacuo. Purification by flash silica chromatography and elution with 0–10% MeOH in DCM (containing 1% aqueous NH<sub>3</sub>) provided (<i>E</i>)-<i>N</i>-{3-[5-chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}-4-(dimethylamino)but-2-enamide (30 mg, 23%) as an orange solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.19 (6H, s), 3.06 (2H, d), 3.79 (3H, s), 6.23 (1H, d), 6.69 (1H, dt), 7.06–7.15 (2H, m), 7.29–7.35 (1H, m), 7.56 (1H, dd), 7.96 (1H, d), 8.42 (1H, d), 8.46 (1H, s), 8.73 (1H, s), 8.86 (1H, d), 8.99 (1H, s), 9.97 (1H, s); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 42.05, 55.77, 56.82, 106.97, 111.52, 114.37, 114.77, 116.28, 116.66, 120.60, 126.88, 128.00, 129.49, 130.89, 131.62, 132.22, 139.33, 143.38, 148.54, 155.61, 157.80, 158.76, 161.48. HRMS–ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>24</sub>H<sub>24</sub>O<sub>2</sub>N<sub>7</sub>Cl, 478.17502; found, 478.17528.</div></div><div id="sec4_10_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> (<i>E</i>)-<i>N</i>-{3-[5-Chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}-4-(dimethylamino)but-2-enamide (<b>15</b>) Mesylate Salt</h4><div class="NLM_p last">(<i>E</i>)-<i>N</i>-{3-[5-Chloro-4-(pyrazolo[1,5-<i>a</i>]pyridin-3-yl)pyrimidin-2-ylamino]-4-methoxyphenyl}-4-(dimethylamino)but-2-enamide (<b>15</b>) (50 mg, 0.104 mmol) was dissolved in hot MeCN (5 mL) and combined with a solution of methanesulfonic acid (10 mg, 0.104 mmol) in MeCN (1 mL). The resultant mixture was then stirred at room temperature for 24 h. The resulting off-white solid was collected by filtration and analyzed by XRD and thermal methods. On analysis, this solid gave a different X-ray powder diffraction pattern from that of the starting material, indicating a new crystalline phase had been formed. This phase was shown by differential scanning calorimetry to have an onset of melting of around 235 °C.</div></div></div><div id="sec4_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i59" class="anchor-spacer"></div><h3 class="article-section__title" id="_i59"> Synthesis of Compound <b>58</b></h3><div id="sec4_11_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> 4-Fluoro-2-methoxy-5-nitroaniline (<b>72</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0045.gif" alt="" id="fx15" /></img><div class="NLM_p last">4-Fluoro-2-methoxyaniline (2.4 g, 17.00 mmol) was added portionwise to concd H<sub>2</sub>SO<sub>4</sub> (15 mL) and cooled in a ice-water bath, keeping the temperature below 15 °C. The mixture was stirred until all of the solid that formed had dissolved. Potassium nitrate (0.815 mL, 17.00 mmol) was added portionwise such that the temperature was maintained below 10 °C. The mixture was stirred overnight and then poured onto ice/water. The mixture was basified with concd NH<sub>4</sub>OH. The solid was filtered off and then dissolved in DCM, washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>), and concentrated onto silica. The crude product was purified by flash silica chromatography and eluted with a gradient of 50–100% DCM in heptane. Pure fractions were evaporated to dryness to afford 4-fluoro-2-methoxy-5-nitroaniline (2.450 g, 77%) as a yellow crystalline solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.91 (3H, s), 5.21 (2H, s), 7.03 (1H, d), 7.35 (1H, d); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 187.4.</div></div><div id="sec4_11_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> 5-Chloro-<i>N</i>-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-amine (<b>73</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0046.gif" alt="" id="fx16" /></img><div class="NLM_p last">3-(2,5-Dichloropyrimidin-4-yl)-1<i>H</i>-indole (<b>61</b>) (7.5 g, 28.40 mmol), 4-fluoro-2-methoxy-5-nitroaniline (<b>72</b>) (5.55 g, 29.82 mmol), and <i>p</i>-toluenesulfonic acid monohydrate (5.94 g, 31.24 mmol) were heated at 120 °C in 2-pentanol (210 mL) for 18 h. The mixture was cooled and filtered. The solid was washed with MeOH and Et<sub>2</sub>O and dried on the filter to give 5-chloro-<i>N</i>-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-amine (7.28 g, 62%). <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 3.98 (3H, s), 6.97–7.05 (1H, m), 7.17–7.24 (1H, m), 7.40 (1H, d), 7.49 (1H, dd), 8.29 (1H, d), 8.49 (1H, s), 8.52 (1H, d), 8.68 (1H, d), 8.71 (1H, s), 11.92 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 414.1.</div></div><div id="sec4_11_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> 5-Chloro-4-(1<i>H</i>-indol-3-yl)-<i>N</i>-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidin-2-amine (<b>74</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0047.gif" alt="" id="fx17" /></img><div class="NLM_p last">1-Methylpiperazine (492 μL, 4.44 mmol) was added to a suspension of 5-chloro-<i>N</i>-(4-fluoro-2-methoxy-5-nitrophenyl)-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-amine (<b>73</b>) (612 mg, 1.48 mmol), and the reaction was stirred at 120 °C for 1 h. The reaction mixture was evaporated to dryness, redissolved in DCM (25 mL), and washed sequentially with water (2 × 25 mL) and saturated brine (25 mL). The organic layer was dried (MgSO<sub>4</sub>) and evaporated to afford the crude product. The crude product was purified by flash silica chromatography, with an elution gradient of 1–10% MeOH in DCM. Pure fractions were evaporated to dryness, the resulting gum was dissolved in EtOH (25 mL), and a solid precipitated. The solid was collected by filtration and washed with EtOH and Et<sub>2</sub>O to give 5-chloro-4-(1<i>H</i>-indol-3-yl)-<i>N</i>-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidin-2-amine (365 mg, 50%) as a yellow solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.26 (3H, s), 2.47–2.55 (4H, m), 3.07–3.13 (4H, m), 3.93 (3H, s), 6.85 (1H, s), 6.99 (1H, t), 7.16–7.22 (1H, m), 7.48 (1H, d), 8.26 (1H, d), 8.36 (1H, s), 8.42 (1H, d), 8.51 (1H, s), 8.54 (1H, s), 11.88 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 494.5.</div></div><div id="sec4_11_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>′-[5-Chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]-4-methoxy-6-(4-methylpiperazin-1-yl)benzene-1,3-diamine (<b>75</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0048.gif" alt="" id="fx18" /></img><div class="NLM_p last">5-Chloro-4-(1<i>H</i>-indol-3-yl)-<i>N</i>-[2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrophenyl]pyrimidin-2-amine (<b>74</b>) (350 mg, 0.71 mmol), iron (237 mg, 4.25 mmol), and ammonium chloride (26.5 mg, 0.50 mmol) were heated in EtOH (24 mL) and water (8 mL) at reflux for 2 h. The mixture was cooled and concentrated to a thick slurry. DCM (100 mL) and MeOH (10 mL) were added, and the mixture was stirred for 15 min and filtered. The filtrate was dried (MgSO<sub>4</sub>) and concentrated. The crude product was purified by flash silica chromatography, eluting with 1–5% MeOH/NH<sub>3</sub> in DCM. Pure fractions were evaporated to dryness to afford <i>N</i>′-[5-chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]-4-methoxy-6-(4-methylpiperazin-1-yl)benzene-1,3-diamine (288 mg, 88%) as a pale-yellow foam. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.26 (3H, s), 2.47–2.56 (4H, m), 2.88 (4H, t), 3.70 (3H, s), 4.29 (2H, d), 6.72 (1H, s), 7.04 (1H, t), 7.14 (1H, s), 7.15–7.22 (1H, m), 7.46 (1H, d), 8.18 (1H, s), 8.35 (2H, d), 8.48 (1H, d), 11.81 (1H, s); ES+<i> m</i>/<i>z</i>: (M + H)<sup>+</sup> 464.5.</div></div><div id="sec4_11_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>-[5-[[5-Chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide (<b>58</b>)</h4><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0049.gif" alt="" id="fx19" /></img><div class="NLM_p">Acryloyl chloride (1 M in THF, 0.621 mL, 0.62 mmol) was added dropwise to <i>N</i>′-[5-chloro-4-(<i>1H</i>-indol-3-yl)pyrimidin-2-yl]-4-methoxy-6-(4-methylpiperazin-1-yl)benzene-1,3-diamine (<b>75</b>) (288 mg, 0.62 mmol) and DIPEA (0.119 mL, 0.68 mmol) in THF (15 mL) at 0 °C under nitrogen. The resulting suspension was stirred at 0 °C for 1 h and then allowed to warm to room temperature. The reaction mixture was diluted with water (15 mL) and reduced in vacuo. The resultant crude product was dissolved in DCM (20 mL) and MeOH (5 mL) and washed with water and saturated brine. The organic layer was dried (MgSO<sub>4</sub>) and evaporated. The crude product was purified by flash silica chromatography, with an elution gradient of 1–8% MeOH/NH<sub>3</sub> in DCM. Pure fractions were evaporated to dryness. The product was dissolved in DCM, and a beige solid precipitated from the solution. This solid was diluted with Et<sub>2</sub>O and filtered, washed with further Et<sub>2</sub>O, and dried to give <i>N</i>-[5-[[5-chloro-4-(1<i>H</i>-indol-3-yl)pyrimidin-2-yl]amino]-4-methoxy-2-(4-methylpiperazin-1-yl)phenyl]prop-2-enamide (134 mg, 42%) as a beige solid. <sup>1</sup>H NMR (DMSO-<i>d</i><sub>6</sub>) δ 2.27 (3H, s), 2.53–2.59 (4H, m), 2.87–2.94 (4H, m), 3.79 (3H, s), 5.70 (1H, d), 6.17 (1H, dd), 6.60 (1H, dd), 6.89 (1H, s), 7.01 (1H, t), 7.16 (1H, t), 7.45 (1H, d), 8.20 (1H, s), 8.27 (1H, d), 8.35 (1H, s), 8.43 (1H, s), 8.49 (1H, d), 8.96 (1H, s), 11.81 (1H, s); <sup>13</sup>C NMR (DMSO-<i>d</i><sub>6</sub>) δ 45.74, 51.23, 54.77, 55.72, 103.74, 110.82, 111.53, 114.43, 120.14, 120.48, 122.20, 123.03, 123.42, 124.46, 125.90, 126.05, 130.85, 132.23, 135.86, 141.31, 149.80, 157.15, 157.86, 159.13, 162.76; HRMS–ESI (<i>m</i>/<i>z</i>): [M + H]<sup>+</sup> calcd for C<sub>27</sub>H<sub>28</sub>O<sub>2</sub>N<sub>7</sub>Cl, 518.20636; found, 518.20658.</div><div class="NLM_p last">The full synthesis and characterization of the novel compounds is detailed in the <a class="ref internalNav" href="#notes-2" aria-label="Supporting Information">Supporting Information</a>. Additional compounds reported from the reactivity data set from the alternative templates and alternative covalent functionality were synthesized by exploiting the modular approaches reported in this manuscript in addition to using routes subsequently disclosed in the literature.<a onclick="showRef(event, 'ref44 ref52'); return false;" href="javascript:void(0);" class="ref ref44 ref52">(43, 51)</a> Compounds used as model systems (Table <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a>) were either available in our compound collection, purchased from commercial sources, or synthesized from commonly available building blocks.</div></div></div><div id="sec4_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i65" class="anchor-spacer"></div><h3 class="article-section__title" id="_i65"> Measuring Compound Reactivity</h3><div class="NLM_p last">Fifty micromolar of compound was reacted with an excess of glutathione (4.6 mM GSH) in phosphate buffer at pH 7.4 and 37 °C for 24 h.<a onclick="showRef(event, 'ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref37 ref38">(36, 37)</a> The reaction was followed by monitoring the loss of the parent by LC–UV–MS, and the data were fitted to first-order kinetics from which the pseudo-first-order rate constant was produced and subsequently <i>k</i><sub>GSH</sub>. Reaction of <i>para</i>-nitrobenzylchloride (PNBC) with glutathione was used as a positive control for the assay (Log <i>k</i><sub>GSH</sub> −1.747 mol<sup>–1</sup> s<sup>–1</sup>, SD 0.077, and n = 24).</div></div><div id="sec4_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i66" class="anchor-spacer"></div><h3 class="article-section__title" id="_i66"> In Vivo Xenograft Antitumor Studies</h3><div class="NLM_p last">All animal experiments were conducted in full accordance with the U.K. Home Office Animal (Scientific Procedures) Act 1986. Xenografts were established by subcutaneous cell implantation into the left flank of either athymic (Swiss nu/nu; Alpk; H1975 and A431) or severe-combined immunodeficiency (SCID) mice (SCID/CB17; PC9). Animals were randomized into treatment groups of 4–10 mice, with a group mean tumor size of ∼0.2–0.4 cm<sup>3</sup>. Mice were then treated once daily by oral gavage with either vehicle or inhibitor for up to 14 days. Tumor growth inhibition (TGI) was calculated for compound-treated groups compared to vehicle controls (<i>p</i> values provided), where a TGI > 100% indicates tumor regression from the size of the initial tumor. Statistical significance was evaluated using a one-tailed <i>t</i> test.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i67"><a href="/doi/suppl/10.1021/jm400822z">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_08676" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_08676" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">Reaction of compound <b>38</b> in buffer, structure of compound <b>60</b>, chemical structures of the compounds in Tables <a class="ref showTableEvent internalNav" data-ID="tbl7" href="#tbl7">7</a> and <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>, reaction of compounds with glutathione with and without human glutathione-S-transferase, and kinase selectivity of compound <b>15</b>. Methods of protein–ligand docking and full compound synthesis and characterization. This material is available free of charge via the Internet at <a href="http://pubs.acs.org" class="extLink">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400822z/suppl_file/jm400822z_si_001.pdf">jm400822z_si_001.pdf (771.83 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/jm400822z" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_31002" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_31002" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Richard A. Ward</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#a1d3c8c2c9c0d3c58fc08fd6c0d3c5e1c0d2d5d3c0dbc4cfc4c2c08fc2cecc"><span class="__cf_email__" data-cfemail="5e2c373d363f2c3a703f70293f2c3a1e3f2d2a2c3f243b303b3d3f703d3133">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark J. Anderton</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Susan Ashton</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Paul A. Bethel</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Box</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sam Butterworth</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicola Colclough</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christopher G. Chorley</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Claudio Chuaqui</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Darren A. E. Cross</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Les A. Dakin</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Judit É. Debreczeni</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cath Eberlein</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">M. Raymond V. Finlay</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">George B. Hill</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthew Grist</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teresa C. M. Klinowska</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Clare Lane</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Scott Martin</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jonathon P. Orme</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Smith</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Fengjiang Wang</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael J. Waring</span> - <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology &
Discovery Sciences Innovative Medicines, Mereside, Alderley
Park, Macclesfield, Cheshire SK10 4TG, United Kingdom</span>; 
    <span class="hlFld-Affiliation affiliation">AstraZeneca, Oncology Innovative Medicines, Gatehouse Park, Waltham, Massachusetts 02451, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d1017e4229-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i68">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33252" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33252" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank all of our colleagues at AstraZeneca, past and present, who have contributed to this work. We also thank Proteros for supplying the described X-ray crystal structure and Millipore for providing the early biochemical data. Finally, we thank Dr. Andy Barker who was instrumental in supporting the early efforts on this project.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i70" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i70"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i71" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i71"> Abbreviations Used</h2><tr><td class="NLM_term">EGFR</td><td class="NLM_def"><p class="first last">epidermal growth factor receptor</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small cell lung cancer</p></td></tr><tr><td class="NLM_term">TKI</td><td class="NLM_def"><p class="first last">tyrosine kinase inhibitor</p></td></tr><tr><td class="NLM_term">QSPR</td><td class="NLM_def"><p class="first last">quantitative structure property relationship</p></td></tr><tr><td class="NLM_term">GSH</td><td class="NLM_def"><p class="first last">glutathione</p></td></tr><tr><td class="NLM_term">PK</td><td class="NLM_def"><p class="first last">pharmacokinetics</p></td></tr><tr><td class="NLM_term">WT</td><td class="NLM_def"><p class="first last">wild type</p></td></tr><tr><td class="NLM_term">AM</td><td class="NLM_def"><p class="first last">activating mutant</p></td></tr><tr><td class="NLM_term">DM</td><td class="NLM_def"><p class="first last">double mutant</p></td></tr><tr><td class="NLM_term">LLE</td><td class="NLM_def"><p class="first last">ligand lipophilicity efficiency</p></td></tr><tr><td class="NLM_term">LC–MS</td><td class="NLM_def"><p class="first last">liquid chromatography–mass spectrometry</p></td></tr><tr><td class="NLM_term">QM/MM</td><td class="NLM_def"><p class="first last">quantum mechanical/molecular modeling</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">CRO</td><td class="NLM_def"><p class="first last">contract research organization</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61333" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61333" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 51 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Normanno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Luca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiello, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotenuto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Feo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caponigro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomon, D. S.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) signaling in cancer</span> <span class="citation_source-journal">Gene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.gene.2005.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=16377102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2006&pages=2-16&author=N.+Normannoauthor=A.+De+Lucaauthor=C.+Biancoauthor=L.+Strizziauthor=M.+Mancinoauthor=M.+R.+Maielloauthor=A.+Carotenutoauthor=G.+De+Feoauthor=F.+Caponigroauthor=D.+S.+Salomon&title=Epidermal+growth+factor+receptor+%28EGFR%29+signaling+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR) signaling in cancer</span></div><div class="casAuthors">Normanno, Nicola; De Luca, Antonella; Bianco, Caterina; Strizzi, Luigi; Mancino, Mario; Maiello, Monica R.; Carotenuto, Adele; De Feo, Gianfranco; Caponigro, Francesco; Salomon, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-16</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK).  These trans-membrane proteins are activated following binding with peptide growth factors of the EGF-family of proteins.  Evidence suggests that the EGFR is involved in the pathogenesis and progression of different carcinoma types.  The EGFR and EGF-like peptides are often over-expressed in human carcinomas, and in vivo and in vitro studies have shown that these proteins are able to induce cell transformation.  Amplification of the EGFR gene and mutations of the EGFR tyrosine kinase domain have been recently demonstrated to occur in carcinoma patients.  Interestingly, both these genetic alterations of the EGFR are correlated with high probability to respond to anti-EGFR agents.  However, ErbB proteins and their ligands form a complex system in which the interactions occurring between receptors and ligands affect the type and the duration of the intracellular signals that derive from receptor activation.  In fact, proteins of the ErbB family form either homo- or hetero-dimers following ligand binding, each dimer showing different affinity for ligands and different signaling properties.  In this regard, evidence suggests that cooperation of multiple ErbB receptors and cognate ligands is necessary to induce cell transformation.  In particular, the growth and the survival of carcinoma cells appear to be sustained by a network of receptors/ligands of the ErbB family.  This phenomenon is also important for therapeutic approaches, since the response to anti-EGFR agents might depend on the total level of expression of ErbB receptors and ligands in tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetexmky_mlrVg90H21EOLACvtfcHk0lh55hbmGSQ3qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Crs7k%253D&md5=107171bebde465197e71bd59b15dd590</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2005.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2005.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DBianco%26aufirst%3DC.%26aulast%3DStrizzi%26aufirst%3DL.%26aulast%3DMancino%26aufirst%3DM.%26aulast%3DMaiello%26aufirst%3DM.%2BR.%26aulast%3DCarotenuto%26aufirst%3DA.%26aulast%3DDe%2BFeo%26aufirst%3DG.%26aulast%3DCaponigro%26aufirst%3DF.%26aulast%3DSalomon%26aufirst%3DD.%2BS.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520signaling%2520in%2520cancer%26jtitle%3DGene%26date%3D2006%26volume%3D366%26spage%3D2%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lh55hbmGSQ3qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+biologically+based+treatment+of+EGFR-mutant+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0liwdIvSzSkQ1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520biologically%2520based%2520treatment%2520of%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oizumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span> </span><span class="NLM_article-title">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">2380</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Sugawaraauthor=S.+Oizumiauthor=H.+Isobeauthor=A.+Gemmaauthor=M.+Haradaauthor=H.+Yoshizawaauthor=I.+Kinoshitaauthor=Y.+Fujitaauthor=S.+Okinagaauthor=H.+Hiranoauthor=K.+Yoshimoriauthor=T.+Haradaauthor=T.+Oguraauthor=M.+Andoauthor=H.+Miyazawaauthor=T.+Tanakaauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=S.+Moritaauthor=T.+Nukiwa&title=Gefitinib+or+chemotherapy+for+non-small-cell+lung+cancer+with+mutated+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0liwdIvSzSkQ1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DI.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DH.%26aulast%3DYoshimori%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DMiyazawa%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26atitle%3DGefitinib%2520or%2520chemotherapy%2520for%2520non-small-cell%2520lung%2520cancer%2520with%2520mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Jaenneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0liwdIvSzSkQ1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0liJANXiyw5b1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maoleekoonpiroj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kooten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dediu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezjk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span> </span><span class="NLM_article-title">Erlotinib in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&author=F.+A.+Shepherdauthor=J.+R.+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjkauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=Erlotinib+in+previously+treated+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0liJANXiyw5b1A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DPereira%26aufirst%3DJ.%2BR.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjk%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DErlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D123%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stiegler, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR-mutated lung cancer: A paradigm of molecular oncology</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A280%3ADC%252BC3M7os1agsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=497-514&author=Z.+Zhangauthor=A.+L.+Stieglerauthor=T.+J.+Boggonauthor=S.+Kobayashiauthor=B.+Halmos&title=EGFR-mutated+lung+cancer%3A+A+paradigm+of+molecular+oncology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-mutated lung cancer: a paradigm of molecular oncology</span></div><div class="casAuthors">Zhang Zhenfeng; Stiegler Amy L; Boggon Titus J; Kobayashi Susumu; Halmos Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">497-514</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research.  EGFR-mutated adenocarcinoma of the lung has clearly emerged as a unique clinical entity necessitating the routine introduction of molecular diagnostics into our current diagnostic algorithms and leading to the evidence-based preferential usage of EGFR-targeted agents for patients with EGFR-mutant lung cancers.  This review will summarize our current understanding of the functional role of activating mutations, key downstream signaling pathways and regulatory mechanisms, pivotal primary and acquired resistance mechanisms, structure-function relationships and ultimately the incorporation of molecular diagnostics and small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxT8cHyGfvWwpJitSxOdIlfW6udTcc2eaGF1-9FruYfrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7os1agsQ%253D%253D&md5=f37988e50e4e504cea5a4449b1b10d1f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DStiegler%26aufirst%3DA.%2BL.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR-mutated%2520lung%2520cancer%253A%2520A%2520paradigm%2520of%2520molecular%2520oncology%26jtitle%3DOncoTargets%2520Ther.%26date%3D2010%26volume%3D1%26spage%3D497%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cary, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M/L858R mutant inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml300327z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCqsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=201-205&author=S.+Sogabeauthor=Y.+Kawakitaauthor=S.+Igakiauthor=H.+Iwataauthor=H.+Mikiauthor=D.+R.+Caryauthor=T.+Takagiauthor=S.+Takagiauthor=Y.+Ohtaauthor=T.+Ishikawa&title=Structure-based+approach+for+the+discovery+of+pyrrolo%5B3%2C2-d%5Dpyrimidine-based+EGFR+T790M%2FL858R+mutant+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors</span></div><div class="casAuthors">Sogabe, Satoshi; Kawakita, Youichi; Igaki, Shigeru; Iwata, Hidehisa; Miki, Hiroshi; Cary, Douglas R.; Takagi, Terufumi; Takagi, Shinji; Ohta, Yoshikazu; Ishikawa, Tomoyasu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-205</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) family plays a crit. role in vital cellular processes and in various cancers.  Known EGFR inhibitors exhibit distinct antitumor responses against the various EGFR mutants assocd. with nonsmall-cell lung cancer.  The L858R mutation enhances clin. sensitivity to gefitinib and erlotinib as compared with wild type and reduces the relative sensitivity to lapatinib.  In contrast, the T790M mutation confers drug resistance to gefitinib and erlotinib.  We detd. crystal structures of the wild-type and T790M/L858R double mutant EGFR kinases with reversible and irreversible pyrrolo[3,2-d]pyrimidine inhibitors based on analogs of TAK-285 and neratinib.  In these structures, M790 adopts distinct conformations to accommodate different inhibitors, whereas R858 allows conformational variations of the activation loop.  These results provide structural insights for understanding the structure-activity relationships that should contribute to the development of potent inhibitors against drug-sensitive or -resistant EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod8LbyufWJoLVg90H21EOLACvtfcHk0lgZ3rJL3kJw1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCqsb%252FO&md5=5d4d8ba552d7e98f9ac1eb07d1e882cd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fml300327z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300327z%26sid%3Dliteratum%253Aachs%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DIgaki%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DCary%26aufirst%3DD.%2BR.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DStructure-based%2520approach%2520for%2520the%2520discovery%2520of%2520pyrrolo%255B3%252C2-d%255Dpyrimidine-based%2520EGFR%2520T790M%252FL858R%2520mutant%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett%26date%3D2013%26volume%3D4%26spage%3D201%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span> </span><span class="NLM_article-title">Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition</span> <span class="citation_source-journal">Structure (Oxford, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+aberrant+activity+of+mutant+EGFR+kinase+domain+and+drug+recognition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span></div><div class="casAuthors">Gajiwala, Ketan S.; Feng, Junli; Ferre, RoseAnn; Ryan, Kevin; Brodsky, Oleg; Weinrich, Scott; Kath, John C.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain.  The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR.  We present crystal structures showing that neither L858R nor the drug-resistant L858R+T790M EGFR kinase domain is in the constitutively active conformation.  Addnl. co-crystal structures show that gefitinib and dacomitinib, an irreversible anilinoquinazoline deriv. currently in clin. development, may not be conformation specific for the active state of the enzyme.  Structural data further reveal the potential mode of recognition of one of the autophosphorylation sites in the C-terminal tail, Tyr-1016, by the kinase domain.  Biochem. and biophys. evidence suggest that the oncogenic mutations impact the conformational dynamics of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6kAQLM6h7LVg90H21EOLACvtfcHk0lgZ3rJL3kJw1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeq&md5=439bfda2e4e33786a15742e53cc271bc</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520aberrant%2520activity%2520of%2520mutant%2520EGFR%2520kinase%2520domain%2520and%2520drug%2520recognition%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D21%26spage%3D209%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Yun, C.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J.; Wong, K.</span> In <span> </span><span class="NLM_article-title"><i>Structural and mechanistic studies of lung cancer mutations in the EGFR kinase reveal a novel mechanism of drug resistance</i></span>, <span class="NLM_conf-name">236th National Meeting of the American Chemical Society</span>, <span class="NLM_conf-loc">Philadelphia, PA</span>, <span class="NLM_conf-date">Aug 17–21, 2008</span>; <span class="NLM_publisher-name">American Chemisal Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>COMP 373.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&conference=236th+National+Meeting+of+the+American+Chemical+Society&author=C.+Yun&author=M.+S.+Woo&author=H.+Greulich&author=M.+Meyerson&author=M.+J.+Eck&author=K.+Wong&title=Structural+and+mechanistic+studies+of+lung+cancer+mutations+in+the+EGFR+kinase+reveal+a+novel+mechanism+of+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%26atitle%3DStructural%2520and%2520mechanistic%2520studies%2520of%2520lung%2520cancer%2520mutations%2520in%2520the%2520EGFR%2520kinase%2520reveal%2520a%2520novel%2520mechanism%2520of%2520drug%2520resistance%26pub%3DAmerican%2520Chemisal%2520Society%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lizD-oBBuubsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+Mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0lizD-oBBuubsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520Mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span> </span><span class="NLM_article-title">Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC</span> <span class="citation_source-journal">Curr. Treat. Options Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1007%2Fs11864-012-0204-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22833206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A280%3ADC%252BC38fjtV2jsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=516-526&author=C.+M.+Lovlyauthor=L.+Horn&title=Strategies+for+overcoming+EGFR+resistance+in+the+treatment+of+advanced-stage+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC</span></div><div class="casAuthors">Lovly Christine M; Horn Leora</div><div class="citationInfo"><span class="NLM_cas:title">Current treatment options in oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">516-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OPINION STATEMENT:  Patients whose tumors harbor somatic-activating mutations within the epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of lung cancers with increased sensitivity to the EGFR tyrosine kinase inhibitors (TKIs), including the "first-generation" reversible inhibitors, erlotinib and gefitinib, and the "second-generation" irreversible inhibitors, afatinib and dacomitinib.  Several, large, phase III studies have shown already that patients with EGFR-mutant tumors display radiographic response rates of >60 % and improved progression free survival (PFS) when treated with an EGFR TKI compared with chemotherapy.  Unfortunately, despite these initial responses, patients inevitably develop progressive disease, a concept referred to clinically as acquired resistance.  Novel strategies are needed to delay or overcome acquired resistance to EGFR TKIs.  These strategies include second-generation EGFR inhibitors, rationale combinations of targeted small molecule inhibitors and/or monoclonal antibodies, and addition of traditional cytotoxic chemotherapy to EGFR TKI therapy at the time of progression.  Unfortunately, to date, there is no genotype-specific standard of care, and enrollment of patients with acquired resistance to EGFR TKIs into clinical trials specifically addressed at overcoming resistance is paramount to continue to advance the field and to improve outcomes for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDoPP1h2yk22yYR5VtavbzfW6udTcc2ea38vj4MWKeA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fjtV2jsA%253D%253D&md5=120951d5f7ddca457581fc3421bca772</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11864-012-0204-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11864-012-0204-6%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHorn%26aufirst%3DL.%26atitle%3DStrategies%2520for%2520overcoming%2520EGFR%2520resistance%2520in%2520the%2520treatment%2520of%2520advanced-stage%2520NSCLC%26jtitle%3DCurr.%2520Treat.%2520Options%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D516%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Ou, S. I.</span><span> </span><span class="NLM_article-title">Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.critrevonc.2011.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22257651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A280%3ADC%252BC38vgs1GrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=407-421&author=S.+I.+Ou&title=Second-generation+irreversible+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29%3A+A+better+mousetrap%3F+A+review+of+the+clinical+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence</span></div><div class="casAuthors">Ou Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC.  First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations.  However, resistance to gefitinib and erlotinib invariably develops after prolonged clinical use.  Two second-generation irreversible EGFR TKIs, afatinib (BIBW 2992) and dacomitinib (PF-00299804), that can potentially overcome the majority of these resistances are in late stage clinical development.  Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB3Zud0oX1WCM8MEzWGjS9fW6udTcc2ea38vj4MWKeA7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vgs1GrsA%253D%253D&md5=df9e3f1fe1c2bb8f328f925725024d40</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2011.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2011.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DSecond-generation%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%253A%2520A%2520better%2520mousetrap%253F%2520A%2520review%2520of%2520the%2520clinical%2520evidence%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2012%26volume%3D83%26spage%3D407%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+Chenauthor=K.+Parkauthor=S.+Kimauthor=C.+Zhouauthor=W.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.+Tanauthor=T.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+A+phase+2b%2F3+randomised+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lhlRQ348NqwMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChao%26aufirst%3DT.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520A%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Allen, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span> </span><span class="NLM_article-title">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1053%2Fj.seminoncol.2003.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=14613028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=65-78&author=L.+F.+Allenauthor=I.+A.+Eisemanauthor=D.+W.+Fryauthor=P.+F.+Lenehan&title=CI-1033%2C+an+irreversible+pan-erbB+receptor+inhibitor+and+its+potential+application+for+the+treatment+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span></div><div class="casAuthors">Allen, Lee F.; Eiseman, Irene A.; Fry, David W.; Lenehan, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  The erbB family of cell surface receptor proteins consists of four members, all of which play a role in the development and growth of the normal breast.  The activity of this signaling pathway is normally tightly controlled, and dysregulation has been shown to play a significant role in the pathogenesis and progression of breast and other cancers.  The potent transforming potential of these receptors is further enhanced by the coexpression of multiple members of this receptor family, which worsens prognosis.  Therapeutic blockade of erbB-2 receptor signaling has to date been shown to be effective in only a subset of chemotherapy-resistant breast cancer patients.  CI-1033 is a highly potent and selective pan-erbB inhibitor that efficiently blocks signal transduction through all four members of the erbB receptor family.  In addn., it covalently binds to these receptors, irreversibility inhibiting them, and thereby provides for prolonged suppression of erbB receptor-mediated signaling.  Clin., it has been shown to have an acceptable side effect profile at potentially therapeutic doses and schedules.  Biomarker studies have shown target inhibition in patients, and evidence of antitumor activity has also been obsd. in phase I studies.  Given the broad expression pattern of the erbB family of receptors in solid tumors, and the important proliferative effect of co-expression of multiple erbB receptors, CI-1033, as an irreversible, pan-erbB inhibitor, has the potential to have an important role in the future treatment of breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnHJoa4ri9ObVg90H21EOLACvtfcHk0lir2DQUOAwl-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF&md5=13e9d00d8a20f3c79b4f7fe1032f07b5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2003.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2003.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DL.%2BF.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26atitle%3DCI-1033%252C%2520an%2520irreversible%2520pan-erbB%2520receptor%2520inhibitor%2520and%2520its%2520potential%2520application%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26spage%3D65%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Dacomitinib (PF-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to Trastuzumab and Lapatinib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1978</span><span class="NLM_x">–</span> <span class="NLM_lpage">1987</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1158%2F1535-7163.MCT-11-0730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22761403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1978-1987&author=O.+Kalousauthor=D.+Conklinauthor=A.+J.+Desaiauthor=N.+A.+O%E2%80%99Brienauthor=C.+Gintherauthor=L.+Andersonauthor=D.+J.+Cohenauthor=C.+D.+Brittenauthor=I.+Taylorauthor=J.+G.+Christensenauthor=D.+J.+Slamonauthor=R.+S.+Finn&title=Dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-HER+inhibitor%2C+inhibits+proliferation+of+HER2-amplified+breast+cancer+cell+lines+resistant+to+Trastuzumab+and+Lapatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib</span></div><div class="casAuthors">Kalous, Ondrej; Conklin, Dylan; Desai, Amrita J.; O'Brien, Neil A.; Ginther, Charles; Anderson, Lee; Cohen, David J.; Britten, Carolyn D.; Taylor, Ian; Christensen, James G.; Slamon, Dennis J.; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1978-1987</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies.  Trastuzumab and lapatinib are std. treatments for HER2-amplified breast cancer, but a significant no. of patients do not respond or develop resistance to these drugs.  Here we evaluate the in vitro activity of dacomitinib (PF-00299804), an irreversible small mol. pan-HER inhibitor, in a large panel of human breast cancer cell lines with variable expression of the HER family receptors and ligands, and with variable sensitivity to trastuzumab and lapatinib.  Forty-seven human breast cancer and immortalized breast epithelial lines representing the known mol. subgroups of breast cancer were treated with dacomitinib to det. IC50 values.  HER2-amplified lines were far more likely to respond to dacomitinib than nonamplified lines (RR, 3.39; P < 0.0001).  Furthermore, HER2 mRNA and protein expression were quant. assocd. with response.  Dacomitinib reduced the phosphorylation of HER2, EGFR, HER4, AKT, and ERK in the majority of sensitive lines.  Dacomitinib exerted its antiproliferative effect through a combined G0-G1 arrest and an induction of apoptosis.  Dacomitinib inhibited growth in several HER2-amplified lines with de novo and acquired resistance to trastuzumab.  Dacomitinib maintained a high activity in lines with acquired resistance to lapatinib.  This study identifies HER2-amplified breast cancer lines as most sensitive to the antiproliferative effect of dacomitinib and provides a strong rationale for its clin. testing in HER2-amplified breast cancers resistant to trastuzumab and lapatinib.  Mol Cancer Ther; 11(9); 1978-87. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp55-QHIJqDk7Vg90H21EOLACvtfcHk0lir2DQUOAwl-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI&md5=b2b0677cbecb66e1e629742adffb0782</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0730%26sid%3Dliteratum%253Aachs%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DDacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520inhibits%2520proliferation%2520of%2520HER2-amplified%2520breast%2520cancer%2520cell%2520lines%2520resistant%2520to%2520Trastuzumab%2520and%2520Lapatinib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1978%26epage%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Johnston, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navaratnam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniate, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiechec, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baust, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingerich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skliris, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, M.</span><span> </span><span class="NLM_article-title">Targeting the EGFR pathway for cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3483</span><span class="NLM_x">–</span> <span class="NLM_lpage">3492</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.2174%2F092986706779026174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17168718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1aks7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=3483-3492&author=J.+B.+Johnstonauthor=S.+Navaratnamauthor=M.+W.+Pitzauthor=J.+M.+Maniateauthor=E.+Wiechecauthor=H.+Baustauthor=J.+Gingerichauthor=G.+P.+Sklirisauthor=L.+C.+Murphyauthor=M.+Los&title=Targeting+the+EGFR+pathway+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the EGFR pathway for cancer therapy</span></div><div class="casAuthors">Johnston, James B.; Navaratnam, Sri; Pitz, Marshall W.; Maniate, Jerry M.; Wiechec, Emilia; Baust, Heinrich; Gingerich, Joel; Skliris, Georgios P.; Murphy, Leigh C.; Los, Marek</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3483-3492</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Clin. studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant to conventional chemo-therapies.  Addnl., in most patients with multiple myeloma, the malignant cells over-express a no. of epidermal growth factor receptors (EGFR)s and their ligands, HB-EGF and amphiregulin, thus this growth-factor family may be an important aspect in the patho-biol. of this disease.  These and other, related findings have provided the rationale for the targeting of the components of the EGFR signaling pathways for cancer therapy.  Below we discuss various aspects of EGFR-targeted therapies mainly in hematol. malignancies, lung cancer and breast cancer.  Beside novel therapeutic approaches, we also discuss specific side effects assocd. with the therapeutic inhibition of components of the EGFR-pathways.  Alongside small inhibitors, such as Lapatinib (Tykerb, GW572016), Gefitinib (Iressa, ZD1839), and Erlotinib (Tarceva, OSI-774), a significant part of the review is also dedicated to therapeutic antibodies (e.g.: Trastuzumab / Herceptin, Pertuzumab / Omnitarg / rhuMab-2C4, Cetuximab / Erbitux / IMC-C225, Panitumumab / Abenix / ABX-EGF, and also ZD6474).  In addn., we summarize, both current therapy development driven by antibody-based targeting of the EGFR-dependent signaling pathways, and furthermore, we provide a background on the history and the development of therapeutic antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKtrrqQ9o2ubVg90H21EOLACvtfcHk0lir2DQUOAwl-w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1aks7fF&md5=79ea40904fab4efd0ca908e2269da1a4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F092986706779026174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706779026174%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BB.%26aulast%3DNavaratnam%26aufirst%3DS.%26aulast%3DPitz%26aufirst%3DM.%2BW.%26aulast%3DManiate%26aufirst%3DJ.%2BM.%26aulast%3DWiechec%26aufirst%3DE.%26aulast%3DBaust%26aufirst%3DH.%26aulast%3DGingerich%26aufirst%3DJ.%26aulast%3DSkliris%26aufirst%3DG.%2BP.%26aulast%3DMurphy%26aufirst%3DL.%2BC.%26aulast%3DLos%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520EGFR%2520pathway%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26spage%3D3483%26epage%3D3492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0liO-DA-ZgOxLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 → methionine790 mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Bai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span> </span><span class="NLM_article-title">Discovery of novel selective inhibitors for EGFR-T790M/L858R</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span><span class="NLM_x">–</span> <span class="NLM_lpage">1370</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1365-1370&author=F.+Baiauthor=H.+Liuauthor=L.+Tongauthor=W.+Zhouauthor=L.+Liuauthor=Z.+Zhaoauthor=X.+Liuauthor=H.+Jiangauthor=X.+Wangauthor=H.+Xieauthor=H.+Li&title=Discovery+of+novel+selective+inhibitors+for+EGFR-T790M%2FL858R"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520novel%2520selective%2520inhibitors%2520for%2520EGFR-T790M%252FL858R%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1365%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirazzoli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Noncovalent wild-type-sparing inhibitors of EGFR T790M</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=168-181&author=H.+Leeauthor=G.+Schaeferauthor=T.+P.+Heffronauthor=L.+Shaoauthor=X.+Yeauthor=S.+Siderisauthor=S.+Malekauthor=E.+Chanauthor=M.+Merchantauthor=H.+Laauthor=S.+Ubhayakarauthor=R.+L.+Yauchauthor=V.+Pirazzoliauthor=K.+Politiauthor=J.+Settleman&title=Noncovalent+wild-type-sparing+inhibitors+of+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DPirazzoli%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DNoncovalent%2520wild-type-sparing%2520inhibitors%2520of%2520EGFR%2520T790M%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D168%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lj-Uqr0C60S4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit26"><span>Merck Millipore Home Page. <a href="http://www.millipore.com" class="extLink">www.millipore.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Merck+Millipore+Home+Page.+www.millipore.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0lj-Uqr0C60S4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Rauh, D.</span> In <span> </span><span class="NLM_article-title"><i>Targeting protein kinases with irreversible inhibitors</i></span>, <span class="NLM_conf-name">241st National Meeting of the American Chemical Society</span>, <span class="NLM_conf-loc">Anaheim, CA</span>, <span class="NLM_conf-date">March 27–31, 2011</span>; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>MEDI 157.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&conference=241st+National+Meeting+of+the+American+Chemical+Society&author=D.+Rauh&title=Targeting+protein+kinases+with+irreversible+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520protein%2520kinases%2520with%2520irreversible%2520inhibitors%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labinski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">StMartin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span> </span><span class="NLM_article-title">Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">783</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=780-783&author=J.+Singhauthor=E.+Evansauthor=M.+Hagelauthor=M.+Labinskiauthor=A.+Dubrovskiyauthor=M.+Nachtauthor=R.+C.+Petterauthor=A.+Prasadauthor=M.+Sheetsauthor=T.+StMartinauthor=R.+Tjin+Tham+Sjinauthor=W.+Westlinauthor=Z.+Zhu&title=Superiority+of+a+novel+EGFR+targeted+covalent+inhibitor+over+its+reversible+counterpart+in+overcoming+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DE.%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DLabinski%26aufirst%3DM.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DPrasad%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DStMartin%26aufirst%3DT.%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DSuperiority%2520of%2520a%2520novel%2520EGFR%2520targeted%2520covalent%2520inhibitor%2520over%2520its%2520reversible%2520counterpart%2520in%2520overcoming%2520drug%2520resistance%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D780%26epage%3D783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klicic, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoll, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenkin, P. S.</span><span> </span><span class="NLM_article-title">Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1739</span><span class="NLM_x">–</span> <span class="NLM_lpage">1749</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+A+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Å in nearly half of the cases and are greater than 2 Å in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0liTLiSvq74FFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520A%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Ehmke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinsaat, J. E. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera-Fuentes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heindl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freymond, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirmeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span> </span><span class="NLM_article-title">Tuning and predicting biological affinity: Aryl nitriles as cysteine protease inhibitors</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">5764</span><span class="NLM_x">–</span> <span class="NLM_lpage">5768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1039%2Fc2ob00034b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22336919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSlsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=5764-5768&author=V.+Ehmkeauthor=J.+E.+Q.+Quinsaatauthor=P.+Rivera-Fuentesauthor=C.+Heindlauthor=C.+Freymondauthor=M.+Rottmannauthor=R.+Brunauthor=T.+Schirmeisterauthor=F.+Diederich&title=Tuning+and+predicting+biological+affinity%3A+Aryl+nitriles+as+cysteine+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning and predicting biological affinity: aryl nitriles as cysteine protease inhibitors</span></div><div class="casAuthors">Ehmke, Veronika; Quinsaat, Jose Enrico Q.; Rivera-Fuentes, Pablo; Heindl, Cornelia; Freymond, Celine; Rottmann, Matthias; Brun, Reto; Schirmeister, Tanja; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">5764-5768</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of aryl nitrile-based ligands were prepd. to investigate the effect of their electrophilicity on the affinity against the cysteine proteases rhodesain and human cathepsin L. D. functional theory calcns. provided relative reactivities of the nitriles, enabling prediction of their biol. affinity and cytotoxicity and a clear structure-activity relationship.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOglKLK34p47Vg90H21EOLACvtfcHk0liTLiSvq74FFA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSlsr3J&md5=45858b629d24a54b72cd7e3b7ba15e5b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fc2ob00034b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob00034b%26sid%3Dliteratum%253Aachs%26aulast%3DEhmke%26aufirst%3DV.%26aulast%3DQuinsaat%26aufirst%3DJ.%2BE.%2BQ.%26aulast%3DRivera-Fuentes%26aufirst%3DP.%26aulast%3DHeindl%26aufirst%3DC.%26aulast%3DFreymond%26aufirst%3DC.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DSchirmeister%26aufirst%3DT.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DTuning%2520and%2520predicting%2520biological%2520affinity%253A%2520Aryl%2520nitriles%2520as%2520cysteine%2520protease%2520inhibitors%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2012%26volume%3D10%26spage%3D5764%26epage%3D5768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit32"><span>Proteros Biostructures Home Page. <a href="http://www.proteros.de" class="extLink">www.proteros.de</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Proteros+Biostructures+Home+Page.+www.proteros.de."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+ligand+lipophilicity+efficiency+in+addressing+drug+safety+risks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520ligand%2520lipophilicity%2520efficiency%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lhk7sJK0-g62g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruston, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, B.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure</span> <span class="citation_source-journal">J. Med. Chem .</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6672</span><span class="NLM_x">–</span> <span class="NLM_lpage">6682</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0605233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtV2gtLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6672-6682&author=A.+G.+Leachauthor=H.+D.+Jonesauthor=D.+A.+Cosgroveauthor=P.+W.+Kennyauthor=L.+Rustonauthor=P.+MacFaulauthor=J.+M.+Woodauthor=N.+Colcloughauthor=B.+Law&title=Matched+molecular+pairs+as+a+guide+in+the+optimization+of+pharmaceutical+properties%3B+a+study+of+aqueous+solubility%2C+plasma+protein+binding+and+oral+exposure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure</span></div><div class="casAuthors">Leach, Andrew G.; Jones, Huw D.; Cosgrove, David A.; Kenny, Peter W.; Ruston, Linette; MacFaul, Philip; Wood, J. Matthew; Colclough, Nicola; Law, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6672-6682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By identifying every pair of mols. that differ only by a particular, well-defined, structural transformation in a database of measured properties and computing the corresponding change in property, we obtain an overview of the effect that structural change has upon the property and set an expectation for what will happen when that transformation is applied elsewhere.  The mean change indicates the expected magnitude of the change in the property and the no. of cases in which the property increases give the probability that the structural transformation will cause the property to increase.  Outliers indicate potential ways of avoiding the general trend.  Comparing to changes in lipophilicity highlights structural transformations that have unusual effects, some of which can be explained by conformational changes.  In this paper, we focus upon the effects on aq. soly., plasma protein binding and oral exposure of adding substituents to arom. rings and methylating heteroatoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcyrloR79Oq7Vg90H21EOLACvtfcHk0lhk7sJK0-g62g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtV2gtLnO&md5=2c143b424aee3ddb6c34616aff699ee0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm0605233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0605233%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DH.%2BD.%26aulast%3DCosgrove%26aufirst%3DD.%2BA.%26aulast%3DKenny%26aufirst%3DP.%2BW.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DLaw%26aufirst%3DB.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520guide%2520in%2520the%2520optimization%2520of%2520pharmaceutical%2520properties%253B%2520a%2520study%2520of%2520aqueous%2520solubility%252C%2520plasma%2520protein%2520binding%2520and%2520oral%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem%2520.%26date%3D2006%26volume%3D49%26spage%3D6672%26epage%3D6682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit36R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lhk7sJK0-g62g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Clarke, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenhow, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D.</span><span> </span><span class="NLM_article-title">Metabolism-related assays and their application to agrochemical research: Reactivity of pesticides with glutathione and glutathione transferases</span> <span class="citation_source-journal">Pestic. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1002%2F%28SICI%291096-9063%28199812%2954%3A4%3C385%3A%3AAID-PS842%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADyaK1MXhtlCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=385-393&author=E.+D.+Clarkeauthor=D.+T.+Greenhowauthor=D.+Adams&title=Metabolism-related+assays+and+their+application+to+agrochemical+research%3A+Reactivity+of+pesticides+with+glutathione+and+glutathione+transferases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-related assays and their application to agrochemical research: reactivity of pesticides with glutathione and glutathione transferases</span></div><div class="casAuthors">Clarke, Eric D.; Greenhow, Daren T.; Adams, David</div><div class="citationInfo"><span class="NLM_cas:title">Pesticide Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-393</span>CODEN:
                <span class="NLM_cas:coden">PSSCBG</span>;
        ISSN:<span class="NLM_cas:issn">0031-613X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">An HPLC-based assay system has been developed to measure the reactivity of agrochems. with glutathione (GSH) with and without catalysis by glutathione transferases (GSTs).  Metab.-related parameters based on second-order related rate consts. from nonenzymic GSH and enzymic GSH + GST assays have been derived for use in structure-activity and structure-reactivity relationship studies of exploratory agrochems.  The versatility and sensitivity of the assay system has been established using a diverse range of agrochems. and model compds., e.g. 4-nitrobenzyl chloride, 1-chloro-2,4-dinitrobenzene, atrazine, acetochlor, fluorodifen, fluazifop-Bu, tridiphane, fluazinam, chlorothalonil and diazinon.  For the enzymic GSH + GST assay, second-order related rate consts., ratioed to the assay std., 4-nitrobenzyl chloride to provide a parameter independent of assay conditions, spanned 5 orders of magnitude, fluazinam being the most reactive and atrazine the least.  Within chem. classes, significant variations in reactivity were obsd., alachlor being c. 15-fold more reactive than pretilachlor.  Applications of this assay system based on comparative measures of reactivity across and within chem. classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozE9JcsswrNbVg90H21EOLACvtfcHk0lh4cO7Jst8FSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtlCrsg%253D%253D&md5=5de37b3f68e5df660d917bc17fb4fb16</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-9063%28199812%2954%3A4%3C385%3A%3AAID-PS842%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-9063%2528199812%252954%253A4%253C385%253A%253AAID-PS842%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DE.%2BD.%26aulast%3DGreenhow%26aufirst%3DD.%2BT.%26aulast%3DAdams%26aufirst%3DD.%26atitle%3DMetabolism-related%2520assays%2520and%2520their%2520application%2520to%2520agrochemical%2520research%253A%2520Reactivity%2520of%2520pesticides%2520with%2520glutathione%2520and%2520glutathione%2520transferases%26jtitle%3DPestic.%2520Sci.%26date%3D1998%26volume%3D54%26spage%3D385%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">MacFaul, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morley, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span> </span><span class="NLM_article-title">A simple in vitro assay for assessing the reactivity of nitrile containing compounds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1136</span><span class="NLM_x">–</span> <span class="NLM_lpage">1138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.bmcl.2008.12.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=19168354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1WrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1136-1138&author=P.+A.+MacFaulauthor=A.+D.+Morleyauthor=J.+J.+Crawford&title=A+simple+in+vitro+assay+for+assessing+the+reactivity+of+nitrile+containing+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A simple in vitro assay for assessing the reactivity of nitrile containing compounds</span></div><div class="casAuthors">MacFaul, Philip A.; Morley, Andrew D.; Crawford, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1136-1138</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A quant. assay involving the reaction of nitriles with glutathione and cysteine has been used as a simple in vitro screen to assess potential toxicity risk of candidate compds. in drug discovery.  Studies have indicated that, when benchmarked with selected compds., the reaction of the nitriles with glutathione can provide a useful tool for deciding whether or not to progress compds. in the absence of radiolabelling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro23j0VCklM7Vg90H21EOLACvtfcHk0lh4cO7Jst8FSw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1WrtLs%253D&md5=d949b5d0e76c6d268f3f57cc4584f0b9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.105%26sid%3Dliteratum%253Aachs%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DMorley%26aufirst%3DA.%2BD.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520simple%2520in%2520vitro%2520assay%2520for%2520assessing%2520the%2520reactivity%2520of%2520nitrile%2520containing%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1136%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Schwobel, J. A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madden, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T. D.</span><span> </span><span class="NLM_article-title">Examination of Michael addition reactivity towards glutathione by transition-state calculations</span> <span class="citation_source-journal">SAR QSAR Environ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=693-710&author=J.+A.+H.+Schwobelauthor=J.+C.+Maddenauthor=M.+T.+D.+Cronin&title=Examination+of+Michael+addition+reactivity+towards+glutathione+by+transition-state+calculations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwobel%26aufirst%3DJ.%2BA.%2BH.%26aulast%3DMadden%26aufirst%3DJ.%2BC.%26aulast%3DCronin%26aufirst%3DM.%2BT.%2BD.%26atitle%3DExamination%2520of%2520Michael%2520addition%2520reactivity%2520towards%2520glutathione%2520by%2520transition-state%2520calculations%26jtitle%3DSAR%2520QSAR%2520Environ.%2520Res.%26date%3D2010%26volume%3D21%26spage%3D693%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Esterbauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholz, N.</span><span> </span><span class="NLM_article-title">Reaction of glutathione with conjugated carbonyls</span> <span class="citation_source-journal">Z. Naturforsch., C</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=241172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A280%3ADyaE28%252FjsF2mtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1975&pages=466-473&author=H.+Esterbauerauthor=H.+Zollnerauthor=N.+Scholz&title=Reaction+of+glutathione+with+conjugated+carbonyls"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Reaction of glutathione with conjugated carbonyls</span></div><div class="casAuthors">Esterbauer H; Zollner H; Scholz N</div><div class="citationInfo"><span class="NLM_cas:title">Zeitschrift fur Naturforschung. Section C, Biosciences</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466-73</span>
        ISSN:<span class="NLM_cas:issn">0341-0382</span>.
    </div><div class="casAbstract">1.  GSH reacts with conjugated carbonyls according to the equation: GSH+R-CH=CH-COR in equilibrium R-CH(SG)-CH2-COR.  The forward reaction follows second order, the reverse reaction first order kinetics.  It is assumed that this reaction reflects best the ability of conjugated carbonyls to inactivate SH groups in biological systems. 2.  The rate of forward reaction increases with pH approx. parallel with alphaSH.  Besides OH- ions also proton donors (e.g. buffers) increase the rate.  The catalytic effect of pH and buffer is interpreted in view of the reaction mechanism. 3.  The equilibrium constants as well as the rate constants for forward (k1) and reverse reaction show an extreme variation depending on the carbonyl structure.  Acrolein and methyl vinyl ketone (k1 = 120 and 32 mol-1 sec-1, resp.) react more rapidly than any other carbonyl to give very stable adducts (half-lives for reverse reaction 4.6 and 60.7 days, resp).  Somewhat less reactive are 4-hydroxy-2-alkenals and 4-ketopentenoic acid (k1 between 1 and 3 mol-1 sec-1), but they also form very stable adducts showing half-lives between 3.4 and 19 days.  All other carbonyl studied react either very slowly (e.g. citral, ethly crotonate, mesityl oxide, acrylic acid) or form very labile adducts (crotonal, pentenal, hexenal, 3-methyl-butenone).  Comparing biological activities of conjugated carbonyls their reactivity towards HS (k1) and the stability of the adducts must be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShzMY519srAedfST00W0BcfW6udTcc2eZUkrEuLWgADLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE28%252FjsF2mtg%253D%253D&md5=f1507bf00ea14a2ac7984313525fa485</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEsterbauer%26aufirst%3DH.%26aulast%3DZollner%26aufirst%3DH.%26aulast%3DScholz%26aufirst%3DN.%26atitle%3DReaction%2520of%2520glutathione%2520with%2520conjugated%2520carbonyls%26jtitle%3DZ.%2520Naturforsch.%252C%2520C%26date%3D1975%26volume%3D30%26spage%3D466%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Bohme, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaens, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paschke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuurmann, G.</span><span> </span><span class="NLM_article-title">Kinetic glutathione chemoassay to quantify thiol reactivity of organic electrophiles-application to alpha,beta-unsaturated ketones, acrylates, and propiolates</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx800492x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=742-750&author=A.+Bohmeauthor=D.+Thaensauthor=A.+Paschkeauthor=G.+Schuurmann&title=Kinetic+glutathione+chemoassay+to+quantify+thiol+reactivity+of+organic+electrophiles-application+to+alpha%2Cbeta-unsaturated+ketones%2C+acrylates%2C+and+propiolates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Ftx800492x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800492x%26sid%3Dliteratum%253Aachs%26aulast%3DBohme%26aufirst%3DA.%26aulast%3DThaens%26aufirst%3DD.%26aulast%3DPaschke%26aufirst%3DA.%26aulast%3DSchuurmann%26aufirst%3DG.%26atitle%3DKinetic%2520glutathione%2520chemoassay%2520to%2520quantify%2520thiol%2520reactivity%2520of%2520organic%2520electrophiles-application%2520to%2520alpha%252Cbeta-unsaturated%2520ketones%252C%2520acrylates%252C%2520and%2520propiolates%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D742%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Paasche, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirmeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engels, B.</span><span> </span><span class="NLM_article-title">Mechanistic study of the reaction of thiol-containing enzymes with α,β-unsaturated carbonyl substrates by computation and chemoassays</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">869</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=869-880&author=A.+Paascheauthor=M.+Schillerauthor=T.+Schirmeisterauthor=B.+Engels&title=Mechanistic+study+of+the+reaction+of+thiol-containing+enzymes+with+%CE%B1%2C%CE%B2-unsaturated+carbonyl+substrates+by+computation+and+chemoassays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaasche%26aufirst%3DA.%26aulast%3DSchiller%26aufirst%3DM.%26aulast%3DSchirmeister%26aufirst%3DT.%26aulast%3DEngels%26aufirst%3DB.%26atitle%3DMechanistic%2520study%2520of%2520the%2520reaction%2520of%2520thiol-containing%2520enzymes%2520with%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520carbonyl%2520substrates%2520by%2520computation%2520and%2520chemoassays%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D869%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Krenske, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, K. N.</span><span> </span><span class="NLM_article-title">Transition states and energetics of nucleophilic additions of thiols to substituted α,β-unsaturated ketones: substituent effects involve enone stabilization, product branching, and solvation</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">5074</span><span class="NLM_x">–</span> <span class="NLM_lpage">5081</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo200761w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFWqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=5074-5081&author=E.+H.+Krenskeauthor=R.+C.+Petterauthor=Z.+Zhuauthor=K.+N.+Houk&title=Transition+states+and+energetics+of+nucleophilic+additions+of+thiols+to+substituted+%CE%B1%2C%CE%B2-unsaturated+ketones%3A+substituent+effects+involve+enone+stabilization%2C+product+branching%2C+and+solvation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Transition States and Energetics of Nucleophilic Additions of Thiols to Substituted α,β-Unsaturated Ketones: Substituent Effects Involve Enone Stabilization, Product Branching, and Solvation</span></div><div class="casAuthors">Krenske, Elizabeth H.; Petter, Russell C.; Zhu, Zhendong; Houk, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5074-5081</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CBS-QB3 enthalpies of reaction have been computed for the conjugate addns. of MeSH to six α,β-unsatd. ketones.  Compared with addn. to Me vinyl ketone, the reaction becomes 1-3 kcal mol-1 less exothermic when an α-Me, β-Me, or β-Ph substituent is present on the C=C bond.  The lower exothermicity for the substituted enones occurs because the substituted reactant is stabilized more by hyperconjugation or conjugation than the product is stabilized by branching.  Substituent effects on the activation energies for the rate-detg. step of the thiol addn.(reaction of the enone with MeS-) were also computed.  Loss of reactant stabilization, and not steric hindrance, is the main factor responsible for controlling the relative activation energies in the gas phase.  The substituent effects are further magnified in soln.; in water (simulated by CPCM calcns.), the addn. of MeS- to an enone is disfavored by 2-6 kcal mol-1 when one or two Me groups are present on the C=C bond.  The use of CBS-QB3 gas-phase energies in conjunction with CPCM solvation corrections provides kinetic data in good agreement with exptl. substituent effects.  When the energetics of the thiol addns. were calcd. with several popular d. functional theory and ab initio methods(B3LYP, MPW1PW91, B1B95, PBE0, B2PLYP, and MP2), some substantial inaccuracies were noted.  However, M06-2X(with a large basis set), B2PLYP-D, and SCS-MP2 gave results within 1 kcal mol-1 of the CBS-QB3 benchmark values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfP3ND9L6ax7Vg90H21EOLACvtfcHk0ljkmr1vKLK4JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFWqsLs%253D&md5=8f0bbd69b9d81814d196327fb3f878ea</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjo200761w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo200761w%26sid%3Dliteratum%253Aachs%26aulast%3DKrenske%26aufirst%3DE.%2BH.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHouk%26aufirst%3DK.%2BN.%26atitle%3DTransition%2520states%2520and%2520energetics%2520of%2520nucleophilic%2520additions%2520of%2520thiols%2520to%2520substituted%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520ketones%253A%2520substituent%2520effects%2520involve%2520enone%2520stabilization%252C%2520product%2520branching%252C%2520and%2520solvation%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D5074%26epage%3D5081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Gray, N. S.; Zhou, W.</span> WIPO Patent WO2011140338,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gray%2C+N.+S.%3B+Zhou%2C+W.+WIPO+Patent+WO2011140338%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Tsou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBlanc, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehn, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2734</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0005555" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2719-2734&author=H.+Tsouauthor=N.+Mamuyaauthor=B.+D.+Johnsonauthor=M.+F.+Reichauthor=B.+C.+Gruberauthor=F.+Yeauthor=R.+Nilakantanauthor=R.+Shenauthor=C.+Discafaniauthor=R.+DeBlancauthor=R.+Davisauthor=F.+E.+Koehnauthor=L.+M.+Greenbergerauthor=Y.+Wangauthor=A.+Wissner&title=6-Substituted-4-%283-bromophenylamino%29quinazolines+as+putative+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+human+epidermal+growth+factor+receptor+%28HER-2%29+tyrosine+kinases+with+enhanced+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm0005555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0005555%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDeBlanc%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DKoehn%26aufirst%3DF.%2BE.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3D6-Substituted-4-%25283-bromophenylamino%2529quinazolines%2520as%2520putative%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528HER-2%2529%2520tyrosine%2520kinases%2520with%2520enhanced%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2719%26epage%3D2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pufall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathlin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froedin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Froedinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0ljkmr1vKLK4JQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFroedin%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Bain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plater, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shpiro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastie, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLauchlan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klevernic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, J. S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span> </span><span class="NLM_article-title">The selectivity of protein kinase inhibitors: a further update</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1042%2FBJ20070797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17850214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmtbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2007&pages=297-315&author=J.+Bainauthor=L.+Platerauthor=M.+Elliottauthor=N.+Shpiroauthor=C.+J.+Hastieauthor=H.+McLauchlanauthor=I.+Klevernicauthor=J.+S.+C.+Arthurauthor=D.+R.+Alessiauthor=P.+Cohen&title=The+selectivity+of+protein+kinase+inhibitors%3A+a+further+update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of protein kinase inhibitors: a further update</span></div><div class="casAuthors">Bain, Jenny; Plater, Lorna; Elliott, Matt; Shpiro, Natalia; Hastie, C. James; McLauchlan, Hilary; Klevernic, Iva; Arthur, J. Simon C.; Alessi, Dario R.; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-315</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 65 compds. reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein kinases.  On the basis of this information, the effects of compds. that we have studied in cells and other data in the literature, we recommend the use of the following small-mol. inhibitors: SB 203580/SB202190 and BIRB 0796 to be used in parallel to assess the physiol. roles of p38 MAPK (mitogen-activated protein kinase) isoforms, PI-103 and wortmannin to be used in parallel to inhibit phosphatidylinositol (phosphoinositide) 3-kinases, PP1 or PP2 to be used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 to inhibit MKK1 (MAPK kinase-1) or MKK1 plus MKK5, Akt-I-1/2 to inhibit the activation of PKB (protein kinase B/Akt), rapamycin to inhibit TORC1 [mTOR (mammalian target of rapamycin)-raptor (regulatory assocd. protein of mTOR) complex], CT 99021 to inhibit GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethylketone) to be used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 to inhibit CK1 (casein kinase 1), VX680 to inhibit Aurora kinases, and roscovitine as a pan-CDK (cyclin-dependent kinase) inhibitor.  We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro.  The results have further emphasized the need for considerable caution in using small-mol. inhibitors of protein kinases to assess the physiol. roles of these enzymes.  Despite being used widely, many of the compds. that we analyzed were too non-specific for useful conclusions to be made, other than to exclude the involvement of particular protein kinases in cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQPaieWftdVrVg90H21EOLACvtfcHk0lhFYoeGH1tO5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmtbjE&md5=e2334e35897dd1b9770bbcca8f82bb9c</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1042%2FBJ20070797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070797%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DJ.%26aulast%3DPlater%26aufirst%3DL.%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DShpiro%26aufirst%3DN.%26aulast%3DHastie%26aufirst%3DC.%2BJ.%26aulast%3DMcLauchlan%26aufirst%3DH.%26aulast%3DKlevernic%26aufirst%3DI.%26aulast%3DArthur%26aufirst%3DJ.%2BS.%2BC.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520selectivity%2520of%2520protein%2520kinase%2520inhibitors%253A%2520a%2520further%2520update%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D408%26spage%3D297%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Å resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0lhFYoeGH1tO5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Software XDS for image rotation, recognition and crystal symmetry assignment</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=Software+XDS+for+image+rotation%2C+recognition+and+crystal+symmetry+assignment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lhFYoeGH1tO5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DSoftware%2520XDS%2520for%2520image%2520rotation%252C%2520recognition%2520and%2520crystal%2520symmetry%2520assignment%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: Model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+Model-building+tools+for+molecular+graphics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0ljSWLpYIcC5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebedev, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potterton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNicholas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murshudov, G. N.</span><span> </span><span class="NLM_article-title">REFMAC5 dictionary: Organization of prior chemical knowledge and guidelines for its use</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2184</span><span class="NLM_x">–</span> <span class="NLM_lpage">2195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1107%2FS0907444904023510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=15572771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2184-2195&author=A.+A.+Vaginauthor=R.+A.+Steinerauthor=A.+A.+Lebedevauthor=L.+Pottertonauthor=S.+McNicholasauthor=F.+Longauthor=G.+N.+Murshudov&title=REFMAC5+dictionary%3A+Organization+of+prior+chemical+knowledge+and+guidelines+for+its+use"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use</span></div><div class="casAuthors">Vagin, Alexei A.; Steiner, Roberto A.; Lebedev, Andrey A.; Potterton, Liz; McNicholas, Stuart; Long, Fei; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2184-2195</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">One of the most important aspects of macromol. structure refinement is the use of prior chem. knowledge.  Bond lengths, bond angles and other chem. properties are used in restrained refinement as subsidiary conditions.  This contribution describes the organization and some aspects of the use of the flexible and human/machine-readable dictionary of prior chem. knowledge used by the max.-likelihood macromol.-refinement program REFMAC5.  The dictionary stores information about monomers which represent the constitutive building blocks of biol. macromols. (amino acids, nucleic acids and saccharides) and about numerous org./inorg. compds. commonly found in macromol. crystallog.  It also describes the modifications the building blocks undergo as a result of chem. reactions and the links required for polymer formation.  More than 2000 monomer entries, 100 modification entries and 200 link entries are currently available.  Algorithms and tools for updating and adding new entries to the dictionary have also been developed and are presented here.  In many cases, the REFMAC5 dictionary allows entirely automatic generation of restraints within REFMAC5 refinement runs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjDd-k3YHGrVg90H21EOLACvtfcHk0ljSWLpYIcC5IA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F&md5=005910422c5fb72fe2434c39b5321bf4</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1107%2FS0907444904023510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904023510%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPotterton%26aufirst%3DL.%26aulast%3DMcNicholas%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DREFMAC5%2520dictionary%253A%2520Organization%2520of%2520prior%2520chemical%2520knowledge%2520and%2520guidelines%2520for%2520its%2520use%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%26date%3D2004%26volume%3D60%26spage%3D2184%26epage%3D2195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Gray, N. S.; Zhou, W.</span> WIPO Patent WO2011079231,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gray%2C+N.+S.%3B+Zhou%2C+W.+WIPO+Patent+WO2011079231%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 131 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Richard A. Ward, Stephen Fawell, Nicolas Floc’h, Vikki Flemington, Darren McKerrecher, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Smith</span>. </span><span class="cited-content_cbyCitation_article-title">Challenges and Opportunities in Cancer Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Chemical Reviews</span><span> <strong>2021,</strong> <em>121 </em>
                                    (6)
                                     , 3297-3351. <a href="https://doi.org/10.1021/acs.chemrev.0c00383" title="DOI URL">https://doi.org/10.1021/acs.chemrev.0c00383</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.chemrev.0c00383&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.chemrev.0c00383%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Reviews%26atitle%3DChallenges%252Band%252BOpportunities%252Bin%252BCancer%252BDrug%252BResistance%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D29042020%26date%3D21072020%26volume%3D121%26issue%3D6%26spage%3D3297%26epage%3D3351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Leonie Heyden, Tobias Grabe, Matthias P. Müller, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Complex Crystal Structures of EGFR with Third-Generation Kinase Inhibitors and Simultaneously Bound Allosteric Ligands. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2020,</strong> <em>11 </em>
                                    (12)
                                     , 2484-2490. <a href="https://doi.org/10.1021/acsmedchemlett.0c00472" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.0c00472</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.0c00472&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.0c00472%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DComplex%252BCrystal%252BStructures%252Bof%252BEGFR%252Bwith%252BThird-Generation%252BKinase%252BInhibitors%252Band%252BSimultaneously%252BBound%252BAllosteric%252BLigands%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D26082020%26date%3D28092020%26date%3D05112020%26volume%3D11%26issue%3D12%26spage%3D2484%26epage%3D2490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Adam Birkholz, David J. Kopecky, Laurie P. Volak, Michael D. Bartberger, Yuping Chen, Christopher M. Tegley, Tara Arvedson, John D. McCarter, Christopher Fotsch, <span class="NLM_string-name hlFld-ContribAuthor">Victor J. Cee</span>. </span><span class="cited-content_cbyCitation_article-title">Systematic Study of the Glutathione Reactivity of N-Phenylacrylamides: 2. Effects of Acrylamide Substitution. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (20)
                                     , 11602-11614. <a href="https://doi.org/10.1021/acs.jmedchem.0c00749" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00749</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00749&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00749%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252BStudy%252Bof%252Bthe%252BGlutathione%252BReactivity%252Bof%252BN-Phenylacrylamides%25253A%252B2.%252BEffects%252Bof%252BAcrylamide%252BSubstitution%26aulast%3DBirkholz%26aufirst%3DAdam%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D04052020%26date%3D09102020%26date%3D23092020%26volume%3D63%26issue%3D20%26spage%3D11602%26epage%3D11614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ferruccio Palazzesi, Markus R. Hermann, Marc A. Grundl, Alexander Pautsch, Daniel Seeliger, Christofer S. Tautermann, <span class="NLM_string-name hlFld-ContribAuthor">Alexander Weber</span>. </span><span class="cited-content_cbyCitation_article-title">BIreactive: A Machine-Learning Model to Estimate Covalent Warhead Reactivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2020,</strong> <em>60 </em>
                                    (6)
                                     , 2915-2923. <a href="https://doi.org/10.1021/acs.jcim.9b01058" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b01058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b01058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b01058%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DBIreactive%25253A%252BA%252BMachine-Learning%252BModel%252Bto%252BEstimate%252BCovalent%252BWarhead%252BReactivity%26aulast%3DPalazzesi%26aufirst%3DFerruccio%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D14112019%26date%3D06052020%26date%3D06042020%26volume%3D60%26issue%3D6%26spage%3D2915%26epage%3D2923" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qibin Su, Erica Banks, Geraldine Bebernitz, Kirsten Bell, Cassandra F. Borenstein, Huawei Chen, Claudio E. Chuaqui, Nanhua Deng, Andrew D. Ferguson, Sameer Kawatkar, Neil P. Grimster, Linette Ruston, Paul D. Lyne, Jon A. Read, Xianyou Peng, Xiaohui Pei, Stephen Fawell, Zhanlei Tang, Scott Throner, Melissa M. Vasbinder, Haoyu Wang, Jon Winter-Holt, Richard Woessner, Allan Wu, Wenzhan Yang, Michael Zinda, <span class="NLM_string-name hlFld-ContribAuthor">Jason G. Kettle</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of (2R)-N-[3-[2-[(3-Methoxy-1-methyl-pyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propenamide (AZD4205) as a Potent and Selective Janus Kinase 1 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (9)
                                     , 4517-4527. <a href="https://doi.org/10.1021/acs.jmedchem.9b01392" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b01392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b01392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b01392%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%2525282R%252529-N-%25255B3-%25255B2-%25255B%2525283-Methoxy-1-methyl-pyrazol-4-yl%252529amino%25255Dpyrimidin-4-yl%25255D-1H-indol-7-yl%25255D-2-%2525284-methylpiperazin-1-yl%252529propenamide%252B%252528AZD4205%252529%252Bas%252Ba%252BPotent%252Band%252BSelective%252BJanus%252BKinase%252B1%252BInhibitor%26aulast%3DSu%26aufirst%3DQibin%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D22082019%26date%3D28042020%26date%3D16042020%26volume%3D63%26issue%3D9%26spage%3D4517%26epage%3D4527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Xiang Zhai, Richard A. Ward, Peter Doig, <span class="NLM_string-name hlFld-ContribAuthor">Argyrides Argyrou</span>. </span><span class="cited-content_cbyCitation_article-title">Insight into the Therapeutic Selectivity of the Irreversible EGFR Tyrosine Kinase Inhibitor Osimertinib through Enzyme Kinetic Studies. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2020,</strong> <em>59 </em>
                                    (14)
                                     , 1428-1441. <a href="https://doi.org/10.1021/acs.biochem.0c00104" title="DOI URL">https://doi.org/10.1021/acs.biochem.0c00104</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.0c00104&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.0c00104%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DInsight%252Binto%252Bthe%252BTherapeutic%252BSelectivity%252Bof%252Bthe%252BIrreversible%252BEGFR%252BTyrosine%252BKinase%252BInhibitor%252BOsimertinib%252Bthrough%252BEnzyme%252BKinetic%252BStudies%26aulast%3DZhai%26aufirst%3DXiang%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D05022020%26date%3D20032020%26date%3D31032020%26date%3D24032020%26volume%3D59%26issue%3D14%26spage%3D1428%26epage%3D1441" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Rick C. Betori, Yue Liu, Rama K. Mishra, Scott B. Cohen, Stephen J. Kron, <span class="NLM_string-name hlFld-ContribAuthor">Karl A. Scheidt</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted Covalent Inhibition of Telomerase. </span><span class="cited-content_cbyCitation_journal-name">ACS Chemical Biology</span><span> <strong>2020,</strong> <em>15 </em>
                                    (3)
                                     , 706-717. <a href="https://doi.org/10.1021/acschembio.9b00945" title="DOI URL">https://doi.org/10.1021/acschembio.9b00945</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acschembio.9b00945&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facschembio.9b00945%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Chemical%2520Biology%26atitle%3DTargeted%252BCovalent%252BInhibition%252Bof%252BTelomerase%26aulast%3DBetori%26aufirst%3DRick%2BC.%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2019%26date%3D23112019%26date%3D04022020%26date%3D24022020%26date%3D04022020%26volume%3D15%26issue%3D3%26spage%3D706%26epage%3D717" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Janina Niggenaber, Julia Hardick, Jonas Lategahn, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Structure Defines Function: Clinically Relevant Mutations in ErbB Kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (1)
                                     , 40-51. <a href="https://doi.org/10.1021/acs.jmedchem.9b00964" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00964</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00964&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00964%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure%252BDefines%252BFunction%25253A%252BClinically%252BRelevant%252BMutations%252Bin%252BErbB%252BKinases%26aulast%3DNiggenaber%26aufirst%3DJanina%26date%3D2020%26date%3D2019%26date%3D2019%26date%3D17062019%26date%3D28082019%26date%3D15082019%26volume%3D63%26issue%3D1%26spage%3D40%26epage%3D51" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Angus Voice, Gary Tresadern, Herman van Vlijmen, <span class="NLM_string-name hlFld-ContribAuthor">Adrian Mulholland</span>. </span><span class="cited-content_cbyCitation_article-title">Limitations of Ligand-Only Approaches for Predicting the Reactivity of Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (10)
                                     , 4220-4227. <a href="https://doi.org/10.1021/acs.jcim.9b00404" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00404</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00404&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00404%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DLimitations%252Bof%252BLigand-Only%252BApproaches%252Bfor%252BPredicting%252Bthe%252BReactivity%252Bof%252BCovalent%252BInhibitors%26aulast%3DVoice%26aufirst%3DAngus%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13052019%26date%3D24092019%26date%3D09092019%26volume%3D59%26issue%3D10%26spage%3D4220%26epage%3D4227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Farideh Badichi Akher, Abdolkarim Farrokhzadeh, Neil Ravenscroft, <span class="NLM_string-name hlFld-ContribAuthor">Michelle M. Kuttel</span>. </span><span class="cited-content_cbyCitation_article-title">A Mechanistic Study of a Potent and Selective Epidermal Growth Factor Receptor Inhibitor against the L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Biochemistry</span><span> <strong>2019,</strong> <em>58 </em>
                                    (41)
                                     , 4246-4259. <a href="https://doi.org/10.1021/acs.biochem.9b00710" title="DOI URL">https://doi.org/10.1021/acs.biochem.9b00710</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.biochem.9b00710&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.biochem.9b00710%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemistry%26atitle%3DA%252BMechanistic%252BStudy%252Bof%252Ba%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BInhibitor%252Bagainst%252Bthe%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DAkher%26aufirst%3DFarideh%2BBadichi%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D13082019%26date%3D23092019%26date%3D07102019%26volume%3D58%26issue%3D41%26spage%3D4246%26epage%3D4259" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ferruccio Palazzesi, Marc A. Grundl, Alexander Pautsch, Alexander Weber, <span class="NLM_string-name hlFld-ContribAuthor">Christofer S. Tautermann</span>. </span><span class="cited-content_cbyCitation_article-title">A Fast Ab Initio Predictor Tool for Covalent Reactivity Estimation of Acrylamides. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2019,</strong> <em>59 </em>
                                    (8)
                                     , 3565-3571. <a href="https://doi.org/10.1021/acs.jcim.9b00316" title="DOI URL">https://doi.org/10.1021/acs.jcim.9b00316</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.9b00316&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.9b00316%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DA%252BFast%252BAb%252BInitio%252BPredictor%252BTool%252Bfor%252BCovalent%252BReactivity%252BEstimation%252Bof%252BAcrylamides%26aulast%3DPalazzesi%26aufirst%3DFerruccio%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D17042019%26date%3D15072019%26date%3D27062019%26volume%3D59%26issue%3D8%26spage%3D3565%26epage%3D3571" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Qiannan Li, Tao Zhang, Shiliang Li, Linjiang Tong, Junyu Li, Zhicheng Su, Fang Feng, Deheng Sun, Yi Tong, Xia Wang, Zhenjiang Zhao, Lili Zhu, Jian Ding, Honglin Li, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Yufang Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of Potent and Noncovalent Reversible EGFR Kinase Inhibitors of EGFRL858R/T790M/C797S. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2019,</strong> <em>10 </em>
                                    (6)
                                     , 869-873. <a href="https://doi.org/10.1021/acsmedchemlett.8b00564" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.8b00564</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.8b00564&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.8b00564%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252BPotent%252Band%252BNoncovalent%252BReversible%252BEGFR%252BKinase%252BInhibitors%252Bof%252BEGFRL858R%25252FT790M%25252FC797S%26aulast%3DLi%26aufirst%3DQiannan%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2018%26date%3D21112018%26date%3D21052019%26date%3D29052019%26date%3D22052019%26volume%3D10%26issue%3D6%26spage%3D869%26epage%3D873" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Patrik Wolle, Julia Hardick, Shane J. F. Cronin, Julian Engel, Matthias Baumann, Jonas Lategahn, Josef M. Penninger, <span class="NLM_string-name hlFld-ContribAuthor">Daniel Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the MKK7–JNK (Mitogen-Activated Protein Kinase Kinase 7–c-Jun N-Terminal Kinase) Pathway with Covalent Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>62 </em>
                                    (5)
                                     , 2843-2848. <a href="https://doi.org/10.1021/acs.jmedchem.9b00102" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00102</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.9b00102%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252Bthe%252BMKK7%2525E2%252580%252593JNK%252B%252528Mitogen-Activated%252BProtein%252BKinase%252BKinase%252B7%2525E2%252580%252593c-Jun%252BN-Terminal%252BKinase%252529%252BPathway%252Bwith%252BCovalent%252BInhibitors%26aulast%3DWolle%26aufirst%3DPatrik%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D16012019%26date%3D21022019%26date%3D15022019%26volume%3D62%26issue%3D5%26spage%3D2843%26epage%3D2848" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Robert J. Young, <span class="NLM_string-name hlFld-ContribAuthor">Paul D. Leeson</span>. </span><span class="cited-content_cbyCitation_article-title">Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (15)
                                     , 6421-6467. <a href="https://doi.org/10.1021/acs.jmedchem.8b00180" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00180</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00180&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00180%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMapping%252Bthe%252BEfficiency%252Band%252BPhysicochemical%252BTrajectories%252Bof%252BSuccessful%252BOptimizations%26aulast%3DYoung%26aufirst%3DRobert%2BJ.%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D03022018%26date%3D25042018%26date%3D05042018%26volume%3D61%26issue%3D15%26spage%3D6421%26epage%3D6467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Yongjia Hao, Jiankun Lyu, Rong Qu, Yi Tong, Deheng Sun, Fang Feng, Linjiang Tong, Tingyuan Yang, Zhenjiang Zhao, Lili Zhu, Jian Ding, Yufang Xu, Hua Xie, <span class="NLM_string-name hlFld-ContribAuthor">Honglin Li</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis, and Biological Evaluation of Pyrimido[4,5-d]pyrimidine-2,4(1H,3H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (13)
                                     , 5609-5622. <a href="https://doi.org/10.1021/acs.jmedchem.8b00346" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.8b00346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.8b00346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.8b00346%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252BSynthesis%25252C%252Band%252BBiological%252BEvaluation%252Bof%252BPyrimido%25255B4%25252C5-d%25255Dpyrimidine-2%25252C4%2525281H%25252C3H%252529-diones%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DHao%26aufirst%3DYongjia%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D04032018%26date%3D25062018%26date%3D15062018%26volume%3D61%26issue%3D13%26spage%3D5609%26epage%3D5622" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ye Ding, Dengfeng Li, Chunyong Ding, Pingyuan Wang, Zhiqing Liu, Eric A. Wold, Na Ye, Haiying Chen, Mark A. White, Qiang Shen, <span class="NLM_string-name hlFld-ContribAuthor">Jia Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (7)
                                     , 2737-2752. <a href="https://doi.org/10.1021/acs.jmedchem.7b01514" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01514</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01514&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01514%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRegio-%252Band%252BStereospecific%252BSynthesis%252Bof%252BOridonin%252BD-Ring%252BAziridinated%252BAnalogues%252Bfor%252Bthe%252BTreatment%252Bof%252BTriple-Negative%252BBreast%252BCancer%252Bvia%252BMediated%252BIrreversible%252BCovalent%252BWarheads%26aulast%3DDing%26aufirst%3DYe%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D11102017%26date%3D20032018%26date%3D12032018%26volume%3D61%26issue%3D7%26spage%3D2737%26epage%3D2752" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kevin  Pels</span>, <span class="hlFld-ContribAuthor ">Paige  Dickson</span>, <span class="hlFld-ContribAuthor ">Hongchan  An</span>, and <span class="hlFld-ContribAuthor ">Thomas  Kodadek</span>  . </span><span class="cited-content_cbyCitation_article-title">DNA-Compatible Solid-Phase Combinatorial Synthesis of β-Cyanoacrylamides and Related Electrophiles. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2018,</strong> <em>20 </em>
                                    (2)
                                     , 61-69. <a href="https://doi.org/10.1021/acscombsci.7b00169" title="DOI URL">https://doi.org/10.1021/acscombsci.7b00169</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.7b00169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.7b00169%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DDNA-Compatible%252BSolid-Phase%252BCombinatorial%252BSynthesis%252Bof%252B%2525CE%2525B2-Cyanoacrylamides%252Band%252BRelated%252BElectrophiles%26aulast%3DPels%26aufirst%3DKevin%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D2017%26date%3D07112017%26date%3D30122017%26date%3D17012018%26date%3D12022018%26date%3D03012018%26volume%3D20%26issue%3D2%26spage%3D61%26epage%3D69" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard  Lonsdale</span>, <span class="hlFld-ContribAuthor ">Jonathan  Burgess</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Nichola L.  Davies</span>, <span class="hlFld-ContribAuthor ">Eva M.  Lenz</span>, <span class="hlFld-ContribAuthor ">Alexandra L.  Orton</span>, and <span class="hlFld-ContribAuthor ">Richard A.  Ward</span>  . </span><span class="cited-content_cbyCitation_article-title">Expanding the Armory: Predicting and Tuning Covalent Warhead Reactivity. </span><span class="cited-content_cbyCitation_journal-name">Journal of Chemical Information and Modeling</span><span> <strong>2017,</strong> <em>57 </em>
                                    (12)
                                     , 3124-3137. <a href="https://doi.org/10.1021/acs.jcim.7b00553" title="DOI URL">https://doi.org/10.1021/acs.jcim.7b00553</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jcim.7b00553&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jcim.7b00553%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Chemical%2520Information%2520and%2520Modeling%26atitle%3DExpanding%252Bthe%252BArmory%25253A%252BPredicting%252Band%252BTuning%252BCovalent%252BWarhead%252BReactivity%26aulast%3DLonsdale%26aufirst%3DRichard%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D13092017%26date%3D21112017%26date%3D26122017%26date%3D13112017%26volume%3D57%26issue%3D12%26spage%3D3124%26epage%3D3137" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ken A.  Brameld</span>, <span class="hlFld-ContribAuthor ">Timothy D.  Owens</span>, <span class="hlFld-ContribAuthor ">Erik  Verner</span>, <span class="hlFld-ContribAuthor ">Eleni  Venetsanakos</span>, <span class="hlFld-ContribAuthor ">J. Michael  Bradshaw</span>, <span class="hlFld-ContribAuthor ">Vernon T.  Phan</span>, <span class="hlFld-ContribAuthor ">Danny  Tam</span>, <span class="hlFld-ContribAuthor ">Kwan  Leung</span>, <span class="hlFld-ContribAuthor ">Jin  Shu</span>, <span class="hlFld-ContribAuthor ">Jacob  LaStant</span>, <span class="hlFld-ContribAuthor ">David G.  Loughhead</span>, <span class="hlFld-ContribAuthor ">Tony  Ton</span>, <span class="hlFld-ContribAuthor ">Dane E.  Karr</span>, <span class="hlFld-ContribAuthor ">Mary E.  Gerritsen</span>, <span class="hlFld-ContribAuthor ">David M.  Goldstein</span>, and <span class="hlFld-ContribAuthor ">Jens Oliver  Funk</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (15)
                                     , 6516-6527. <a href="https://doi.org/10.1021/acs.jmedchem.7b00360" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b00360</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b00360&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b00360%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bthe%252BIrreversible%252BCovalent%252BFGFR%252BInhibitor%252B8-%2525283-%2525284-Acryloylpiperazin-1-yl%252529propyl%252529-6-%2525282%25252C6-dichloro-3%25252C5-dimethoxyphenyl%252529-2-%252528methylamino%252529pyrido%25255B2%25252C3-d%25255Dpyrimidin-7%2525288H%252529-one%252B%252528PRN1371%252529%252Bfor%252Bthe%252BTreatment%252Bof%252BSolid%252BTumors%26aulast%3DBrameld%26aufirst%3DKen%2BA.%26date%3D2017%26date%3D2017%26date%3D2017%26date%3D07032017%26date%3D25072017%26date%3D10082017%26date%3D30062017%26volume%3D60%26issue%3D15%26spage%3D6516%26epage%3D6527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Tomassi</span>, <span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Hannah L.  Tumbrink</span>, <span class="hlFld-ContribAuthor ">Julia  Ketzer</span>, <span class="hlFld-ContribAuthor ">Thomas  Mühlenberg</span>, <span class="hlFld-ContribAuthor ">Matthias  Baumann</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bauer</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Indazole-Based Covalent Inhibitors To Target Drug-Resistant Epidermal Growth Factor Receptor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (6)
                                     , 2361-2372. <a href="https://doi.org/10.1021/acs.jmedchem.6b01626" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01626</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01626%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DIndazole-Based%252BCovalent%252BInhibitors%252BTo%252BTarget%252BDrug-Resistant%252BEpidermal%252BGrowth%252BFactor%252BReceptor%26aulast%3DTomassi%26aufirst%3DStefano%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D02112016%26date%3D10032017%26date%3D23032017%26date%3D22022017%26volume%3D60%26issue%3D6%26spage%3D2361%26epage%3D2372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yongjia  Hao</span>, <span class="hlFld-ContribAuthor ">Xia  Wang</span>, <span class="hlFld-ContribAuthor ">Tao  Zhang</span>, <span class="hlFld-ContribAuthor ">Deheng  Sun</span>, <span class="hlFld-ContribAuthor ">Yi  Tong</span>, <span class="hlFld-ContribAuthor ">Yuqiong  Xu</span>, <span class="hlFld-ContribAuthor ">Haiyang  Chen</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lili  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhenjiang  Zhao</span>, <span class="hlFld-ContribAuthor ">Zhuo  Chen</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Yufang  Xu</span>, and <span class="hlFld-ContribAuthor ">Honglin  Li</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery and Structural Optimization of N5-Substituted 6,7-Dioxo-6,7-dihydropteridines as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (15)
                                     , 7111-7124. <a href="https://doi.org/10.1021/acs.jmedchem.6b00403" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00403</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00403&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00403%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Band%252BStructural%252BOptimization%252Bof%252BN5-Substituted%252B6%25252C7-Dioxo-6%25252C7-dihydropteridines%252Bas%252BPotent%252Band%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%252Bagainst%252BL858R%25252FT790M%252BResistance%252BMutation%26aulast%3DHao%26aufirst%3DYongjia%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D26032016%26date%3D21072016%26date%3D11082016%26date%3D11072016%26volume%3D59%26issue%3D15%26spage%3D7111%26epage%3D7124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhendong  Song</span>, <span class="hlFld-ContribAuthor ">Yang  Ge</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Shanshan  Huang</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Youwen  Zhou</span>, and <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>  . </span><span class="cited-content_cbyCitation_article-title">Challenges and Perspectives on the Development of Small-Molecule EGFR Inhibitors against T790M-Mediated Resistance in Non-Small-Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6580-6594. <a href="https://doi.org/10.1021/acs.jmedchem.5b00840" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00840</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00840&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00840%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChallenges%252Band%252BPerspectives%252Bon%252Bthe%252BDevelopment%252Bof%252BSmall-Molecule%252BEGFR%252BInhibitors%252Bagainst%252BT790M-Mediated%252BResistance%252Bin%252BNon-Small-Cell%252BLung%252BCancer%26aulast%3DSong%26aufirst%3DZhendong%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D02062015%26date%3D26022016%26date%3D28072016%26date%3D16022016%26volume%3D59%26issue%3D14%26spage%3D6580%26epage%3D6594" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gérald  Lelais</span>, <span class="hlFld-ContribAuthor ">Robert  Epple</span>, <span class="hlFld-ContribAuthor ">Thomas H.  Marsilje</span>, <span class="hlFld-ContribAuthor ">Yun O.  Long</span>, <span class="hlFld-ContribAuthor ">Matthew  McNeill</span>, <span class="hlFld-ContribAuthor ">Bei  Chen</span>, <span class="hlFld-ContribAuthor ">Wenshuo  Lu</span>, <span class="hlFld-ContribAuthor ">Jaganmohan  Anumolu</span>, <span class="hlFld-ContribAuthor ">Sangamesh  Badiger</span>, <span class="hlFld-ContribAuthor ">Badry  Bursulaya</span>, <span class="hlFld-ContribAuthor ">Michael  DiDonato</span>, <span class="hlFld-ContribAuthor ">Rina  Fong</span>, <span class="hlFld-ContribAuthor ">Jose  Juarez</span>, <span class="hlFld-ContribAuthor ">Jie  Li</span>, <span class="hlFld-ContribAuthor ">Mari  Manuia</span>, <span class="hlFld-ContribAuthor ">Daniel E.  Mason</span>, <span class="hlFld-ContribAuthor ">Perry  Gordon</span>, <span class="hlFld-ContribAuthor ">Todd  Groessl</span>, <span class="hlFld-ContribAuthor ">Kevin  Johnson</span>, <span class="hlFld-ContribAuthor ">Yong  Jia</span>, <span class="hlFld-ContribAuthor ">Shailaja  Kasibhatla</span>, <span class="hlFld-ContribAuthor ">Chun  Li</span>, <span class="hlFld-ContribAuthor ">John  Isbell</span>, <span class="hlFld-ContribAuthor ">Glen  Spraggon</span>, <span class="hlFld-ContribAuthor ">Steven  Bender</span>, and <span class="hlFld-ContribAuthor ">Pierre-Yves  Michellys</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of (R,E)-N-(7-Chloro-1-(1-[4-(dimethylamino)but-2-enoyl]azepan-3-yl)-1H-benzo[d]imidazol-2-yl)-2-methylisonicotinamide (EGF816), a Novel, Potent, and WT Sparing Covalent Inhibitor of Oncogenic (L858R, ex19del) and Resistant (T790M) EGFR Mutants for the Treatment of EGFR Mutant Non-Small-Cell Lung Cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6671-6689. <a href="https://doi.org/10.1021/acs.jmedchem.5b01985" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01985</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01985%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B%252528R%25252CE%252529-N-%2525287-Chloro-1-%2525281-%25255B4-%252528dimethylamino%252529but-2-enoyl%25255Dazepan-3-yl%252529-1H-benzo%25255Bd%25255Dimidazol-2-yl%252529-2-methylisonicotinamide%252B%252528EGF816%252529%25252C%252Ba%252BNovel%25252C%252BPotent%25252C%252Band%252BWT%252BSparing%252BCovalent%252BInhibitor%252Bof%252BOncogenic%252B%252528L858R%25252C%252Bex19del%252529%252Band%252BResistant%252B%252528T790M%252529%252BEGFR%252BMutants%252Bfor%252Bthe%252BTreatment%252Bof%252BEGFR%252BMutant%252BNon-Small-Cell%252BLung%252BCancers%26aulast%3DLelais%26aufirst%3DG%25C3%25A9rald%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D22122015%26date%3D19072016%26date%3D28072016%26volume%3D59%26issue%3D14%26spage%3D6671%26epage%3D6689" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edward J.  Hennessy</span>, <span class="hlFld-ContribAuthor ">Claudio  Chuaqui</span>, <span class="hlFld-ContribAuthor ">Susan  Ashton</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Darren A. E.  Cross</span>, <span class="hlFld-ContribAuthor ">Judit É.  Debreczeni</span>, <span class="hlFld-ContribAuthor ">Cath  Eberlein</span>, <span class="hlFld-ContribAuthor ">Lakshmaiah  Gingipalli</span>, <span class="hlFld-ContribAuthor ">Teresa C. M.  Klinowska</span>, <span class="hlFld-ContribAuthor ">Jonathan P.  Orme</span>, <span class="hlFld-ContribAuthor ">Li  Sha</span>, and <span class="hlFld-ContribAuthor ">Xiaoyun  Wu</span>  . </span><span class="cited-content_cbyCitation_article-title">Utilization of Structure-Based Design to Identify Novel, Irreversible Inhibitors of EGFR Harboring the T790M Mutation. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2016,</strong> <em>7 </em>
                                    (5)
                                     , 514-519. <a href="https://doi.org/10.1021/acsmedchemlett.6b00058" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.6b00058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.6b00058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.6b00058%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DUtilization%252Bof%252BStructure-Based%252BDesign%252Bto%252BIdentify%252BNovel%25252C%252BIrreversible%252BInhibitors%252Bof%252BEGFR%252BHarboring%252Bthe%252BT790M%252BMutation%26aulast%3DHennessy%26aufirst%3DEdward%2BJ.%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D09022016%26date%3D21032016%26date%3D24032016%26date%3D12052016%26date%3D21032016%26volume%3D7%26issue%3D5%26spage%3D514%26epage%3D519" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hengmiao  Cheng</span>, <span class="hlFld-ContribAuthor ">Sajiv K.  Nair</span>, <span class="hlFld-ContribAuthor ">Brion W.  Murray</span>, <span class="hlFld-ContribAuthor ">Chau  Almaden</span>, <span class="hlFld-ContribAuthor ">Simon  Bailey</span>, <span class="hlFld-ContribAuthor ">Sangita  Baxi</span>, <span class="hlFld-ContribAuthor ">Doug  Behenna</span>, <span class="hlFld-ContribAuthor ">Sujin  Cho-Schultz</span>, <span class="hlFld-ContribAuthor ">Deepak  Dalvie</span>, <span class="hlFld-ContribAuthor ">Dac M.  Dinh</span>, <span class="hlFld-ContribAuthor ">Martin P.  Edwards</span>, <span class="hlFld-ContribAuthor ">Jun Li  Feng</span>, <span class="hlFld-ContribAuthor ">Rose Ann  Ferre</span>, <span class="hlFld-ContribAuthor ">Ketan S.  Gajiwala</span>, <span class="hlFld-ContribAuthor ">Michelle D.  Hemkens</span>, <span class="hlFld-ContribAuthor ">Amy  Jackson-Fisher</span>, <span class="hlFld-ContribAuthor ">Mehran  Jalaie</span>, <span class="hlFld-ContribAuthor ">Ted O.  Johnson</span>, <span class="hlFld-ContribAuthor ">Robert S.  Kania</span>, <span class="hlFld-ContribAuthor ">Susan  Kephart</span>, <span class="hlFld-ContribAuthor ">Jennifer  Lafontaine</span>, <span class="hlFld-ContribAuthor ">Beth  Lunney</span>, <span class="hlFld-ContribAuthor ">Kevin K.-C.  Liu</span>, <span class="hlFld-ContribAuthor ">Zhengyu  Liu</span>, <span class="hlFld-ContribAuthor ">Jean  Matthews</span>, <span class="hlFld-ContribAuthor ">Asako  Nagata</span>, <span class="hlFld-ContribAuthor ">Sherry  Niessen</span>, <span class="hlFld-ContribAuthor ">Martha A.  Ornelas</span>, <span class="hlFld-ContribAuthor ">Suvi T. M.  Orr</span>, <span class="hlFld-ContribAuthor ">Mason  Pairish</span>, <span class="hlFld-ContribAuthor ">Simon  Planken</span>, <span class="hlFld-ContribAuthor ">Shijian  Ren</span>, <span class="hlFld-ContribAuthor ">Daniel  Richter</span>, <span class="hlFld-ContribAuthor ">Kevin  Ryan</span>, <span class="hlFld-ContribAuthor ">Neal  Sach</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Tod  Smeal</span>, <span class="hlFld-ContribAuthor ">Jim  Solowiej</span>, <span class="hlFld-ContribAuthor ">Scott  Sutton</span>, <span class="hlFld-ContribAuthor ">Khanh  Tran</span>, <span class="hlFld-ContribAuthor ">Elaine  Tseng</span>, <span class="hlFld-ContribAuthor ">William  Vernier</span>, <span class="hlFld-ContribAuthor ">Marlena  Walls</span>, <span class="hlFld-ContribAuthor ">Shuiwang  Wang</span>, <span class="hlFld-ContribAuthor ">Scott L.  Weinrich</span>, <span class="hlFld-ContribAuthor ">Shuibo  Xin</span>, <span class="hlFld-ContribAuthor ">Haiwei  Xu</span>, <span class="hlFld-ContribAuthor ">Min-Jean  Yin</span>, <span class="hlFld-ContribAuthor ">Michael  Zientek</span>, <span class="hlFld-ContribAuthor ">Ru  Zhou</span>, and <span class="hlFld-ContribAuthor ">John C.  Kath</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of 1-{(3R,4R)-3-[({5-Chloro-2-[(1-methyl-1H-pyrazol-4-yl)amino]-7H-pyrrolo[2,3-d]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (5)
                                     , 2005-2024. <a href="https://doi.org/10.1021/acs.jmedchem.5b01633" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01633</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01633&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01633%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252B1-%25257B%2525283R%25252C4R%252529-3-%25255B%252528%25257B5-Chloro-2-%25255B%2525281-methyl-1H-pyrazol-4-yl%252529amino%25255D-7H-pyrrolo%25255B2%25252C3-d%25255Dpyrimidin-4-yl%25257Doxy%252529methyl%25255D-4-methoxypyrrolidin-1-yl%25257Dprop-2-en-1-one%252B%252528PF-06459988%252529%25252C%252Ba%252BPotent%25252C%252BWT%252BSparing%25252C%252BIrreversible%252BInhibitor%252Bof%252BT790M-Containing%252BEGFR%252BMutants%26aulast%3DCheng%26aufirst%3DHengmiao%26date%3D2016%26date%3D2016%26date%3D2015%26date%3D17102015%26date%3D28012016%26date%3D10032016%26date%3D12012016%26volume%3D59%26issue%3D5%26spage%3D2005%26epage%3D2024" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Victor J.  Cee</span>, <span class="hlFld-ContribAuthor ">Laurie P.  Volak</span>, <span class="hlFld-ContribAuthor ">Yuping  Chen</span>, <span class="hlFld-ContribAuthor ">Michael D.  Bartberger</span>, <span class="hlFld-ContribAuthor ">Chris  Tegley</span>, <span class="hlFld-ContribAuthor ">Tara  Arvedson</span>, <span class="hlFld-ContribAuthor ">John  McCarter</span>, <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>, and <span class="hlFld-ContribAuthor ">Christopher  Fotsch</span>  . </span><span class="cited-content_cbyCitation_article-title">Systematic Study of the Glutathione (GSH) Reactivity of N-Arylacrylamides: 1. Effects of Aryl Substitution. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (23)
                                     , 9171-9178. <a href="https://doi.org/10.1021/acs.jmedchem.5b01018" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01018</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01018%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSystematic%252BStudy%252Bof%252Bthe%252BGlutathione%252B%252528GSH%252529%252BReactivity%252Bof%252BN-Arylacrylamides%25253A%252B1.%252BEffects%252Bof%252BAryl%252BSubstitution%26aulast%3DCee%26aufirst%3DVictor%2BJ.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D29062015%26date%3D18112015%26date%3D10122015%26volume%3D58%26issue%3D23%26spage%3D9171%26epage%3D9178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">André  Richters</span>, <span class="hlFld-ContribAuthor ">Matthäus  Getlik</span>, <span class="hlFld-ContribAuthor ">Stefano  Tomassi</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Martin  Termathe</span>, <span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Christian  Becker</span>, <span class="hlFld-ContribAuthor ">Svenja  Mayer-Wrangowski</span>, <span class="hlFld-ContribAuthor ">Christian  Grütter</span>, <span class="hlFld-ContribAuthor ">Niklas  Uhlenbrock</span>, <span class="hlFld-ContribAuthor ">Jasmin  Krüll</span>, <span class="hlFld-ContribAuthor ">Niklas  Schaumann</span>, <span class="hlFld-ContribAuthor ">Simone  Eppmann</span>, <span class="hlFld-ContribAuthor ">Patrick  Kibies</span>, <span class="hlFld-ContribAuthor ">Franziska  Hoffgaard</span>, <span class="hlFld-ContribAuthor ">Jochen  Heil</span>, <span class="hlFld-ContribAuthor ">Sascha  Menninger</span>, <span class="hlFld-ContribAuthor ">Sandra  Ortiz-Cuaran</span>, <span class="hlFld-ContribAuthor ">Johannes M.  Heuckmann</span>, <span class="hlFld-ContribAuthor ">Verena  Tinnefeld</span>, <span class="hlFld-ContribAuthor ">René P.  Zahedi</span>, <span class="hlFld-ContribAuthor ">Martin L.  Sos</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Roman K.  Thomas</span>, <span class="hlFld-ContribAuthor ">Stefan M.  Kast</span>, and <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>  . </span><span class="cited-content_cbyCitation_article-title">Targeting Drug Resistance in EGFR with Covalent Inhibitors: A Structure-Based Design Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (17)
                                     , 6844-6863. <a href="https://doi.org/10.1021/acs.jmedchem.5b01082" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01082</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01082&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b01082%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DTargeting%252BDrug%252BResistance%252Bin%252BEGFR%252Bwith%252BCovalent%252BInhibitors%25253A%252BA%252BStructure-Based%252BDesign%252BApproach%26aulast%3DEngel%26aufirst%3DJulian%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D16042015%26date%3D31082015%26date%3D10092015%26date%3D14082015%26volume%3D58%26issue%3D17%26spage%3D6844%26epage%3D6863" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ryan P.  Wurz</span>, <span class="hlFld-ContribAuthor ">Liping H.  Pettus</span>, <span class="hlFld-ContribAuthor ">Kate  Ashton</span>, <span class="hlFld-ContribAuthor ">James  Brown</span>, <span class="hlFld-ContribAuthor ">Jian Jeffrey  Chen</span>, <span class="hlFld-ContribAuthor ">Brad  Herberich</span>, <span class="hlFld-ContribAuthor ">Fang-Tsao  Hong</span>, <span class="hlFld-ContribAuthor ">Essa  Hu-Harrington</span>, <span class="hlFld-ContribAuthor ">Tom  Nguyen</span>, <span class="hlFld-ContribAuthor ">David J.  St. Jean, Jr.</span>, <span class="hlFld-ContribAuthor ">Seifu  Tadesse</span>, <span class="hlFld-ContribAuthor ">David  Bauer</span>, <span class="hlFld-ContribAuthor ">Michele  Kubryk</span>, <span class="hlFld-ContribAuthor ">Jinghui  Zhan</span>, <span class="hlFld-ContribAuthor ">Keegan  Cooke</span>, <span class="hlFld-ContribAuthor ">Petia  Mitchell</span>, <span class="hlFld-ContribAuthor ">Kristin L.  Andrews</span>, <span class="hlFld-ContribAuthor ">Faye  Hsieh</span>, <span class="hlFld-ContribAuthor ">Dean  Hickman</span>, <span class="hlFld-ContribAuthor ">Nataraj  Kalyanaraman</span>, <span class="hlFld-ContribAuthor ">Tian  Wu</span>, <span class="hlFld-ContribAuthor ">Darren L.  Reid</span>, <span class="hlFld-ContribAuthor ">Edward K.  Lobenhofer</span>, <span class="hlFld-ContribAuthor ">Dina A.  Andrews</span>, <span class="hlFld-ContribAuthor ">Nancy  Everds</span>, <span class="hlFld-ContribAuthor ">Roberto  Guzman</span>, <span class="hlFld-ContribAuthor ">Andrew T.  Parsons</span>, <span class="hlFld-ContribAuthor ">Simon J.  Hedley</span>, <span class="hlFld-ContribAuthor ">Jason  Tedrow</span>, <span class="hlFld-ContribAuthor ">Oliver R.  Thiel</span>, <span class="hlFld-ContribAuthor ">Matthew  Potter</span>, <span class="hlFld-ContribAuthor ">Robert  Radinsky</span>, <span class="hlFld-ContribAuthor ">Pedro J.  Beltran</span>, and <span class="hlFld-ContribAuthor ">Andrew S.  Tasker</span>  . </span><span class="cited-content_cbyCitation_article-title">Oxopyrido[2,3-d]pyrimidines as Covalent L858R/T790M Mutant Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ACS Medicinal Chemistry Letters</span><span> <strong>2015,</strong> <em>6 </em>
                                    (9)
                                     , 987-992. <a href="https://doi.org/10.1021/acsmedchemlett.5b00193" title="DOI URL">https://doi.org/10.1021/acsmedchemlett.5b00193</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsmedchemlett.5b00193&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsmedchemlett.5b00193%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DOxopyrido%25255B2%25252C3-d%25255Dpyrimidines%252Bas%252BCovalent%252BL858R%25252FT790M%252BMutant%252BSelective%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252B%252528EGFR%252529%252BInhibitors%26aulast%3DWurz%26aufirst%3DRyan%2BP.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D08052015%26date%3D27072015%26date%3D31072015%26date%3D10092015%26date%3D27072015%26volume%3D6%26issue%3D9%26spage%3D987%26epage%3D992" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Mairi  Challinor</span>, <span class="hlFld-ContribAuthor ">Judit E.  Debreczeni</span>, <span class="hlFld-ContribAuthor ">Kay  Eckersley</span>, <span class="hlFld-ContribAuthor ">Gary  Fairley</span>, <span class="hlFld-ContribAuthor ">Lyman  Feron</span>, <span class="hlFld-ContribAuthor ">Vikki  Flemington</span>, <span class="hlFld-ContribAuthor ">Mark A.  Graham</span>, <span class="hlFld-ContribAuthor ">Ryan  Greenwood</span>, <span class="hlFld-ContribAuthor ">Philip  Hopcroft</span>, <span class="hlFld-ContribAuthor ">Tina D.  Howard</span>, <span class="hlFld-ContribAuthor ">Michael  James</span>, <span class="hlFld-ContribAuthor ">Clifford D.  Jones</span>, <span class="hlFld-ContribAuthor ">Christopher R.  Jones</span>, <span class="hlFld-ContribAuthor ">Jonathan  Renshaw</span>, <span class="hlFld-ContribAuthor ">Karen  Roberts</span>, <span class="hlFld-ContribAuthor ">Lindsay  Snow</span>, <span class="hlFld-ContribAuthor ">Michael  Tonge</span>, and <span class="hlFld-ContribAuthor ">Kay  Yeung</span>  . </span><span class="cited-content_cbyCitation_article-title">Structure-Guided Design of Highly Selective and Potent Covalent Inhibitors of ERK1/2. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (11)
                                     , 4790-4801. <a href="https://doi.org/10.1021/acs.jmedchem.5b00466" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b00466</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b00466&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.5b00466%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-Guided%252BDesign%252Bof%252BHighly%252BSelective%252Band%252BPotent%252BCovalent%252BInhibitors%252Bof%252BERK1%25252F2%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2015%26date%3D2015%26date%3D2015%26date%3D22032015%26date%3D28052015%26date%3D11062015%26date%3D15052015%26volume%3D58%26issue%3D11%26spage%3D4790%26epage%3D4801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jon J. G.  Winter</span>, <span class="hlFld-ContribAuthor ">Malcolm  Anderson</span>, <span class="hlFld-ContribAuthor ">Kevin  Blades</span>, <span class="hlFld-ContribAuthor ">Claire  Brassington</span>, <span class="hlFld-ContribAuthor ">Alexander L.  Breeze</span>, <span class="hlFld-ContribAuthor ">Christine  Chresta</span>, <span class="hlFld-ContribAuthor ">Kevin  Embrey</span>, <span class="hlFld-ContribAuthor ">Gary  Fairley</span>, <span class="hlFld-ContribAuthor ">Paul  Faulder</span>, <span class="hlFld-ContribAuthor ">M. Raymond V.  Finlay</span>, <span class="hlFld-ContribAuthor ">Jason G.  Kettle</span>, <span class="hlFld-ContribAuthor ">Thorsten  Nowak</span>, <span class="hlFld-ContribAuthor ">Ross  Overman</span>, <span class="hlFld-ContribAuthor ">S. Joe  Patel</span>, <span class="hlFld-ContribAuthor ">Paula  Perkins</span>, <span class="hlFld-ContribAuthor ">Loredana  Spadola</span>, <span class="hlFld-ContribAuthor ">Jonathan  Tart</span>, <span class="hlFld-ContribAuthor ">Julie A.  Tucker</span>, and <span class="hlFld-ContribAuthor ">Gail  Wrigley</span>  . </span><span class="cited-content_cbyCitation_article-title">Small Molecule Binding Sites on the Ras:SOS Complex Can Be Exploited for Inhibition of Ras Activation. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2015,</strong> <em>58 </em>
                                    (5)
                                     , 2265-2274. <a href="https://doi.org/10.1021/jm501660t" title="DOI URL">https://doi.org/10.1021/jm501660t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501660t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501660t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSmall%252BMolecule%252BBinding%252BSites%252Bon%252Bthe%252BRas%25253ASOS%252BComplex%252BCan%252BBe%252BExploited%252Bfor%252BInhibition%252Bof%252BRas%252BActivation%26aulast%3DWinter%26aufirst%3DJon%2BJ.%2BG.%26date%3D2015%26date%3D2015%26date%3D2014%26date%3D28102014%26date%3D26022015%26date%3D12032015%26date%3D19022015%26volume%3D58%26issue%3D5%26spage%3D2265%26epage%3D2274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mark E.  Flanagan</span>, <span class="hlFld-ContribAuthor ">Joseph A.  Abramite</span>, <span class="hlFld-ContribAuthor ">Dennis P.  Anderson</span>, <span class="hlFld-ContribAuthor ">Ann  Aulabaugh</span>, <span class="hlFld-ContribAuthor ">Upendra P.  Dahal</span>, <span class="hlFld-ContribAuthor ">Adam M.  Gilbert</span>, <span class="hlFld-ContribAuthor ">Chao  Li</span>, <span class="hlFld-ContribAuthor ">Justin  Montgomery</span>, <span class="hlFld-ContribAuthor ">Stacey R.  Oppenheimer</span>, <span class="hlFld-ContribAuthor ">Tim  Ryder</span>, <span class="hlFld-ContribAuthor ">Brandon P.  Schuff</span>, <span class="hlFld-ContribAuthor ">Daniel P.  Uccello</span>, <span class="hlFld-ContribAuthor ">Gregory S.  Walker</span>, <span class="hlFld-ContribAuthor ">Yan  Wu</span>, <span class="hlFld-ContribAuthor ">Matthew F.  Brown</span>, <span class="hlFld-ContribAuthor ">Jinshan M.  Chen</span>, <span class="hlFld-ContribAuthor ">Matthew M.  Hayward</span>, <span class="hlFld-ContribAuthor ">Mark C.  Noe</span>, <span class="hlFld-ContribAuthor ">R. Scott  Obach</span>, <span class="hlFld-ContribAuthor ">Laurence  Philippe</span>, <span class="hlFld-ContribAuthor ">Veerabahu  Shanmugasundaram</span>, <span class="hlFld-ContribAuthor ">Michael J.  Shapiro</span>, <span class="hlFld-ContribAuthor ">Jeremy  Starr</span>, <span class="hlFld-ContribAuthor ">Justin  Stroh</span>, and <span class="hlFld-ContribAuthor ">Ye  Che</span>  . </span><span class="cited-content_cbyCitation_article-title">Chemical and Computational Methods for the Characterization of Covalent Reactive Groups for the Prospective Design of Irreversible Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (23)
                                     , 10072-10079. <a href="https://doi.org/10.1021/jm501412a" title="DOI URL">https://doi.org/10.1021/jm501412a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm501412a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm501412a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DChemical%252Band%252BComputational%252BMethods%252Bfor%252Bthe%252BCharacterization%252Bof%252BCovalent%252BReactive%252BGroups%252Bfor%252Bthe%252BProspective%252BDesign%252Bof%252BIrreversible%252BInhibitors%26aulast%3DFlanagan%26aufirst%3DMark%2BE.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D17092014%26date%3D26112014%26date%3D11122014%26date%3D06112014%26volume%3D57%26issue%3D23%26spage%3D10072%26epage%3D10079" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. Raymond V.  Finlay</span>, <span class="hlFld-ContribAuthor ">Mark  Anderton</span>, <span class="hlFld-ContribAuthor ">Susan  Ashton</span>, <span class="hlFld-ContribAuthor ">Peter  Ballard</span>, <span class="hlFld-ContribAuthor ">Paul A.  Bethel</span>, <span class="hlFld-ContribAuthor ">Matthew R.  Box</span>, <span class="hlFld-ContribAuthor ">Robert H.  Bradbury</span>, <span class="hlFld-ContribAuthor ">Simon J.  Brown</span>, <span class="hlFld-ContribAuthor ">Sam  Butterworth</span>, <span class="hlFld-ContribAuthor ">Andrew  Campbell</span>, <span class="hlFld-ContribAuthor ">Christopher  Chorley</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Darren A. E.  Cross</span>, <span class="hlFld-ContribAuthor ">Gordon S.  Currie</span>, <span class="hlFld-ContribAuthor ">Matthew  Grist</span>, <span class="hlFld-ContribAuthor ">Lorraine  Hassall</span>, <span class="hlFld-ContribAuthor ">George B.  Hill</span>, <span class="hlFld-ContribAuthor ">Daniel  James</span>, <span class="hlFld-ContribAuthor ">Michael  James</span>, <span class="hlFld-ContribAuthor ">Paul  Kemmitt</span>, <span class="hlFld-ContribAuthor ">Teresa  Klinowska</span>, <span class="hlFld-ContribAuthor ">Gillian  Lamont</span>, <span class="hlFld-ContribAuthor ">Scott G.  Lamont</span>, <span class="hlFld-ContribAuthor ">Nathaniel  Martin</span>, <span class="hlFld-ContribAuthor ">Heather L.  McFarland</span>, <span class="hlFld-ContribAuthor ">Martine J.  Mellor</span>, <span class="hlFld-ContribAuthor ">Jonathon P.  Orme</span>, <span class="hlFld-ContribAuthor ">David  Perkins</span>, <span class="hlFld-ContribAuthor ">Paula  Perkins</span>, <span class="hlFld-ContribAuthor ">Graham  Richmond</span>, <span class="hlFld-ContribAuthor ">Peter  Smith</span>, <span class="hlFld-ContribAuthor ">Richard A.  Ward</span>, <span class="hlFld-ContribAuthor ">Michael J.  Waring</span>, <span class="hlFld-ContribAuthor ">David  Whittaker</span>, <span class="hlFld-ContribAuthor ">Stuart  Wells</span>, and <span class="hlFld-ContribAuthor ">Gail L.  Wrigley</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2014,</strong> <em>57 </em>
                                    (20)
                                     , 8249-8267. <a href="https://doi.org/10.1021/jm500973a" title="DOI URL">https://doi.org/10.1021/jm500973a</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/jm500973a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fjm500973a%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252Band%252BSelective%252BEGFR%252BInhibitor%252B%252528AZD9291%252529%252Bof%252BBoth%252BSensitizing%252Band%252BT790M%252BResistance%252BMutations%252BThat%252BSpares%252Bthe%252BWild%252BType%252BForm%252Bof%252Bthe%252BReceptor%26aulast%3DFinlay%26aufirst%3DM.%2BRaymond%2BV.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D27062014%26date%3D01102014%26date%3D23102014%26volume%3D57%26issue%3D20%26spage%3D8249%26epage%3D8267" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julie K.-L.  Sinclair</span>, <span class="hlFld-ContribAuthor ">Elizabeth V.  Denton</span>, and <span class="hlFld-ContribAuthor ">Alanna  Schepartz</span>  . </span><span class="cited-content_cbyCitation_article-title">Inhibiting Epidermal Growth Factor Receptor at a Distance. </span><span class="cited-content_cbyCitation_journal-name">Journal of the American Chemical Society</span><span> <strong>2014,</strong> <em>136 </em>
                                    (32)
                                     , 11232-11235. <a href="https://doi.org/10.1021/ja504076t" title="DOI URL">https://doi.org/10.1021/ja504076t</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/ja504076t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Fja504076t%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520the%2520American%2520Chemical%2520Society%26atitle%3DInhibiting%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252Bat%252Ba%252BDistance%26aulast%3DSinclair%26aufirst%3DJulie%2BK.-L.%26date%3D2014%26date%3D2014%26date%3D2014%26date%3D23042014%26date%3D30072014%26date%3D13082014%26volume%3D136%26issue%3D32%26spage%3D11232%26epage%3D11235" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haibin  Zhou</span>, <span class="hlFld-ContribAuthor ">Jianfeng  Lu</span>, <span class="hlFld-ContribAuthor ">Krishnapriya  Chinnaswamy</span>, <span class="hlFld-ContribAuthor ">Jeanne A.  Stuckey</span>, <span class="hlFld-ContribAuthor ">Liu  Liu</span>, <span class="hlFld-ContribAuthor ">Donna  McEachern</span>, <span class="hlFld-ContribAuthor ">Chao-Yie  Yang</span>, <span class="hlFld-ContribAuthor ">Denzil  Bernard</span>, <span class="hlFld-ContribAuthor ">Hong  Shen</span>, <span class="hlFld-ContribAuthor ">Liangyou  Rui</span>, <span class="hlFld-ContribAuthor ">Yi  Sun</span>, <span class="hlFld-ContribAuthor ">Shaomeng  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Selective inhibition of cullin 3 neddylation through covalent targeting DCN1 protects mice from acetaminophen-induced liver toxicity. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2021,</strong> <em>12 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-021-22924-4" title="DOI URL">https://doi.org/10.1038/s41467-021-22924-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-021-22924-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-021-22924-4%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DSelective%252Binhibition%252Bof%252Bcullin%252B3%252Bneddylation%252Bthrough%252Bcovalent%252Btargeting%252BDCN1%252Bprotects%252Bmice%252Bfrom%252Bacetaminophen-induced%252Bliver%252Btoxicity%26aulast%3DZhou%26aufirst%3DHaibin%26date%3D2021%26date%3D2021%26volume%3D12%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Laura  Scalvini</span>, <span class="hlFld-ContribAuthor ">Riccardo  Castelli</span>, <span class="hlFld-ContribAuthor ">Silvia  La Monica</span>, <span class="hlFld-ContribAuthor ">Marcello  Tiseo</span>, <span class="hlFld-ContribAuthor ">Roberta  Alfieri</span>. </span><span class="cited-content_cbyCitation_article-title">Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2021,</strong> <em>190 </em>, 114643. <a href="https://doi.org/10.1016/j.bcp.2021.114643" title="DOI URL">https://doi.org/10.1016/j.bcp.2021.114643</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2021.114643&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2021.114643%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DFighting%252Btertiary%252Bmutations%252Bin%252BEGFR-driven%252Blung-cancers%25253A%252BCurrent%252Badvances%252Band%252Bfuture%252Bperspectives%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DScalvini%26aufirst%3DLaura%26date%3D2021%26volume%3D190%26spage%3D114643" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Florian  Wittlinger</span>, <span class="hlFld-ContribAuthor ">Stefan A.  Laufer</span>. </span><span class="cited-content_cbyCitation_article-title">The pre-clinical discovery and development of osimertinib used to treat non-small cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Drug Discovery</span><span> <strong>2021,</strong> <em>40 </em>, 1-13. <a href="https://doi.org/10.1080/17460441.2021.1936496" title="DOI URL">https://doi.org/10.1080/17460441.2021.1936496</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/17460441.2021.1936496&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F17460441.2021.1936496%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Drug%2520Discovery%26atitle%3DThe%252Bpre-clinical%252Bdiscovery%252Band%252Bdevelopment%252Bof%252Bosimertinib%252Bused%252Bto%252Btreat%252Bnon-small%252Bcell%252Blung%252Bcancer%26aulast%3DWittlinger%26aufirst%3DFlorian%26date%3D2021%26date%3D2021%26volume%3D40%26spage%3D1%26epage%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Elise  Bouffard</span>, <span class="hlFld-ContribAuthor ">Balyn W.  Zaro</span>, <span class="hlFld-ContribAuthor ">Melissa M.  Dix</span>, <span class="hlFld-ContribAuthor ">Benjamin  Cravatt</span>, <span class="hlFld-ContribAuthor ">Chi-Huey  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">Refinement of covalent EGFR inhibitor AZD9291 to eliminate off-target activity. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2021,</strong> <em>74 </em>, 153178. <a href="https://doi.org/10.1016/j.tetlet.2021.153178" title="DOI URL">https://doi.org/10.1016/j.tetlet.2021.153178</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2021.153178&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2021.153178%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DRefinement%252Bof%252Bcovalent%252BEGFR%252Binhibitor%252BAZD9291%252Bto%252Beliminate%252Boff-target%252Bactivity%26aulast%3DBouffard%26aufirst%3DElise%26date%3D2021%26volume%3D74%26spage%3D153178" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yueyu  Dai</span>, <span class="hlFld-ContribAuthor ">Fangyuan  Zhong</span>, <span class="hlFld-ContribAuthor ">Wenbin  Liu</span>, <span class="hlFld-ContribAuthor ">Qibin  Song</span>, <span class="hlFld-ContribAuthor ">Weiguo  Hu</span>. </span><span class="cited-content_cbyCitation_article-title">Mycoplasma hyorhinis infection promotes tyrosine kinase inhibitor (TKI) resistance in lung adenocarcinoma patients. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cancer Research and Clinical Oncology</span><span> <strong>2021,</strong> <em>147 </em>
                                    (5)
                                     , 1379-1388. <a href="https://doi.org/10.1007/s00432-021-03547-0" title="DOI URL">https://doi.org/10.1007/s00432-021-03547-0</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00432-021-03547-0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00432-021-03547-0%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cancer%2520Research%2520and%2520Clinical%2520Oncology%26atitle%3DMycoplasma%252Bhyorhinis%252Binfection%252Bpromotes%252Btyrosine%252Bkinase%252Binhibitor%252B%252528TKI%252529%252Bresistance%252Bin%252Blung%252Badenocarcinoma%252Bpatients%26aulast%3DDai%26aufirst%3DYueyu%26date%3D2021%26date%3D2021%26volume%3D147%26issue%3D5%26spage%3D1379%26epage%3D1388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Bin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhikun  Liu</span>, <span class="hlFld-ContribAuthor ">Shengjin  Xia</span>, <span class="hlFld-ContribAuthor ">Qingqing  Liu</span>, <span class="hlFld-ContribAuthor ">Shaohua  Gou</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of sulfamoylphenyl-quinazoline derivatives as potential EGFR/CAIX dual inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>216 </em>, 113300. <a href="https://doi.org/10.1016/j.ejmech.2021.113300" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113300</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113300&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113300%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsulfamoylphenyl-quinazoline%252Bderivatives%252Bas%252Bpotential%252BEGFR%25252FCAIX%252Bdual%252Binhibitors%26aulast%3DZhang%26aufirst%3DBin%26date%3D2021%26volume%3D216%26spage%3D113300" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qiao  Liu</span>, <span class="hlFld-ContribAuthor ">Yanli  Luo</span>, <span class="hlFld-ContribAuthor ">Zerui  Li</span>, <span class="hlFld-ContribAuthor ">Chen  Chen</span>, <span class="hlFld-ContribAuthor ">Lei  Fang</span>. </span><span class="cited-content_cbyCitation_article-title">Structural modifications on indole and pyrimidine rings of osimertinib lead to high selectivity towards L858R/T790M double mutant enzyme and potent antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>, 116094. <a href="https://doi.org/10.1016/j.bmc.2021.116094" title="DOI URL">https://doi.org/10.1016/j.bmc.2021.116094</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2021.116094&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2021.116094%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DStructural%252Bmodifications%252Bon%252Bindole%252Band%252Bpyrimidine%252Brings%252Bof%252Bosimertinib%252Blead%252Bto%252Bhigh%252Bselectivity%252Btowards%252BL858R%25252FT790M%252Bdouble%252Bmutant%252Benzyme%252Band%252Bpotent%252Bantitumor%252Bactivity%26aulast%3DLiu%26aufirst%3DQiao%26date%3D2021%26volume%3D36%26spage%3D116094" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lei  Zhao</span>, <span class="hlFld-ContribAuthor ">Tingting  Fan</span>, <span class="hlFld-ContribAuthor ">Zhichao  Shi</span>, <span class="hlFld-ContribAuthor ">Chao  Ding</span>, <span class="hlFld-ContribAuthor ">Cunlong  Zhang</span>, <span class="hlFld-ContribAuthor ">Zigao  Yuan</span>, <span class="hlFld-ContribAuthor ">Qinsheng  Sun</span>, <span class="hlFld-ContribAuthor ">Chunyan  Tan</span>, <span class="hlFld-ContribAuthor ">Bizhu  Chu</span>, <span class="hlFld-ContribAuthor ">Yuyang  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and evaluation of novel ErbB/HDAC multitargeted inhibitors with selectivity in EGFRT790M mutant cell lines. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>213 </em>, 113173. <a href="https://doi.org/10.1016/j.ejmech.2021.113173" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113173</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113173%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bevaluation%252Bof%252Bnovel%252BErbB%25252FHDAC%252Bmultitargeted%252Binhibitors%252Bwith%252Bselectivity%252Bin%252BEGFRT790M%252Bmutant%252Bcell%252Blines%26aulast%3DZhao%26aufirst%3DLei%26date%3D2021%26volume%3D213%26spage%3D113173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongyan  Du</span>, <span class="hlFld-ContribAuthor ">Junbo  Gao</span>, <span class="hlFld-ContribAuthor ">Gaoqi  Weng</span>, <span class="hlFld-ContribAuthor ">Junjie  Ding</span>, <span class="hlFld-ContribAuthor ">Xin  Chai</span>, <span class="hlFld-ContribAuthor ">Jinping  Pang</span>, <span class="hlFld-ContribAuthor ">Yu  Kang</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Dongsheng  Cao</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">CovalentInDB: a comprehensive database facilitating the discovery of covalent inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Nucleic Acids Research</span><span> <strong>2021,</strong> <em>49 </em>
                                    (D1)
                                     , D1122-D1129. <a href="https://doi.org/10.1093/nar/gkaa876" title="DOI URL">https://doi.org/10.1093/nar/gkaa876</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/nar/gkaa876&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fnar%2Fgkaa876%26sid%3Dliteratum%253Aachs%26jtitle%3DNucleic%2520Acids%2520Research%26atitle%3DCovalentInDB%25253A%252Ba%252Bcomprehensive%252Bdatabase%252Bfacilitating%252Bthe%252Bdiscovery%252Bof%252Bcovalent%252Binhibitors%26aulast%3DDu%26aufirst%3DHongyan%26date%3D2021%26date%3D2020%26volume%3D49%26issue%3DD1%26spage%3DD1122%26epage%3DD1129" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Richard A.  Ward</span>. </span><span class="cited-content_cbyCitation_article-title">Modeling Covalent Protein-Ligand Interactions. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 174-189. <a href="https://doi.org/10.1016/B978-0-12-801238-3.11519-3" title="DOI URL">https://doi.org/10.1016/B978-0-12-801238-3.11519-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-801238-3.11519-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-801238-3.11519-3%26sid%3Dliteratum%253Aachs%26atitle%3DModeling%252BCovalent%252BProtein-Ligand%252BInteractions%26aulast%3DWard%26aufirst%3DRichard%2BA.%26date%3D2021%26spage%3D174%26epage%3D189%26pub%3DElsevier%26atitle%3DSystems%252BMedicine%26date%3D2021%26volume%3D15" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ernest  Awoonor-Williams</span>, <span class="hlFld-ContribAuthor ">Jacob  Kennedy</span>, <span class="hlFld-ContribAuthor ">Christopher N.  Rowley</span>. </span><span class="cited-content_cbyCitation_article-title">Measuring and predicting warhead and residue reactivity. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2021,</strong>,, 203-227. <a href="https://doi.org/10.1016/bs.armc.2020.09.001" title="DOI URL">https://doi.org/10.1016/bs.armc.2020.09.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.armc.2020.09.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.armc.2020.09.001%26sid%3Dliteratum%253Aachs%26atitle%3DMeasuring%252Band%252Bpredicting%252Bwarhead%252Band%252Bresidue%252Breactivity%26aulast%3DAwoonor-Williams%26aufirst%3DErnest%26date%3D2021%26spage%3D203%26epage%3D227%26pub%3DElsevier%26atitle%3DThe%252BDesign%252Bof%252BCovalent-Based%252BInhibitors%26date%3D2021%26volume%3D56" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Su-Zhen  Zhou</span>, <span class="hlFld-ContribAuthor ">Han  Li</span>, <span class="hlFld-ContribAuthor ">Zhi-Wan  Wang</span>, <span class="hlFld-ContribAuthor ">Ming-Hang  Wang</span>, <span class="hlFld-ContribAuthor ">Ning  Li</span>, <span class="hlFld-ContribAuthor ">Yan-Fang  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">LncRNA TSLNC8 synergizes with EGFR inhibitor osimertinib to inhibit lung cancer tumorigenesis by blocking the EGFR-STAT3 pathway. </span><span class="cited-content_cbyCitation_journal-name">Cell Cycle</span><span> <strong>2020,</strong> <em>19 </em>
                                    (21)
                                     , 2776-2792. <a href="https://doi.org/10.1080/15384101.2020.1820697" title="DOI URL">https://doi.org/10.1080/15384101.2020.1820697</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/15384101.2020.1820697&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F15384101.2020.1820697%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Cycle%26atitle%3DLncRNA%252BTSLNC8%252Bsynergizes%252Bwith%252BEGFR%252Binhibitor%252Bosimertinib%252Bto%252Binhibit%252Blung%252Bcancer%252Btumorigenesis%252Bby%252Bblocking%252Bthe%252BEGFR-STAT3%252Bpathway%26aulast%3DZhou%26aufirst%3DSu-Zhen%26date%3D2020%26date%3D2020%26volume%3D19%26issue%3D21%26spage%3D2776%26epage%3D2792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhen  Xiao</span>, <span class="hlFld-ContribAuthor ">Zhihui  Zhou</span>, <span class="hlFld-ContribAuthor ">Cilong  Chu</span>, <span class="hlFld-ContribAuthor ">Qian  Zhang</span>, <span class="hlFld-ContribAuthor ">Lingjia  Zhou</span>, <span class="hlFld-ContribAuthor ">Zunhua  Yang</span>, <span class="hlFld-ContribAuthor ">Xin  Li</span>, <span class="hlFld-ContribAuthor ">Liying  Yu</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and antitumor activity of novel thiophene-pyrimidine derivatives as EGFR inhibitors overcoming T790M and L858R/T790M mutations. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>203 </em>, 112511. <a href="https://doi.org/10.1016/j.ejmech.2020.112511" title="DOI URL">https://doi.org/10.1016/j.ejmech.2020.112511</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2020.112511&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2020.112511%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bantitumor%252Bactivity%252Bof%252Bnovel%252Bthiophene-pyrimidine%252Bderivatives%252Bas%252BEGFR%252Binhibitors%252Bovercoming%252BT790M%252Band%252BL858R%25252FT790M%252Bmutations%26aulast%3DXiao%26aufirst%3DZhen%26date%3D2020%26volume%3D203%26spage%3D112511" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zichao  Yang</span>, <span class="hlFld-ContribAuthor ">Haikui  Yang</span>, <span class="hlFld-ContribAuthor ">Yangcheng  Ai</span>, <span class="hlFld-ContribAuthor ">Lishun  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhonghuang  Li</span>, <span class="hlFld-ContribAuthor ">Shanhe  Wan</span>, <span class="hlFld-ContribAuthor ">Xuan  Xu</span>, <span class="hlFld-ContribAuthor ">Huiwu  Zhang</span>, <span class="hlFld-ContribAuthor ">Shaoyu  Wu</span>, <span class="hlFld-ContribAuthor ">Jiajie  Zhang</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Computational studies of potent covalent inhibitors on wild type or T790M/L858R mutant epidermal growth factor receptor. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmaceutical Sciences</span><span> <strong>2020,</strong> <em>152 </em>, 105463. <a href="https://doi.org/10.1016/j.ejps.2020.105463" title="DOI URL">https://doi.org/10.1016/j.ejps.2020.105463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejps.2020.105463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejps.2020.105463%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmaceutical%2520Sciences%26atitle%3DComputational%252Bstudies%252Bof%252Bpotent%252Bcovalent%252Binhibitors%252Bon%252Bwild%252Btype%252Bor%252BT790M%25252FL858R%252Bmutant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%26aulast%3DYang%26aufirst%3DZichao%26date%3D2020%26volume%3D152%26spage%3D105463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Beth  Williamson</span>, <span class="hlFld-ContribAuthor ">Nicola  Colclough</span>, <span class="hlFld-ContribAuthor ">Adrian John  Fretland</span>, <span class="hlFld-ContribAuthor ">Barry Christopher  Jones</span>, <span class="hlFld-ContribAuthor ">Rhys Dafydd Owen  Jones</span>, <span class="hlFld-ContribAuthor ">Dermot Francis  McGinnity</span>. </span><span class="cited-content_cbyCitation_article-title">Further Considerations Towards an Effective and Efficient Oncology Drug Discovery DMPK Strategy. </span><span class="cited-content_cbyCitation_journal-name">Current Drug Metabolism</span><span> <strong>2020,</strong> <em>21 </em>
                                    (2)
                                     , 145-162. <a href="https://doi.org/10.2174/1389200221666200312104837" title="DOI URL">https://doi.org/10.2174/1389200221666200312104837</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1389200221666200312104837&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1389200221666200312104837%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Drug%2520Metabolism%26atitle%3DFurther%252BConsiderations%252BTowards%252Ban%252BEffective%252Band%252BEfficient%252BOncology%252BDrug%252BDiscovery%252BDMPK%252BStrategy%26aulast%3DWilliamson%26aufirst%3DBeth%26date%3D2020%26volume%3D21%26issue%3D2%26spage%3D145%26epage%3D162" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Adileh  Ayati</span>, <span class="hlFld-ContribAuthor ">Setareh  Moghimi</span>, <span class="hlFld-ContribAuthor ">Somayeh  Salarinejad</span>, <span class="hlFld-ContribAuthor ">Maliheh  Safavi</span>, <span class="hlFld-ContribAuthor ">Behjat  Pouramiri</span>, <span class="hlFld-ContribAuthor ">Alireza  Foroumadi</span>. </span><span class="cited-content_cbyCitation_article-title">A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>99 </em>, 103811. <a href="https://doi.org/10.1016/j.bioorg.2020.103811" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103811</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103811&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103811%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DA%252Breview%252Bon%252Bprogression%252Bof%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bas%252Ban%252Befficient%252Bapproach%252Bin%252Bcancer%252Btargeted%252Btherapy%26aulast%3DAyati%26aufirst%3DAdileh%26date%3D2020%26volume%3D99%26spage%3D103811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aaron  Keeley</span>, <span class="hlFld-ContribAuthor ">László  Petri</span>, <span class="hlFld-ContribAuthor ">Péter  Ábrányi-Balogh</span>, <span class="hlFld-ContribAuthor ">György M.  Keserű</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent fragment libraries in drug discovery. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (6)
                                     , 983-996. <a href="https://doi.org/10.1016/j.drudis.2020.03.016" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.03.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.03.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.03.016%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DCovalent%252Bfragment%252Blibraries%252Bin%252Bdrug%252Bdiscovery%26aulast%3DKeeley%26aufirst%3DAaron%26date%3D2020%26volume%3D25%26issue%3D6%26spage%3D983%26epage%3D996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ayah  Abdeldayem</span>, <span class="hlFld-ContribAuthor ">Yasir S.  Raouf</span>, <span class="hlFld-ContribAuthor ">Stefan N.  Constantinescu</span>, <span class="hlFld-ContribAuthor ">Richard  Moriggl</span>, <span class="hlFld-ContribAuthor ">Patrick T.  Gunning</span>. </span><span class="cited-content_cbyCitation_article-title">Advances in covalent kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemical Society Reviews</span><span> <strong>2020,</strong> <em>49 </em>
                                    (9)
                                     , 2617-2687. <a href="https://doi.org/10.1039/C9CS00720B" title="DOI URL">https://doi.org/10.1039/C9CS00720B</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9CS00720B&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9CS00720B%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Society%2520Reviews%26atitle%3DAdvances%252Bin%252Bcovalent%252Bkinase%252Binhibitors%26aulast%3DAbdeldayem%26aufirst%3DAyah%26date%3D2020%26date%3D2020%26volume%3D49%26issue%3D9%26spage%3D2617%26epage%3D2687" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Samuel E.  Dalton</span>, <span class="hlFld-ContribAuthor ">Sebastien  Campos</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Small Molecules as Enabling Platforms for Drug Discovery. </span><span class="cited-content_cbyCitation_journal-name">ChemBioChem</span><span> <strong>2020,</strong> <em>21 </em>
                                    (8)
                                     , 1080-1100. <a href="https://doi.org/10.1002/cbic.201900674" title="DOI URL">https://doi.org/10.1002/cbic.201900674</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cbic.201900674&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcbic.201900674%26sid%3Dliteratum%253Aachs%26jtitle%3DChemBioChem%26atitle%3DCovalent%252BSmall%252BMolecules%252Bas%252BEnabling%252BPlatforms%252Bfor%252BDrug%252BDiscovery%26aulast%3DDalton%26aufirst%3DSamuel%2BE.%26date%3D2020%26date%3D2020%26volume%3D21%26issue%3D8%26spage%3D1080%26epage%3D1100" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Abdulaziz B.  Hamid</span>, <span class="hlFld-ContribAuthor ">Ruben C.  Petreaca</span>. </span><span class="cited-content_cbyCitation_article-title">Secondary Resistant Mutations to Small Molecule Inhibitors in Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (4)
                                     , 927. <a href="https://doi.org/10.3390/cancers12040927" title="DOI URL">https://doi.org/10.3390/cancers12040927</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12040927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12040927%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DSecondary%252BResistant%252BMutations%252Bto%252BSmall%252BMolecule%252BInhibitors%252Bin%252BCancer%252BCells%26aulast%3DHamid%26aufirst%3DAbdulaziz%2BB.%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D4%26spage%3D927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Luiz Claudio  Ferreira Pimentel</span>, <span class="hlFld-ContribAuthor ">Anna Claudia  Cunha</span>, <span class="hlFld-ContribAuthor ">Lucas Villas  Boas Hoelz</span>, <span class="hlFld-ContribAuthor ">Henayle Fernandes  Canzian</span>, <span class="hlFld-ContribAuthor ">Debora Inacio  Leite Firmino Marinho</span>, <span class="hlFld-ContribAuthor ">Nubia  Boechat</span>, <span class="hlFld-ContribAuthor ">Monica Macedo  Bastos</span>. </span><span class="cited-content_cbyCitation_article-title">Phenylamino-pyrimidine (PAP) Privileged Structure: Synthesis and Medicinal Applications. </span><span class="cited-content_cbyCitation_journal-name">Current Topics in Medicinal Chemistry</span><span> <strong>2020,</strong> <em>20 </em>
                                    (3)
                                     , 227-243. <a href="https://doi.org/10.2174/1568026620666200124094949" title="DOI URL">https://doi.org/10.2174/1568026620666200124094949</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1568026620666200124094949&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1568026620666200124094949%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Topics%2520in%2520Medicinal%2520Chemistry%26atitle%3DPhenylamino-pyrimidine%252B%252528PAP%252529%252BPrivileged%252BStructure%25253A%252BSynthesis%252Band%252BMedicinal%252BApplications%26aulast%3DFerreira%2BPimentel%26aufirst%3DLuiz%2BClaudio%26date%3D2020%26volume%3D20%26issue%3D3%26spage%3D227%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel Nascimento  do Amaral</span>, <span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Harold Hilarion  Fokoue</span>, <span class="hlFld-ContribAuthor ">Eduardo Miguez Bastos  da Silva</span>, <span class="hlFld-ContribAuthor ">Carlos Mauricio R.  Sant’Anna</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>, <span class="hlFld-ContribAuthor ">Eliezer J.  Barreiro</span>, <span class="hlFld-ContribAuthor ">Stefan  Laufer</span>, <span class="hlFld-ContribAuthor ">Lidia Moreira  Lima</span>. </span><span class="cited-content_cbyCitation_article-title">A novel scaffold for EGFR inhibition: Introducing N-(3-(3-phenylureido)quinoxalin-6-yl) acrylamide derivatives. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2019,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-36846-7" title="DOI URL">https://doi.org/10.1038/s41598-018-36846-7</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-36846-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-36846-7%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DA%252Bnovel%252Bscaffold%252Bfor%252BEGFR%252Binhibition%25253A%252BIntroducing%252BN-%2525283-%2525283-phenylureido%252529quinoxalin-6-yl%252529%252Bacrylamide%252Bderivatives%26aulast%3Ddo%2BAmaral%26aufirst%3DDaniel%2BNascimento%26date%3D2019%26date%3D2019%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jonas  Lategahn</span>, <span class="hlFld-ContribAuthor ">Marina  Keul</span>, <span class="hlFld-ContribAuthor ">Philip  Klövekorn</span>, <span class="hlFld-ContribAuthor ">Hannah L.  Tumbrink</span>, <span class="hlFld-ContribAuthor ">Janina  Niggenaber</span>, <span class="hlFld-ContribAuthor ">Matthias P.  Müller</span>, <span class="hlFld-ContribAuthor ">Luke  Hodson</span>, <span class="hlFld-ContribAuthor ">Maren  Flaßhoff</span>, <span class="hlFld-ContribAuthor ">Julia  Hardick</span>, <span class="hlFld-ContribAuthor ">Tobias  Grabe</span>, <span class="hlFld-ContribAuthor ">Julian  Engel</span>, <span class="hlFld-ContribAuthor ">Carsten  Schultz-Fademrecht</span>, <span class="hlFld-ContribAuthor ">Matthias  Baumann</span>, <span class="hlFld-ContribAuthor ">Julia  Ketzer</span>, <span class="hlFld-ContribAuthor ">Thomas  Mühlenberg</span>, <span class="hlFld-ContribAuthor ">Wolf  Hiller</span>, <span class="hlFld-ContribAuthor ">Georgia  Günther</span>, <span class="hlFld-ContribAuthor ">Anke  Unger</span>, <span class="hlFld-ContribAuthor ">Heiko  Müller</span>, <span class="hlFld-ContribAuthor ">Alena  Heimsoeth</span>, <span class="hlFld-ContribAuthor ">Christopher  Golz</span>, <span class="hlFld-ContribAuthor ">Bernhard  Blank-Landeshammer</span>, <span class="hlFld-ContribAuthor ">Laxmikanth  Kollipara</span>, <span class="hlFld-ContribAuthor ">René P.  Zahedi</span>, <span class="hlFld-ContribAuthor ">Carsten  Strohmann</span>, <span class="hlFld-ContribAuthor ">Jan G.  Hengstler</span>, <span class="hlFld-ContribAuthor ">Willem A. L.  van Otterlo</span>, <span class="hlFld-ContribAuthor ">Sebastian  Bauer</span>, <span class="hlFld-ContribAuthor ">Daniel  Rauh</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of osimertinib-resistant epidermal growth factor receptor EGFR-T790M/C797S. </span><span class="cited-content_cbyCitation_journal-name">Chemical Science</span><span> <strong>2019,</strong> <em>10 </em>
                                    (46)
                                     , 10789-10801. <a href="https://doi.org/10.1039/C9SC03445E" title="DOI URL">https://doi.org/10.1039/C9SC03445E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C9SC03445E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC9SC03445E%26sid%3Dliteratum%253Aachs%26jtitle%3DChemical%2520Science%26atitle%3DInhibition%252Bof%252Bosimertinib-resistant%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252BEGFR-T790M%25252FC797S%26aulast%3DLategahn%26aufirst%3DJonas%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D46%26spage%3D10789%26epage%3D10801" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Supaphorn  Seetaha</span>, <span class="hlFld-ContribAuthor ">Siriluk  Ratanabanyong</span>, <span class="hlFld-ContribAuthor ">Kiattawee  Choowongkomon</span>. </span><span class="cited-content_cbyCitation_article-title">Expression, purification, and characterization of the native intracellular domain of human epidermal growth factor receptors 1 and 2 in Escherichia coli. </span><span class="cited-content_cbyCitation_journal-name">Applied Microbiology and Biotechnology</span><span> <strong>2019,</strong> <em>103 </em>
                                    (20)
                                     , 8427-8438. <a href="https://doi.org/10.1007/s00253-019-10116-6" title="DOI URL">https://doi.org/10.1007/s00253-019-10116-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00253-019-10116-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00253-019-10116-6%26sid%3Dliteratum%253Aachs%26jtitle%3DApplied%2520Microbiology%2520and%2520Biotechnology%26atitle%3DExpression%25252C%252Bpurification%25252C%252Band%252Bcharacterization%252Bof%252Bthe%252Bnative%252Bintracellular%252Bdomain%252Bof%252Bhuman%252Bepidermal%252Bgrowth%252Bfactor%252Breceptors%252B1%252Band%252B2%252Bin%252BEscherichia%252Bcoli%26aulast%3DSeetaha%26aufirst%3DSupaphorn%26date%3D2019%26date%3D2019%26volume%3D103%26issue%3D20%26spage%3D8427%26epage%3D8438" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruchi  Gaikwad</span>, <span class="hlFld-ContribAuthor ">Yamini  Bobde</span>, <span class="hlFld-ContribAuthor ">Routholla  Ganesh</span>, <span class="hlFld-ContribAuthor ">Tarun  Patel</span>, <span class="hlFld-ContribAuthor ">Anju  Rathore</span>, <span class="hlFld-ContribAuthor ">Balaram  Ghosh</span>, <span class="hlFld-ContribAuthor ">Kalpataru  Das</span>, <span class="hlFld-ContribAuthor ">Shovanlal  Gayen</span>. </span><span class="cited-content_cbyCitation_article-title">2-Phenylindole derivatives as anticancer agents: synthesis and screening against murine melanoma, human lung and breast cancer cell lines. </span><span class="cited-content_cbyCitation_journal-name">Synthetic Communications</span><span> <strong>2019,</strong> <em>49 </em>
                                    (17)
                                     , 2258-2269. <a href="https://doi.org/10.1080/00397911.2019.1620282" title="DOI URL">https://doi.org/10.1080/00397911.2019.1620282</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/00397911.2019.1620282&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F00397911.2019.1620282%26sid%3Dliteratum%253Aachs%26jtitle%3DSynthetic%2520Communications%26atitle%3D2-Phenylindole%252Bderivatives%252Bas%252Banticancer%252Bagents%25253A%252Bsynthesis%252Band%252Bscreening%252Bagainst%252Bmurine%252Bmelanoma%25252C%252Bhuman%252Blung%252Band%252Bbreast%252Bcancer%252Bcell%252Blines%26aulast%3DGaikwad%26aufirst%3DRuchi%26date%3D2019%26date%3D2019%26volume%3D49%26issue%3D17%26spage%3D2258%26epage%3D2269" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keriann M.  Backus</span>, <span class="hlFld-ContribAuthor ">Jian  Cao</span>, <span class="hlFld-ContribAuthor ">Sean M.  Maddox</span>. </span><span class="cited-content_cbyCitation_article-title">Opportunities and challenges for the development of covalent chemical immunomodulators. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2019,</strong> <em>27 </em>
                                    (15)
                                     , 3421-3439. <a href="https://doi.org/10.1016/j.bmc.2019.05.050" title="DOI URL">https://doi.org/10.1016/j.bmc.2019.05.050</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2019.05.050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2019.05.050%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DOpportunities%252Band%252Bchallenges%252Bfor%252Bthe%252Bdevelopment%252Bof%252Bcovalent%252Bchemical%252Bimmunomodulators%26aulast%3DBackus%26aufirst%3DKeriann%2BM.%26date%3D2019%26volume%3D27%26issue%3D15%26spage%3D3421%26epage%3D3439" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vahideh  Assadollahi</span>, <span class="hlFld-ContribAuthor ">Behnam  Rashidieh</span>, <span class="hlFld-ContribAuthor ">Masoud  Alasvand</span>, <span class="hlFld-ContribAuthor ">Alina  Abdolahi</span>, <span class="hlFld-ContribAuthor ">J. Alejandro  Lopez</span>. </span><span class="cited-content_cbyCitation_article-title">Interaction and molecular dynamics simulation study of Osimertinib (AstraZeneca 9291) anticancer drug with the EGFR kinase domain in native protein and mutated L844V and C797S. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Biochemistry</span><span> <strong>2019,</strong> <em>120 </em>
                                    (8)
                                     , 13046-13055. <a href="https://doi.org/10.1002/jcb.28575" title="DOI URL">https://doi.org/10.1002/jcb.28575</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcb.28575&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcb.28575%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Biochemistry%26atitle%3DInteraction%252Band%252Bmolecular%252Bdynamics%252Bsimulation%252Bstudy%252Bof%252BOsimertinib%252B%252528AstraZeneca%252B9291%252529%252Banticancer%252Bdrug%252Bwith%252Bthe%252BEGFR%252Bkinase%252Bdomain%252Bin%252Bnative%252Bprotein%252Band%252Bmutated%252BL844V%252Band%252BC797S%26aulast%3DAssadollahi%26aufirst%3DVahideh%26date%3D2019%26date%3D2019%26volume%3D120%26issue%3D8%26spage%3D13046%26epage%3D13055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Agnello</span>, <span class="hlFld-ContribAuthor ">Michael  Brand</span>, <span class="hlFld-ContribAuthor ">Mathieu F.  Chellat</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Rainer  Riedl</span>. </span><span class="cited-content_cbyCitation_article-title">Eine strukturelle Evaluierung medizinalchemischer Strategien gegen Wirkstoffresistenzen. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie</span><span> <strong>2019,</strong> <em>131 </em>
                                    (11)
                                     , 3336-3383. <a href="https://doi.org/10.1002/ange.201802416" title="DOI URL">https://doi.org/10.1002/ange.201802416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/ange.201802416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fange.201802416%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%26atitle%3DEine%252Bstrukturelle%252BEvaluierung%252Bmedizinalchemischer%252BStrategien%252Bgegen%252BWirkstoffresistenzen%26aulast%3DAgnello%26aufirst%3DStefano%26date%3D2019%26date%3D2019%26volume%3D131%26issue%3D11%26spage%3D3336%26epage%3D3383" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Agnello</span>, <span class="hlFld-ContribAuthor ">Michael  Brand</span>, <span class="hlFld-ContribAuthor ">Mathieu F.  Chellat</span>, <span class="hlFld-ContribAuthor ">Silvia  Gazzola</span>, <span class="hlFld-ContribAuthor ">Rainer  Riedl</span>. </span><span class="cited-content_cbyCitation_article-title">A Structural View on Medicinal Chemistry Strategies against Drug Resistance. </span><span class="cited-content_cbyCitation_journal-name">Angewandte Chemie International Edition</span><span> <strong>2019,</strong> <em>58 </em>
                                    (11)
                                     , 3300-3345. <a href="https://doi.org/10.1002/anie.201802416" title="DOI URL">https://doi.org/10.1002/anie.201802416</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/anie.201802416&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fanie.201802416%26sid%3Dliteratum%253Aachs%26jtitle%3DAngewandte%2520Chemie%2520International%2520Edition%26atitle%3DA%252BStructural%252BView%252Bon%252BMedicinal%252BChemistry%252BStrategies%252Bagainst%252BDrug%252BResistance%26aulast%3DAgnello%26aufirst%3DStefano%26date%3D2019%26date%3D2019%26volume%3D58%26issue%3D11%26spage%3D3300%26epage%3D3345" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jan P.  Wintgens</span>, <span class="hlFld-ContribAuthor ">Sven P.  Wichert</span>, <span class="hlFld-ContribAuthor ">Luksa  Popovic</span>, <span class="hlFld-ContribAuthor ">Moritz J.  Rossner</span>, <span class="hlFld-ContribAuthor ">Michael C.  Wehr</span>. </span><span class="cited-content_cbyCitation_article-title">Monitoring activities of receptor tyrosine
            kinases using a universal adapter in genetically encoded split TEV assays. </span><span class="cited-content_cbyCitation_journal-name">Cellular and Molecular Life Sciences</span><span> <strong>2019,</strong> <em>76 </em>
                                    (6)
                                     , 1185-1199. <a href="https://doi.org/10.1007/s00018-018-03003-2" title="DOI URL">https://doi.org/10.1007/s00018-018-03003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00018-018-03003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00018-018-03003-2%26sid%3Dliteratum%253Aachs%26jtitle%3DCellular%2520and%2520Molecular%2520Life%2520Sciences%26atitle%3DMonitoring%252Bactivities%252Bof%252Breceptor%252Btyrosine%252Bkinases%252Busing%252Ba%252Buniversal%252Badapter%252Bin%252Bgenetically%252Bencoded%252Bsplit%252BTEV%252Bassays%26aulast%3DWintgens%26aufirst%3DJan%2BP.%26date%3D2019%26date%3D2019%26volume%3D76%26issue%3D6%26spage%3D1185%26epage%3D1199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer W  Carlisle</span>, <span class="hlFld-ContribAuthor ">Suresh S  Ramalingam</span>. </span><span class="cited-content_cbyCitation_article-title">Role of osimertinib in the treatment of EGFR-mutation positive non-small-cell lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (8)
                                     , 805-816. <a href="https://doi.org/10.2217/fon-2018-0626" title="DOI URL">https://doi.org/10.2217/fon-2018-0626</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2018-0626&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2018-0626%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DRole%252Bof%252Bosimertinib%252Bin%252Bthe%252Btreatment%252Bof%252BEGFR-mutation%252Bpositive%252Bnon-small-cell%252Blung%252Bcancer%26aulast%3DCarlisle%26aufirst%3DJennifer%2BW%26date%3D2019%26volume%3D15%26issue%3D8%26spage%3D805%26epage%3D816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karthick  Vishwanathan</span>, <span class="hlFld-ContribAuthor ">Karen  So</span>, <span class="hlFld-ContribAuthor ">Karen  Thomas</span>, <span class="hlFld-ContribAuthor ">Alex  Bramley</span>, <span class="hlFld-ContribAuthor ">Stephen  English</span>, <span class="hlFld-ContribAuthor ">Jo  Collier</span>. </span><span class="cited-content_cbyCitation_article-title">Absolute Bioavailability of Osimertinib in Healthy Adults. </span><span class="cited-content_cbyCitation_journal-name">Clinical Pharmacology in Drug Development</span><span> <strong>2019,</strong> <em>8 </em>
                                    (2)
                                     , 198-207. <a href="https://doi.org/10.1002/cpdd.467" title="DOI URL">https://doi.org/10.1002/cpdd.467</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cpdd.467&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcpdd.467%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Pharmacology%2520in%2520Drug%2520Development%26atitle%3DAbsolute%252BBioavailability%252Bof%252BOsimertinib%252Bin%252BHealthy%252BAdults%26aulast%3DVishwanathan%26aufirst%3DKarthick%26date%3D2019%26date%3D2018%26volume%3D8%26issue%3D2%26spage%3D198%26epage%3D207" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kei  Namba</span>, <span class="hlFld-ContribAuthor ">Kazuhiko  Shien</span>, <span class="hlFld-ContribAuthor ">Yuta  Takahashi</span>, <span class="hlFld-ContribAuthor ">Hidejiro  Torigoe</span>, <span class="hlFld-ContribAuthor ">Hiroki  Sato</span>, <span class="hlFld-ContribAuthor ">Takahiro  Yoshioka</span>, <span class="hlFld-ContribAuthor ">Tatsuaki  Takeda</span>, <span class="hlFld-ContribAuthor ">Eisuke  Kurihara</span>, <span class="hlFld-ContribAuthor ">Yusuke  Ogoshi</span>, <span class="hlFld-ContribAuthor ">Hiromasa  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Junichi  Soh</span>, <span class="hlFld-ContribAuthor ">Shuta  Tomida</span>, <span class="hlFld-ContribAuthor ">Shinichi  Toyooka</span>. </span><span class="cited-content_cbyCitation_article-title">Activation of AXL as a Preclinical Acquired Resistance Mechanism Against Osimertinib Treatment in
              EGFR
              -Mutant Non–Small Cell Lung Cancer Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Research</span><span> <strong>2019,</strong> <em>17 </em>
                                    (2)
                                     , 499-507. <a href="https://doi.org/10.1158/1541-7786.MCR-18-0628" title="DOI URL">https://doi.org/10.1158/1541-7786.MCR-18-0628</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1541-7786.MCR-18-0628&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1541-7786.MCR-18-0628%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Research%26atitle%3DActivation%252Bof%252BAXL%252Bas%252Ba%252BPreclinical%252BAcquired%252BResistance%252BMechanism%252BAgainst%252BOsimertinib%252BTreatment%252Bin%252BEGFR%252B-Mutant%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%252BCells%26aulast%3DNamba%26aufirst%3DKei%26date%3D2019%26date%3D2018%26volume%3D17%26issue%3D2%26spage%3D499%26epage%3D507" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruth  Nussinov</span>, <span class="hlFld-ContribAuthor ">Chung-Jung  Tsai</span>, <span class="hlFld-ContribAuthor ">Amarda  Shehu</span>, <span class="hlFld-ContribAuthor ">Hyunbum  Jang</span>. </span><span class="cited-content_cbyCitation_article-title">Computational Structural Biology: Successes, Future Directions, and Challenges. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2019,</strong> <em>24 </em>
                                    (3)
                                     , 637. <a href="https://doi.org/10.3390/molecules24030637" title="DOI URL">https://doi.org/10.3390/molecules24030637</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules24030637&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules24030637%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DComputational%252BStructural%252BBiology%25253A%252BSuccesses%25252C%252BFuture%252BDirections%25252C%252Band%252BChallenges%26aulast%3DNussinov%26aufirst%3DRuth%26date%3D2019%26date%3D2019%26volume%3D24%26issue%3D3%26spage%3D637" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun M.  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Sanjay J.  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Current Approaches in the Development of Covalent Irreversible EGFR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 45-128. <a href="https://doi.org/10.1016/B978-0-08-102661-8.00003-2" title="DOI URL">https://doi.org/10.1016/B978-0-08-102661-8.00003-2</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-08-102661-8.00003-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-08-102661-8.00003-2%26sid%3Dliteratum%253Aachs%26atitle%3DCurrent%252BApproaches%252Bin%252Bthe%252BDevelopment%252Bof%252BCovalent%252BIrreversible%252BEGFR%252BInhibitors%26aulast%3DPatel%26aufirst%3DHarun%2BM.%26date%3D2019%26spage%3D45%26epage%3D128%26pub%3DElsevier%26atitle%3DThird%252BGeneration%252BEGFR%252BInhibitors%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Manzo</span>, <span class="hlFld-ContribAuthor ">Agnese  Montanino</span>, <span class="hlFld-ContribAuthor ">Raffaele  Costanzo</span>, <span class="hlFld-ContribAuthor ">Claudia  Sandomenico</span>, <span class="hlFld-ContribAuthor ">Giuliano  Palumbo</span>, <span class="hlFld-ContribAuthor ">Clorinda  Schettino</span>, <span class="hlFld-ContribAuthor ">Gennaro  Daniele</span>, <span class="hlFld-ContribAuthor ">Alessandro  Morabito</span>, <span class="hlFld-ContribAuthor ">Francesco  Perrone</span>, <span class="hlFld-ContribAuthor ">Maria Carmela  Piccirillo</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR Mutations. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2019,</strong>,, 477-486. <a href="https://doi.org/10.1016/B978-0-12-811785-9.00033-8" title="DOI URL">https://doi.org/10.1016/B978-0-12-811785-9.00033-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-811785-9.00033-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-811785-9.00033-8%26sid%3Dliteratum%253Aachs%26atitle%3DEGFR%252BMutations%26aulast%3DManzo%26aufirst%3DAnna%26date%3D2019%26spage%3D477%26epage%3D486%26pub%3DElsevier%26atitle%3DOncogenomics%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Amit  Shraga</span>, <span class="hlFld-ContribAuthor ">Evgenia  Olshvang</span>, <span class="hlFld-ContribAuthor ">Natalia  Davidzohn</span>, <span class="hlFld-ContribAuthor ">Payam  Khoshkenar</span>, <span class="hlFld-ContribAuthor ">Nicolas  Germain</span>, <span class="hlFld-ContribAuthor ">Khriesto  Shurrush</span>, <span class="hlFld-ContribAuthor ">Silvia  Carvalho</span>, <span class="hlFld-ContribAuthor ">Liat  Avram</span>, <span class="hlFld-ContribAuthor ">Shira  Albeck</span>, <span class="hlFld-ContribAuthor ">Tamar  Unger</span>, <span class="hlFld-ContribAuthor ">Bruce  Lefker</span>, <span class="hlFld-ContribAuthor ">Chakrapani  Subramanyam</span>, <span class="hlFld-ContribAuthor ">Robert L.  Hudkins</span>, <span class="hlFld-ContribAuthor ">Amir  Mitchell</span>, <span class="hlFld-ContribAuthor ">Ziv  Shulman</span>, <span class="hlFld-ContribAuthor ">Takayoshi  Kinoshita</span>, <span class="hlFld-ContribAuthor ">Nir  London</span>. </span><span class="cited-content_cbyCitation_article-title">Covalent Docking Identifies a Potent and Selective MKK7 Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Cell Chemical Biology</span><span> <strong>2019,</strong> <em>26 </em>
                                    (1)
                                     , 98-108.e5. <a href="https://doi.org/10.1016/j.chembiol.2018.10.011" title="DOI URL">https://doi.org/10.1016/j.chembiol.2018.10.011</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.chembiol.2018.10.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.chembiol.2018.10.011%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Chemical%2520Biology%26atitle%3DCovalent%252BDocking%252BIdentifies%252Ba%252BPotent%252Band%252BSelective%252BMKK7%252BInhibitor%26aulast%3DShraga%26aufirst%3DAmit%26date%3D2019%26volume%3D26%26issue%3D1%26spage%3D98%26epage%3D108.e5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Caolin  Wang</span>, <span class="hlFld-ContribAuthor ">Shan  Xu</span>, <span class="hlFld-ContribAuthor ">Liang  Peng</span>, <span class="hlFld-ContribAuthor ">Bingliang  Zhang</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Yingying  Hu</span>, <span class="hlFld-ContribAuthor ">Pengwu  Zheng</span>, <span class="hlFld-ContribAuthor ">Wufu  Zhu</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of novel 4-anlinoquinazoline derivatives as EGFR inhibitors with the potential to inhibit the gefitinib-resistant nonsmall cell lung cancers. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2019,</strong> <em>34 </em>
                                    (1)
                                     , 203-217. <a href="https://doi.org/10.1080/14756366.2018.1518957" title="DOI URL">https://doi.org/10.1080/14756366.2018.1518957</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2018.1518957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2018.1518957%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252B4-anlinoquinazoline%252Bderivatives%252Bas%252BEGFR%252Binhibitors%252Bwith%252Bthe%252Bpotential%252Bto%252Binhibit%252Bthe%252Bgefitinib-resistant%252Bnonsmall%252Bcell%252Blung%252Bcancers%26aulast%3DWang%26aufirst%3DCaolin%26date%3D2019%26date%3D2018%26volume%3D34%26issue%3D1%26spage%3D203%26epage%3D217" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhirui  Zhang</span>, <span class="hlFld-ContribAuthor ">Mengxiao  Zhang</span>, <span class="hlFld-ContribAuthor ">Hao  Liu</span>, <span class="hlFld-ContribAuthor ">Wu  Yin</span>. </span><span class="cited-content_cbyCitation_article-title">AZD9291 promotes autophagy and inhibits PI3K/Akt pathway in NSCLC cancer cells. </span><span class="cited-content_cbyCitation_journal-name">Journal of Cellular Biochemistry</span><span> <strong>2019,</strong> <em>120 </em>
                                    (1)
                                     , 756-767. <a href="https://doi.org/10.1002/jcb.27434" title="DOI URL">https://doi.org/10.1002/jcb.27434</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/jcb.27434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fjcb.27434%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Cellular%2520Biochemistry%26atitle%3DAZD9291%252Bpromotes%252Bautophagy%252Band%252Binhibits%252BPI3K%25252FAkt%252Bpathway%252Bin%252BNSCLC%252Bcancer%252Bcells%26aulast%3DZhang%26aufirst%3DZhirui%26date%3D2019%26date%3D2018%26volume%3D120%26issue%3D1%26spage%3D756%26epage%3D767" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ruth A.  Mitchell</span>, <span class="hlFld-ContribAuthor ">Rodney B.  Luwor</span>, <span class="hlFld-ContribAuthor ">Antony W.  Burgess</span>. </span><span class="cited-content_cbyCitation_article-title">Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics. </span><span class="cited-content_cbyCitation_journal-name">Experimental Cell Research</span><span> <strong>2018,</strong> <em>371 </em>
                                    (1)
                                     , 1-19. <a href="https://doi.org/10.1016/j.yexcr.2018.08.009" title="DOI URL">https://doi.org/10.1016/j.yexcr.2018.08.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.yexcr.2018.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.yexcr.2018.08.009%26sid%3Dliteratum%253Aachs%26jtitle%3DExperimental%2520Cell%2520Research%26atitle%3DEpidermal%252Bgrowth%252Bfactor%252Breceptor%25253A%252BStructure-function%252Binforming%252Bthe%252Bdesign%252Bof%252Banticancer%252Btherapeutics%26aulast%3DMitchell%26aufirst%3DRuth%2BA.%26date%3D2018%26volume%3D371%26issue%3D1%26spage%3D1%26epage%3D19" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>, <span class="hlFld-ContribAuthor ">Lei  Yu</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Jeff B.  Smaill</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR
              L858R/T790M
              and EGFR
              L858R/T790M/C797S
              resistance mutations in NSCLC: Current developments in medicinal chemistry. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2018,</strong> <em>38 </em>
                                    (5)
                                     , 1550-1581. <a href="https://doi.org/10.1002/med.21488" title="DOI URL">https://doi.org/10.1002/med.21488</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21488&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21488%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DTargeting%252BEGFR%252BL858R%25252FT790M%252Band%252BEGFR%252BL858R%25252FT790M%25252FC797S%252Bresistance%252Bmutations%252Bin%252BNSCLC%25253A%252BCurrent%252Bdevelopments%252Bin%252Bmedicinal%252Bchemistry%26aulast%3DLu%26aufirst%3DXiaoyun%26date%3D2018%26date%3D2018%26volume%3D38%26issue%3D5%26spage%3D1550%26epage%3D1581" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chia‐Yu  Chu</span>, <span class="hlFld-ContribAuthor ">Jennifer  Choi</span>, <span class="hlFld-ContribAuthor ">Beth  Eaby‐Sandy</span>, <span class="hlFld-ContribAuthor ">Corey J.  Langer</span>, <span class="hlFld-ContribAuthor ">Mario E.  Lacouture</span>. </span><span class="cited-content_cbyCitation_article-title">Osimertinib: A Novel Dermatologic Adverse Event Profile in Patients with Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">The Oncologist</span><span> <strong>2018,</strong> <em>23 </em>
                                    (8)
                                     , 891-899. <a href="https://doi.org/10.1634/theoncologist.2017-0582" title="DOI URL">https://doi.org/10.1634/theoncologist.2017-0582</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1634/theoncologist.2017-0582&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1634%2Ftheoncologist.2017-0582%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Oncologist%26atitle%3DOsimertinib%25253A%252BA%252BNovel%252BDermatologic%252BAdverse%252BEvent%252BProfile%252Bin%252BPatients%252Bwith%252BLung%252BCancer%26aulast%3DChu%26aufirst%3DChia%25E2%2580%2590Yu%26date%3D2018%26date%3D2018%26volume%3D23%26issue%3D8%26spage%3D891%26epage%3D899" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuwei  Wang</span>, <span class="hlFld-ContribAuthor ">Huanling  Lai</span>, <span class="hlFld-ContribAuthor ">Xingxing  Fan</span>, <span class="hlFld-ContribAuthor ">Lianxiang  Luo</span>, <span class="hlFld-ContribAuthor ">Fugang  Duan</span>, <span class="hlFld-ContribAuthor ">Zebo  Jiang</span>, <span class="hlFld-ContribAuthor ">Qianqian  Wang</span>, <span class="hlFld-ContribAuthor ">Elaine Lai Han  Leung</span>, <span class="hlFld-ContribAuthor ">Liang  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>. </span><span class="cited-content_cbyCitation_article-title">Gossypol Inhibits Non-small Cell Lung Cancer Cells Proliferation by Targeting EGFRL858R/T790M. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2018,</strong> <em>9 </em><a href="https://doi.org/10.3389/fphar.2018.00728" title="DOI URL">https://doi.org/10.3389/fphar.2018.00728</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2018.00728&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2018.00728%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DGossypol%252BInhibits%252BNon-small%252BCell%252BLung%252BCancer%252BCells%252BProliferation%252Bby%252BTargeting%252BEGFRL858R%25252FT790M%26aulast%3DWang%26aufirst%3DYuwei%26date%3D2018%26date%3D2018%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">James S.  Scott</span>, <span class="hlFld-ContribAuthor ">Michael J.  Waring</span>. </span><span class="cited-content_cbyCitation_article-title">Practical application of ligand efficiency metrics in lead optimisation. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (11)
                                     , 3006-3015. <a href="https://doi.org/10.1016/j.bmc.2018.04.004" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.04.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.04.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.04.004%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DPractical%252Bapplication%252Bof%252Bligand%252Befficiency%252Bmetrics%252Bin%252Blead%252Boptimisation%26aulast%3DScott%26aufirst%3DJames%2BS.%26date%3D2018%26volume%3D26%26issue%3D11%26spage%3D3006%26epage%3D3015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhe  Yang</span>, <span class="hlFld-ContribAuthor ">Nong  Yang</span>, <span class="hlFld-ContribAuthor ">Qiuxiang  Ou</span>, <span class="hlFld-ContribAuthor ">Yi  Xiang</span>, <span class="hlFld-ContribAuthor ">Tao  Jiang</span>, <span class="hlFld-ContribAuthor ">Xue  Wu</span>, <span class="hlFld-ContribAuthor ">Hua  Bao</span>, <span class="hlFld-ContribAuthor ">Xiaoling  Tong</span>, <span class="hlFld-ContribAuthor ">Xiaonan  Wang</span>, <span class="hlFld-ContribAuthor ">Yang W.  Shao</span>, <span class="hlFld-ContribAuthor ">Yunpeng  Liu</span>, <span class="hlFld-ContribAuthor ">Yan  Wang</span>, <span class="hlFld-ContribAuthor ">Caicun  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non–Small Cell Lung Cancer Patients. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (13)
                                     , 3097-3107. <a href="https://doi.org/10.1158/1078-0432.CCR-17-2310" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-2310</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-2310&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-2310%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DInvestigating%252BNovel%252BResistance%252BMechanisms%252Bto%252BThird-Generation%252BEGFR%252BTyrosine%252BKinase%252BInhibitor%252BOsimertinib%252Bin%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%252BPatients%26aulast%3DYang%26aufirst%3DZhe%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D13%26spage%3D3097%26epage%3D3107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Asunción  Díaz-Serrano</span>, <span class="hlFld-ContribAuthor ">Pablo  Gella</span>, <span class="hlFld-ContribAuthor ">Elisabeth  Jiménez</span>, <span class="hlFld-ContribAuthor ">Jon  Zugazagoitia</span>, <span class="hlFld-ContribAuthor ">Luis  Paz-Ares Rodríguez</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting EGFR in Lung Cancer: Current Standards and Developments. </span><span class="cited-content_cbyCitation_journal-name">Drugs</span><span> <strong>2018,</strong> <em>78 </em>
                                    (9)
                                     , 893-911. <a href="https://doi.org/10.1007/s40265-018-0916-4" title="DOI URL">https://doi.org/10.1007/s40265-018-0916-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s40265-018-0916-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs40265-018-0916-4%26sid%3Dliteratum%253Aachs%26jtitle%3DDrugs%26atitle%3DTargeting%252BEGFR%252Bin%252BLung%252BCancer%25253A%252BCurrent%252BStandards%252Band%252BDevelopments%26aulast%3DD%25C3%25ADaz-Serrano%26aufirst%3DAsunci%25C3%25B3n%26date%3D2018%26date%3D2018%26volume%3D78%26issue%3D9%26spage%3D893%26epage%3D911" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stefano  Fogli</span>, <span class="hlFld-ContribAuthor ">Beatrice  Polini</span>, <span class="hlFld-ContribAuthor ">Marzia Del  Re</span>, <span class="hlFld-ContribAuthor ">Iacopo  Petrini</span>, <span class="hlFld-ContribAuthor ">Antonio  Passaro</span>, <span class="hlFld-ContribAuthor ">Stefania  Crucitta</span>, <span class="hlFld-ContribAuthor ">Eleonora  Rofi</span>, <span class="hlFld-ContribAuthor ">Romano  Danesi</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR-TKIs in non-small-cell lung cancer: focus on clinical pharmacology and mechanisms of resistance. </span><span class="cited-content_cbyCitation_journal-name">Pharmacogenomics</span><span> <strong>2018,</strong> <em>19 </em>
                                    (8)
                                     , 727-740. <a href="https://doi.org/10.2217/pgs-2018-0038" title="DOI URL">https://doi.org/10.2217/pgs-2018-0038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/pgs-2018-0038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Fpgs-2018-0038%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacogenomics%26atitle%3DEGFR-TKIs%252Bin%252Bnon-small-cell%252Blung%252Bcancer%25253A%252Bfocus%252Bon%252Bclinical%252Bpharmacology%252Band%252Bmechanisms%252Bof%252Bresistance%26aulast%3DFogli%26aufirst%3DStefano%26date%3D2018%26volume%3D19%26issue%3D8%26spage%3D727%26epage%3D740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Arenda D.  Meedendorp</span>, <span class="hlFld-ContribAuthor ">Arja  ter Elst</span>, <span class="hlFld-ContribAuthor ">Nils A.  ’t Hart</span>, <span class="hlFld-ContribAuthor ">Harry J. M.  Groen</span>, <span class="hlFld-ContribAuthor ">Ed  Schuuring</span>, <span class="hlFld-ContribAuthor ">Anthonie J.  van der Wekken</span>. </span><span class="cited-content_cbyCitation_article-title">Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2018,</strong> <em>8 </em><a href="https://doi.org/10.3389/fonc.2018.00176" title="DOI URL">https://doi.org/10.3389/fonc.2018.00176</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2018.00176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2018.00176%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DResponse%252Bto%252BHER2%252BInhibition%252Bin%252Ba%252BPatient%252BWith%252BBrain%252BMetastasis%252BWith%252BEGFR%252BTKI%252BAcquired%252BResistance%252Band%252Ban%252BHER2%252BAmplification%26aulast%3DMeedendorp%26aufirst%3DArenda%2BD.%26date%3D2018%26date%3D2018%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qi  Yan</span>, <span class="hlFld-ContribAuthor ">Yuzhe  Chen</span>, <span class="hlFld-ContribAuthor ">Baiyou  Tang</span>, <span class="hlFld-ContribAuthor ">Qiang  Xiao</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Jian  Liu</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Yi  Chen</span>, <span class="hlFld-ContribAuthor ">Ning  Ding</span>, <span class="hlFld-ContribAuthor ">Wenfu  Tan</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Yingxia  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>152 </em>, 298-306. <a href="https://doi.org/10.1016/j.ejmech.2018.04.052" title="DOI URL">https://doi.org/10.1016/j.ejmech.2018.04.052</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2018.04.052&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2018.04.052%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bnovel%252B2%25252C4-diarylaminopyrimidine%252Bderivatives%252Bas%252Bpotent%252Band%252Bselective%252Bepidermal%252Bgrowth%252Bfactor%252Breceptor%252B%252528EGFR%252529%252Binhibitors%252Bagainst%252BL858R%25252FT790M%252Bresistance%252Bmutation%26aulast%3DYan%26aufirst%3DQi%26date%3D2018%26volume%3D152%26spage%3D298%26epage%3D306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A. Kenneth  MacLeod</span>, <span class="hlFld-ContribAuthor ">De  Lin</span>, <span class="hlFld-ContribAuthor ">Jeffrey T.–J.  Huang</span>, <span class="hlFld-ContribAuthor ">Lesley A.  McLaughlin</span>, <span class="hlFld-ContribAuthor ">Colin J.  Henderson</span>, <span class="hlFld-ContribAuthor ">C. Roland  Wolf</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of Novel Pathways of Osimertinib Disposition and Potential Implications for the Outcome of Lung Cancer Therapy. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2018,</strong> <em>24 </em>
                                    (9)
                                     , 2138-2147. <a href="https://doi.org/10.1158/1078-0432.CCR-17-3555" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-17-3555</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-17-3555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-17-3555%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DIdentification%252Bof%252BNovel%252BPathways%252Bof%252BOsimertinib%252BDisposition%252Band%252BPotential%252BImplications%252Bfor%252Bthe%252BOutcome%252Bof%252BLung%252BCancer%252BTherapy%26aulast%3DMacLeod%26aufirst%3DA.%2BKenneth%26date%3D2018%26date%3D2018%26volume%3D24%26issue%3D9%26spage%3D2138%26epage%3D2147" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Michael J.  Waring</span>. </span><span class="cited-content_cbyCitation_article-title">The Discovery of Osimertinib (TAGRISSO™): An Irreversible Inhibitor of Activating and T790M Resistant Forms of the Epidermal Growth Factor Receptor Tyrosine Kinase for the Treatment of Non-Small Cell Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 341-357. <a href="https://doi.org/10.1002/9783527808694.ch12" title="DOI URL">https://doi.org/10.1002/9783527808694.ch12</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/9783527808694.ch12&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F9783527808694.ch12%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BDiscovery%252Bof%252BOsimertinib%252B%252528TAGRISSO%2525E2%252584%2525A2%252529%25253A%252BAn%252BIrreversible%252BInhibitor%252Bof%252BActivating%252Band%252BT790M%252BResistant%252BForms%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%252BTyrosine%252BKinase%252Bfor%252Bthe%252BTreatment%252Bof%252BNon-Small%252BCell%252BLung%252BCancer%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26date%3D2018%26spage%3D341%26epage%3D357%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DSuccessful%252BDrug%252BDiscovery%26aulast%3DFischer%26aufirst%3DJ%25C3%25A1nos%26date%3D2018%26volume%3D378" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean-Nicolas  Gallant</span>, <span class="hlFld-ContribAuthor ">Christine M  Lovly</span>. </span><span class="cited-content_cbyCitation_article-title">Established, emerging and elusive molecular targets in the treatment of lung cancer. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Pathology</span><span> <strong>2018,</strong> <em>244 </em>
                                    (5)
                                     , 565-577. <a href="https://doi.org/10.1002/path.5038" title="DOI URL">https://doi.org/10.1002/path.5038</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/path.5038&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpath.5038%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Pathology%26atitle%3DEstablished%25252C%252Bemerging%252Band%252Belusive%252Bmolecular%252Btargets%252Bin%252Bthe%252Btreatment%252Bof%252Blung%252Bcancer%26aulast%3DGallant%26aufirst%3DJean-Nicolas%26date%3D2018%26date%3D2018%26volume%3D244%26issue%3D5%26spage%3D565%26epage%3D577" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keriann M.  Backus</span>. </span><span class="cited-content_cbyCitation_article-title">Applications of Reactive Cysteine Profiling. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 375-417. <a href="https://doi.org/10.1007/82_2018_120" title="DOI URL">https://doi.org/10.1007/82_2018_120</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/82_2018_120&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F82_2018_120%26sid%3Dliteratum%253Aachs%26atitle%3DApplications%252Bof%252BReactive%252BCysteine%252BProfiling%26aulast%3DBackus%26aufirst%3DKeriann%2BM.%26date%3D2018%26date%3D2018%26spage%3D375%26epage%3D417%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DActivity-Based%252BProtein%252BProfiling%26aulast%3DCravatt%26aufirst%3DBenjamin%2BF.%26date%3D2019%26volume%3D420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Nadza  Tokaca</span>, <span class="hlFld-ContribAuthor ">Sarah  Barth</span>, <span class="hlFld-ContribAuthor ">Mary  O’Brien</span>, <span class="hlFld-ContribAuthor ">Jaishree  Bhosle</span>, <span class="hlFld-ContribAuthor ">Nicos  Fotiadis</span>, <span class="hlFld-ContribAuthor ">Andrew  Wotherspoon</span>, <span class="hlFld-ContribAuthor ">Lisa  Thompson</span>, <span class="hlFld-ContribAuthor ">Sanjay  Popat</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular Adequacy of Image-Guided Rebiopsies for Molecular Retesting in Advanced Non–Small Cell Lung Cancer: A Single-Center Experience. </span><span class="cited-content_cbyCitation_journal-name">Journal of Thoracic Oncology</span><span> <strong>2018,</strong> <em>13 </em>
                                    (1)
                                     , 63-72. <a href="https://doi.org/10.1016/j.jtho.2017.09.1958" title="DOI URL">https://doi.org/10.1016/j.jtho.2017.09.1958</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jtho.2017.09.1958&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jtho.2017.09.1958%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Thoracic%2520Oncology%26atitle%3DMolecular%252BAdequacy%252Bof%252BImage-Guided%252BRebiopsies%252Bfor%252BMolecular%252BRetesting%252Bin%252BAdvanced%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%25253A%252BA%252BSingle-Center%252BExperience%26aulast%3DTokaca%26aufirst%3DNadza%26date%3D2018%26volume%3D13%26issue%3D1%26spage%3D63%26epage%3D72" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yang  Geng</span>, <span class="hlFld-ContribAuthor ">Mingxiang  Zhu</span>, <span class="hlFld-ContribAuthor ">Apeng  Liang</span>, <span class="hlFld-ContribAuthor ">Chengshan  Niu</span>, <span class="hlFld-ContribAuthor ">Jingya  Li</span>, <span class="hlFld-ContribAuthor ">Dapeng  Zou</span>, <span class="hlFld-ContribAuthor ">Yusheng  Wu</span>, <span class="hlFld-ContribAuthor ">Yangjie  Wu</span>. </span><span class="cited-content_cbyCitation_article-title">O
              -Difluorodeuteromethylation of phenols using difluorocarbene precursors and deuterium oxide. </span><span class="cited-content_cbyCitation_journal-name">Organic & Biomolecular Chemistry</span><span> <strong>2018,</strong> <em>16 </em>
                                    (11)
                                     , 1807-1811. <a href="https://doi.org/10.1039/C7OB03088F" title="DOI URL">https://doi.org/10.1039/C7OB03088F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/C7OB03088F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FC7OB03088F%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520%2526%2520Biomolecular%2520Chemistry%26atitle%3DO%252B-Difluorodeuteromethylation%252Bof%252Bphenols%252Busing%252Bdifluorocarbene%252Bprecursors%252Band%252Bdeuterium%252Boxide%26aulast%3DGeng%26aufirst%3DYang%26date%3D2018%26date%3D2018%26volume%3D16%26issue%3D11%26spage%3D1807%26epage%3D1811" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">C.  Ricordel</span>, <span class="hlFld-ContribAuthor ">L.  Friboulet</span>, <span class="hlFld-ContribAuthor ">F.  Facchinetti</span>, <span class="hlFld-ContribAuthor ">J -C  Soria</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular mechanisms of acquired resistance to third-generation EGFR-TKIs in EGFR T790M-mutant lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Annals of Oncology</span><span> <strong>2018,</strong> <em>29 </em>, i28-i37. <a href="https://doi.org/10.1093/annonc/mdx705" title="DOI URL">https://doi.org/10.1093/annonc/mdx705</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/annonc/mdx705&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fannonc%2Fmdx705%26sid%3Dliteratum%253Aachs%26jtitle%3DAnnals%2520of%2520Oncology%26atitle%3DMolecular%252Bmechanisms%252Bof%252Bacquired%252Bresistance%252Bto%252Bthird-generation%252BEGFR-TKIs%252Bin%252BEGFR%252BT790M-mutant%252Blung%252Bcancer%26aulast%3DRicordel%26aufirst%3DC.%26date%3D2018%26volume%3D29%26spage%3Di28%26epage%3Di37" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Harun  Patel</span>, <span class="hlFld-ContribAuthor ">Rahul  Pawara</span>, <span class="hlFld-ContribAuthor ">Azim  Ansari</span>, <span class="hlFld-ContribAuthor ">Sanjay  Surana</span>. </span><span class="cited-content_cbyCitation_article-title">Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>142 </em>, 32-47. <a href="https://doi.org/10.1016/j.ejmech.2017.05.027" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.05.027</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.05.027&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.05.027%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bupdates%252Bon%252Bthird%252Bgeneration%252BEGFR%252Binhibitors%252Band%252Bemergence%252Bof%252Bfourth%252Bgeneration%252BEGFR%252Binhibitors%252Bto%252Bcombat%252BC797S%252Bresistance%26aulast%3DPatel%26aufirst%3DHarun%26date%3D2017%26volume%3D142%26spage%3D32%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingfeng  Chen</span>, <span class="hlFld-ContribAuthor ">Weitao  Fu</span>, <span class="hlFld-ContribAuthor ">Chen  Feng</span>, <span class="hlFld-ContribAuthor ">Rong  Qu</span>, <span class="hlFld-ContribAuthor ">Linjiang  Tong</span>, <span class="hlFld-ContribAuthor ">Lulu  Zheng</span>, <span class="hlFld-ContribAuthor ">Bo  Fang</span>, <span class="hlFld-ContribAuthor ">Yinda  Qiu</span>, <span class="hlFld-ContribAuthor ">Jie  Hu</span>, <span class="hlFld-ContribAuthor ">Yuepiao  Cai</span>, <span class="hlFld-ContribAuthor ">Jianpeng  Feng</span>, <span class="hlFld-ContribAuthor ">Hua  Xie</span>, <span class="hlFld-ContribAuthor ">Jian  Ding</span>, <span class="hlFld-ContribAuthor ">Zhiguo  Liu</span>, <span class="hlFld-ContribAuthor ">Guang  Liang</span>. </span><span class="cited-content_cbyCitation_article-title">Structure-based design and synthesis of 2,4-diaminopyrimidines as EGFR L858R/T790M selective inhibitors for NSCLC. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>140 </em>, 510-527. <a href="https://doi.org/10.1016/j.ejmech.2017.08.061" title="DOI URL">https://doi.org/10.1016/j.ejmech.2017.08.061</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2017.08.061&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2017.08.061%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DStructure-based%252Bdesign%252Band%252Bsynthesis%252Bof%252B2%25252C4-diaminopyrimidines%252Bas%252BEGFR%252BL858R%25252FT790M%252Bselective%252Binhibitors%252Bfor%252BNSCLC%26aulast%3DChen%26aufirst%3DLingfeng%26date%3D2017%26volume%3D140%26spage%3D510%26epage%3D527" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.  Russo</span>, <span class="hlFld-ContribAuthor ">T.  Franchina</span>, <span class="hlFld-ContribAuthor ">G.R.R.  Ricciardi</span>, <span class="hlFld-ContribAuthor ">V.  Smiroldo</span>, <span class="hlFld-ContribAuthor ">M.  Picciotto</span>, <span class="hlFld-ContribAuthor ">M.  Zanghì</span>, <span class="hlFld-ContribAuthor ">C.  Rolfo</span>, <span class="hlFld-ContribAuthor ">V.  Adamo</span>. </span><span class="cited-content_cbyCitation_article-title">Third generation EGFR TKIs in EGFR-mutated NSCLC: Where are we now and where are we going. </span><span class="cited-content_cbyCitation_journal-name">Critical Reviews in Oncology/Hematology</span><span> <strong>2017,</strong> <em>117 </em>, 38-47. <a href="https://doi.org/10.1016/j.critrevonc.2017.07.003" title="DOI URL">https://doi.org/10.1016/j.critrevonc.2017.07.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.critrevonc.2017.07.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.critrevonc.2017.07.003%26sid%3Dliteratum%253Aachs%26jtitle%3DCritical%2520Reviews%2520in%2520Oncology%252FHematology%26atitle%3DThird%252Bgeneration%252BEGFR%252BTKIs%252Bin%252BEGFR-mutated%252BNSCLC%25253A%252BWhere%252Bare%252Bwe%252Bnow%252Band%252Bwhere%252Bare%252Bwe%252Bgoing%26aulast%3DRusso%26aufirst%3DA.%26date%3D2017%26volume%3D117%26spage%3D38%26epage%3D47" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Alexandr V.  Kormanov</span>, <span class="hlFld-ContribAuthor ">Dmitry L.  Lipilin</span>, <span class="hlFld-ContribAuthor ">Tatyana K.  Shkineva</span>, <span class="hlFld-ContribAuthor ">Irina A.  Vatsadze</span>, <span class="hlFld-ContribAuthor ">Andrei M.  Kozeev</span>, <span class="hlFld-ContribAuthor ">Igor L.  Dalinger</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and transformations of 3(5)-(3-methylfurazan-4-yl)-4-nitro-1Н-pyrazole-5(3)-carboxylic acid. </span><span class="cited-content_cbyCitation_journal-name">Chemistry of Heterocyclic Compounds</span><span> <strong>2017,</strong> <em>53 </em>
                                    (8)
                                     , 876-882. <a href="https://doi.org/10.1007/s10593-017-2141-6" title="DOI URL">https://doi.org/10.1007/s10593-017-2141-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10593-017-2141-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10593-017-2141-6%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520of%2520Heterocyclic%2520Compounds%26atitle%3DSynthesis%252Band%252Btransformations%252Bof%252B3%2525285%252529-%2525283-methylfurazan-4-yl%252529-4-nitro-1%2525D0%25259D-pyrazole-5%2525283%252529-carboxylic%252Bacid%26aulast%3DKormanov%26aufirst%3DAlexandr%2BV.%26date%3D2017%26date%3D2017%26volume%3D53%26issue%3D8%26spage%3D876%26epage%3D882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Menghua  Qu</span>, <span class="hlFld-ContribAuthor ">Zhihao  Liu</span>, <span class="hlFld-ContribAuthor ">Dan  Zhao</span>, <span class="hlFld-ContribAuthor ">Changyuan  Wang</span>, <span class="hlFld-ContribAuthor ">Jianbin  Zhang</span>, <span class="hlFld-ContribAuthor ">Zeyao  Tang</span>, <span class="hlFld-ContribAuthor ">Kexin  Liu</span>, <span class="hlFld-ContribAuthor ">Xiaohong  Shu</span>, <span class="hlFld-ContribAuthor ">Hong  Yuan</span>, <span class="hlFld-ContribAuthor ">Xiaodong  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of sulfonamide-substituted diphenylpyrimidine derivatives (Sul-DPPYs) as potent focal adhesion kinase (FAK) inhibitors with antitumor activity. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2017,</strong> <em>25 </em>
                                    (15)
                                     , 3989-3996. <a href="https://doi.org/10.1016/j.bmc.2017.05.044" title="DOI URL">https://doi.org/10.1016/j.bmc.2017.05.044</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2017.05.044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2017.05.044%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bsulfonamide-substituted%252Bdiphenylpyrimidine%252Bderivatives%252B%252528Sul-DPPYs%252529%252Bas%252Bpotent%252Bfocal%252Badhesion%252Bkinase%252B%252528FAK%252529%252Binhibitors%252Bwith%252Bantitumor%252Bactivity%26aulast%3DQu%26aufirst%3DMenghua%26date%3D2017%26volume%3D25%26issue%3D15%26spage%3D3989%26epage%3D3996" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Di  Zheng</span>, <span class="hlFld-ContribAuthor ">Min  Hu</span>, <span class="hlFld-ContribAuthor ">Yu  Bai</span>, <span class="hlFld-ContribAuthor ">Xuehua  Zhu</span>, <span class="hlFld-ContribAuthor ">Xuesong  Lu</span>, <span class="hlFld-ContribAuthor ">Chunyan  Wu</span>, <span class="hlFld-ContribAuthor ">Jiying  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Liu</span>, <span class="hlFld-ContribAuthor ">Zheng  Wang</span>, <span class="hlFld-ContribAuthor ">Jian  Ni</span>, <span class="hlFld-ContribAuthor ">Zhenfan  Yang</span>, <span class="hlFld-ContribAuthor ">Jianfang  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">EGFR G796D mutation mediates resistance to osimertinib. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2017,</strong> <em>8 </em>
                                    (30)
                                     , 49671-49679. <a href="https://doi.org/10.18632/oncotarget.17913" title="DOI URL">https://doi.org/10.18632/oncotarget.17913</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.17913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.17913%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DEGFR%252BG796D%252Bmutation%252Bmediates%252Bresistance%252Bto%252Bosimertinib%26aulast%3DZheng%26aufirst%3DDi%26date%3D2017%26date%3D2017%26volume%3D8%26issue%3D30%26spage%3D49671%26epage%3D49679" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Azusa  Tanimoto</span>, <span class="hlFld-ContribAuthor ">Shinji  Takeuchi</span>, <span class="hlFld-ContribAuthor ">Sachiko  Arai</span>, <span class="hlFld-ContribAuthor ">Koji  Fukuda</span>, <span class="hlFld-ContribAuthor ">Tadaaki  Yamada</span>, <span class="hlFld-ContribAuthor ">Xavier  Roca</span>, <span class="hlFld-ContribAuthor ">S. Tiong  Ong</span>, <span class="hlFld-ContribAuthor ">Seiji  Yano</span>. </span><span class="cited-content_cbyCitation_article-title">Histone Deacetylase 3 Inhibition Overcomes
              BIM
              Deletion Polymorphism–Mediated Osimertinib Resistance in
              EGFR-
              Mutant Lung Cancer. </span><span class="cited-content_cbyCitation_journal-name">Clinical Cancer Research</span><span> <strong>2017,</strong> <em>23 </em>
                                    (12)
                                     , 3139-3149. <a href="https://doi.org/10.1158/1078-0432.CCR-16-2271" title="DOI URL">https://doi.org/10.1158/1078-0432.CCR-16-2271</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1078-0432.CCR-16-2271&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1078-0432.CCR-16-2271%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520Cancer%2520Research%26atitle%3DHistone%252BDeacetylase%252B3%252BInhibition%252BOvercomes%252BBIM%252BDeletion%252BPolymorphism%2525E2%252580%252593Mediated%252BOsimertinib%252BResistance%252Bin%252BEGFR-%252BMutant%252BLung%252BCancer%26aulast%3DTanimoto%26aufirst%3DAzusa%26date%3D2017%26date%3D2016%26volume%3D23%26issue%3D12%26spage%3D3139%26epage%3D3149" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shawn  Johnstone</span>, <span class="hlFld-ContribAuthor ">Jeffrey S.  Albert</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (11)
                                     , 2239-2258. <a href="https://doi.org/10.1016/j.bmcl.2017.03.084" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.03.084</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.03.084&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.03.084%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DPharmacological%252Bproperty%252Boptimization%252Bfor%252Ballosteric%252Bligands%25253A%252BA%252Bmedicinal%252Bchemistry%252Bperspective%26aulast%3DJohnstone%26aufirst%3DShawn%26date%3D2017%26volume%3D27%26issue%3D11%26spage%3D2239%26epage%3D2258" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wen  Hwang</span>, <span class="hlFld-ContribAuthor ">Yu-Fan  Chiu</span>, <span class="hlFld-ContribAuthor ">Ming-Han  Kuo</span>, <span class="hlFld-ContribAuthor ">Kuan-Lin  Lee</span>, <span class="hlFld-ContribAuthor ">An-Chun  Lee</span>, <span class="hlFld-ContribAuthor ">Chia-Cherng  Yu</span>, <span class="hlFld-ContribAuthor ">Junn-Liang  Chang</span>, <span class="hlFld-ContribAuthor ">Wen-Chien  Huang</span>, <span class="hlFld-ContribAuthor ">Shih-Hsin  Hsiao</span>, <span class="hlFld-ContribAuthor ">Sey-En  Lin</span>, <span class="hlFld-ContribAuthor ">Yu-Ting  Chou</span>. </span><span class="cited-content_cbyCitation_article-title">Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2017,</strong> <em>77 </em>
                                    (11)
                                     , 3013-3026. <a href="https://doi.org/10.1158/0008-5472.CAN-16-3168" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-16-3168</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-16-3168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-16-3168%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DExpression%252Bof%252BNeuroendocrine%252BFactor%252BVGF%252Bin%252BLung%252BCancer%252BCells%252BConfers%252BResistance%252Bto%252BEGFR%252BKinase%252BInhibitors%252Band%252BTriggers%252BEpithelial-to-Mesenchymal%252BTransition%26aulast%3DHwang%26aufirst%3DWen%26date%3D2017%26date%3D2017%26volume%3D77%26issue%3D11%26spage%3D3013%26epage%3D3026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">M. Raymond V.  Finlay</span>, <span class="hlFld-ContribAuthor ">Richard A.  Ward</span>. </span><span class="cited-content_cbyCitation_article-title">Small Molecule Inhibitors of the Epidermal Growth Factor Receptor. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-39. <a href="https://doi.org/10.1007/7355_2016_26" title="DOI URL">https://doi.org/10.1007/7355_2016_26</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/7355_2016_26&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F7355_2016_26%26sid%3Dliteratum%253Aachs%26atitle%3DSmall%252BMolecule%252BInhibitors%252Bof%252Bthe%252BEpidermal%252BGrowth%252BFactor%252BReceptor%26aulast%3DFinlay%26aufirst%3DM.%2BRaymond%2BV.%26date%3D2017%26spage%3D39%26epage%3D39%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCancer%252BII%26aulast%3DWaring%26aufirst%3DMichael%2BJ.%26date%3D2018%26volume%3D28" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">A.A.  Mortlock</span>, <span class="hlFld-ContribAuthor ">D.M.  Wilson</span>, <span class="hlFld-ContribAuthor ">J.G.  Kettle</span>, <span class="hlFld-ContribAuthor ">F.W.  Goldberg</span>, <span class="hlFld-ContribAuthor ">K.M.  Foote</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Kinase Inhibitors in Cancer. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 39-75. <a href="https://doi.org/10.1016/B978-0-12-409547-2.12391-1" title="DOI URL">https://doi.org/10.1016/B978-0-12-409547-2.12391-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/B978-0-12-409547-2.12391-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2FB978-0-12-409547-2.12391-1%26sid%3Dliteratum%253Aachs%26atitle%3DSelective%252BKinase%252BInhibitors%252Bin%252BCancer%26aulast%3DMortlock%26aufirst%3DA.A.%26date%3D2017%26spage%3D39%26epage%3D75%26pub%3DElsevier%26atitle%3DComprehensive%252BMedicinal%252BChemistry%252BIII%26date%3D2017%26volume%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Fjm400822z&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-17%3Barticle%3Aarticle%3A10.1021%2Fjm400822z%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=131&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0052.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0052.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Location of activating (L858R and exon 19 deletion) and resistant secondary mutations (T790M) in the kinase domain of EGFR (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY">2ITY</a><a onclick="showRef(event, 'ref14'); return false;" href="javascript:void(0);" class="ref ref14">(13)</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Selection of published EGFR inhibitors disclosed in the literature.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. General Synthesis Approach to the Key Novel Compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a>) Reported in This Manuscript<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) Aniline displacement: excess NaHCO<sub>3</sub>, 2-pentanol or EtOH, 85 °C; suzuki coupling: Na<sub>2</sub>CO<sub>3</sub>, ArB(OR)<sub>2</sub>, Pd(PPh<sub>3</sub>)<sub>4</sub>, MeCN, water, 100 °C; indole displacement: MeMgBr (1 equiv, 3.2 M in 2-methyl THF), indole (1 equiv), THF, 0–60 °C. (ii) Et<sub>3</sub>N (1.1 equiv), butyl-vinyl-ether (1.1 equiv), Pd(OAc)<sub>2</sub> (0.03 equiv), PEG 200, 80 °C. (iii) Either 1-aminopyridinium iodide (1 equiv), K<sub>2</sub>CO<sub>3</sub> (2.5 equiv), DMA, 110 °C or 2-amino-pyridine (1 equiv), NBS (1.2 equiv), 1,4-dioxane, water, 85 °C. (iv) Either aniline (1.1 equiv), <i>p</i>-TSA (1.1 equiv), 2-pentanol, 80–120 °C, or aniline (1.1 equiv), 4 M HCl in 1,4-dioxane, TFE, 150 °C (μW), or aniline (1.1 equiv), Pd(OAc)<sub>2</sub> (0.08 equiv), Xantphos (0.1 equiv), Cs<sub>2</sub>CO<sub>3</sub> (2 equiv), 1,4-dioxane, 80 °C. (v) Acetyl aniline (1 equiv), <i>p</i>-TSA (3 equiv), <i>n</i>-pentanol/NMP, 150 °C. (vi) 1-Methylpiperazine (2.5 equiv), TFE, 120 °C. (vii) Either iron (3 equiv), NH<sub>4</sub>Cl (0.7 equiv), EtOH, water, 100 °C or Pt/C (1 equiv), ZnI<sub>2</sub> (0.1 equiv), H<sub>2</sub>, MeOH, EtOAc. (viii) Either acryloyl chloride (1M, THF, 1 equiv), DIPEA (1.1 equiv), THF, 0 °C, or (<i>E</i>)-4-(dimethylamino)but-2-enoic acid (1 equiv), HATU (1.1 equiv), DIPEA (2.5 equiv), DCM, or (<i>E</i>)-4-bromobut-2-enoic acid (1.1 equiv), HATU (1.1 equiv), DIPEA (2.5 equiv), 0 °C then Me<sub>2</sub>NH (20 equiv). (ix) Deprotection (where required): Either K<sub>2</sub>CO<sub>3</sub> (3 equiv), THF, MeOH or Cs<sub>2</sub>CO<sub>3</sub> (3 equiv), THF, MeOH, 0 °C. (x) Zn(CN)<sub>2</sub> (0.6 equiv), Zn (0.1 equiv), Pd<sub>2</sub>(dba)<sub>3</sub> (0.1 equiv), dicyclohexyl(2′,4′,6′-triisopropylbiphenyl-2-yl)phosphine (0.2 equiv), DMA, 90 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of the Intermediate for Compound <b>7</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (i) 1-Acetyl piperazine (1.2 equiv), DIPEA (1 equiv), DMA, 90 °C, 18 h, 90%. (ii) Platinum oxide (5 mol %), EtOH, hydrogen (1.3 bar), 3 h, 99%. (iii) Acetic anhydride (6.6 equiv), acetic acid (4.5 equiv), 1 h, 73%.</p></p></figure><figure data-id="fig3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. EGFR wild-type (WT) and T790M/L858R (DM) biochemical inhibition data on a probe set of compounds. Red points show reversible EGFR inhibitors, yellow points show covalent EGFR inhibitors, and blue points show selected compounds from internal AstraZeneca projects. Compound activity is expressed as a pIC<sub>50</sub>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Modeled binding mode of compound <b>7</b> in a published EGFR crystal structure (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT">2JIT</a>) that contains a T790M mutation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Protein crystal structure of compound <b>9</b> bound in wild-type EGFR. The described covalent bond to Cys-797 is shown (PDB code <a href="https://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LI5">4LI5</a>).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch3" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Addition Reaction of Model Compounds with Glutathione</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Hammett plot of σ<sub>meta</sub> and σ<sub>ind</sub> properties versus compound reactivity (Log <i>k</i><sub>GSH</sub>) across the model compound set.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Reactivity data for elaborated acrylamide compounds overlaid onto Log <i>k</i><sub>GSH</sub> versus σ<sub>meta</sub> Hammett plot for model systems. Data on the model-system compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl8" href="#tbl8">8</a>) are shown in red and elaborated compounds (Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a>) are shown in green. The data is further classified by a selection of the β substituents (R<sub>1</sub>′) defined in Table <a class="ref showTableEvent internalNav" data-ID="tbl9" href="#tbl9">9</a> (not defined for compounds <b>47</b> and <b>48</b> because of a lack of observed reactivity).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch4" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Postulated Mechanisms for the Nucleophilic Substitution Reaction Observed for Compound <b>46</b> with Glutathione</div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch5" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0015.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0015.jpeg" id="rightTab-gr15" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Proposed Intramolecular Reaction of Compound <b>38</b> in Buffer at pH 7.4<sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0015.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Formation of cyclic quaternary confirmed by MSMS <i>m</i>/<i>z</i> = 478.18.</p></p></figure><figure data-id="fig8" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Novel compounds reported in this manuscript containing alpha substitutions (R<sub>2</sub>′).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Compound reactivity measured by Log <i>k</i><sub>GSH</sub> (M<sup>–1</sup> s<sup>–1</sup>) plotted against EGFR double-mutant (DM) cellular pIC<sub>50</sub> for the elaborated compounds reported in this manuscript. Dashed lines indicate the ‘reactivity window’ in which the design of novel compounds was subsequently focused.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="15" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/medium/jm-2013-00822z_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Antitumor efficacy study data on compound <b>15</b> across the double (H1975), activating (PC9), and wild-type (A431) EGFR xenograft models. Tumor growth inhibition (% TGI) was calculated between the compound treated and vehicle groups, with a % TGI > 100 indicating tumor regression from the initial tumor size.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2013/jmcmar.2013.56.issue-17/jm400822z/production/images/large/jm-2013-00822z_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/jm400822z&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i72">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51536" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51536" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 51 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Normanno, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Luca, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bianco, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Strizzi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mancino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maiello, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carotenuto, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Feo, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caponigro, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salomon, D. S.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor (EGFR) signaling in cancer</span> <span class="citation_source-journal">Gene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">366</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">16</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.gene.2005.10.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=16377102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1Crs7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=366&publication_year=2006&pages=2-16&author=N.+Normannoauthor=A.+De+Lucaauthor=C.+Biancoauthor=L.+Strizziauthor=M.+Mancinoauthor=M.+R.+Maielloauthor=A.+Carotenutoauthor=G.+De+Feoauthor=F.+Caponigroauthor=D.+S.+Salomon&title=Epidermal+growth+factor+receptor+%28EGFR%29+signaling+in+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor (EGFR) signaling in cancer</span></div><div class="casAuthors">Normanno, Nicola; De Luca, Antonella; Bianco, Caterina; Strizzi, Luigi; Mancino, Mario; Maiello, Monica R.; Carotenuto, Adele; De Feo, Gianfranco; Caponigro, Francesco; Salomon, David S.</div><div class="citationInfo"><span class="NLM_cas:title">Gene</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">366</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">2-16</span>CODEN:
                <span class="NLM_cas:coden">GENED6</span>;
        ISSN:<span class="NLM_cas:issn">0378-1119</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  The epidermal growth factor receptor (EGFR) belongs to the ErbB family of receptor tyrosine kinases (RTK).  These trans-membrane proteins are activated following binding with peptide growth factors of the EGF-family of proteins.  Evidence suggests that the EGFR is involved in the pathogenesis and progression of different carcinoma types.  The EGFR and EGF-like peptides are often over-expressed in human carcinomas, and in vivo and in vitro studies have shown that these proteins are able to induce cell transformation.  Amplification of the EGFR gene and mutations of the EGFR tyrosine kinase domain have been recently demonstrated to occur in carcinoma patients.  Interestingly, both these genetic alterations of the EGFR are correlated with high probability to respond to anti-EGFR agents.  However, ErbB proteins and their ligands form a complex system in which the interactions occurring between receptors and ligands affect the type and the duration of the intracellular signals that derive from receptor activation.  In fact, proteins of the ErbB family form either homo- or hetero-dimers following ligand binding, each dimer showing different affinity for ligands and different signaling properties.  In this regard, evidence suggests that cooperation of multiple ErbB receptors and cognate ligands is necessary to induce cell transformation.  In particular, the growth and the survival of carcinoma cells appear to be sustained by a network of receptors/ligands of the ErbB family.  This phenomenon is also important for therapeutic approaches, since the response to anti-EGFR agents might depend on the total level of expression of ErbB receptors and ligands in tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpetexmky_mlrVg90H21EOLACvtfcHk0lgd26fb78vnZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1Crs7k%253D&md5=107171bebde465197e71bd59b15dd590</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1016%2Fj.gene.2005.10.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.gene.2005.10.018%26sid%3Dliteratum%253Aachs%26aulast%3DNormanno%26aufirst%3DN.%26aulast%3DDe%2BLuca%26aufirst%3DA.%26aulast%3DBianco%26aufirst%3DC.%26aulast%3DStrizzi%26aufirst%3DL.%26aulast%3DMancino%26aufirst%3DM.%26aulast%3DMaiello%26aufirst%3DM.%2BR.%26aulast%3DCarotenuto%26aufirst%3DA.%26aulast%3DDe%2BFeo%26aufirst%3DG.%26aulast%3DCaponigro%26aufirst%3DF.%26aulast%3DSalomon%26aufirst%3DD.%2BS.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520signaling%2520in%2520cancer%26jtitle%3DGene%26date%3D2006%26volume%3D366%26spage%3D2%26epage%3D16" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Sharma, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bell, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span> </span><span class="NLM_article-title">Epidermal growth factor receptor mutations in lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">169</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnrc2088" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17318210" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2007&pages=169-181&author=S.+V.+Sharmaauthor=D.+W.+Bellauthor=J.+Settlemanauthor=D.+A.+Haber&title=Epidermal+growth+factor+receptor+mutations+in+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Epidermal growth factor receptor mutations in lung cancer</span></div><div class="casAuthors">Sharma, Sreenath V.; Bell, Daphne W.; Settleman, Jeffrey; Haber, Daniel A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">169-181</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The development and clin. application of inhibitors that target the epidermal growth factor receptor (EGFR) provide important insights for new lung cancer therapies, as well as for the broader field of targeted cancer therapies.  We review the results of genetic, biochem. and clin. studies focused on somatic mutations of EGFR that are assocd. with the phenomenon of oncogene addiction, describing 'oncogenic shock' as a mechanistic explanation for the apoptosis that follows the acute treatment of susceptible cells with kinase inhibitors.  Understanding the genetic heterogeneity of epithelial tumors and devising strategies to circumvent their rapid acquisition of resistance to targeted kinase inhibitors are essential to the successful use of targeted therapies in common epithelial cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrMKw7Y4FUFM7Vg90H21EOLACvtfcHk0lgd26fb78vnZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXitVGrsbo%253D&md5=46219ea3ae7b9f0977e4a4b7243fd875</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1038%2Fnrc2088&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2088%26sid%3Dliteratum%253Aachs%26aulast%3DSharma%26aufirst%3DS.%2BV.%26aulast%3DBell%26aufirst%3DD.%2BW.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26atitle%3DEpidermal%2520growth%2520factor%2520receptor%2520mutations%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2007%26volume%3D7%26spage%3D169%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Pao, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chmielecki, J.</span><span> </span><span class="NLM_article-title">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">760</span><span class="NLM_x">–</span> <span class="NLM_lpage">774</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnrc2947" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20966921" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2010&pages=760-774&author=W.+Paoauthor=J.+Chmielecki&title=Rational%2C+biologically+based+treatment+of+EGFR-mutant+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer</span></div><div class="casAuthors">Pao, William; Chmielecki, Juliann</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">760-774</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clin. relevant mol. subset of lung cancer.  The disease has been the subject of intensive research at both the basic scientific and clin. levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas.  Although patients with EGFR-mutant tumors have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clin. problem.  This Review summarizes recent developments aimed at treating and ultimately curing the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo_b4ITVJ2ZnrVg90H21EOLACvtfcHk0lgd26fb78vnZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlWlsrrN&md5=448b40d66a0a5f171106baa1dc709c29</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1038%2Fnrc2947&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc2947%26sid%3Dliteratum%253Aachs%26aulast%3DPao%26aufirst%3DW.%26aulast%3DChmielecki%26aufirst%3DJ.%26atitle%3DRational%252C%2520biologically%2520based%2520treatment%2520of%2520EGFR-mutant%2520non-small-cell%2520lung%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2010%26volume%3D10%26spage%3D760%26epage%3D774" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Maemondo, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inoue, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sugawara, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oizumi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Isobe, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gemma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshizawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kinoshita, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fujita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Okinaga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirano, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoshimori, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harada, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ogura, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ando, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miyazawa, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saijo, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagiwara, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morita, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nukiwa, T.</span><span> </span><span class="NLM_article-title">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">362</span><span class="NLM_x">, </span> <span class="NLM_fpage">2380</span><span class="NLM_x">–</span> <span class="NLM_lpage">2388</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1056%2FNEJMoa0909530" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20573926" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=362&publication_year=2010&pages=2380-2388&author=M.+Maemondoauthor=A.+Inoueauthor=K.+Kobayashiauthor=S.+Sugawaraauthor=S.+Oizumiauthor=H.+Isobeauthor=A.+Gemmaauthor=M.+Haradaauthor=H.+Yoshizawaauthor=I.+Kinoshitaauthor=Y.+Fujitaauthor=S.+Okinagaauthor=H.+Hiranoauthor=K.+Yoshimoriauthor=T.+Haradaauthor=T.+Oguraauthor=M.+Andoauthor=H.+Miyazawaauthor=T.+Tanakaauthor=Y.+Saijoauthor=K.+Hagiwaraauthor=S.+Moritaauthor=T.+Nukiwa&title=Gefitinib+or+chemotherapy+for+non-small-cell+lung+cancer+with+mutated+EGFR"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR</span></div><div class="casAuthors">Maemondo, Makoto; Inoue, Akira; Kobayashi, Kunihiko; Sugawara, Shunichi; Oizumi, Satoshi; Isobe, Hiroshi; Gemma, Akihiko; Harada, Masao; Yoshizawa, Hirohisa; Kinoshita, Ichiro; Fujita, Yuka; Okinaga, Shoji; Hirano, Haruto; Yoshimori, Kozo; Harada, Toshiyuki; Ogura, Takashi; Ando, Masahiro; Miyazawa, Hitoshi; Tanaka, Tomoaki; Saijo, Yasuo; Hagiwara, Koichi; Morita, Satoshi; Nukiwa, Toshihiro</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">362</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2380-2388</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Non-small-cell lung cancer with sensitive mutations of the epidermal growth factor receptor (EGFR) is highly responsive to EGFR tyrosine kinase inhibitors such as gefitinib, but little is known about how its efficacy and safety profile compares with that of std. chemotherapy.  We randomly assigned 230 patients with metastatic, non-small-cell lung cancer and EGFR mutations who had not previously received chemotherapy to receive gefitinib or carboplatin-paclitaxel.  The primary end point was progression-free survival; secondary end points included overall survival, response rate, and toxic effects.  In the planned interim anal. of data for the first 200 patients, progression-free survival was significantly longer in the gefitinib group than in the std.-chemotherapy group (hazard ratio for death or disease progression with gefitinib, 0.36; P<0.001), resulting in early termination of the study.  The gefitinib group had a significantly longer median progression-free survival (10.8 mo, vs. 5.4 mo in the chemotherapy group; hazard ratio, 0.30; 95% confidence interval, 0.22 to 0.41; P<0.001), as well as a higher response rate (73.7% vs. 30.7%, P<0.001).  The median overall survival was 30.5 mo in the gefitinib group and 23.6 mo in the chemotherapy group (P = 0.31).  The most common adverse events in the gefitinib group were rash (71.1%) and elevated aminotransferase levels (55.3%), and in the chemotherapy group, neutropenia (77.0%), anemia (64.6%), appetite loss (56.6%), and sensory neuropathy (54.9%).  One patient receiving gefitinib died from interstitial lung disease.  First-line gefitinib for patients with advanced non-small-cell lung cancer who were selected on the basis of EGFR mutations improved progression-free survival, with acceptable toxicity, as compared with std. chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1G31xQ-ZFWLVg90H21EOLACvtfcHk0lgJZVGjBSOmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Gjt7Y%253D&md5=603963e646bf20ecfd936fc98467f5fd</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa0909530&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa0909530%26sid%3Dliteratum%253Aachs%26aulast%3DMaemondo%26aufirst%3DM.%26aulast%3DInoue%26aufirst%3DA.%26aulast%3DKobayashi%26aufirst%3DK.%26aulast%3DSugawara%26aufirst%3DS.%26aulast%3DOizumi%26aufirst%3DS.%26aulast%3DIsobe%26aufirst%3DH.%26aulast%3DGemma%26aufirst%3DA.%26aulast%3DHarada%26aufirst%3DM.%26aulast%3DYoshizawa%26aufirst%3DH.%26aulast%3DKinoshita%26aufirst%3DI.%26aulast%3DFujita%26aufirst%3DY.%26aulast%3DOkinaga%26aufirst%3DS.%26aulast%3DHirano%26aufirst%3DH.%26aulast%3DYoshimori%26aufirst%3DK.%26aulast%3DHarada%26aufirst%3DT.%26aulast%3DOgura%26aufirst%3DT.%26aulast%3DAndo%26aufirst%3DM.%26aulast%3DMiyazawa%26aufirst%3DH.%26aulast%3DTanaka%26aufirst%3DT.%26aulast%3DSaijo%26aufirst%3DY.%26aulast%3DHagiwara%26aufirst%3DK.%26aulast%3DMorita%26aufirst%3DS.%26aulast%3DNukiwa%26aufirst%3DT.%26atitle%3DGefitinib%2520or%2520chemotherapy%2520for%2520non-small-cell%2520lung%2520cancer%2520with%2520mutated%2520EGFR%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D362%26spage%3D2380%26epage%3D2388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dayaram, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaenne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kocher, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tenen, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">352</span><span class="NLM_x">, </span> <span class="NLM_fpage">786</span><span class="NLM_x">–</span> <span class="NLM_lpage">792</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1056%2FNEJMoa044238" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=15728811" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=352&publication_year=2005&pages=786-792&author=S.+Kobayashiauthor=T.+J.+Boggonauthor=T.+Dayaramauthor=P.+A.+Jaenneauthor=O.+Kocherauthor=M.+Meyersonauthor=B.+E.+Johnsonauthor=M.+J.+Eckauthor=D.+G.+Tenenauthor=B.+Halmos&title=EGFR+mutation+and+resistance+of+non-small-cell+lung+cancer+to+gefitinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR mutation and resistance of non-small-cell lung cancer to gefitinib</span></div><div class="casAuthors">Kobayashi, Susumu; Boggon, Titus J.; Dayaram, Tajhal; Jaenne, Pasi A.; Kocher, Olivier; Meyerson, Matthew; Johnson, Bruce E.; Eck, Michael J.; Tenen, Daniel G.; Halmos, Balizs</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">352</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">786-792</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Mutations of the epidermal growth factor receptor (EGFR) gene were identified in specimens from patients with non-small-cell lung cancer who have a response to anilinoquinazoline EGFR inhibitors.  Despite the dramatic responses to such inhibitors, most patients ultimately have a relapse.  The mechanism of the drug resistance is unknown.  Here the authors report the case of a patient with EGFR-mutant, gefitinib-responsive, advanced non-small-cell lung cancer who had a relapse after 2 years of complete remission during treatment with gefitinib.  The DNA sequence of the EGFR gene in his tumor biopsy specimen at relapse revealed the presence of a second point mutation, resulting in threonine-to-methionine amino acid change at position 790 of EGFR.  Structural modeling and biochem. studies showed that this second mutation led to gefitinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo8XXhT1hrbe7Vg90H21EOLACvtfcHk0lgJZVGjBSOmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhsFCiurk%253D&md5=808223ad566e2a3748977727cc5a9846</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa044238&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa044238%26sid%3Dliteratum%253Aachs%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DDayaram%26aufirst%3DT.%26aulast%3DJaenne%26aufirst%3DP.%2BA.%26aulast%3DKocher%26aufirst%3DO.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DB.%2BE.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DTenen%26aufirst%3DD.%2BG.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR%2520mutation%2520and%2520resistance%2520of%2520non-small-cell%2520lung%2520cancer%2520to%2520gefitinib%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D352%26spage%3D786%26epage%3D792" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mengwasser, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toms, A. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U.S.A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">105</span><span class="NLM_x">, </span> <span class="NLM_fpage">2070</span><span class="NLM_x">–</span> <span class="NLM_lpage">2075</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1073%2Fpnas.0709662105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=18227510" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=105&publication_year=2008&pages=2070-2075&author=C.+Yunauthor=K.+E.+Mengwasserauthor=A.+V.+Tomsauthor=M.+S.+Wooauthor=H.+Greulichauthor=K.+Wongauthor=M.+Meyersonauthor=M.+J.+Eck&title=The+T790M+mutation+in+EGFR+kinase+causes+drug+resistance+by+increasing+the+affinity+for+ATP"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP</span></div><div class="casAuthors">Yun, Cai-Hong; Mengwasser, Kristen E.; Toms, Angela V.; Woo, Michele S.; Greulich, Heidi; Wong, Kwok-Kin; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">105</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2070-2075</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Lung cancers caused by activating mutations in the epidermal growth factor receptor (EGFR) are initially responsive to small mol. tyrosine kinase inhibitors (TKIs), but the efficacy of these agents is often limited because of the emergence of drug resistance conferred by a second mutation, T790M.  Threonine 790 is the "gatekeeper" residue, an important determinant of inhibitor specificity in the ATP binding pocket.  The T790M mutation has been thought to cause resistance by sterically blocking binding of TKIs such as gefitinib and erlotinib, but this explanation is difficult to reconcile with the fact that it remains sensitive to structurally similar irreversible inhibitors.  Here, we show by using a direct binding assay that T790M mutants retain low-nanomolar affinity for gefitinib.  Furthermore, we show that the T790M mutation activates WT EGFR and that introduction of the T790M mutation increases the ATP affinity of the oncogenic L858R mutant by more than an order of magnitude.  The increased ATP affinity is the primary mechanism by which the T790M mutation confers drug resistance.  Crystallog. anal. of the T790M mutant shows how it can adapt to accommodate tight binding of diverse inhibitors, including the irreversible inhibitor HKI-272, and also suggests a structural mechanism for catalytic activation.  We conclude that the T790M mutation is a "generic" resistance mutation that will reduce the potency of any ATP-competitive kinase inhibitor and that irreversible inhibitors overcome this resistance simply through covalent binding, not as a result of an alternative binding mode.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoXXP7TBlyrdrVg90H21EOLACvtfcHk0lgJZVGjBSOmdQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXitl2mu7k%253D&md5=f5f5d791a65f73ca628d95e9922b8ea8</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0709662105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0709662105%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%26aulast%3DMengwasser%26aufirst%3DK.%2BE.%26aulast%3DToms%26aufirst%3DA.%2BV.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DThe%2520T790M%2520mutation%2520in%2520EGFR%2520kinase%2520causes%2520drug%2520resistance%2520by%2520increasing%2520the%2520affinity%2520for%2520ATP%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D2008%26volume%3D105%26spage%3D2070%26epage%3D2075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Shepherd, F. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pereira, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciuleanu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thongprasert, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campos, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maoleekoonpiroj, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smylie, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martins, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">van Kooten, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dediu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Findlay, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bezjk, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santabarbara, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seymour, L.</span><span> </span><span class="NLM_article-title">Erlotinib in previously treated non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">353</span><span class="NLM_x">, </span> <span class="NLM_fpage">123</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1056%2FNEJMoa050753" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=16014882" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=353&publication_year=2005&pages=123-132&author=F.+A.+Shepherdauthor=J.+R.+Pereiraauthor=T.+Ciuleanuauthor=E.+H.+Tanauthor=V.+Hirshauthor=S.+Thongprasertauthor=D.+Camposauthor=S.+Maoleekoonpirojauthor=M.+Smylieauthor=R.+Martinsauthor=M.+van+Kootenauthor=M.+Dediuauthor=B.+Findlayauthor=D.+Tuauthor=D.+Johnstonauthor=A.+Bezjkauthor=G.+Clarkauthor=P.+Santabarbaraauthor=L.+Seymour&title=Erlotinib+in+previously+treated+non-small-cell+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Erlotinib in previously treated non-small-cell lung cancer</span></div><div class="casAuthors">Shepherd, Frances A.; Pereira, Jose Rodrigues; Ciuleanu, Tudor; Tan, Eng Huat; Hirsh, Vera; Thongprasert, Sumitra; Campos, Daniel; Maoleekoonpiroj, Savitree; Smylie, Michael; Martins, Renato; van Kooten, Maximiliano; Dediu, Mircea; Findlay, Brian; Tu, Dongsheng; Johnston, Dianne; Bezjk, Andrea; Clark, Gary; Santabarbara, Pedro; Seymour, Lesley</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">353</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">123-132</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">We conducted a randomized, placebo-controlled, double-blind trial to det. whether the epidermal growth factor receptor inhibitor erlotinib prolongs survival in non-small-cell lung cancer after the failure of first-line or second-line chemotherapy.  Patients with stage IIIB or IV non-small-cell lung cancer, with performance status from 0 to 3, were eligible if they had received one or two prior chemotherapy regimens.  The patients were stratified according to center, performance status, response to prior chemotherapy, no. of prior regimens, and prior platinum-based therapy and were randomly assigned in a 2:1 ratio to receive oral erlotinib, at a dose of 150 mg daily, or placebo.  The median age of the 731 patients who underwent randomization was 61.4 yeas; 49 % had received two prior chemotherapy regimens, and 93 % had received platinum-based chemotherapy.  The response rate was 8.9 % in the erlotinib group and less than 1 % in the placebo group (P < 0.001); the median duration of the response wa 7.9 mo and 3.7 mo, resp.  Progression-free survival was 2.2 mo and 1.8 mo, resp. (hazard ratio, 0.61, adjusted for stratification categories; P < 0.001).  Overall survival was 6.7 mo and 4.7 mo, resp. (hazard ratio, 0.70; P < 0.001), in favor of erlotinib.  Five percent of patients discontinued erlotinib because of toxic effects.  Erlotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrkr8tjSBsYtbVg90H21EOLACvtfcHk0lgvfUrBGt5a0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXmtFaksbo%253D&md5=1633999cf09b8387ad88f40f75a5bb93</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa050753&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa050753%26sid%3Dliteratum%253Aachs%26aulast%3DShepherd%26aufirst%3DF.%2BA.%26aulast%3DPereira%26aufirst%3DJ.%2BR.%26aulast%3DCiuleanu%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DE.%2BH.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DThongprasert%26aufirst%3DS.%26aulast%3DCampos%26aufirst%3DD.%26aulast%3DMaoleekoonpiroj%26aufirst%3DS.%26aulast%3DSmylie%26aufirst%3DM.%26aulast%3DMartins%26aufirst%3DR.%26aulast%3Dvan%2BKooten%26aufirst%3DM.%26aulast%3DDediu%26aufirst%3DM.%26aulast%3DFindlay%26aufirst%3DB.%26aulast%3DTu%26aufirst%3DD.%26aulast%3DJohnston%26aufirst%3DD.%26aulast%3DBezjk%26aufirst%3DA.%26aulast%3DClark%26aufirst%3DG.%26aulast%3DSantabarbara%26aufirst%3DP.%26aulast%3DSeymour%26aufirst%3DL.%26atitle%3DErlotinib%2520in%2520previously%2520treated%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2005%26volume%3D353%26spage%3D123%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stiegler, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kobayashi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">EGFR-mutated lung cancer: A paradigm of molecular oncology</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">497</span><span class="NLM_x">–</span> <span class="NLM_lpage">514</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A280%3ADC%252BC3M7os1agsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2010&pages=497-514&author=Z.+Zhangauthor=A.+L.+Stieglerauthor=T.+J.+Boggonauthor=S.+Kobayashiauthor=B.+Halmos&title=EGFR-mutated+lung+cancer%3A+A+paradigm+of+molecular+oncology"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">EGFR-mutated lung cancer: a paradigm of molecular oncology</span></div><div class="casAuthors">Zhang Zhenfeng; Stiegler Amy L; Boggon Titus J; Kobayashi Susumu; Halmos Balazs</div><div class="citationInfo"><span class="NLM_cas:title">Oncotarget</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">497-514</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The development of EGFR tyrosine kinase inhibitors for clinical use in non-small cell lung cancer and the subsequent discovery of activating EGFR mutations have led to an explosion of knowledge in the fields of EGFR biology, targeted therapeutics and lung cancer research.  EGFR-mutated adenocarcinoma of the lung has clearly emerged as a unique clinical entity necessitating the routine introduction of molecular diagnostics into our current diagnostic algorithms and leading to the evidence-based preferential usage of EGFR-targeted agents for patients with EGFR-mutant lung cancers.  This review will summarize our current understanding of the functional role of activating mutations, key downstream signaling pathways and regulatory mechanisms, pivotal primary and acquired resistance mechanisms, structure-function relationships and ultimately the incorporation of molecular diagnostics and small molecule EGFR tyrosine kinase inhibitors into our current treatment paradigms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRxT8cHyGfvWwpJitSxOdIlfW6udTcc2ebvTCOnDZdl5rntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3M7os1agsQ%253D%253D&md5=f37988e50e4e504cea5a4449b1b10d1f</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DStiegler%26aufirst%3DA.%2BL.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DKobayashi%26aufirst%3DS.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DEGFR-mutated%2520lung%2520cancer%253A%2520A%2520paradigm%2520of%2520molecular%2520oncology%26jtitle%3DOncoTargets%2520Ther.%26date%3D2010%26volume%3D1%26spage%3D497%26epage%3D514" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Sogabe, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kawakita, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Igaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwata, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cary, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Takagi, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ohta, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ishikawa, T.</span><span> </span><span class="NLM_article-title">Structure-based approach for the discovery of pyrrolo[3,2-d]pyrimidine-based EGFR T790M/L858R mutant inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">201</span><span class="NLM_x">–</span> <span class="NLM_lpage">205</span></span><div class="citationLinks">[<a href="/doi/10.1021/ml300327z" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVCqsb%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2013&pages=201-205&author=S.+Sogabeauthor=Y.+Kawakitaauthor=S.+Igakiauthor=H.+Iwataauthor=H.+Mikiauthor=D.+R.+Caryauthor=T.+Takagiauthor=S.+Takagiauthor=Y.+Ohtaauthor=T.+Ishikawa&title=Structure-based+approach+for+the+discovery+of+pyrrolo%5B3%2C2-d%5Dpyrimidine-based+EGFR+T790M%2FL858R+mutant+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Based Approach for the Discovery of Pyrrolo[3,2-d]pyrimidine-Based EGFR T790M/L858R Mutant Inhibitors</span></div><div class="casAuthors">Sogabe, Satoshi; Kawakita, Youichi; Igaki, Shigeru; Iwata, Hidehisa; Miki, Hiroshi; Cary, Douglas R.; Takagi, Terufumi; Takagi, Shinji; Ohta, Yoshikazu; Ishikawa, Tomoyasu</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">201-205</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The epidermal growth factor receptor (EGFR) family plays a crit. role in vital cellular processes and in various cancers.  Known EGFR inhibitors exhibit distinct antitumor responses against the various EGFR mutants assocd. with nonsmall-cell lung cancer.  The L858R mutation enhances clin. sensitivity to gefitinib and erlotinib as compared with wild type and reduces the relative sensitivity to lapatinib.  In contrast, the T790M mutation confers drug resistance to gefitinib and erlotinib.  We detd. crystal structures of the wild-type and T790M/L858R double mutant EGFR kinases with reversible and irreversible pyrrolo[3,2-d]pyrimidine inhibitors based on analogs of TAK-285 and neratinib.  In these structures, M790 adopts distinct conformations to accommodate different inhibitors, whereas R858 allows conformational variations of the activation loop.  These results provide structural insights for understanding the structure-activity relationships that should contribute to the development of potent inhibitors against drug-sensitive or -resistant EGFR mutations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGod8LbyufWJoLVg90H21EOLACvtfcHk0lgvfUrBGt5a0g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVCqsb%252FO&md5=5d4d8ba552d7e98f9ac1eb07d1e882cd</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1021%2Fml300327z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml300327z%26sid%3Dliteratum%253Aachs%26aulast%3DSogabe%26aufirst%3DS.%26aulast%3DKawakita%26aufirst%3DY.%26aulast%3DIgaki%26aufirst%3DS.%26aulast%3DIwata%26aufirst%3DH.%26aulast%3DMiki%26aufirst%3DH.%26aulast%3DCary%26aufirst%3DD.%2BR.%26aulast%3DTakagi%26aufirst%3DT.%26aulast%3DTakagi%26aufirst%3DS.%26aulast%3DOhta%26aufirst%3DY.%26aulast%3DIshikawa%26aufirst%3DT.%26atitle%3DStructure-based%2520approach%2520for%2520the%2520discovery%2520of%2520pyrrolo%255B3%252C2-d%255Dpyrimidine-based%2520EGFR%2520T790M%252FL858R%2520mutant%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett%26date%3D2013%26volume%3D4%26spage%3D201%26epage%3D205" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Gajiwala, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferre, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodsky, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinrich, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kath, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, A.</span><span> </span><span class="NLM_article-title">Insights into the aberrant activity of mutant EGFR kinase domain and drug recognition</span> <span class="citation_source-journal">Structure (Oxford, U. K.)</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">209</span><span class="NLM_x">–</span> <span class="NLM_lpage">219</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.str.2012.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3sXotFeq" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2013&pages=209-219&author=K.+S.+Gajiwalaauthor=J.+Fengauthor=R.+Ferreauthor=K.+Ryanauthor=O.+Brodskyauthor=S.+Weinrichauthor=J.+C.+Kathauthor=A.+Stewart&title=Insights+into+the+aberrant+activity+of+mutant+EGFR+kinase+domain+and+drug+recognition"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Insights into the Aberrant Activity of Mutant EGFR Kinase Domain and Drug Recognition</span></div><div class="casAuthors">Gajiwala, Ketan S.; Feng, Junli; Ferre, RoseAnn; Ryan, Kevin; Brodsky, Oleg; Weinrich, Scott; Kath, John C.; Stewart, Al</div><div class="citationInfo"><span class="NLM_cas:title">Structure (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">209-219</span>CODEN:
                <span class="NLM_cas:coden">STRUE6</span>;
        ISSN:<span class="NLM_cas:issn">0969-2126</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The oncogenicity of the L858R mutant form of the epidermal growth factor receptor (EGFR) in non-small-cell lung cancer is thought to be due to the constitutive activation of its kinase domain.  The selectivity of the marketed drugs gefitinib and erlotinib for L858R mutant is attributed to their specific recognition of the active kinase and to weaker ATP binding by L858R EGFR.  We present crystal structures showing that neither L858R nor the drug-resistant L858R+T790M EGFR kinase domain is in the constitutively active conformation.  Addnl. co-crystal structures show that gefitinib and dacomitinib, an irreversible anilinoquinazoline deriv. currently in clin. development, may not be conformation specific for the active state of the enzyme.  Structural data further reveal the potential mode of recognition of one of the autophosphorylation sites in the C-terminal tail, Tyr-1016, by the kinase domain.  Biochem. and biophys. evidence suggest that the oncogenic mutations impact the conformational dynamics of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoi6kAQLM6h7LVg90H21EOLACvtfcHk0liHilMNuFdlsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXotFeq&md5=439bfda2e4e33786a15742e53cc271bc</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.str.2012.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.str.2012.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DGajiwala%26aufirst%3DK.%2BS.%26aulast%3DFeng%26aufirst%3DJ.%26aulast%3DFerre%26aufirst%3DR.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DBrodsky%26aufirst%3DO.%26aulast%3DWeinrich%26aufirst%3DS.%26aulast%3DKath%26aufirst%3DJ.%2BC.%26aulast%3DStewart%26aufirst%3DA.%26atitle%3DInsights%2520into%2520the%2520aberrant%2520activity%2520of%2520mutant%2520EGFR%2520kinase%2520domain%2520and%2520drug%2520recognition%26jtitle%3DStructure%2520%2528Oxford%252C%2520U.%2520K.%2529%26date%3D2013%26volume%3D21%26spage%3D209%26epage%3D219" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Yun, C.; Woo, M. S.; Greulich, H.; Meyerson, M.; Eck, M. J.; Wong, K.</span> In <span> </span><span class="NLM_article-title"><i>Structural and mechanistic studies of lung cancer mutations in the EGFR kinase reveal a novel mechanism of drug resistance</i></span>, <span class="NLM_conf-name">236th National Meeting of the American Chemical Society</span>, <span class="NLM_conf-loc">Philadelphia, PA</span>, <span class="NLM_conf-date">Aug 17–21, 2008</span>; <span class="NLM_publisher-name">American Chemisal Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2008</span><span class="NLM_x">; </span>COMP 373.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2008&conference=236th+National+Meeting+of+the+American+Chemical+Society&author=C.+Yun&author=M.+S.+Woo&author=H.+Greulich&author=M.+Meyerson&author=M.+J.+Eck&author=K.+Wong&title=Structural+and+mechanistic+studies+of+lung+cancer+mutations+in+the+EGFR+kinase+reveal+a+novel+mechanism+of+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%26atitle%3DStructural%2520and%2520mechanistic%2520studies%2520of%2520lung%2520cancer%2520mutations%2520in%2520the%2520EGFR%2520kinase%2520reveal%2520a%2520novel%2520mechanism%2520of%2520drug%2520resistance%26pub%3DAmerican%2520Chemisal%2520Society%26date%3D2008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0liHilMNuFdlsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woo, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greulich, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meyerson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span> </span><span class="NLM_article-title">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: Mechanism of activation and insights into differential inhibitor sensitivity</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">217</span><span class="NLM_x">–</span> <span class="NLM_lpage">227</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.ccr.2006.12.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17349580" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2007&pages=217-227&author=C.+Yunauthor=T.+J.+Boggonauthor=Y.+Liauthor=M.+S.+Wooauthor=H.+Greulichauthor=M.+Meyersonauthor=M.+J.+Eck&title=Structures+of+lung+cancer-derived+EGFR+mutants+and+inhibitor+complexes%3A+Mechanism+of+activation+and+insights+into+differential+inhibitor+sensitivity"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity</span></div><div class="casAuthors">Yun, Cai-Hong; Boggon, Titus J.; Li, Yiqun; Woo, Michele S.; Greulich, Heidi; Meyerson, Matthew; Eck, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">217-227</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Mutations in the EGFR kinase are a cause of non-small-cell lung cancer.  To understand their mechanism of activation and effects on drug binding, we studied the kinetics of the L858R and G719S mutants and detd. their crystal structures with inhibitors including gefitinib, AEE788, and a staurosporine.  We find that the mutations activate the kinase by disrupting autoinhibitory interactions, and that they accelerate catalysis as much as 50-fold in vitro.  Structures of inhibitors in complex with both wild-type and mutant kinases reveal similar binding modes for gefitinib and AEE788, but a marked rotation of the staurosporine in the G719S mutant.  Strikingly, direct binding measurements show that gefitinib binds 20-fold more tightly to the L858R mutant than to the wild-type enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoogeLQ1CuEnLVg90H21EOLACvtfcHk0liHilMNuFdlsw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjsVymtL4%253D&md5=6bc3223df84d829d9cb2bb00fd88ca29</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.ccr.2006.12.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccr.2006.12.017%26sid%3Dliteratum%253Aachs%26aulast%3DYun%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DWoo%26aufirst%3DM.%2BS.%26aulast%3DGreulich%26aufirst%3DH.%26aulast%3DMeyerson%26aufirst%3DM.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26atitle%3DStructures%2520of%2520lung%2520cancer-derived%2520EGFR%2520mutants%2520and%2520inhibitor%2520complexes%253A%2520Mechanism%2520of%2520activation%2520and%2520insights%2520into%2520differential%2520inhibitor%2520sensitivity%26jtitle%3DCancer%2520Cell%26date%3D2007%26volume%3D11%26spage%3D217%26epage%3D227" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Lovly, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Horn, L.</span><span> </span><span class="NLM_article-title">Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC</span> <span class="citation_source-journal">Curr. Treat. Options Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">516</span><span class="NLM_x">–</span> <span class="NLM_lpage">526</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1007%2Fs11864-012-0204-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22833206" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A280%3ADC%252BC38fjtV2jsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=516-526&author=C.+M.+Lovlyauthor=L.+Horn&title=Strategies+for+overcoming+EGFR+resistance+in+the+treatment+of+advanced-stage+NSCLC"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC</span></div><div class="casAuthors">Lovly Christine M; Horn Leora</div><div class="citationInfo"><span class="NLM_cas:title">Current treatment options in oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">516-26</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OPINION STATEMENT:  Patients whose tumors harbor somatic-activating mutations within the epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of lung cancers with increased sensitivity to the EGFR tyrosine kinase inhibitors (TKIs), including the "first-generation" reversible inhibitors, erlotinib and gefitinib, and the "second-generation" irreversible inhibitors, afatinib and dacomitinib.  Several, large, phase III studies have shown already that patients with EGFR-mutant tumors display radiographic response rates of >60 % and improved progression free survival (PFS) when treated with an EGFR TKI compared with chemotherapy.  Unfortunately, despite these initial responses, patients inevitably develop progressive disease, a concept referred to clinically as acquired resistance.  Novel strategies are needed to delay or overcome acquired resistance to EGFR TKIs.  These strategies include second-generation EGFR inhibitors, rationale combinations of targeted small molecule inhibitors and/or monoclonal antibodies, and addition of traditional cytotoxic chemotherapy to EGFR TKI therapy at the time of progression.  Unfortunately, to date, there is no genotype-specific standard of care, and enrollment of patients with acquired resistance to EGFR TKIs into clinical trials specifically addressed at overcoming resistance is paramount to continue to advance the field and to improve outcomes for these patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQDoPP1h2yk22yYR5VtavbzfW6udTcc2eY7ZWoEXsc6Srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fjtV2jsA%253D%253D&md5=120951d5f7ddca457581fc3421bca772</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1007%2Fs11864-012-0204-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs11864-012-0204-6%26sid%3Dliteratum%253Aachs%26aulast%3DLovly%26aufirst%3DC.%2BM.%26aulast%3DHorn%26aufirst%3DL.%26atitle%3DStrategies%2520for%2520overcoming%2520EGFR%2520resistance%2520in%2520the%2520treatment%2520of%2520advanced-stage%2520NSCLC%26jtitle%3DCurr.%2520Treat.%2520Options%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D516%26epage%3D526" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Ou, S. I.</span><span> </span><span class="NLM_article-title">Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): A better mousetrap? A review of the clinical evidence</span> <span class="citation_source-journal">Crit. Rev. Oncol. Hematol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">83</span><span class="NLM_x">, </span> <span class="NLM_fpage">407</span><span class="NLM_x">–</span> <span class="NLM_lpage">421</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.critrevonc.2011.11.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22257651" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A280%3ADC%252BC38vgs1GrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=2012&pages=407-421&author=S.+I.+Ou&title=Second-generation+irreversible+epidermal+growth+factor+receptor+%28EGFR%29+tyrosine+kinase+inhibitors+%28TKIs%29%3A+A+better+mousetrap%3F+A+review+of+the+clinical+evidence"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Second-generation irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs): a better mousetrap? A review of the clinical evidence</span></div><div class="casAuthors">Ou Sai-Hong Ignatius</div><div class="citationInfo"><span class="NLM_cas:title">Critical reviews in oncology/hematology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-21</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The discovery of activating epidermal growth factor receptor (EGFR) mutations in non-small cell lung cancer (NSCLC) in 2004 heralded the era of molecular targeted therapy in NSCLC.  First-generation small molecule, reversible tyrosine kinase inhibitors (TKIs) of EGFR, gefitinib and erlotinib, had been approved for second- or third-line treatment of NSCLC prior to the knowledge of these mutations.  However, resistance to gefitinib and erlotinib invariably develops after prolonged clinical use.  Two second-generation irreversible EGFR TKIs, afatinib (BIBW 2992) and dacomitinib (PF-00299804), that can potentially overcome the majority of these resistances are in late stage clinical development.  Here I will review the clinical data of EGFR TKIs and discuss the appropriate future role of afatinib and dacomitinib in NSCLC: whether as replacement of erlotinib or gefitinib or only after erlotinib or gefitinib failure and whether different subgroups would benefit from different approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQB3Zud0oX1WCM8MEzWGjS9fW6udTcc2eY7ZWoEXsc6Srntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38vgs1GrsA%253D%253D&md5=df9e3f1fe1c2bb8f328f925725024d40</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1016%2Fj.critrevonc.2011.11.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.critrevonc.2011.11.010%26sid%3Dliteratum%253Aachs%26aulast%3DOu%26aufirst%3DS.%2BI.%26atitle%3DSecond-generation%2520irreversible%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520tyrosine%2520kinase%2520inhibitors%2520%2528TKIs%2529%253A%2520A%2520better%2520mousetrap%253F%2520A%2520review%2520of%2520the%2520clinical%2520evidence%26jtitle%3DCrit.%2520Rev.%2520Oncol.%2520Hematol.%26date%3D2012%26volume%3D83%26spage%3D407%26epage%3D421" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cadranel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Su, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heo, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crino, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shahidi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cong, X. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorence, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, J. C.</span><span> </span><span class="NLM_article-title">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): A phase 2b/3 randomised trial</span> <span class="citation_source-journal">Lancet Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">528</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2FS1470-2045%2812%2970087-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22452896" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2012&pages=528-538&author=V.+A.+Millerauthor=V.+Hirshauthor=J.+Cadranelauthor=Y.+Chenauthor=K.+Parkauthor=S.+Kimauthor=C.+Zhouauthor=W.+Suauthor=M.+Wangauthor=Y.+Sunauthor=D.+S.+Heoauthor=L.+Crinoauthor=E.+Tanauthor=T.+Chaoauthor=M.+Shahidiauthor=X.+J.+Congauthor=R.+M.+Lorenceauthor=J.+C.+Yang&title=Afatinib+versus+placebo+for+patients+with+advanced%2C+metastatic+non-small-cell+lung+cancer+after+failure+of+erlotinib%2C+gefitinib%2C+or+both%2C+and+one+or+two+lines+of+chemotherapy+%28LUX-Lung+1%29%3A+A+phase+2b%2F3+randomised+trial"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial</span></div><div class="casAuthors">Miller, Vincent A.; Hirsh, Vera; Cadranel, Jacques; Chen, Yuh-Min; Park, Keunchil; Kim, Sang-We; Zhou, Caicun; Su, Wu-Chou; Wang, Mengzhao; Sun, Yan; Heo, Dae Seog; Crino, Lucio; Tan, Eng-Huat; Chao, Tsu-Yi; Shahidi, Mehdi; Cong, Xiuyu Julie; Lorence, Robert M.; Yang, James Chih-Hsin</div><div class="citationInfo"><span class="NLM_cas:title">Lancet Oncology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">528-538</span>CODEN:
                <span class="NLM_cas:coden">LOANBN</span>;
        ISSN:<span class="NLM_cas:issn">1470-2045</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Summary: Background: Afatinib, an irreversible ErbB-family blocker, has shown preclin. activity when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase inhibitors.  We aimed to assess its efficacy in patients with advanced lung adenocarcinoma with previous treatment failure on EGFR tyrosine-kinase inhibitors.  Methods: In this phase 2b/3 trial, we enrolled patients with stage IIIB or IV adenocarcinoma and an Eastern Cooperative Oncol. Group performance (ECOG) performance score of 0-2 who had received one or two previous chemotherapy regimens and had disease progression after at least 12 wk of treatment with erlotinib or gefitinib.  We used a computer-generated sequence to randomly allocate patients (2:1) to either afatinib (50 mg per day) or placebo; all patients received best supportive care.  Randomisation was done in blocks of three and was stratified by sex and baseline ECOG performance status (0-1 vs 2).  Investigators, patients, and the trial sponsor were masked to treatment assignment.  The primary endpoint was overall survival (from date of randomisation to death), analyzed on an intention-to-treat basis.  This study is registered with ClinicalTrials.gov, no. NCT00656136.  Findings: Between May 26, 2008, and Sept 21, 2009, we identified 697 patients, 585 of whom were randomly allocated to treatment (390 to afatinib, 195 to placebo).  Median overall survival was 10·8 mo (95% CI 10·0-12·0) in the afatinib group and 12·0 mo (10·2-14·3) in the placebo group (hazard ratio 1·08, 95% CI 0·86-1·35; p=0·74).  Median progression-free survival was longer in the afatinib group (3·3 mo, 95% CI 2·79-4·40) than it was in the placebo group (1·1 mo, 0·95-1·68; hazard ratio 0·38, 95% CI 0·31-0·48; p<0·0001).  No complete responses to treatment were noted; 29 (7%) patients had a partial response in the afatinib group, as did one patient in the placebo group.  Subsequent cancer treatment was given to 257 (68%) patients in the afatinib group and 153 (79%) patients in the placebo group.  The most common adverse events in the afatinib group were diarrhoea (339 [87%] of 390 patients; 66 [17%] were grade 3) and rash or acne (305 [78%] patients; 56 [14%] were grade 3).  These events occurred less often in the placebo group (18 [9%] of 195 patients had diarrhoea; 31 [16%] had rash or acne), all being grade 1 or 2.  Drug-related serious adverse events occurred in 39 (10%) patients in the afatinib group and one (<1%) patient in the placebo group.  We recorded two possibly treatment-related deaths in the afatinib group.  Interpretation: Although we recorded no benefit in terms of overall survival with afatinib (which might have been affected by cancer treatments given after progression in both groups), our findings for progression-free survival and response to treatment suggest that afatinib could be of some benefit to patients with advanced lung adenocarcinoma who have failed at least 12 wk of previous EGFR tyrosine-kinase inhibitor treatment.  Funding: Boehringer Ingelheim Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpDrR4FNSnKJbVg90H21EOLACvtfcHk0lgtOCLksUIBKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xmslyhsbg%253D&md5=6ddd7f552e8ab1ebb43fb699e27894f5</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1016%2FS1470-2045%2812%2970087-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS1470-2045%252812%252970087-6%26sid%3Dliteratum%253Aachs%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DCadranel%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DPark%26aufirst%3DK.%26aulast%3DKim%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DSu%26aufirst%3DW.%26aulast%3DWang%26aufirst%3DM.%26aulast%3DSun%26aufirst%3DY.%26aulast%3DHeo%26aufirst%3DD.%2BS.%26aulast%3DCrino%26aufirst%3DL.%26aulast%3DTan%26aufirst%3DE.%26aulast%3DChao%26aufirst%3DT.%26aulast%3DShahidi%26aufirst%3DM.%26aulast%3DCong%26aufirst%3DX.%2BJ.%26aulast%3DLorence%26aufirst%3DR.%2BM.%26aulast%3DYang%26aufirst%3DJ.%2BC.%26atitle%3DAfatinib%2520versus%2520placebo%2520for%2520patients%2520with%2520advanced%252C%2520metastatic%2520non-small-cell%2520lung%2520cancer%2520after%2520failure%2520of%2520erlotinib%252C%2520gefitinib%252C%2520or%2520both%252C%2520and%2520one%2520or%2520two%2520lines%2520of%2520chemotherapy%2520%2528LUX-Lung%25201%2529%253A%2520A%2520phase%25202b%252F3%2520randomised%2520trial%26jtitle%3DLancet%2520Oncol.%26date%3D2012%26volume%3D13%26spage%3D528%26epage%3D538" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Allen, L. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eiseman, I. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fry, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lenehan, P. F.</span><span> </span><span class="NLM_article-title">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span> <span class="citation_source-journal">Semin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2003</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">65</span><span class="NLM_x">–</span> <span class="NLM_lpage">78</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1053%2Fj.seminoncol.2003.08.009" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=14613028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2003&pages=65-78&author=L.+F.+Allenauthor=I.+A.+Eisemanauthor=D.+W.+Fryauthor=P.+F.+Lenehan&title=CI-1033%2C+an+irreversible+pan-erbB+receptor+inhibitor+and+its+potential+application+for+the+treatment+of+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">CI-1033, an irreversible pan-erbB receptor inhibitor and its potential application for the treatment of breast cancer</span></div><div class="casAuthors">Allen, Lee F.; Eiseman, Irene A.; Fry, David W.; Lenehan, Peter F.</div><div class="citationInfo"><span class="NLM_cas:title">Seminars in Oncology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">5, Suppl. 16</span>),
    <span class="NLM_cas:pages">65-78</span>CODEN:
                <span class="NLM_cas:coden">SOLGAV</span>;
        ISSN:<span class="NLM_cas:issn">0093-7754</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">A review.  The erbB family of cell surface receptor proteins consists of four members, all of which play a role in the development and growth of the normal breast.  The activity of this signaling pathway is normally tightly controlled, and dysregulation has been shown to play a significant role in the pathogenesis and progression of breast and other cancers.  The potent transforming potential of these receptors is further enhanced by the coexpression of multiple members of this receptor family, which worsens prognosis.  Therapeutic blockade of erbB-2 receptor signaling has to date been shown to be effective in only a subset of chemotherapy-resistant breast cancer patients.  CI-1033 is a highly potent and selective pan-erbB inhibitor that efficiently blocks signal transduction through all four members of the erbB receptor family.  In addn., it covalently binds to these receptors, irreversibility inhibiting them, and thereby provides for prolonged suppression of erbB receptor-mediated signaling.  Clin., it has been shown to have an acceptable side effect profile at potentially therapeutic doses and schedules.  Biomarker studies have shown target inhibition in patients, and evidence of antitumor activity has also been obsd. in phase I studies.  Given the broad expression pattern of the erbB family of receptors in solid tumors, and the important proliferative effect of co-expression of multiple erbB receptors, CI-1033, as an irreversible, pan-erbB inhibitor, has the potential to have an important role in the future treatment of breast and other cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpnHJoa4ri9ObVg90H21EOLACvtfcHk0lj9J90ZeJ0eiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXhtVSjtrrF&md5=13e9d00d8a20f3c79b4f7fe1032f07b5</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1053%2Fj.seminoncol.2003.08.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1053%252Fj.seminoncol.2003.08.009%26sid%3Dliteratum%253Aachs%26aulast%3DAllen%26aufirst%3DL.%2BF.%26aulast%3DEiseman%26aufirst%3DI.%2BA.%26aulast%3DFry%26aufirst%3DD.%2BW.%26aulast%3DLenehan%26aufirst%3DP.%2BF.%26atitle%3DCI-1033%252C%2520an%2520irreversible%2520pan-erbB%2520receptor%2520inhibitor%2520and%2520its%2520potential%2520application%2520for%2520the%2520treatment%2520of%2520breast%2520cancer%26jtitle%3DSemin.%2520Oncol.%26date%3D2003%26volume%3D30%26spage%3D65%26epage%3D78" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Kalous, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Conklin, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, N. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ginther, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anderson, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Britten, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taylor, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Slamon, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finn, R. S.</span><span> </span><span class="NLM_article-title">Dacomitinib (PF-00299804), an irreversible pan-HER inhibitor, inhibits proliferation of HER2-amplified breast cancer cell lines resistant to Trastuzumab and Lapatinib</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">1978</span><span class="NLM_x">–</span> <span class="NLM_lpage">1987</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1158%2F1535-7163.MCT-11-0730" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22761403" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2012&pages=1978-1987&author=O.+Kalousauthor=D.+Conklinauthor=A.+J.+Desaiauthor=N.+A.+O%E2%80%99Brienauthor=C.+Gintherauthor=L.+Andersonauthor=D.+J.+Cohenauthor=C.+D.+Brittenauthor=I.+Taylorauthor=J.+G.+Christensenauthor=D.+J.+Slamonauthor=R.+S.+Finn&title=Dacomitinib+%28PF-00299804%29%2C+an+irreversible+pan-HER+inhibitor%2C+inhibits+proliferation+of+HER2-amplified+breast+cancer+cell+lines+resistant+to+Trastuzumab+and+Lapatinib"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib</span></div><div class="casAuthors">Kalous, Ondrej; Conklin, Dylan; Desai, Amrita J.; O'Brien, Neil A.; Ginther, Charles; Anderson, Lee; Cohen, David J.; Britten, Carolyn D.; Taylor, Ian; Christensen, James G.; Slamon, Dennis J.; Finn, Richard S.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1978-1987</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The human EGF (HER) family of receptors has been pursued as therapeutic targets in breast cancer and other malignancies.  Trastuzumab and lapatinib are std. treatments for HER2-amplified breast cancer, but a significant no. of patients do not respond or develop resistance to these drugs.  Here we evaluate the in vitro activity of dacomitinib (PF-00299804), an irreversible small mol. pan-HER inhibitor, in a large panel of human breast cancer cell lines with variable expression of the HER family receptors and ligands, and with variable sensitivity to trastuzumab and lapatinib.  Forty-seven human breast cancer and immortalized breast epithelial lines representing the known mol. subgroups of breast cancer were treated with dacomitinib to det. IC50 values.  HER2-amplified lines were far more likely to respond to dacomitinib than nonamplified lines (RR, 3.39; P < 0.0001).  Furthermore, HER2 mRNA and protein expression were quant. assocd. with response.  Dacomitinib reduced the phosphorylation of HER2, EGFR, HER4, AKT, and ERK in the majority of sensitive lines.  Dacomitinib exerted its antiproliferative effect through a combined G0-G1 arrest and an induction of apoptosis.  Dacomitinib inhibited growth in several HER2-amplified lines with de novo and acquired resistance to trastuzumab.  Dacomitinib maintained a high activity in lines with acquired resistance to lapatinib.  This study identifies HER2-amplified breast cancer lines as most sensitive to the antiproliferative effect of dacomitinib and provides a strong rationale for its clin. testing in HER2-amplified breast cancers resistant to trastuzumab and lapatinib.  Mol Cancer Ther; 11(9); 1978-87. ©2012 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp55-QHIJqDk7Vg90H21EOLACvtfcHk0lj9J90ZeJ0eiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtlWhsrvI&md5=b2b0677cbecb66e1e629742adffb0782</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0730&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0730%26sid%3Dliteratum%253Aachs%26aulast%3DKalous%26aufirst%3DO.%26aulast%3DConklin%26aufirst%3DD.%26aulast%3DDesai%26aufirst%3DA.%2BJ.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DN.%2BA.%26aulast%3DGinther%26aufirst%3DC.%26aulast%3DAnderson%26aufirst%3DL.%26aulast%3DCohen%26aufirst%3DD.%2BJ.%26aulast%3DBritten%26aufirst%3DC.%2BD.%26aulast%3DTaylor%26aufirst%3DI.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DSlamon%26aufirst%3DD.%2BJ.%26aulast%3DFinn%26aufirst%3DR.%2BS.%26atitle%3DDacomitinib%2520%2528PF-00299804%2529%252C%2520an%2520irreversible%2520pan-HER%2520inhibitor%252C%2520inhibits%2520proliferation%2520of%2520HER2-amplified%2520breast%2520cancer%2520cell%2520lines%2520resistant%2520to%2520Trastuzumab%2520and%2520Lapatinib%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2012%26volume%3D11%26spage%3D1978%26epage%3D1987" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Johnston, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Navaratnam, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pitz, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maniate, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiechec, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baust, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gingerich, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Skliris, G. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, L. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, M.</span><span> </span><span class="NLM_article-title">Targeting the EGFR pathway for cancer therapy</span> <span class="citation_source-journal">Curr. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">3483</span><span class="NLM_x">–</span> <span class="NLM_lpage">3492</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.2174%2F092986706779026174" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17168718" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1aks7fF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2006&pages=3483-3492&author=J.+B.+Johnstonauthor=S.+Navaratnamauthor=M.+W.+Pitzauthor=J.+M.+Maniateauthor=E.+Wiechecauthor=H.+Baustauthor=J.+Gingerichauthor=G.+P.+Sklirisauthor=L.+C.+Murphyauthor=M.+Los&title=Targeting+the+EGFR+pathway+for+cancer+therapy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting the EGFR pathway for cancer therapy</span></div><div class="casAuthors">Johnston, James B.; Navaratnam, Sri; Pitz, Marshall W.; Maniate, Jerry M.; Wiechec, Emilia; Baust, Heinrich; Gingerich, Joel; Skliris, Georgios P.; Murphy, Leigh C.; Los, Marek</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3483-3492</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Clin. studies have shown that HER-2/Neu is over-expressed in up to one-third of patients with a variety of cancers, including B-cell acute lymphoblastic leukemia (B-ALL), breast cancer and lung cancer, and that these patients are frequently resistant to conventional chemo-therapies.  Addnl., in most patients with multiple myeloma, the malignant cells over-express a no. of epidermal growth factor receptors (EGFR)s and their ligands, HB-EGF and amphiregulin, thus this growth-factor family may be an important aspect in the patho-biol. of this disease.  These and other, related findings have provided the rationale for the targeting of the components of the EGFR signaling pathways for cancer therapy.  Below we discuss various aspects of EGFR-targeted therapies mainly in hematol. malignancies, lung cancer and breast cancer.  Beside novel therapeutic approaches, we also discuss specific side effects assocd. with the therapeutic inhibition of components of the EGFR-pathways.  Alongside small inhibitors, such as Lapatinib (Tykerb, GW572016), Gefitinib (Iressa, ZD1839), and Erlotinib (Tarceva, OSI-774), a significant part of the review is also dedicated to therapeutic antibodies (e.g.: Trastuzumab / Herceptin, Pertuzumab / Omnitarg / rhuMab-2C4, Cetuximab / Erbitux / IMC-C225, Panitumumab / Abenix / ABX-EGF, and also ZD6474).  In addn., we summarize, both current therapy development driven by antibody-based targeting of the EGFR-dependent signaling pathways, and furthermore, we provide a background on the history and the development of therapeutic antibodies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqKtrrqQ9o2ubVg90H21EOLACvtfcHk0ljxUgrmtVhSrA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1aks7fF&md5=79ea40904fab4efd0ca908e2269da1a4</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.2174%2F092986706779026174&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F092986706779026174%26sid%3Dliteratum%253Aachs%26aulast%3DJohnston%26aufirst%3DJ.%2BB.%26aulast%3DNavaratnam%26aufirst%3DS.%26aulast%3DPitz%26aufirst%3DM.%2BW.%26aulast%3DManiate%26aufirst%3DJ.%2BM.%26aulast%3DWiechec%26aufirst%3DE.%26aulast%3DBaust%26aufirst%3DH.%26aulast%3DGingerich%26aufirst%3DJ.%26aulast%3DSkliris%26aufirst%3DG.%2BP.%26aulast%3DMurphy%26aufirst%3DL.%2BC.%26aulast%3DLos%26aufirst%3DM.%26atitle%3DTargeting%2520the%2520EGFR%2520pathway%2520for%2520cancer%2520therapy%26jtitle%3DCurr.%2520Med.%2520Chem.%26date%3D2006%26volume%3D13%26spage%3D3483%26epage%3D3492" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lg7hdKWom0j_A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Chang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Geng, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, K.</span><span> </span><span class="NLM_article-title">Design, synthesis, and biological evaluation of novel conformationally constrained inhibitors targeting epidermal growth factor receptor threonine790 → methionine790 mutant</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">2711</span><span class="NLM_x">–</span> <span class="NLM_lpage">2723</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm201591k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=2711-2723&author=S.+Changauthor=L.+Zhangauthor=S.+Xuauthor=J.+Luoauthor=X.+Luauthor=Z.+Zhangauthor=T.+Xuauthor=Y.+Liuauthor=Z.+Tuauthor=Y.+Xuauthor=X.+Renauthor=M.+Gengauthor=J.+Dingauthor=D.+Peiauthor=K.+Ding&title=Design%2C+synthesis%2C+and+biological+evaluation+of+novel+conformationally+constrained+inhibitors+targeting+epidermal+growth+factor+receptor+threonine790+%E2%86%92+methionine790+mutant"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm201591k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201591k%26sid%3Dliteratum%253Aachs%26aulast%3DChang%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DX.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DT.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DTu%26aufirst%3DZ.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DRen%26aufirst%3DX.%26aulast%3DGeng%26aufirst%3DM.%26aulast%3DDing%26aufirst%3DJ.%26aulast%3DPei%26aufirst%3DD.%26aulast%3DDing%26aufirst%3DK.%26atitle%3DDesign%252C%2520synthesis%252C%2520and%2520biological%2520evaluation%2520of%2520novel%2520conformationally%2520constrained%2520inhibitors%2520targeting%2520epidermal%2520growth%2520factor%2520receptor%2520threonine790%2520%25E2%2586%2592%2520methionine790%2520mutant%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D2711%26epage%3D2723" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Bai, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tong, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jiang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, H.</span><span> </span><span class="NLM_article-title">Discovery of novel selective inhibitors for EGFR-T790M/L858R</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">1365</span><span class="NLM_x">–</span> <span class="NLM_lpage">1370</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2012&pages=1365-1370&author=F.+Baiauthor=H.+Liuauthor=L.+Tongauthor=W.+Zhouauthor=L.+Liuauthor=Z.+Zhaoauthor=X.+Liuauthor=H.+Jiangauthor=X.+Wangauthor=H.+Xieauthor=H.+Li&title=Discovery+of+novel+selective+inhibitors+for+EGFR-T790M%2FL858R"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DBai%26aufirst%3DF.%26aulast%3DLiu%26aufirst%3DH.%26aulast%3DTong%26aufirst%3DL.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DJiang%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DXie%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DH.%26atitle%3DDiscovery%2520of%2520novel%2520selective%2520inhibitors%2520for%2520EGFR-T790M%252FL858R%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D22%26spage%3D1365%26epage%3D1370" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lee, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schaefer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heffron, T. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sideris, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malek, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Merchant, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">La, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ubhayakar, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yauch, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirazzoli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Politi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Noncovalent wild-type-sparing inhibitors of EGFR T790M</span> <span class="citation_source-journal">Cancer Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">168</span><span class="NLM_x">–</span> <span class="NLM_lpage">181</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=168-181&author=H.+Leeauthor=G.+Schaeferauthor=T.+P.+Heffronauthor=L.+Shaoauthor=X.+Yeauthor=S.+Siderisauthor=S.+Malekauthor=E.+Chanauthor=M.+Merchantauthor=H.+Laauthor=S.+Ubhayakarauthor=R.+L.+Yauchauthor=V.+Pirazzoliauthor=K.+Politiauthor=J.+Settleman&title=Noncovalent+wild-type-sparing+inhibitors+of+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%26aulast%3DSchaefer%26aufirst%3DG.%26aulast%3DHeffron%26aufirst%3DT.%2BP.%26aulast%3DShao%26aufirst%3DL.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DSideris%26aufirst%3DS.%26aulast%3DMalek%26aufirst%3DS.%26aulast%3DChan%26aufirst%3DE.%26aulast%3DMerchant%26aufirst%3DM.%26aulast%3DLa%26aufirst%3DH.%26aulast%3DUbhayakar%26aufirst%3DS.%26aulast%3DYauch%26aufirst%3DR.%2BL.%26aulast%3DPirazzoli%26aufirst%3DV.%26aulast%3DPoliti%26aufirst%3DK.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DNoncovalent%2520wild-type-sparing%2520inhibitors%2520of%2520EGFR%2520T790M%26jtitle%3DCancer%2520Discovery%26date%3D2013%26volume%3D3%26spage%3D168%26epage%3D181" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ercan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yun, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortot, A. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chirieac, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iacob, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padera, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engen, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eck, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janne, P. A.</span><span> </span><span class="NLM_article-title">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">462</span><span class="NLM_x">, </span> <span class="NLM_fpage">1070</span><span class="NLM_x">–</span> <span class="NLM_lpage">1074</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnature08622" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20033049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=462&publication_year=2009&pages=1070-1074&author=W.+Zhouauthor=D.+Ercanauthor=L.+Chenauthor=C.+Yunauthor=D.+Liauthor=M.+Capellettiauthor=A.+B.+Cortotauthor=L.+Chirieacauthor=R.+E.+Iacobauthor=R.+Paderaauthor=J.+R.+Engenauthor=K.+Wongauthor=M.+J.+Eckauthor=N.+S.+Grayauthor=P.+A.+Janne&title=Novel+mutant-selective+EGFR+kinase+inhibitors+against+EGFR+T790M"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Novel mutant-selective EGFR kinase inhibitors against EGFR T790M</span></div><div class="casAuthors">Zhou, Wenjun; Ercan, Dalia; Chen, Liang; Yun, Cai-Hong; Li, Danan; Capelletti, Marzia; Cortot, Alexis B.; Chirieac, Lucian; Iacob, Roxana E.; Padera, Robert; Engen, John R.; Wong, Kwok-Kin; Eck, Michael J.; Gray, Nathanael S.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">462</span>
        (<span class="NLM_cas:issue">7276</span>),
    <span class="NLM_cas:pages">1070-1074</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The clin. efficacy of epidermal growth factor receptor (EGFR) kinase inhibitors in EGFR-mutant non-small-cell lung cancer (NSCLC) is limited by the development of drug-resistance mutations, including the gatekeeper T790M mutation.  Strategies targeting EGFR T790M with irreversible inhibitors have had limited success and are assocd. with toxicity due to concurrent inhibition of wild-type EGFR.  All current EGFR inhibitors possess a structurally related quinazoline-based core scaffold and were identified as ATP-competitive inhibitors of wild-type EGFR.  Here we identify a covalent pyrimidine EGFR inhibitor by screening an irreversible kinase inhibitor library specifically against EGFR T790M.  These agents are 30- to 100-fold more potent against EGFR T790M, and up to 100-fold less potent against wild-type EGFR, than quinazoline-based EGFR inhibitors in vitro.  They are also effective in murine models of lung cancer driven by EGFR T790M.  Co-crystn. studies reveal a structural basis for the increased potency and mutant selectivity of these agents.  These mutant-selective irreversible EGFR kinase inhibitors may be clin. more effective and better tolerated than quinazoline-based inhibitors.  Our findings demonstrate that functional pharmacol. screens against clin. important mutant kinases represent a powerful strategy to identify new classes of mutant-selective kinase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrcksZlIe-1bbVg90H21EOLACvtfcHk0lglZjMmqPzwzA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhs1SktbvI&md5=9b5d41a2be401c67a4b9f04a41cf1725</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1038%2Fnature08622&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature08622%26sid%3Dliteratum%253Aachs%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DErcan%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DYun%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DCapelletti%26aufirst%3DM.%26aulast%3DCortot%26aufirst%3DA.%2BB.%26aulast%3DChirieac%26aufirst%3DL.%26aulast%3DIacob%26aufirst%3DR.%2BE.%26aulast%3DPadera%26aufirst%3DR.%26aulast%3DEngen%26aufirst%3DJ.%2BR.%26aulast%3DWong%26aufirst%3DK.%26aulast%3DEck%26aufirst%3DM.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DJanne%26aufirst%3DP.%2BA.%26atitle%3DNovel%2520mutant-selective%2520EGFR%2520kinase%2520inhibitors%2520against%2520EGFR%2520T790M%26jtitle%3DNature%26date%3D2009%26volume%3D462%26spage%3D1070%26epage%3D1074" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit26"><span>Merck Millipore Home Page. <a href="http://www.millipore.com" class="extLink">www.millipore.com</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Merck+Millipore+Home+Page.+www.millipore.com."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baillie, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whitty, A.</span><span> </span><span class="NLM_article-title">The resurgence of covalent drugs</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">307</span><span class="NLM_x">–</span> <span class="NLM_lpage">317</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnrd3410" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=21455239" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=307-317&author=J.+Singhauthor=R.+C.+Petterauthor=T.+A.+Baillieauthor=A.+Whitty&title=The+resurgence+of+covalent+drugs"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">The resurgence of covalent drugs</span></div><div class="casAuthors">Singh, Juswinder; Petter, Russell C.; Baillie, Thomas A.; Whitty, Adrian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">307-317</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Covalent drugs haveproved to be successful therapies for various indications, but largely owing to safety concerns, they are rarely considered when initiating a target-directed drug discovery project.  There is a need to reassess this important class of drugs, and to reconcile the discordance between the historic success of covalent drugs and the reluctance of most drug discovery teams to include them in their armamentarium.  This Review surveys the prevalence and pharmacol. advantages of covalent drugs, discusses how potential risks and challenges may be addressed through innovative design, and presents the broad opportunities provided by targeted covalent inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGreDCEmORV_NbVg90H21EOLACvtfcHk0ljgmgZO0qvbbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXktVGmu7g%253D&md5=2190289081e151416c097be4a5b04460</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1038%2Fnrd3410&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd3410%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DBaillie%26aufirst%3DT.%2BA.%26aulast%3DWhitty%26aufirst%3DA.%26atitle%3DThe%2520resurgence%2520of%2520covalent%2520drugs%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2011%26volume%3D10%26spage%3D307%26epage%3D317" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Rauh, D.</span> In <span> </span><span class="NLM_article-title"><i>Targeting protein kinases with irreversible inhibitors</i></span>, <span class="NLM_conf-name">241st National Meeting of the American Chemical Society</span>, <span class="NLM_conf-loc">Anaheim, CA</span>, <span class="NLM_conf-date">March 27–31, 2011</span>; <span class="NLM_publisher-name">American Chemical Society</span>: <span class="NLM_publisher-loc">Washington, DC</span>,<span class="NLM_x"> </span><span class="NLM_year">2011</span><span class="NLM_x">; </span>MEDI 157.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2011&conference=241st+National+Meeting+of+the+American+Chemical+Society&author=D.+Rauh&title=Targeting+protein+kinases+with+irreversible+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dconf-proc%26sid%3Dliteratum%253Aachs%26aulast%3DRauh%26aufirst%3DD.%26atitle%3DTargeting%2520protein%2520kinases%2520with%2520irreversible%2520inhibitors%26pub%3DAmerican%2520Chemical%2520Society%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Singh, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Labinski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dubrovskiy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nacht, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prasad, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">StMartin, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tjin Tham Sjin, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Westlin, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span> </span><span class="NLM_article-title">Superiority of a novel EGFR targeted covalent inhibitor over its reversible counterpart in overcoming drug resistance</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">780</span><span class="NLM_x">–</span> <span class="NLM_lpage">783</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=780-783&author=J.+Singhauthor=E.+Evansauthor=M.+Hagelauthor=M.+Labinskiauthor=A.+Dubrovskiyauthor=M.+Nachtauthor=R.+C.+Petterauthor=A.+Prasadauthor=M.+Sheetsauthor=T.+StMartinauthor=R.+Tjin+Tham+Sjinauthor=W.+Westlinauthor=Z.+Zhu&title=Superiority+of+a+novel+EGFR+targeted+covalent+inhibitor+over+its+reversible+counterpart+in+overcoming+drug+resistance"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DJ.%26aulast%3DEvans%26aufirst%3DE.%26aulast%3DHagel%26aufirst%3DM.%26aulast%3DLabinski%26aufirst%3DM.%26aulast%3DDubrovskiy%26aufirst%3DA.%26aulast%3DNacht%26aufirst%3DM.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DPrasad%26aufirst%3DA.%26aulast%3DSheets%26aufirst%3DM.%26aulast%3DStMartin%26aufirst%3DT.%26aulast%3DTjin%2BTham%2BSjin%26aufirst%3DR.%26aulast%3DWestlin%26aufirst%3DW.%26aulast%3DZhu%26aufirst%3DZ.%26atitle%3DSuperiority%2520of%2520a%2520novel%2520EGFR%2520targeted%2520covalent%2520inhibitor%2520over%2520its%2520reversible%2520counterpart%2520in%2520overcoming%2520drug%2520resistance%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D780%26epage%3D783" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Friesner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banks, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murphy, R. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halgren, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klicic, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainz, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Repasky, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knoll, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shelley, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perry, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, D. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Francis, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shenkin, P. S.</span><span> </span><span class="NLM_article-title">Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">47</span><span class="NLM_x">, </span> <span class="NLM_fpage">1739</span><span class="NLM_x">–</span> <span class="NLM_lpage">1749</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0306430" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=47&publication_year=2004&pages=1739-1749&author=R.+A.+Friesnerauthor=J.+L.+Banksauthor=R.+B.+Murphyauthor=T.+A.+Halgrenauthor=J.+J.+Klicicauthor=D.+T.+Mainzauthor=M.+P.+Repaskyauthor=E.+H.+Knollauthor=M.+Shelleyauthor=J.+K.+Perryauthor=D.+E.+Shawauthor=P.+Francisauthor=P.+S.+Shenkin&title=Glide%3A+A+new+approach+for+rapid%2C+accurate+docking+and+scoring.+1.+Method+and+assessment+of+docking+accuracy"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Glide: A new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy</span></div><div class="casAuthors">Friesner, Richard A.; Banks, Jay L.; Murphy, Robert B.; Halgren, Thomas A.; Klicic, Jasna J.; Mainz, Daniel T.; Repasky, Matthew P.; Knoll, Eric H.; Shelley, Mee; Perry, Jason K.; Shaw, David E.; Francis, Perry; Shenkin, Peter S.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">47</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1739-1749</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Unlike other methods for docking ligands to the rigid 3D structure of a known protein receptor, Glide approximates a complete systematic search of the conformational, orientational, and positional space of the docked ligand.  In this search, an initial rough positioning and scoring phase that dramatically narrows the search space is followed by torsionally flexible energy optimization on an OPLS-AA nonbonded potential grid for a few hundred surviving candidate poses.  The very best candidates are further refined via a Monte Carlo sampling of pose conformation; in some cases, this is crucial to obtaining an accurate docked pose.  Selection of the best docked pose uses a model energy function that combines empirical and force-field-based terms.  Docking accuracy is assessed by redocking ligands from 282 cocrystd. PDB complexes starting from conformationally optimized ligand geometries that bear no memory of the correctly docked pose.  Errors in geometry for the top-ranked pose are less than 1 Å in nearly half of the cases and are greater than 2 Å in only about one-third of them.  Comparisons to published data on rms deviations show that Glide is nearly twice as accurate as GOLD and more than twice as accurate as FlexX for ligands having up to 20 rotatable bonds.  Glide is also found to be more accurate than the recently described Surflex method.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPuigu31qMMLVg90H21EOLACvtfcHk0lhK8MCBvCEUuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhsFyit74%253D&md5=8cc2f0022318b12dd972e9c493375bf9</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1021%2Fjm0306430&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0306430%26sid%3Dliteratum%253Aachs%26aulast%3DFriesner%26aufirst%3DR.%2BA.%26aulast%3DBanks%26aufirst%3DJ.%2BL.%26aulast%3DMurphy%26aufirst%3DR.%2BB.%26aulast%3DHalgren%26aufirst%3DT.%2BA.%26aulast%3DKlicic%26aufirst%3DJ.%2BJ.%26aulast%3DMainz%26aufirst%3DD.%2BT.%26aulast%3DRepasky%26aufirst%3DM.%2BP.%26aulast%3DKnoll%26aufirst%3DE.%2BH.%26aulast%3DShelley%26aufirst%3DM.%26aulast%3DPerry%26aufirst%3DJ.%2BK.%26aulast%3DShaw%26aufirst%3DD.%2BE.%26aulast%3DFrancis%26aufirst%3DP.%26aulast%3DShenkin%26aufirst%3DP.%2BS.%26atitle%3DGlide%253A%2520A%2520new%2520approach%2520for%2520rapid%252C%2520accurate%2520docking%2520and%2520scoring.%25201.%2520Method%2520and%2520assessment%2520of%2520docking%2520accuracy%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2004%26volume%3D47%26spage%3D1739%26epage%3D1749" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Ehmke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quinsaat, J. E. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rivera-Fuentes, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heindl, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Freymond, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rottmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brun, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirmeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diederich, F.</span><span> </span><span class="NLM_article-title">Tuning and predicting biological affinity: Aryl nitriles as cysteine protease inhibitors</span> <span class="citation_source-journal">Org. Biomol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">5764</span><span class="NLM_x">–</span> <span class="NLM_lpage">5768</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1039%2Fc2ob00034b" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22336919" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVSlsr3J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2012&pages=5764-5768&author=V.+Ehmkeauthor=J.+E.+Q.+Quinsaatauthor=P.+Rivera-Fuentesauthor=C.+Heindlauthor=C.+Freymondauthor=M.+Rottmannauthor=R.+Brunauthor=T.+Schirmeisterauthor=F.+Diederich&title=Tuning+and+predicting+biological+affinity%3A+Aryl+nitriles+as+cysteine+protease+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Tuning and predicting biological affinity: aryl nitriles as cysteine protease inhibitors</span></div><div class="casAuthors">Ehmke, Veronika; Quinsaat, Jose Enrico Q.; Rivera-Fuentes, Pablo; Heindl, Cornelia; Freymond, Celine; Rottmann, Matthias; Brun, Reto; Schirmeister, Tanja; Diederich, Francois</div><div class="citationInfo"><span class="NLM_cas:title">Organic & Biomolecular Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">30</span>),
    <span class="NLM_cas:pages">5764-5768</span>CODEN:
                <span class="NLM_cas:coden">OBCRAK</span>;
        ISSN:<span class="NLM_cas:issn">1477-0520</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">A series of aryl nitrile-based ligands were prepd. to investigate the effect of their electrophilicity on the affinity against the cysteine proteases rhodesain and human cathepsin L. D. functional theory calcns. provided relative reactivities of the nitriles, enabling prediction of their biol. affinity and cytotoxicity and a clear structure-activity relationship.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoOglKLK34p47Vg90H21EOLACvtfcHk0lhK8MCBvCEUuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVSlsr3J&md5=45858b629d24a54b72cd7e3b7ba15e5b</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1039%2Fc2ob00034b&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2ob00034b%26sid%3Dliteratum%253Aachs%26aulast%3DEhmke%26aufirst%3DV.%26aulast%3DQuinsaat%26aufirst%3DJ.%2BE.%2BQ.%26aulast%3DRivera-Fuentes%26aufirst%3DP.%26aulast%3DHeindl%26aufirst%3DC.%26aulast%3DFreymond%26aufirst%3DC.%26aulast%3DRottmann%26aufirst%3DM.%26aulast%3DBrun%26aufirst%3DR.%26aulast%3DSchirmeister%26aufirst%3DT.%26aulast%3DDiederich%26aufirst%3DF.%26atitle%3DTuning%2520and%2520predicting%2520biological%2520affinity%253A%2520Aryl%2520nitriles%2520as%2520cysteine%2520protease%2520inhibitors%26jtitle%3DOrg.%2520Biomol.%2520Chem.%26date%3D2012%26volume%3D10%26spage%3D5764%26epage%3D5768" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit32"><span>Proteros Biostructures Home Page. <a href="http://www.proteros.de" class="extLink">www.proteros.de</a>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Proteros+Biostructures+Home+Page.+www.proteros.de."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Edwards, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Price, D. A.</span><span> </span><span class="NLM_article-title">Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks</span> <span class="citation_source-journal">Annu. Rep. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">45</span><span class="NLM_x">, </span> <span class="NLM_fpage">381</span><span class="NLM_x">–</span> <span class="NLM_lpage">391</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2010&pages=381-391&author=M.+P.+Edwardsauthor=D.+A.+Price&title=Role+of+physicochemical+properties+and+ligand+lipophilicity+efficiency+in+addressing+drug+safety+risks"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26aulast%3DPrice%26aufirst%3DD.%2BA.%26atitle%3DRole%2520of%2520physicochemical%2520properties%2520and%2520ligand%2520lipophilicity%2520efficiency%2520in%2520addressing%2520drug%2520safety%2520risks%26jtitle%3DAnnu.%2520Rep.%2520Med.%2520Chem.%26date%3D2010%26volume%3D45%26spage%3D381%26epage%3D391" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Leeson, P. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Springthorpe, B.</span><span> </span><span class="NLM_article-title">The influence of drug-like concepts on decision-making in medicinal chemistry</span> <span class="citation_source-journal">Nat. Rev. Drug Discovery</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">881</span><span class="NLM_x">–</span> <span class="NLM_lpage">890</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnrd2445" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17971784" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2007&pages=881-890&author=P.+D.+Leesonauthor=B.+Springthorpe&title=The+influence+of+drug-like+concepts+on+decision-making+in+medicinal+chemistry"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The influence of drug-like concepts on decision-making in medicinal chemistry</span></div><div class="casAuthors">Leeson, Paul D.; Springthorpe, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">881-890</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Despite the wide acceptance of drug-like principles such as the 'rule of five', this anal. of mols. currently being synthesized in leading pharmaceutical companies reveals that their phys. properties differ significantly from those of recently discovered oral drugs.  The marked increase in lipophilicity in particular could increase the likelihood of attrition in drug development.  The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development.  However, despite this acceptance, anal. of recent trends reveals that the phys. properties of mols. that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compds. in clin. development.  The consequences of the marked increase in lipophilicity - the most important drug-like phys. property - include a greater likelihood of lack of selectivity and attrition in drug development.  Tackling the threat of compd.-related toxicol. attrition needs to move to the mainstream of medicinal chem. decision-making.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTUeonLD6iebVg90H21EOLACvtfcHk0lhK8MCBvCEUuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXht1els7rL&md5=5665a9e2dc266a1ee096e20625757ef7</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fnrd2445&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd2445%26sid%3Dliteratum%253Aachs%26aulast%3DLeeson%26aufirst%3DP.%2BD.%26aulast%3DSpringthorpe%26aufirst%3DB.%26atitle%3DThe%2520influence%2520of%2520drug-like%2520concepts%2520on%2520decision-making%2520in%2520medicinal%2520chemistry%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discovery%26date%3D2007%26volume%3D6%26spage%3D881%26epage%3D890" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Leach, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, H. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cosgrove, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kenny, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruston, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">MacFaul, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colclough, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Law, B.</span><span> </span><span class="NLM_article-title">Matched molecular pairs as a guide in the optimization of pharmaceutical properties; a study of aqueous solubility, plasma protein binding and oral exposure</span> <span class="citation_source-journal">J. Med. Chem .</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">6672</span><span class="NLM_x">–</span> <span class="NLM_lpage">6682</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0605233" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD28XhtV2gtLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=6672-6682&author=A.+G.+Leachauthor=H.+D.+Jonesauthor=D.+A.+Cosgroveauthor=P.+W.+Kennyauthor=L.+Rustonauthor=P.+MacFaulauthor=J.+M.+Woodauthor=N.+Colcloughauthor=B.+Law&title=Matched+molecular+pairs+as+a+guide+in+the+optimization+of+pharmaceutical+properties%3B+a+study+of+aqueous+solubility%2C+plasma+protein+binding+and+oral+exposure"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Matched Molecular Pairs as a Guide in the Optimization of Pharmaceutical Properties; a Study of Aqueous Solubility, Plasma Protein Binding and Oral Exposure</span></div><div class="casAuthors">Leach, Andrew G.; Jones, Huw D.; Cosgrove, David A.; Kenny, Peter W.; Ruston, Linette; MacFaul, Philip; Wood, J. Matthew; Colclough, Nicola; Law, Brian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">6672-6682</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">By identifying every pair of mols. that differ only by a particular, well-defined, structural transformation in a database of measured properties and computing the corresponding change in property, we obtain an overview of the effect that structural change has upon the property and set an expectation for what will happen when that transformation is applied elsewhere.  The mean change indicates the expected magnitude of the change in the property and the no. of cases in which the property increases give the probability that the structural transformation will cause the property to increase.  Outliers indicate potential ways of avoiding the general trend.  Comparing to changes in lipophilicity highlights structural transformations that have unusual effects, some of which can be explained by conformational changes.  In this paper, we focus upon the effects on aq. soly., plasma protein binding and oral exposure of adding substituents to arom. rings and methylating heteroatoms.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpcyrloR79Oq7Vg90H21EOLACvtfcHk0lgsUiCApxm6-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XhtV2gtLnO&md5=2c143b424aee3ddb6c34616aff699ee0</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1021%2Fjm0605233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0605233%26sid%3Dliteratum%253Aachs%26aulast%3DLeach%26aufirst%3DA.%2BG.%26aulast%3DJones%26aufirst%3DH.%2BD.%26aulast%3DCosgrove%26aufirst%3DD.%2BA.%26aulast%3DKenny%26aufirst%3DP.%2BW.%26aulast%3DRuston%26aufirst%3DL.%26aulast%3DMacFaul%26aufirst%3DP.%26aulast%3DWood%26aufirst%3DJ.%2BM.%26aulast%3DColclough%26aufirst%3DN.%26aulast%3DLaw%26aufirst%3DB.%26atitle%3DMatched%2520molecular%2520pairs%2520as%2520a%2520guide%2520in%2520the%2520optimization%2520of%2520pharmaceutical%2520properties%253B%2520a%2520study%2520of%2520aqueous%2520solubility%252C%2520plasma%2520protein%2520binding%2520and%2520oral%2520exposure%26jtitle%3DJ.%2520Med.%2520Chem%2520.%26date%3D2006%26volume%3D49%26spage%3D6672%26epage%3D6682" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Johnson, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weerapana, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cravatt, B. F.</span><span> </span><span class="NLM_article-title">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">949</span><span class="NLM_x">–</span> <span class="NLM_lpage">964</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.4155%2Ffmc.10.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20640225" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2010&pages=949-964&author=D.+S.+Johnsonauthor=E.+Weerapanaauthor=B.+F.+Cravatt&title=Strategies+for+discovering+and+derisking+covalent%2C+irreversible+enzyme+inhibitors"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit36R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Strategies for discovering and derisking covalent, irreversible enzyme inhibitors</span></div><div class="casAuthors">Johnson, Douglas S.; Weerapana, Eranthie; Cravatt, Benjamin F.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">949-964</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  This article presents several covalent inhibitors, including examples of successful drugs, as well as highly selective, irreversible inhibitors of emerging therapeutic targets, such as fatty acid amide hydolase.  Covalent inhibitors have many desirable features, including increased biochem. efficiency of target disruption, less sensitivity toward pharmacokinetic parameters and increased duration of action that outlasts the pharmacokinetics of the compd.  Safety concerns that must be mitigated include lack of specificity and the potential immunogenicity of protein-inhibitor adduct(s).  Particular attention will be given to recent technologies, such as activity-based protein profiling, which allow one to define the proteome-wide selectivity patterns for covalent inhibitors in vitro and in vivo.  For instance, any covalent inhibitor can, in principle, be modified with a 'clickable' tag to generate an activity probe that is almost indistinguishable from the original agent.  These probes can be applied to any living system across a broad dose range to fully inventory their on and off targets.  The substantial no. of drugs on the market today that act by a covalent mechanism belies historical prejudices against the development of irreversibly acting therapeutic small mols.  Emerging proteomic technologies offer a means to systematically discriminate safe (selective) vs. deleterious (nonselective) covalent inhibitors and thus should inspire their future design and development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrqm0whEybB-LVg90H21EOLACvtfcHk0lgsUiCApxm6-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXpsFakur4%253D&md5=07e1f89418b168798ae5c1a9fa43e9c1</span></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.4155%2Ffmc.10.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.10.21%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DD.%2BS.%26aulast%3DWeerapana%26aufirst%3DE.%26aulast%3DCravatt%26aufirst%3DB.%2BF.%26atitle%3DStrategies%2520for%2520discovering%2520and%2520derisking%2520covalent%252C%2520irreversible%2520enzyme%2520inhibitors%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2010%26volume%3D2%26spage%3D949%26epage%3D964" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Clarke, E. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenhow, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Adams, D.</span><span> </span><span class="NLM_article-title">Metabolism-related assays and their application to agrochemical research: Reactivity of pesticides with glutathione and glutathione transferases</span> <span class="citation_source-journal">Pestic. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">385</span><span class="NLM_x">–</span> <span class="NLM_lpage">393</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1002%2F%28SICI%291096-9063%28199812%2954%3A4%3C385%3A%3AAID-PS842%3E3.0.CO%3B2-C" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADyaK1MXhtlCrsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=1998&pages=385-393&author=E.+D.+Clarkeauthor=D.+T.+Greenhowauthor=D.+Adams&title=Metabolism-related+assays+and+their+application+to+agrochemical+research%3A+Reactivity+of+pesticides+with+glutathione+and+glutathione+transferases"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">36</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-related assays and their application to agrochemical research: reactivity of pesticides with glutathione and glutathione transferases</span></div><div class="casAuthors">Clarke, Eric D.; Greenhow, Daren T.; Adams, David</div><div class="citationInfo"><span class="NLM_cas:title">Pesticide Science</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">385-393</span>CODEN:
                <span class="NLM_cas:coden">PSSCBG</span>;
        ISSN:<span class="NLM_cas:issn">0031-613X</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">An HPLC-based assay system has been developed to measure the reactivity of agrochems. with glutathione (GSH) with and without catalysis by glutathione transferases (GSTs).  Metab.-related parameters based on second-order related rate consts. from nonenzymic GSH and enzymic GSH + GST assays have been derived for use in structure-activity and structure-reactivity relationship studies of exploratory agrochems.  The versatility and sensitivity of the assay system has been established using a diverse range of agrochems. and model compds., e.g. 4-nitrobenzyl chloride, 1-chloro-2,4-dinitrobenzene, atrazine, acetochlor, fluorodifen, fluazifop-Bu, tridiphane, fluazinam, chlorothalonil and diazinon.  For the enzymic GSH + GST assay, second-order related rate consts., ratioed to the assay std., 4-nitrobenzyl chloride to provide a parameter independent of assay conditions, spanned 5 orders of magnitude, fluazinam being the most reactive and atrazine the least.  Within chem. classes, significant variations in reactivity were obsd., alachlor being c. 15-fold more reactive than pretilachlor.  Applications of this assay system based on comparative measures of reactivity across and within chem. classes are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGozE9JcsswrNbVg90H21EOLACvtfcHk0lgsUiCApxm6-g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhtlCrsg%253D%253D&md5=5de37b3f68e5df660d917bc17fb4fb16</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1002%2F%28SICI%291096-9063%28199812%2954%3A4%3C385%3A%3AAID-PS842%3E3.0.CO%3B2-C&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252F%2528SICI%25291096-9063%2528199812%252954%253A4%253C385%253A%253AAID-PS842%253E3.0.CO%253B2-C%26sid%3Dliteratum%253Aachs%26aulast%3DClarke%26aufirst%3DE.%2BD.%26aulast%3DGreenhow%26aufirst%3DD.%2BT.%26aulast%3DAdams%26aufirst%3DD.%26atitle%3DMetabolism-related%2520assays%2520and%2520their%2520application%2520to%2520agrochemical%2520research%253A%2520Reactivity%2520of%2520pesticides%2520with%2520glutathione%2520and%2520glutathione%2520transferases%26jtitle%3DPestic.%2520Sci.%26date%3D1998%26volume%3D54%26spage%3D385%26epage%3D393" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">MacFaul, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morley, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crawford, J. J.</span><span> </span><span class="NLM_article-title">A simple in vitro assay for assessing the reactivity of nitrile containing compounds</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">1136</span><span class="NLM_x">–</span> <span class="NLM_lpage">1138</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1016%2Fj.bmcl.2008.12.105" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=19168354" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD1MXit1WrtLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2009&pages=1136-1138&author=P.+A.+MacFaulauthor=A.+D.+Morleyauthor=J.+J.+Crawford&title=A+simple+in+vitro+assay+for+assessing+the+reactivity+of+nitrile+containing+compounds"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">A simple in vitro assay for assessing the reactivity of nitrile containing compounds</span></div><div class="casAuthors">MacFaul, Philip A.; Morley, Andrew D.; Crawford, James J.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1136-1138</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A quant. assay involving the reaction of nitriles with glutathione and cysteine has been used as a simple in vitro screen to assess potential toxicity risk of candidate compds. in drug discovery.  Studies have indicated that, when benchmarked with selected compds., the reaction of the nitriles with glutathione can provide a useful tool for deciding whether or not to progress compds. in the absence of radiolabelling studies.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGro23j0VCklM7Vg90H21EOLACvtfcHk0lgd21H-iCBKpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXit1WrtLs%253D&md5=d949b5d0e76c6d268f3f57cc4584f0b9</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.12.105&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.12.105%26sid%3Dliteratum%253Aachs%26aulast%3DMacFaul%26aufirst%3DP.%2BA.%26aulast%3DMorley%26aufirst%3DA.%2BD.%26aulast%3DCrawford%26aufirst%3DJ.%2BJ.%26atitle%3DA%2520simple%2520in%2520vitro%2520assay%2520for%2520assessing%2520the%2520reactivity%2520of%2520nitrile%2520containing%2520compounds%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2009%26volume%3D19%26spage%3D1136%26epage%3D1138" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Schwobel, J. A. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Madden, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, M. T. D.</span><span> </span><span class="NLM_article-title">Examination of Michael addition reactivity towards glutathione by transition-state calculations</span> <span class="citation_source-journal">SAR QSAR Environ. Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">693</span><span class="NLM_x">–</span> <span class="NLM_lpage">710</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2010&pages=693-710&author=J.+A.+H.+Schwobelauthor=J.+C.+Maddenauthor=M.+T.+D.+Cronin&title=Examination+of+Michael+addition+reactivity+towards+glutathione+by+transition-state+calculations"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DSchwobel%26aufirst%3DJ.%2BA.%2BH.%26aulast%3DMadden%26aufirst%3DJ.%2BC.%26aulast%3DCronin%26aufirst%3DM.%2BT.%2BD.%26atitle%3DExamination%2520of%2520Michael%2520addition%2520reactivity%2520towards%2520glutathione%2520by%2520transition-state%2520calculations%26jtitle%3DSAR%2520QSAR%2520Environ.%2520Res.%26date%3D2010%26volume%3D21%26spage%3D693%26epage%3D710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Esterbauer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zollner, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholz, N.</span><span> </span><span class="NLM_article-title">Reaction of glutathione with conjugated carbonyls</span> <span class="citation_source-journal">Z. Naturforsch., C</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1975</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">466</span><span class="NLM_x">–</span> <span class="NLM_lpage">473</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=241172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A280%3ADyaE28%252FjsF2mtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=1975&pages=466-473&author=H.+Esterbauerauthor=H.+Zollnerauthor=N.+Scholz&title=Reaction+of+glutathione+with+conjugated+carbonyls"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Reaction of glutathione with conjugated carbonyls</span></div><div class="casAuthors">Esterbauer H; Zollner H; Scholz N</div><div class="citationInfo"><span class="NLM_cas:title">Zeitschrift fur Naturforschung. Section C, Biosciences</span>
        (<span class="NLM_cas:date">1975</span>),
    <span class="NLM_cas:volume">30</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">466-73</span>
        ISSN:<span class="NLM_cas:issn">0341-0382</span>.
    </div><div class="casAbstract">1.  GSH reacts with conjugated carbonyls according to the equation: GSH+R-CH=CH-COR in equilibrium R-CH(SG)-CH2-COR.  The forward reaction follows second order, the reverse reaction first order kinetics.  It is assumed that this reaction reflects best the ability of conjugated carbonyls to inactivate SH groups in biological systems. 2.  The rate of forward reaction increases with pH approx. parallel with alphaSH.  Besides OH- ions also proton donors (e.g. buffers) increase the rate.  The catalytic effect of pH and buffer is interpreted in view of the reaction mechanism. 3.  The equilibrium constants as well as the rate constants for forward (k1) and reverse reaction show an extreme variation depending on the carbonyl structure.  Acrolein and methyl vinyl ketone (k1 = 120 and 32 mol-1 sec-1, resp.) react more rapidly than any other carbonyl to give very stable adducts (half-lives for reverse reaction 4.6 and 60.7 days, resp).  Somewhat less reactive are 4-hydroxy-2-alkenals and 4-ketopentenoic acid (k1 between 1 and 3 mol-1 sec-1), but they also form very stable adducts showing half-lives between 3.4 and 19 days.  All other carbonyl studied react either very slowly (e.g. citral, ethly crotonate, mesityl oxide, acrylic acid) or form very labile adducts (crotonal, pentenal, hexenal, 3-methyl-butenone).  Comparing biological activities of conjugated carbonyls their reactivity towards HS (k1) and the stability of the adducts must be considered.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcShzMY519srAedfST00W0BcfW6udTcc2eZx63NdunZUt7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaE28%252FjsF2mtg%253D%253D&md5=f1507bf00ea14a2ac7984313525fa485</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DEsterbauer%26aufirst%3DH.%26aulast%3DZollner%26aufirst%3DH.%26aulast%3DScholz%26aufirst%3DN.%26atitle%3DReaction%2520of%2520glutathione%2520with%2520conjugated%2520carbonyls%26jtitle%3DZ.%2520Naturforsch.%252C%2520C%26date%3D1975%26volume%3D30%26spage%3D466%26epage%3D473" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Bohme, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thaens, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Paschke, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schuurmann, G.</span><span> </span><span class="NLM_article-title">Kinetic glutathione chemoassay to quantify thiol reactivity of organic electrophiles-application to alpha,beta-unsaturated ketones, acrylates, and propiolates</span> <span class="citation_source-journal">Chem. Res. Toxicol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">742</span><span class="NLM_x">–</span> <span class="NLM_lpage">750</span></span><div class="citationLinks">[<a href="/doi/10.1021/tx800492x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2009&pages=742-750&author=A.+Bohmeauthor=D.+Thaensauthor=A.+Paschkeauthor=G.+Schuurmann&title=Kinetic+glutathione+chemoassay+to+quantify+thiol+reactivity+of+organic+electrophiles-application+to+alpha%2Cbeta-unsaturated+ketones%2C+acrylates%2C+and+propiolates"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1021%2Ftx800492x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Ftx800492x%26sid%3Dliteratum%253Aachs%26aulast%3DBohme%26aufirst%3DA.%26aulast%3DThaens%26aufirst%3DD.%26aulast%3DPaschke%26aufirst%3DA.%26aulast%3DSchuurmann%26aufirst%3DG.%26atitle%3DKinetic%2520glutathione%2520chemoassay%2520to%2520quantify%2520thiol%2520reactivity%2520of%2520organic%2520electrophiles-application%2520to%2520alpha%252Cbeta-unsaturated%2520ketones%252C%2520acrylates%252C%2520and%2520propiolates%26jtitle%3DChem.%2520Res.%2520Toxicol.%26date%3D2009%26volume%3D22%26spage%3D742%26epage%3D750" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Paasche, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schiller, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schirmeister, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engels, B.</span><span> </span><span class="NLM_article-title">Mechanistic study of the reaction of thiol-containing enzymes with α,β-unsaturated carbonyl substrates by computation and chemoassays</span> <span class="citation_source-journal">ChemMedChem</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">869</span><span class="NLM_x">–</span> <span class="NLM_lpage">880</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2010&pages=869-880&author=A.+Paascheauthor=M.+Schillerauthor=T.+Schirmeisterauthor=B.+Engels&title=Mechanistic+study+of+the+reaction+of+thiol-containing+enzymes+with+%CE%B1%2C%CE%B2-unsaturated+carbonyl+substrates+by+computation+and+chemoassays"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DPaasche%26aufirst%3DA.%26aulast%3DSchiller%26aufirst%3DM.%26aulast%3DSchirmeister%26aufirst%3DT.%26aulast%3DEngels%26aufirst%3DB.%26atitle%3DMechanistic%2520study%2520of%2520the%2520reaction%2520of%2520thiol-containing%2520enzymes%2520with%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520carbonyl%2520substrates%2520by%2520computation%2520and%2520chemoassays%26jtitle%3DChemMedChem%26date%3D2010%26volume%3D5%26spage%3D869%26epage%3D880" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Krenske, E. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petter, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Houk, K. N.</span><span> </span><span class="NLM_article-title">Transition states and energetics of nucleophilic additions of thiols to substituted α,β-unsaturated ketones: substituent effects involve enone stabilization, product branching, and solvation</span> <span class="citation_source-journal">J. Org. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">5074</span><span class="NLM_x">–</span> <span class="NLM_lpage">5081</span></span><div class="citationLinks">[<a href="/doi/10.1021/jo200761w" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmtFWqsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=2011&pages=5074-5081&author=E.+H.+Krenskeauthor=R.+C.+Petterauthor=Z.+Zhuauthor=K.+N.+Houk&title=Transition+states+and+energetics+of+nucleophilic+additions+of+thiols+to+substituted+%CE%B1%2C%CE%B2-unsaturated+ketones%3A+substituent+effects+involve+enone+stabilization%2C+product+branching%2C+and+solvation"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Transition States and Energetics of Nucleophilic Additions of Thiols to Substituted α,β-Unsaturated Ketones: Substituent Effects Involve Enone Stabilization, Product Branching, and Solvation</span></div><div class="casAuthors">Krenske, Elizabeth H.; Petter, Russell C.; Zhu, Zhendong; Houk, K. N.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Organic Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">76</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">5074-5081</span>CODEN:
                <span class="NLM_cas:coden">JOCEAH</span>;
        ISSN:<span class="NLM_cas:issn">0022-3263</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">CBS-QB3 enthalpies of reaction have been computed for the conjugate addns. of MeSH to six α,β-unsatd. ketones.  Compared with addn. to Me vinyl ketone, the reaction becomes 1-3 kcal mol-1 less exothermic when an α-Me, β-Me, or β-Ph substituent is present on the C=C bond.  The lower exothermicity for the substituted enones occurs because the substituted reactant is stabilized more by hyperconjugation or conjugation than the product is stabilized by branching.  Substituent effects on the activation energies for the rate-detg. step of the thiol addn.(reaction of the enone with MeS-) were also computed.  Loss of reactant stabilization, and not steric hindrance, is the main factor responsible for controlling the relative activation energies in the gas phase.  The substituent effects are further magnified in soln.; in water (simulated by CPCM calcns.), the addn. of MeS- to an enone is disfavored by 2-6 kcal mol-1 when one or two Me groups are present on the C=C bond.  The use of CBS-QB3 gas-phase energies in conjunction with CPCM solvation corrections provides kinetic data in good agreement with exptl. substituent effects.  When the energetics of the thiol addns. were calcd. with several popular d. functional theory and ab initio methods(B3LYP, MPW1PW91, B1B95, PBE0, B2PLYP, and MP2), some substantial inaccuracies were noted.  However, M06-2X(with a large basis set), B2PLYP-D, and SCS-MP2 gave results within 1 kcal mol-1 of the CBS-QB3 benchmark values.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrfP3ND9L6ax7Vg90H21EOLACvtfcHk0lgd21H-iCBKpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmtFWqsLs%253D&md5=8f0bbd69b9d81814d196327fb3f878ea</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1021%2Fjo200761w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjo200761w%26sid%3Dliteratum%253Aachs%26aulast%3DKrenske%26aufirst%3DE.%2BH.%26aulast%3DPetter%26aufirst%3DR.%2BC.%26aulast%3DZhu%26aufirst%3DZ.%26aulast%3DHouk%26aufirst%3DK.%2BN.%26atitle%3DTransition%2520states%2520and%2520energetics%2520of%2520nucleophilic%2520additions%2520of%2520thiols%2520to%2520substituted%2520%25CE%25B1%252C%25CE%25B2-unsaturated%2520ketones%253A%2520substituent%2520effects%2520involve%2520enone%2520stabilization%252C%2520product%2520branching%252C%2520and%2520solvation%26jtitle%3DJ.%2520Org.%2520Chem.%26date%3D2011%26volume%3D76%26spage%3D5074%26epage%3D5081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Gray, N. S.; Zhou, W.</span> WIPO Patent WO2011140338,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gray%2C+N.+S.%3B+Zhou%2C+W.+WIPO+Patent+WO2011140338%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Tsou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mamuya, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, B. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reich, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilakantan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Discafani, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeBlanc, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koehn, F. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greenberger, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wissner, A.</span><span> </span><span class="NLM_article-title">6-Substituted-4-(3-bromophenylamino)quinazolines as putative irreversible inhibitors of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor (HER-2) tyrosine kinases with enhanced antitumor activity</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">2719</span><span class="NLM_x">–</span> <span class="NLM_lpage">2734</span></span><div class="citationLinks">[<a href="/doi/10.1021/jm0005555" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2001&pages=2719-2734&author=H.+Tsouauthor=N.+Mamuyaauthor=B.+D.+Johnsonauthor=M.+F.+Reichauthor=B.+C.+Gruberauthor=F.+Yeauthor=R.+Nilakantanauthor=R.+Shenauthor=C.+Discafaniauthor=R.+DeBlancauthor=R.+Davisauthor=F.+E.+Koehnauthor=L.+M.+Greenbergerauthor=Y.+Wangauthor=A.+Wissner&title=6-Substituted-4-%283-bromophenylamino%29quinazolines+as+putative+irreversible+inhibitors+of+the+epidermal+growth+factor+receptor+%28EGFR%29+and+human+epidermal+growth+factor+receptor+%28HER-2%29+tyrosine+kinases+with+enhanced+antitumor+activity"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm0005555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm0005555%26sid%3Dliteratum%253Aachs%26aulast%3DTsou%26aufirst%3DH.%26aulast%3DMamuya%26aufirst%3DN.%26aulast%3DJohnson%26aufirst%3DB.%2BD.%26aulast%3DReich%26aufirst%3DM.%2BF.%26aulast%3DGruber%26aufirst%3DB.%2BC.%26aulast%3DYe%26aufirst%3DF.%26aulast%3DNilakantan%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DR.%26aulast%3DDiscafani%26aufirst%3DC.%26aulast%3DDeBlanc%26aufirst%3DR.%26aulast%3DDavis%26aufirst%3DR.%26aulast%3DKoehn%26aufirst%3DF.%2BE.%26aulast%3DGreenberger%26aufirst%3DL.%2BM.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWissner%26aufirst%3DA.%26atitle%3D6-Substituted-4-%25283-bromophenylamino%2529quinazolines%2520as%2520putative%2520irreversible%2520inhibitors%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520%2528EGFR%2529%2520and%2520human%2520epidermal%2520growth%2520factor%2520receptor%2520%2528HER-2%2529%2520tyrosine%2520kinases%2520with%2520enhanced%2520antitumor%2520activity%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2001%26volume%3D44%26spage%3D2719%26epage%3D2734" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Serafimova, I. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pufall, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krishnan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duda, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maglathlin, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McFarland, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Froedin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taunton, J.</span><span> </span><span class="NLM_article-title">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span> <span class="citation_source-journal">Nat. Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">471</span><span class="NLM_x">–</span> <span class="NLM_lpage">476</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1038%2Fnchembio.925" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=22466421" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2012&pages=471-476&author=I.+M.+Serafimovaauthor=M.+A.+Pufallauthor=S.+Krishnanauthor=K.+Dudaauthor=M.+S.+Cohenauthor=R.+L.+Maglathlinauthor=J.+M.+McFarlandauthor=R.+M.+Millerauthor=M.+Froedinauthor=J.+Taunton&title=Reversible+targeting+of+noncatalytic+cysteines+with+chemically+tuned+electrophiles"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Reversible targeting of noncatalytic cysteines with chemically tuned electrophiles</span></div><div class="casAuthors">Serafimova, Iana M.; Pufall, Miles A.; Krishnan, Shyam; Duda, Katarzyna; Cohen, Michael S.; Maglathlin, Rebecca L.; McFarland, Jesse M.; Miller, Rand M.; Froedin, Morten; Taunton, Jack</div><div class="citationInfo"><span class="NLM_cas:title">Nature Chemical Biology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">471-476</span>CODEN:
                <span class="NLM_cas:coden">NCBABT</span>;
        ISSN:<span class="NLM_cas:issn">1552-4450</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Targeting noncatalytic cysteine residues with irreversible acrylamide-based inhibitors is a powerful approach for enhancing pharmacol. potency and selectivity.  Nevertheless, concerns about off-target modification motivate the development of reversible cysteine-targeting strategies.  Here we show that electron-deficient olefins, including acrylamides, can be tuned to react with cysteine thiols in a rapidly reversible manner.  Installation of a nitrile group increased the olefins' intrinsic reactivity, but, paradoxically, eliminated the formation of irreversible adducts.  Incorporation of these electrophiles into a noncovalent kinase-recognition scaffold produced slowly dissocg., covalent inhibitors of the p90 ribosomal protein S6 kinase RSK2.  A cocrystal structure revealed specific noncovalent interactions that stabilize the complex by positioning the electrophilic carbon near the targeted cysteine.  Disruption of these interactions by protein unfolding or proteolysis promoted instantaneous cleavage of the covalent bond.  Our results establish a chem.-based framework for engineering sustained covalent inhibition without accumulating permanently modified proteins and peptides.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqlcv3GjPOB6rVg90H21EOLACvtfcHk0li3sB-8_xE7qA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XkvVKitrw%253D&md5=6455a9a029714beb317286f71ac1326b</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1038%2Fnchembio.925&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnchembio.925%26sid%3Dliteratum%253Aachs%26aulast%3DSerafimova%26aufirst%3DI.%2BM.%26aulast%3DPufall%26aufirst%3DM.%2BA.%26aulast%3DKrishnan%26aufirst%3DS.%26aulast%3DDuda%26aufirst%3DK.%26aulast%3DCohen%26aufirst%3DM.%2BS.%26aulast%3DMaglathlin%26aufirst%3DR.%2BL.%26aulast%3DMcFarland%26aufirst%3DJ.%2BM.%26aulast%3DMiller%26aufirst%3DR.%2BM.%26aulast%3DFroedin%26aufirst%3DM.%26aulast%3DTaunton%26aufirst%3DJ.%26atitle%3DReversible%2520targeting%2520of%2520noncatalytic%2520cysteines%2520with%2520chemically%2520tuned%2520electrophiles%26jtitle%3DNat.%2520Chem.%2520Biol.%26date%3D2012%26volume%3D8%26spage%3D471%26epage%3D476" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Bain, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Plater, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Elliott, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shpiro, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hastie, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLauchlan, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klevernic, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arthur, J. S. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alessi, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, P.</span><span> </span><span class="NLM_article-title">The selectivity of protein kinase inhibitors: a further update</span> <span class="citation_source-journal">Biochem. J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">408</span><span class="NLM_x">, </span> <span class="NLM_fpage">297</span><span class="NLM_x">–</span> <span class="NLM_lpage">315</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1042%2FBJ20070797" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=17850214" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhtlGmtbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=408&publication_year=2007&pages=297-315&author=J.+Bainauthor=L.+Platerauthor=M.+Elliottauthor=N.+Shpiroauthor=C.+J.+Hastieauthor=H.+McLauchlanauthor=I.+Klevernicauthor=J.+S.+C.+Arthurauthor=D.+R.+Alessiauthor=P.+Cohen&title=The+selectivity+of+protein+kinase+inhibitors%3A+a+further+update"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">The selectivity of protein kinase inhibitors: a further update</span></div><div class="casAuthors">Bain, Jenny; Plater, Lorna; Elliott, Matt; Shpiro, Natalia; Hastie, C. James; McLauchlan, Hilary; Klevernic, Iva; Arthur, J. Simon C.; Alessi, Dario R.; Cohen, Philip</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Journal</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">408</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">297-315</span>CODEN:
                <span class="NLM_cas:coden">BIJOAK</span>;
        ISSN:<span class="NLM_cas:issn">0264-6021</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">The specificities of 65 compds. reported to be relatively specific inhibitors of protein kinases have been profiled against a panel of 70-80 protein kinases.  On the basis of this information, the effects of compds. that we have studied in cells and other data in the literature, we recommend the use of the following small-mol. inhibitors: SB 203580/SB202190 and BIRB 0796 to be used in parallel to assess the physiol. roles of p38 MAPK (mitogen-activated protein kinase) isoforms, PI-103 and wortmannin to be used in parallel to inhibit phosphatidylinositol (phosphoinositide) 3-kinases, PP1 or PP2 to be used in parallel with Src-I1 (Src inhibitor-1) to inhibit Src family members; PD 184352 or PD 0325901 to inhibit MKK1 (MAPK kinase-1) or MKK1 plus MKK5, Akt-I-1/2 to inhibit the activation of PKB (protein kinase B/Akt), rapamycin to inhibit TORC1 [mTOR (mammalian target of rapamycin)-raptor (regulatory assocd. protein of mTOR) complex], CT 99021 to inhibit GSK3 (glycogen synthase kinase 3), BI-D1870 and SL0101 or FMK (fluoromethylketone) to be used in parallel to inhibit RSK (ribosomal S6 kinase), D4476 to inhibit CK1 (casein kinase 1), VX680 to inhibit Aurora kinases, and roscovitine as a pan-CDK (cyclin-dependent kinase) inhibitor.  We have also identified harmine as a potent and specific inhibitor of DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A) in vitro.  The results have further emphasized the need for considerable caution in using small-mol. inhibitors of protein kinases to assess the physiol. roles of these enzymes.  Despite being used widely, many of the compds. that we analyzed were too non-specific for useful conclusions to be made, other than to exclude the involvement of particular protein kinases in cellular processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQPaieWftdVrVg90H21EOLACvtfcHk0lh6OlcvLNVc3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhtlGmtbjE&md5=e2334e35897dd1b9770bbcca8f82bb9c</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1042%2FBJ20070797&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBJ20070797%26sid%3Dliteratum%253Aachs%26aulast%3DBain%26aufirst%3DJ.%26aulast%3DPlater%26aufirst%3DL.%26aulast%3DElliott%26aufirst%3DM.%26aulast%3DShpiro%26aufirst%3DN.%26aulast%3DHastie%26aufirst%3DC.%2BJ.%26aulast%3DMcLauchlan%26aufirst%3DH.%26aulast%3DKlevernic%26aufirst%3DI.%26aulast%3DArthur%26aufirst%3DJ.%2BS.%2BC.%26aulast%3DAlessi%26aufirst%3DD.%2BR.%26aulast%3DCohen%26aufirst%3DP.%26atitle%3DThe%2520selectivity%2520of%2520protein%2520kinase%2520inhibitors%253A%2520a%2520further%2520update%26jtitle%3DBiochem.%2520J.%26date%3D2007%26volume%3D408%26spage%3D297%26epage%3D315" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Stamos, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sliwkowski, M. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eigenbrot, C.</span><span> </span><span class="NLM_article-title">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">277</span><span class="NLM_x">, </span> <span class="NLM_fpage">46265</span><span class="NLM_x">–</span> <span class="NLM_lpage">46272</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1074%2Fjbc.M207135200" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=12196540" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=277&publication_year=2002&pages=46265-46272&author=J.+Stamosauthor=M.+X.+Sliwkowskiauthor=C.+Eigenbrot&title=Structure+of+the+epidermal+growth+factor+receptor+kinase+domain+alone+and+in+complex+with+a+4-anilinoquinazoline+inhibitor"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor</span></div><div class="casAuthors">Stamos, Jennifer; Sliwkowski, Mark X.; Eigenbrot, Charles</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">277</span>
        (<span class="NLM_cas:issue">48</span>),
    <span class="NLM_cas:pages">46265-46272</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">The crystal structure of the kinase domain from the epidermal growth factor receptor (EGFRK) including forty amino acids from the carboxyl-terminal tail has been detd. to 2.6-Å resoln., both with and without an EGFRK-specific inhibitor currently in Phase III clin. trials as an anti-cancer agent, erlotinib (OSI-774, CP-358,774, Tarceva).  The EGFR family members are distinguished from all other known receptor tyrosine kinases in possessing constitutive kinase activity without a phosphorylation event within their kinase domains.  Despite its lack of phosphorylation, we find that the EGFRK activation loop adopts a conformation similar to that of the phosphorylated active form of the kinase domain from the insulin receptor.  Surprisingly, key residues of a putative dimerization motif lying between the EGFRK domain and carboxyl-terminal substrate docking sites are found in close contact with the kinase domain.  Significant intermol. contacts involving the carboxyl-terminal tail are discussed with respect to receptor oligomerization.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpsObp1WYFaC7Vg90H21EOLACvtfcHk0lh6OlcvLNVc3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XovFKhsL4%253D&md5=c63c60b93756bd45fb2375c56ba38941</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M207135200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M207135200%26sid%3Dliteratum%253Aachs%26aulast%3DStamos%26aufirst%3DJ.%26aulast%3DSliwkowski%26aufirst%3DM.%2BX.%26aulast%3DEigenbrot%26aufirst%3DC.%26atitle%3DStructure%2520of%2520the%2520epidermal%2520growth%2520factor%2520receptor%2520kinase%2520domain%2520alone%2520and%2520in%2520complex%2520with%2520a%25204-anilinoquinazoline%2520inhibitor%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2002%26volume%3D277%26spage%3D46265%26epage%3D46272" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Kabsch, W.</span><span> </span><span class="NLM_article-title">Software XDS for image rotation, recognition and crystal symmetry assignment</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">66</span><span class="NLM_x">, </span> <span class="NLM_fpage">125</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1107%2FS0907444909047337" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=20124692" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=66&publication_year=2010&pages=125-132&author=W.+Kabsch&title=Software+XDS+for+image+rotation%2C+recognition+and+crystal+symmetry+assignment"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Software XDS for image rotation, recognition and crystal symmetry assignment</span></div><div class="casAuthors">Kabsch, Wolfgang</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">66</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">International Union of Crystallography</span>)
        </div><div class="casAbstract">The usage and control of recent modifications of the program package XDS for the processing of rotation images are described in the context of previous versions.  New features include automatic detn. of spot size and reflecting range and recognition and assignment of crystal symmetry.  Moreover, the limitations of earlier package versions on the no. of correction/scaling factors and the representation of pixel contents have been removed.  Large program parts have been restructured for parallel processing so that the quality and completeness of collected data can be assessed soon after measurement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv5AyUw00DYbVg90H21EOLACvtfcHk0lh6OlcvLNVc3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhs1SisLc%253D&md5=1aa9a38aeb3ce95af4ffb7d8b8a142bd</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1107%2FS0907444909047337&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444909047337%26sid%3Dliteratum%253Aachs%26aulast%3DKabsch%26aufirst%3DW.%26atitle%3DSoftware%2520XDS%2520for%2520image%2520rotation%252C%2520recognition%2520and%2520crystal%2520symmetry%2520assignment%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%26date%3D2010%26volume%3D66%26spage%3D125%26epage%3D132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Emsley, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cowtan, K.</span><span> </span><span class="NLM_article-title">Coot: Model-building tools for molecular graphics</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2126</span><span class="NLM_x">–</span> <span class="NLM_lpage">2132</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1107%2FS0907444904019158" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=15572765" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2126-2132&author=P.+Emsleyauthor=K.+Cowtan&title=Coot%3A+Model-building+tools+for+molecular+graphics"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Coot: model-building tools for molecular graphics</span></div><div class="casAuthors">Emsley, Paul; Cowtan, Kevin</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2126-2132</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">CCP4mg is a project that aims to provide a general-purpose tool for structural biologists, providing tools for x-ray structure soln., structure comparison and anal., and publication-quality graphics.  The map-fitting tools are available as a stand-alone package, distributed as 'Coot'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMisM42468k7Vg90H21EOLACvtfcHk0lh6OlcvLNVc3Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73P&md5=1be390f3bb6fd584468499ad0921161e</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1107%2FS0907444904019158&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904019158%26sid%3Dliteratum%253Aachs%26aulast%3DEmsley%26aufirst%3DP.%26aulast%3DCowtan%26aufirst%3DK.%26atitle%3DCoot%253A%2520Model-building%2520tools%2520for%2520molecular%2520graphics%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%26date%3D2004%26volume%3D60%26spage%3D2126%26epage%3D2132" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Vagin, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steiner, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lebedev, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Potterton, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McNicholas, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Long, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murshudov, G. N.</span><span> </span><span class="NLM_article-title">REFMAC5 dictionary: Organization of prior chemical knowledge and guidelines for its use</span> <span class="citation_source-journal">Acta Crystallogr., Sect. D</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2184</span><span class="NLM_x">–</span> <span class="NLM_lpage">2195</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Fjm400822z&amp;key=10.1107%2FS0907444904023510" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Fjm400822z&amp;key=15572771" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Fjm400822z&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2004&pages=2184-2195&author=A.+A.+Vaginauthor=R.+A.+Steinerauthor=A.+A.+Lebedevauthor=L.+Pottertonauthor=S.+McNicholasauthor=F.+Longauthor=G.+N.+Murshudov&title=REFMAC5+dictionary%3A+Organization+of+prior+chemical+knowledge+and+guidelines+for+its+use"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use</span></div><div class="casAuthors">Vagin, Alexei A.; Steiner, Roberto A.; Lebedev, Andrey A.; Potterton, Liz; McNicholas, Stuart; Long, Fei; Murshudov, Garib N.</div><div class="citationInfo"><span class="NLM_cas:title">Acta Crystallographica, Section D: Biological Crystallography</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">D60</span>
        (<span class="NLM_cas:issue">12, Pt. 1</span>),
    <span class="NLM_cas:pages">2184-2195</span>CODEN:
                <span class="NLM_cas:coden">ABCRE6</span>;
        ISSN:<span class="NLM_cas:issn">0907-4449</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">One of the most important aspects of macromol. structure refinement is the use of prior chem. knowledge.  Bond lengths, bond angles and other chem. properties are used in restrained refinement as subsidiary conditions.  This contribution describes the organization and some aspects of the use of the flexible and human/machine-readable dictionary of prior chem. knowledge used by the max.-likelihood macromol.-refinement program REFMAC5.  The dictionary stores information about monomers which represent the constitutive building blocks of biol. macromols. (amino acids, nucleic acids and saccharides) and about numerous org./inorg. compds. commonly found in macromol. crystallog.  It also describes the modifications the building blocks undergo as a result of chem. reactions and the links required for polymer formation.  More than 2000 monomer entries, 100 modification entries and 200 link entries are currently available.  Algorithms and tools for updating and adding new entries to the dictionary have also been developed and are presented here.  In many cases, the REFMAC5 dictionary allows entirely automatic generation of restraints within REFMAC5 refinement runs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRjDd-k3YHGrVg90H21EOLACvtfcHk0ligBFZ2FELmqA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVars73F&md5=005910422c5fb72fe2434c39b5321bf4</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1107%2FS0907444904023510&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1107%252FS0907444904023510%26sid%3Dliteratum%253Aachs%26aulast%3DVagin%26aufirst%3DA.%2BA.%26aulast%3DSteiner%26aufirst%3DR.%2BA.%26aulast%3DLebedev%26aufirst%3DA.%2BA.%26aulast%3DPotterton%26aufirst%3DL.%26aulast%3DMcNicholas%26aufirst%3DS.%26aulast%3DLong%26aufirst%3DF.%26aulast%3DMurshudov%26aufirst%3DG.%2BN.%26atitle%3DREFMAC5%2520dictionary%253A%2520Organization%2520of%2520prior%2520chemical%2520knowledge%2520and%2520guidelines%2520for%2520its%2520use%26jtitle%3DActa%2520Crystallogr.%252C%2520Sect.%2520D%26date%3D2004%26volume%3D60%26spage%3D2184%26epage%3D2195" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Gray, N. S.; Zhou, W.</span> WIPO Patent WO2011079231,<span class="NLM_x"> </span><span class="NLM_year">2011</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=Gray%2C+N.+S.%3B+Zhou%2C+W.+WIPO+Patent+WO2011079231%2C+2011."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26date%3D2011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><div class="accessionCode mb-5"><div class="toolbar-section accession-codes"><ul><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2ITY','PDB','2ITY'); return false;">PDB: 2ITY</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=2JIT','PDB','2JIT'); return false;">PDB: 2JIT</a></li><li><a href="http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LI5" onclick="trackOutboundLink('http://www.rcsb.org/pdb/search/structidSearch.do?structureId=4LI5','PDB','4LI5'); return false;">PDB: 4LI5</a></li></ul></div></div><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-2"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i67"><a href="/doi/suppl/10.1021/jm400822z">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_78738"></div></div></div></div></div><hr /></hr><p class="last">Reaction of compound <b>38</b> in buffer, structure of compound <b>60</b>, chemical structures of the compounds in Tables <a class="ref showTableEvent internalNav" href="#tbl7">7</a> and <a class="ref showTableEvent internalNav" href="#tbl8">8</a>, reaction of compounds with glutathione with and without human glutathione-S-transferase, and kinase selectivity of compound <b>15</b>. Methods of protein–ligand docking and full compound synthesis and characterization. This material is available free of charge via the Internet at <a class="extLink" href="http://pubs.acs.org">http://pubs.acs.org</a>.</p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/jm400822z/suppl_file/jm400822z_si_001.pdf">jm400822z_si_001.pdf (771.83 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Fjm400822z&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2013.56.issue-17%3Barticle%3Aarticle%3A10.1021%2Fjm400822z%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/jm400822z" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677a612b6f093d5a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
